
<html lang="en"     class="pb-page"  data-request-id="367b90e1-cde1-414f-af19-396dc8a1f395"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01367;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception" /></meta><meta name="dc.Creator" content="Mengna  Zhang" /></meta><meta name="dc.Creator" content="Biao  Xu" /></meta><meta name="dc.Creator" content="Ning  Li" /></meta><meta name="dc.Creator" content="Hui  Liu" /></meta><meta name="dc.Creator" content="Xuerui  Shi" /></meta><meta name="dc.Creator" content="Qinqin  Zhang" /></meta><meta name="dc.Creator" content="Yanbin  Shi" /></meta><meta name="dc.Creator" content="Kangtai  Xu" /></meta><meta name="dc.Creator" content="Jian  Xiao" /></meta><meta name="dc.Creator" content="Dan  Chen" /></meta><meta name="dc.Creator" content="Hanwen  Zhu" /></meta><meta name="dc.Creator" content="Yulong  Sun" /></meta><meta name="dc.Creator" content="Ting  Zhang" /></meta><meta name="dc.Creator" content="Run  Zhang" /></meta><meta name="dc.Creator" content="Quan  Fang" /></meta><meta name="dc.Description" content="In a previously described chimeric peptide, we reported that the multifunctional opioid/neuropeptide FF (NPFF) receptor agonist 0 (BN-9) produced antinociception for 1.5 h after supraspinal adminis..." /></meta><meta name="Description" content="In a previously described chimeric peptide, we reported that the multifunctional opioid/neuropeptide FF (NPFF) receptor agonist 0 (BN-9) produced antinociception for 1.5 h after supraspinal adminis..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 3, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01367" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01367" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01367" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01367" /></link>
        
    
    

<title>Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01367" /></meta><meta property="og:title" content="Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0012.jpeg" /></meta><meta property="og:description" content="In a previously described chimeric peptide, we reported that the multifunctional opioid/neuropeptide FF (NPFF) receptor agonist 0 (BN-9) produced antinociception for 1.5 h after supraspinal administration. Herein, four cyclic disulfide analogs containing l- and/or d-type cysteine at positions 2 and 5 were synthesized. The cyclized analogs and their linear counterparts behaved as multifunctional agonists at both opioid and NPFF receptors in vitro and produced potent analgesia without tolerance development. In comparison to 0, cyclized peptide 6 exhibited sevenfold more potent μ-opioid receptor agonistic activity in vitro. Interestingly, the cyclized analog 6 possessed an improved stability in the brain and an increased blood–brain barrier permeability compared to the parent peptide 0 and produced more potent analgesia after supraspinal or subcutaneous administration with improved duration of action of 4 h. In addition, antinociceptive tolerance of analog 6 was greatly reduced after subcutaneous injection compared to fentanyl, as was the rewarding effect, withdrawal reaction, and gastrointestinal inhibition." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01367"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01367">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01367&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01367&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01367&amp;href=/doi/10.1021/acs.jmedchem.0c01367" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15709-15725</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01328" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01372" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Mengna Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mengna Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mengna++Zhang">Mengna Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Biao Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Biao Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Biao++Xu">Biao Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ning Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ning Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ning++Li">Ning Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui++Liu">Hui Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuerui Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuerui Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuerui++Shi">Xuerui Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qinqin Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qinqin Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qinqin++Zhang">Qinqin Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanbin Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanbin Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanbin++Shi">Yanbin Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kangtai Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kangtai Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kangtai++Xu">Kangtai Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Xiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Xiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Xiao">Jian Xiao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dan Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dan++Chen">Dan Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hanwen Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hanwen Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hanwen++Zhu">Hanwen Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yulong Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yulong Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory for Space Biosciences & Biotechnology, Institute of Special Environmental Biophysics, School of Life Sciences, Northwestern Polytechnical University, Xi’an 710000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yulong++Sun">Yulong Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ting Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ting Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ting++Zhang">Ting Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Run Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Run Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Run++Zhang">Run Zhang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Quan Fang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Quan Fang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#593f38373e281935232c773c3d2c773a37"><span class="__cf_email__" data-cfemail="9afcfbf4fdebdaf6e0efb4fffeefb4f9f4">[email protected]</span></a>. Phone: +86-9318915021.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Quan++Fang">Quan Fang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0381-6796" title="Orcid link">http://orcid.org/0000-0003-0381-6796</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01367&amp;href=/doi/10.1021%2Facs.jmedchem.0c01367" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15709–15725</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 3, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 August 2020</li><li><span class="item_label"><b>Published</b> online</span>3 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01367" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01367</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15709%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMengna%2BZhang%252C%2BBiao%2BXu%252C%2BNing%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01367%26title%3DSynthesis%2Band%2BBiological%2BCharacterization%2Bof%2BCyclic%2BDisulfide-Containing%2BPeptide%2BAnalogs%2Bof%2Bthe%2BMultifunctional%2BOpioid%252FNeuropeptide%2BFF%2BReceptor%2BAgonists%2BThat%2BProduce%2BLong-Lasting%2Band%2BNontolerant%2BAntinociception%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15725%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01367"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">648</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01367" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mengna&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Biao&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Ning&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Hui&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xuerui&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Qinqin&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yanbin&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Kangtai&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Xiao&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Hanwen&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Yulong&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Ting&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Run&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Quan&quot;,&quot;last_name&quot;:&quot;Fang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15709-15725&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01367&quot;},&quot;abstract&quot;:&quot;In a previously described chimeric peptide, we reported that the multifunctional opioid/neuropeptide FF (NPFF) receptor agonist 0 (BN-9) produced antinociception for 1.5 h after supraspinal administration. Herein, four cyclic disulfide analogs containing l- and/or d-type cysteine at positions 2 and 5 were synthesized. The cyclized analogs and their linear counterparts behaved as multifunctional agonists at both opioid and NPFF receptors in vitro and produced potent analgesia without tolerance development. In comparison to 0, cyclized peptide 6 exhibited sevenfold more potent μ-opioid receptor agonistic activity in vitro. Interestingly, the cyclized analog 6 possessed an improved stability in the brain and an increased blood–brain barrier permeability compared to the parent peptide 0 and produced more potent analgesia after supraspinal or subcutaneous administration with improved duration of action of 4 h. In addition, antinociceptive tolerance of analog 6 was greatly reduced after subcutaneous injection compa&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01367&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01367" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01367&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01367" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01367&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01367" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01367&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01367&amp;href=/doi/10.1021/acs.jmedchem.0c01367" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01367" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01367" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01367%26sid%3Dliteratum%253Aachs%26pmid%3D33271020%26genre%3Darticle%26aulast%3DZhang%26date%3D2020%26atitle%3DSynthesis%2Band%2BBiological%2BCharacterization%2Bof%2BCyclic%2BDisulfide-Containing%2BPeptide%2BAnalogs%2Bof%2Bthe%2BMultifunctional%2BOpioid%252FNeuropeptide%2BFF%2BReceptor%2BAgonists%2BThat%2BProduce%2BLong-Lasting%2Band%2BNontolerant%2BAntinociception%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15709%26epage%3D15725%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In a previously described chimeric peptide, we reported that the multifunctional opioid/neuropeptide FF (NPFF) receptor agonist <b>0</b> (BN-9) produced antinociception for 1.5 h after supraspinal administration. Herein, four cyclic disulfide analogs containing <span class="smallcaps smallerCapital">l</span>- and/or <span class="smallcaps smallerCapital">d</span>-type cysteine at positions 2 and 5 were synthesized. The cyclized analogs and their linear counterparts behaved as multifunctional agonists at both opioid and NPFF receptors <i>in vitro</i> and produced potent analgesia without tolerance development. In comparison to <b>0</b>, cyclized peptide <b>6</b> exhibited sevenfold more potent μ-opioid receptor agonistic activity <i>in vitro</i>. Interestingly, the cyclized analog <b>6</b> possessed an improved stability in the brain and an increased blood–brain barrier permeability compared to the parent peptide <b>0</b> and produced more potent analgesia after supraspinal or subcutaneous administration with improved duration of action of 4 h. In addition, antinociceptive tolerance of analog <b>6</b> was greatly reduced after subcutaneous injection compared to fentanyl, as was the rewarding effect, withdrawal reaction, and gastrointestinal inhibition.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81083" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81083" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">It is well-known that classical opioid analgesics including morphine and fentanyl effectively activate the μ-opioid receptor, which is most responsible for their desired antinociception and undesired side effects, such as constipation, respiratory depression, tolerance, and addiction.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> Thus, the development of novel opioid drugs lacking side effects is one of the major goals in pain research. Recently, a new generation of opioid analgesics that simultaneously target opioid receptors and some other receptors with modulatory effects on opioid activities has been developed.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> For example, the uses of the nociceptin/orphanin FQ receptor (ant)agonists, neurokinin-1 (NK<sub>1</sub>) receptor (ant)agonists, cannabinoid-1 receptor antagonists, or cholecystokinin type 2 receptor antagonists, are combined with opioids.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8−11)</a> Notably, the Ko group has reported that a series of bifunctional nociceptin and μ-opioid receptor agonists (BU08028, AT-121, and BU10038) produced potent antinociception without opioid-like side effects in nonhuman primates, such as abuse liability and respiratory depression.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a></div><div class="NLM_p">Neuropeptide FF (NPFF) is an endogenous opioid-modulating peptide and plays opioid-modulating roles in antinociception, tolerance, and addition.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16−18)</a> In our previous studies, several multifunctional peptides with opioid/neuropeptide FF receptor agonistic activities, such as EN-9, BN-9 (analog <b>0</b>), and DN-9, were characterized that could produce nontolerant antinociception.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> Our data showed that <b>0</b> simultaneously activated opioid and NPFF receptors and produced potent nontolerance-forming antinociception for 1.5 h after central or peripheral injection.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20,22)</a> However, recent pharmacological characterization has shown that <b>0</b> could not cross the blood–brain barrier (BBB).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In carrageenan-induced hindpaw inflammation model, the antiallodynic potency of BN-9 after central administration was more potent than that of BN-9 given systemically.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In fact, the therapeutics of opioid peptides are often limited due to their low BBB permeabilities and poor resistances to proteolytic degradation.</div><div class="NLM_p last">The advances in medicinal chemistry have shown that the cyclizations of linear peptides improve their potencies, receptor selectivities, bioavailabilities, BBB permeabilities, and biodistributions by limiting their conformational flexibilities and increasing their lipophilicities.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24−27)</a> Compared to their linear parents, cyclic analogs exhibit better defined conformations. Thus, the cyclic peptide analogs can pay lower entropy when binding to target receptors and provide significant insights into a preferred conformation for receptor interaction. In the past years, cyclic constraints of opioid peptides had been used to improve their efficacies, binding affinities, biostabilities, and receptor selectivities.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The successful examples were the δ-opioid receptor selective agonists DPDPE and JOM-13, the μ-opioid receptor selective ligands JOM-6, CTAP, and CTOP, and the κ-opioid receptor selective antagonist zyklophin.<a onclick="showRef(event, 'ref29 ref30 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32 ref33">(29−33)</a> Importantly, the cyclic analogs of EM-1 exhibited improved the half-life up to 27-fold relative to the parent peptide EM-1 (a half-life of 5.6 min) in human plasma.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Recently, cyclization modification was also applied to the bifunctional opioid peptide TY027, and its cyclic analog TY038 maintained opioid receptor agonistic and NK<sub>1</sub> receptor antagonistic activities and had an improved stability with a half-life of more than 24 h in rat plasma.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> To improve bioavailability, BBB permeability, and <i>in vivo</i> efficacy of <b>0</b>, we expanded our original sequence and designed four cyclic disulfide analogs and their linear counterparts. Cysteine was used to replace the positions of <span class="smallcaps smallerCapital">d</span>-Ala<sup>2</sup> and Gln<sup>5</sup> of peptide <b>0</b> (analog <b>5</b>), which was tolerant of substitution with other amino acids in our recent study.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In addition, to further explore the stereochemical features of the Cys residue in positions 2 and 5 of analog <b>5</b>, <span class="smallcaps smallerCapital">d</span>-Cys was also used to replace the Cys<sup>2</sup> or/and Cys<sup>5</sup> position (analogs <b>6–8</b>). The corresponding linear peptides (analogs <b>1–4</b>) of these four cyclic disulfide analogs of <b>0</b> were used as reference compounds. Our data showed that these cyclic disulfide analogs and their corresponding linear peptides functioned as multifunctional agonists for μ-, δ-, κ-opioid, NPFF<sub>1</sub>, and NPFF<sub>2</sub> receptors <i>in vitro</i>. In addition, the antinociceptive activities and side effects of these analogs were evaluated and compared to <b>0</b>. Strikingly, cyclized peptide <b>6</b> possessed an improved stability in the brain and an increased BBB permeability compared to the parent peptide <b>0</b> and produced more potent and nontolerance-forming analgesia with improved duration of action of 4 h. In addition, subcutaneous (s.c.) injection of analog <b>6</b> had a limited rewarding effect, withdrawal reaction, and gastrointestinal inhibition in comparison to fentanyl.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis</h3><div class="NLM_p">In our work, all analogs were designed with the multifunctional peptide <b>0</b> as the template molecule. Previous studies have shown that the peptide <b>0</b> possessed potent antinociceptive activities with reduced side effects.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20,22)</a> To further optimize this multifunctional peptide, we designed and synthesized four cyclic analogs with disulfides linkage at positions 2 and 5 since advantages of the cyclic disulfide linkage have been shown to improve bioavailabilities and membrane permeabilities of opioid peptides.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In this work, the corresponding linear peptides of these four cyclic disulfide analogs of <b>0</b> were used as reference compounds. The peptide sequences of the synthesized analogs of <b>0</b> are presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures of Synthesized Multifunctional Peptide Analogs in the Present Study</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">names</th><th class="colsep0 rowsep0" align="center">abbreviated names</th><th class="colsep0 rowsep0" align="center">sequences</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">BN-9</td><td class="colsep0 rowsep0" align="left">Tyr-<span class="smallcaps smallerCapital">d</span>-Ala-Gly-Phe-Gln-Pro-Gln-Arg-Phe-NH<sub>2</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">OFP001</td><td class="colsep0 rowsep0" align="left">[Cys<sup>2</sup>, Cys<sup>5</sup>]-BN-9</td><td class="colsep0 rowsep0" align="left">Tyr-<b>Cys</b>-Gly-Phe-<b>Cys</b>-Pro-Gln-Arg-Phe-NH<sub>2</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">OFP002</td><td class="colsep0 rowsep0" align="left">[<span class="smallcaps smallerCapital">d</span>-Cys<sup>2</sup>, Cys<sup>5</sup>]-BN-9</td><td class="colsep0 rowsep0" align="left">Tyr-<span class="smallcaps smallerCapital"><b>d</b></span><b>-Cys</b>-Gly-Phe-<b>Cys</b>-Pro-Gln-Arg-Phe-NH<sub>2</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">OFP003</td><td class="colsep0 rowsep0" align="left">[Cys<sup>2</sup>, <span class="smallcaps smallerCapital">d</span>-Cys<sup>5</sup>]-BN-9</td><td class="colsep0 rowsep0" align="left">Tyr-<b>Cys</b>-Gly-Phe-<span class="smallcaps smallerCapital"><b>d</b></span><b>-Cys</b>-Pro-Gln-Arg-Phe-NH<sub>2</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">OFP004</td><td class="colsep0 rowsep0" align="left">[<span class="smallcaps smallerCapital">d</span>-Cys<sup>2</sup>, <span class="smallcaps smallerCapital">d</span>-Cys<sup>5</sup>]-BN-9</td><td class="colsep0 rowsep0" align="left">Tyr-<span class="smallcaps smallerCapital"><b>d</b></span><b>-Cys</b>-Gly-Phe-<span class="smallcaps smallerCapital"><b>d</b></span><b>-Cys</b>-Pro-Gln-Arg-Phe-NH<sub>2</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">OFP005</td><td class="colsep0 rowsep0" align="left">c[Cys<sup>2</sup>, Cys<sup>5</sup>]-BN-9</td><td class="colsep0 rowsep0" align="left">Tyr-c<sup>[2,5]</sup>[<b>Cys</b>-Gly-Phe-<b>Cys</b>]-Pro-Gln-Arg-Phe-NH<sub>2</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">OFP006</td><td class="colsep0 rowsep0" align="left">c[<span class="smallcaps smallerCapital">d</span>-Cys<sup>2</sup>, Cys<sup>5</sup>]-BN-9</td><td class="colsep0 rowsep0" align="left">Tyr-c<sup>[2,5]</sup>[<span class="smallcaps smallerCapital"><b>d</b></span><b>-Cys</b>-Gly-Phe-<b>Cys</b>]-Pro-Gln-Arg-Phe-NH<sub>2</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">OFP007</td><td class="colsep0 rowsep0" align="left">c[Cys<sup>2</sup>, <span class="smallcaps smallerCapital">d</span>-Cys<sup>5</sup>]-BN-9</td><td class="colsep0 rowsep0" align="left">Tyr-c<sup>[2,5]</sup>[<b>Cys</b>-Gly-Phe-<span class="smallcaps smallerCapital"><b>d</b></span><b>-Cys</b>]-Pro-Gln-Arg-Phe-NH<sub>2</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">OFP008</td><td class="colsep0 rowsep0" align="left">c[<span class="smallcaps smallerCapital">d</span>-Cys<sup>2</sup>, <span class="smallcaps smallerCapital">d</span>-Cys<sup>5</sup>]-BN-9</td><td class="colsep0 rowsep0" align="left">Tyr-c<sup>[2,5]</sup>[<span class="smallcaps smallerCapital"><b>d</b></span><b>-Cys</b>-Gly-Phe-<span class="smallcaps smallerCapital"><b>d</b></span><b>-Cys</b>]-Pro-Gln-Arg-Phe-NH<sub>2</sub></td></tr></tbody></table></div></div><div class="NLM_p">To examine the effects of Cys/<span class="smallcaps smallerCapital">d</span>-Cys substitutions and cyclizations at positions 2 and 5 of peptide <b>0</b>, linear peptides (analogs <b>1–4</b>) and their corresponding cyclic analogs (analogs <b>5–8</b>) were synthesized by Fmoc solid-phase methods. Cyclizations of these cyclic peptides were obtained by the oxidations of the thiols groups of the Cys or/and <span class="smallcaps smallerCapital">d</span>-Cys residues with a solution of iodine in dimethylformamide (DMF). Purification was performed by semipreparative reversed-phase high pressure liquid chromatography (RP-HPLC). Purity analysis was then performed by analytical RP-HPLC. Two gradients, acetonitrile from 10 to 80 and 10 to 100% in 30 min, were used for purity analysis, respectively. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the purities of these peptides used in all experiments were ≥95%, which was identified by analytical RP-HPLC. The detailed results of mass spectrometry (ESI-Q-TOF maXis-4G, Bruker Daltonics, Germany) and melting points (mp) of these analogs are provided in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Analytical Data for Multifunctional Peptide Analogs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">RP-HPLC 10–80% in 30 min</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">RP-HPLC 10–100% in 30 min</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">MD-TOF-MS [M + H]<sup>+</sup></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">names</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>R</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (min)</th><th class="colsep0 rowsep0" align="center" char=".">purity<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>R</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (min)</th><th class="colsep0 rowsep0" align="center" char=".">purity<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> (%)</th><th class="colsep0 rowsep0" align="center" char=".">calcd</th><th class="colsep0 rowsep0" align="center" char=".">found</th><th class="colsep0 rowsep0" align="center">mp (°C)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">OFP001</td><td class="colsep0 rowsep0" align="char" char=".">15.4</td><td class="colsep0 rowsep0" align="char" char=".">97.4</td><td class="colsep0 rowsep0" align="char" char=".">13.7</td><td class="colsep0 rowsep0" align="char" char=".">98.6</td><td class="colsep0 rowsep0" align="char" char=".">1119.34</td><td class="colsep0 rowsep0" align="char" char=".">1119.49</td><td class="colsep0 rowsep0" align="left">150–152</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">OFP002</td><td class="colsep0 rowsep0" align="char" char=".">15.7</td><td class="colsep0 rowsep0" align="char" char=".">97.2</td><td class="colsep0 rowsep0" align="char" char=".">13.7</td><td class="colsep0 rowsep0" align="char" char=".">99.0</td><td class="colsep0 rowsep0" align="char" char=".">1119.34</td><td class="colsep0 rowsep0" align="char" char=".">1119.49</td><td class="colsep0 rowsep0" align="left">149–151</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">OFP003</td><td class="colsep0 rowsep0" align="char" char=".">16.4</td><td class="colsep0 rowsep0" align="char" char=".">95.1</td><td class="colsep0 rowsep0" align="char" char=".">16.4</td><td class="colsep0 rowsep0" align="char" char=".">96.1</td><td class="colsep0 rowsep0" align="char" char=".">1119.34</td><td class="colsep0 rowsep0" align="char" char=".">1119.49</td><td class="colsep0 rowsep0" align="left">144–146</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">OFP004</td><td class="colsep0 rowsep0" align="char" char=".">16.7</td><td class="colsep0 rowsep0" align="char" char=".">99.5</td><td class="colsep0 rowsep0" align="char" char=".">16.3</td><td class="colsep0 rowsep0" align="char" char=".">95.7</td><td class="colsep0 rowsep0" align="char" char=".">1119.34</td><td class="colsep0 rowsep0" align="char" char=".">1119.49</td><td class="colsep0 rowsep0" align="left">159–161</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">OFP005</td><td class="colsep0 rowsep0" align="char" char=".">17.8</td><td class="colsep0 rowsep0" align="char" char=".">95.5</td><td class="colsep0 rowsep0" align="char" char=".">16.2</td><td class="colsep0 rowsep0" align="char" char=".">97.4</td><td class="colsep0 rowsep0" align="char" char=".">1117.34</td><td class="colsep0 rowsep0" align="char" char=".">1117.50</td><td class="colsep0 rowsep0" align="left">193–195</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">OFP006</td><td class="colsep0 rowsep0" align="char" char=".">18.2</td><td class="colsep0 rowsep0" align="char" char=".">95.8</td><td class="colsep0 rowsep0" align="char" char=".">16.1</td><td class="colsep0 rowsep0" align="char" char=".">100.0</td><td class="colsep0 rowsep0" align="char" char=".">1117.34</td><td class="colsep0 rowsep0" align="char" char=".">1117.46</td><td class="colsep0 rowsep0" align="left">205–207</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">OFP007</td><td class="colsep0 rowsep0" align="char" char=".">16.3</td><td class="colsep0 rowsep0" align="char" char=".">95.4</td><td class="colsep0 rowsep0" align="char" char=".">13.9</td><td class="colsep0 rowsep0" align="char" char=".">95.6</td><td class="colsep0 rowsep0" align="char" char=".">1117.34</td><td class="colsep0 rowsep0" align="char" char=".">1117.48</td><td class="colsep0 rowsep0" align="left">181–183</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">OFP008</td><td class="colsep0 rowsep0" align="char" char=".">14.6</td><td class="colsep0 rowsep0" align="char" char=".">96.3</td><td class="colsep0 rowsep0" align="char" char=".">13.7</td><td class="colsep0 rowsep0" align="char" char=".">96.7</td><td class="colsep0 rowsep0" align="char" char=".">1117.34</td><td class="colsep0 rowsep0" align="char" char=".">1117.47</td><td class="colsep0 rowsep0" align="left">199–201</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>t</i><sub>R</sub> with XBridge BEH 130 Prep C18 (4.6 mm × 250 mm, 5 μm). The gradients 10–80 and 10–100% indicate solvent gradients of CH<sub>3</sub>CN in water from 10 to 80% in 30 min and from 10 to 100% in 30 min, respectively.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Purity determination based on analytical RP-HPLC.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Biological Results</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8"> <i>In Vitro</i> Cyclic Adenosine Monophosphate Functional Activities</h4><div class="NLM_p">The abilities of these new analogs of peptide <b>0</b> in activating G-protein-coupled opioid and NPFF receptors were evaluated using cyclic adenosine monophosphate (cAMP) functional assay in HEK-293A cells, which stably express opioid or NPFF receptors. The results were expressed as the median effective concentration (EC<sub>50</sub>) and the maximal inhibition of cAMP accumulation (<i>E</i><sub>max</sub>) of these analogs in forskolin-stimulated cAMP assay.</div><div class="NLM_p">The results of functional activities of these analogs at opioid receptors are shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. All analogs concentration dependently exhibited opioid agonistic activities in cells stably expressing μ-, δ-, or κ-opioid receptors. In cells expressing the μ- or δ-opioid receptor, the opioid agonistic activities of most of the analogs were not significantly affected by Cys/<span class="smallcaps smallerCapital">d</span>-Cys substitutions and cyclizations at positions 2 and 5 of peptide <b>0</b>. These results were consistent with our recent structure–activity relationship studies that the single substitution of position 2 or 5 of peptide <b>0</b> with other amino acids had no significant effects on the agonistic activities at μ- and δ-opioid receptors.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> However, both the linear peptide <b>1</b> and its corresponding cyclic analog <b>5</b> showed a slight loss of μ-opioid receptor agonistic activity. In addition, the cyclic analog <b>7</b> showed a lower potency for μ-opioid receptor agonistic activity as compared to its corresponding linear analog <b>3</b> or the parent peptide <b>0</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Notably, the cyclic analog <b>6</b> possessed the highest potencies at μ- and δ-opioid receptors among these analogs. Compared to the parent peptide <b>0</b>, the μ- and δ-opioid receptor agonistic activities of cyclic analog <b>6</b> increased approximately 7.1- and 3.4-fold, respectively.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> However, the μ-opioid receptor agonistic activity of analog <b>6</b> had a 2.5-fold lower than that of fentanyl in cAMP assay.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Functional Activities of Multifunctional Peptide Analogs in cAMP Assays at Opioid Receptors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">μ-opioid receptor</th><th class="rowsep1 colsep0" colspan="3" align="center">κ-opioid receptor</th><th class="rowsep1 colsep0" colspan="3" align="center">δ-opioid receptor</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char="±">log EC<sub>50</sub><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)</th><th class="colsep0 rowsep0" align="center">log EC<sub>50</sub><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> (%)</th><th class="colsep0 rowsep0" align="center">log EC<sub>50</sub><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fentanyl</td><td class="colsep0 rowsep0" align="char" char="±">–7.76 ± 0.17</td><td class="colsep0 rowsep0" align="char" char=".">17.2</td><td class="colsep0 rowsep0" align="char" char="±">87.8 ± 5.5</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="char" char="±">–6.51 ± 0.15<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">308<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">92.4 ± 9.7<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">–6.25 ± 0.25<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">564<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">106 ± 20.7<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">–6.23 ± 0.06<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">587<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">82.2 ± 3.7<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char="±">–5.81 ± 0.42</td><td class="colsep0 rowsep0" align="char" char=".">1550</td><td class="colsep0 rowsep0" align="char" char="±">78.6 ± 12.3</td><td class="colsep0 rowsep0" align="left">–6.74 ± 0.23</td><td class="colsep0 rowsep0" align="left">184</td><td class="colsep0 rowsep0" align="left">78.6 ± 7.8</td><td class="colsep0 rowsep0" align="left">–6.66 ± 0.23</td><td class="colsep0 rowsep0" align="left">218</td><td class="colsep0 rowsep0" align="left">35.8 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char="±">–6.66 ± 0.30</td><td class="colsep0 rowsep0" align="char" char=".">221</td><td class="colsep0 rowsep0" align="char" char="±">75.2 ± 7.7</td><td class="colsep0 rowsep0" align="left">–6.24 ± 0.13</td><td class="colsep0 rowsep0" align="left">581</td><td class="colsep0 rowsep0" align="left">84.0 ± 5.2</td><td class="colsep0 rowsep0" align="left">–6.29 ± 0.29</td><td class="colsep0 rowsep0" align="left">514</td><td class="colsep0 rowsep0" align="left">46.1 ± 6.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char="±">–6.75 ± 0.20</td><td class="colsep0 rowsep0" align="char" char=".">178</td><td class="colsep0 rowsep0" align="char" char="±">88.0 ± 7.0</td><td class="colsep0 rowsep0" align="left">–7.13 ± 0.23</td><td class="colsep0 rowsep0" align="left">75.1</td><td class="colsep0 rowsep0" align="left">92.3 ± 11.0</td><td class="colsep0 rowsep0" align="left">–6.70 ± 0.22</td><td class="colsep0 rowsep0" align="left">199</td><td class="colsep0 rowsep0" align="left">50.4 ± 4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char="±">–6.77 ± 0.20</td><td class="colsep0 rowsep0" align="char" char=".">171</td><td class="colsep0 rowsep0" align="char" char="±">83.9 ± 6.1</td><td class="colsep0 rowsep0" align="left">–5.64 ± 0.26</td><td class="colsep0 rowsep0" align="left">2296</td><td class="colsep0 rowsep0" align="left">114 ± 15.7</td><td class="colsep0 rowsep0" align="left">–6.66 ± 0.27</td><td class="colsep0 rowsep0" align="left">219</td><td class="colsep0 rowsep0" align="left">58.3 ± 4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">–6.10 ± 0.28</td><td class="colsep0 rowsep0" align="char" char=".">788</td><td class="colsep0 rowsep0" align="char" char="±">73.8 ± 8.4</td><td class="colsep0 rowsep0" align="left">–6.51 ± 0.26</td><td class="colsep0 rowsep0" align="left">307</td><td class="colsep0 rowsep0" align="left">92.6 ± 11.0</td><td class="colsep0 rowsep0" align="left">–6.79 ± 0.27</td><td class="colsep0 rowsep0" align="left">162</td><td class="colsep0 rowsep0" align="left">63.6 ± 7.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char="±">–7.37 ± 0.30</td><td class="colsep0 rowsep0" align="char" char=".">43.1</td><td class="colsep0 rowsep0" align="char" char="±">81.5 ± 7.8</td><td class="colsep0 rowsep0" align="left">–6.06 ± 0.28</td><td class="colsep0 rowsep0" align="left">866</td><td class="colsep0 rowsep0" align="left">73.0 ± 4.1</td><td class="colsep0 rowsep0" align="left">–6.76 ± 0.17</td><td class="colsep0 rowsep0" align="left">174</td><td class="colsep0 rowsep0" align="left">65.1 ± 4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char="±">–5.42 ± 0.28</td><td class="colsep0 rowsep0" align="char" char=".">3828</td><td class="colsep0 rowsep0" align="char" char="±">78.6 ± 10.1</td><td class="colsep0 rowsep0" align="left">–6.13 ± 0.20</td><td class="colsep0 rowsep0" align="left">743</td><td class="colsep0 rowsep0" align="left">68.6 ± 6.5</td><td class="colsep0 rowsep0" align="left">–6.31 ± 0.24</td><td class="colsep0 rowsep0" align="left">490</td><td class="colsep0 rowsep0" align="left">60.3 ± 5.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="char" char="±">–6.71 ± 1.29</td><td class="colsep0 rowsep0" align="char" char=".">196</td><td class="colsep0 rowsep0" align="char" char="±">82.0 ± 8.5</td><td class="colsep0 rowsep0" align="left">–5.61 ± 0.27</td><td class="colsep0 rowsep0" align="left">2456</td><td class="colsep0 rowsep0" align="left">68.5 ± 8.8</td><td class="colsep0 rowsep0" align="left">–6.70 ± 0.29</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">63.6 ± 6.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The log EC<sub>50</sub> ± standard error is a logarithmic result of linear analysis of data collected from at least three separate experiments performed in duplicates (<i>n</i> = 3).</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Data cited from our previous report.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">The data were not determined.</p></div></div></div><div class="NLM_p">In cells expressing the κ-opioid receptor, the linear peptides <b>1–3</b> showed slightly improved potencies for κ-opioid receptor agonistic activities compared to that of the parent peptide <b>0</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> However, cyclizations at positions 2 and 5 of the linear peptides <b>1–3</b> slightly decreased their potencies for the κ-opioid receptor. In addition, the multiple substitutions of positions 2 and 5 with <span class="smallcaps smallerCapital">d</span>-Cys (<b>4</b> and <b>8</b>) exhibited drastically reduced potencies for the κ-opioid receptor. Similarly, our previous study demonstrated that replacement Gln<sup>5</sup> of peptide <b>0</b> with <span class="smallcaps smallerCapital">d</span>-type amino acids resulted in the loss of κ-opioid receptor agonistic activity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Thus, these findings suggested that the stereochemical features of amino acids at positions 2 and 5 of the parent peptide <b>0</b> were important for κ-opioid receptor agonistic activity. In addition, compared to the parent peptide, cyclic analog <b>6</b> showed a slight loss of κ-opioid receptor agonistic activity (1.5-fold potency). Furthermore, the functional activities of these analogs at NPFF receptors are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. All analogs concentration dependently exhibited agonistic activities in cells stably expressing NPFF<sub>1</sub> or NPFF<sub>2</sub> receptors. Our recent data obtained from the single substitution at the 5 position of peptide <b>0</b> with <span class="smallcaps smallerCapital">d</span>-type amino acids indicated that the stereochemical configuration of amino acid at position 5 played an important role in the potency for the NPFF<sub>1</sub> receptor agonistic activity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Consistent with the previous study,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> the peptides containing Cys<sup>5</sup> (analogs <b>1</b>, <b>2</b>, <b>5</b>, and <b>6</b>) had significantly improved agonistic activities for the NPFF<sub>1</sub> receptor in comparison to the analogs containing <span class="smallcaps smallerCapital">d</span>-Cys<sup>5</sup> (analogs <b>3</b>, <b>4</b>, <b>7</b>, and <b>8</b>). However, the NPFF<sub>1</sub> receptor agonistic activities of these analogs were not significantly affected by disulfide cyclization at positions 2 and 5. In addition, for the NPFF<sub>2</sub> receptor, the substitutions of positions 2 and 5 with Cys or/and <span class="smallcaps smallerCapital">d</span>-Cys (analogs <b>1–4</b>) had significant decreases in agonistic activities compared to <b>0</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> On the other hand, the cyclization by the disulfide linkages improved 3.7- to 27.7-fold potencies for NPFF<sub>2</sub> receptor agonistic activity compared to their corresponding linear peptides, implying that the cyclization was an effective modification to improve the NPFF<sub>2</sub> receptor agonistic activity. Notably, compared to the parent peptide <b>0</b>, the NPFF<sub>1</sub> and NPFF<sub>2</sub> receptor agonistic activities of cyclic analog <b>6</b> improved approximately 78.8- and 9.6-fold, respectively.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Functional Activities of Multifunctional Peptide Analogs in cAMP Assays at NPFF Receptors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">NPFFR<sub>1</sub></th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">NPFFR<sub>2</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char="±">log EC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)</th><th class="colsep0 rowsep0" align="center" char="±">log EC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="char" char="±">–6.23 ± 0.18<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">591<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">59.9 ± 9.3<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">–6.73 ± 0.36<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">185<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">58.4 ± 15.3<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char="±">–7.60 ± 0.40</td><td class="colsep0 rowsep0" align="char" char=".">24.9</td><td class="colsep0 rowsep0" align="char" char="±">79.7 ± 11.6</td><td class="colsep0 rowsep0" align="char" char="±">–6.12 ± 0.40</td><td class="colsep0 rowsep0" align="char" char=".">752</td><td class="colsep0 rowsep0" align="char" char="±">62.9 ± 11.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char="±">–7.76 ± 0.15</td><td class="colsep0 rowsep0" align="char" char=".">17.5</td><td class="colsep0 rowsep0" align="char" char="±">78.5 ± 3.6</td><td class="colsep0 rowsep0" align="char" char="±">–6.27 ± 0.41</td><td class="colsep0 rowsep0" align="char" char=".">532</td><td class="colsep0 rowsep0" align="char" char="±">46.6 ± 4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char="±">–6.67 ± 0.23</td><td class="colsep0 rowsep0" align="char" char=".">216</td><td class="colsep0 rowsep0" align="char" char="±">81.8 ± 6.2</td><td class="colsep0 rowsep0" align="char" char="±">–6.16 ± 0.15</td><td class="colsep0 rowsep0" align="char" char=".">697</td><td class="colsep0 rowsep0" align="char" char="±">55.1 ± 3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char="±">–6.10 ± 0.15</td><td class="colsep0 rowsep0" align="char" char=".">788</td><td class="colsep0 rowsep0" align="char" char="±">85.7 ± 5.9</td><td class="colsep0 rowsep0" align="char" char="±">–6.14 ± 0.77</td><td class="colsep0 rowsep0" align="char" char=".">719</td><td class="colsep0 rowsep0" align="char" char="±">58.4 ± 20.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">–7.49 ± 0.17</td><td class="colsep0 rowsep0" align="char" char=".">32.5</td><td class="colsep0 rowsep0" align="char" char="±">80.2 ± 3.9</td><td class="colsep0 rowsep0" align="char" char="±">–6.92 ± 0.27</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="char" char="±">79.6 ± 9.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char="±">–8.12 ± 0.19</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char="±">75.9 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">–7.72 ± 0.30</td><td class="colsep0 rowsep0" align="char" char=".">19.2</td><td class="colsep0 rowsep0" align="char" char="±">53.3 ± 2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char="±">–6.45 ± 0.20</td><td class="colsep0 rowsep0" align="char" char=".">354</td><td class="colsep0 rowsep0" align="char" char="±">82.8 ± 6.0</td><td class="colsep0 rowsep0" align="char" char="±">–6.77 ± 0.37</td><td class="colsep0 rowsep0" align="char" char=".">168</td><td class="colsep0 rowsep0" align="char" char="±">61.6 ± 7.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="char" char="±">–6.44 ± 0.23</td><td class="colsep0 rowsep0" align="char" char=".">361</td><td class="colsep0 rowsep0" align="char" char="±">75.6 ± 7.6</td><td class="colsep0 rowsep0" align="char" char="±">–6.72 ± 0.30</td><td class="colsep0 rowsep0" align="char" char=".">192</td><td class="colsep0 rowsep0" align="char" char="±">74.6 ± 7.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The log EC<sub>50</sub> ± standard error is a logarithmic result of linear analysis of data collected from at least three separate experiments performed in duplicates (<i>n</i> = 3).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Data cited from our previous report.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></div></div><div class="NLM_p last">Taken together, the following structure and conformational preferences for opioid and NPFF receptors seemed to be obtained from the <i>in vitro</i> cAMP assays: (1) replacing the amino acids side chain at positions 2 and 5 with the methanethiol group (−CH<sub>2</sub>–SH) (analog <b>2</b>) of <b>0</b> and maintaining the chirality feature (<span class="smallcaps smallerCapital">d</span>/<span class="smallcaps smallerCapital">l</span>-configuration at positions 2 and 5) significantly increased the NPFF<sub>1</sub> receptor agonistic activity, with approximately 33.7-fold potency compared to <b>0</b>, but showed only a slight increase or decrease in potencies at the NPFF<sub>2</sub> and opioid receptors. (2) Incorporating <span class="smallcaps smallerCapital">d</span>/<span class="smallcaps smallerCapital">l</span>-configuration amino acids at positions 2 or/and 5 of analog <b>2</b> had significant effects on the activities for μ-, κ-opioid, and NPFF<sub>1</sub> receptors but not the potencies at the δ-opioid and NPFF<sub>2</sub> receptors. Simultaneous substitution with <span class="smallcaps smallerCapital">l</span>-Cys (analog <b>1</b>) or <span class="smallcaps smallerCapital">d</span>-Cys (analog <b>4</b>) at positions 2 and 5 decreased activities for μ- and κ-opioid receptors, respectively, with approximately 4- to 7-fold potencies compared to analog <b>2</b>. In addition, substitution of <span class="smallcaps smallerCapital">l</span>-amino acid at position 5 with <span class="smallcaps smallerCapital">d</span>-amino acid (analogs <b>3</b> and <b>4</b>) greatly decreased agonistic activities for the NPFF<sub>1</sub> receptor, with approximately 12- to 45-fold potencies compared to analog <b>2</b>. (3) Disulfide cyclization at positions 2 and 5 significantly increased the NPFF<sub>2</sub> receptor agonistic activities, with approximately 3.7- to 27.7-fold potencies compared to their corresponding linear peptides, while maintaining their activity at the NPFF<sub>1</sub> and opioid receptors (except analog <b>7</b>). However, one small exception was the analog <b>7</b> which maintained δ-opioid and NPFF receptor agonistic activities roughly equal to their corresponding linear analog <b>3</b> and 22- and 10-fold less potencies at the μ- and κ-opioid receptors than its corresponding linear peptide <b>3</b>, respectively.</div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> Stability Studies in Brain and Plasma</h4><div class="NLM_p">The brain and plasma stabilities of these analogs were evaluated by incubation in 15% mouse brain homogenate or 100% plasma for 240 min. The half-life values of these analogs were calculated using the first-order kinetic equation, and the obtained data are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Our results indicated that the half-life values of these cyclic analogs <b>5–8</b> were ranging from 58.0 ± 6.1 to 255 ± 30.3 min in the brain homogenate, which were longer than that of peptide <b>0</b> (42.43 ± 6.03 min).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> These findings implied that these cyclized peptides <b>6–8</b> possessed improved enzymatic stabilities in the brain homogenate compared to the parent peptide <b>0</b>. To our surprise, our preliminary results have shown that the linear analogs <b>1–4</b> could be disulfide-cyclized in 15% mouse brain homogenate without the cyclization reagent but not in 100% plasma. Therefore, it was difficult to provide the data about the half-life values of these linear analogs <b>1–4</b> in the brain homogenate.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Half-Lives of Multifunctional Peptide Analogs in Brain and Plasma</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">half-lives in brain and plasma<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">names</th><th class="colsep0 rowsep0" align="center">15% mouse brain (min)</th><th class="colsep0 rowsep0" align="center" char="±">100% plasma (min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">OFP001</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">29.6 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">OFP002</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">27.9 ± 3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">OFP003</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">31.4 ± 3.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">OFP004</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">30.9 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">OFP005</td><td class="colsep0 rowsep0" align="left">58.0 ± 6.1</td><td class="colsep0 rowsep0" align="char" char="±">28.9 ± 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">OFP006</td><td class="colsep0 rowsep0" align="left">173 ± 36.7</td><td class="colsep0 rowsep0" align="char" char="±">53.6 ± 8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">OFP007</td><td class="colsep0 rowsep0" align="left">229 ± 6.60</td><td class="colsep0 rowsep0" align="char" char="±">17.0 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">OFP008</td><td class="colsep0 rowsep0" align="left">255 ± 30.3</td><td class="colsep0 rowsep0" align="char" char="±">14.6 ± 0.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The half-live values are collected from at least three separate experiments (<i>n</i> = 3).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">The data cannot be determined.</p></div></div></div><div class="NLM_p last">In addition, the half-life values of these cyclic analogs and their corresponding linear peptides were ranging from 14.6 ± 0.1 to 53.6 ± 8.9 min in plasma. However, the recent studies have shown that the half-life of the parent peptide <b>0</b> was 44.9 ± 2.1 min in plasma.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Therefore, these results indicated that modification of amino acid side chains or <span class="smallcaps smallerCapital">d</span>/<span class="smallcaps smallerCapital">l</span>-configuration at positions 2 or/and 5 of <b>0</b> slightly decreased the plasma stabilities (analogs <b>1–4</b>). In addition, cyclizations at positions 2 and 5 slightly decreased the stabilities of analogs <b>5</b>, <b>7</b>, and <b>8</b> while increasing the stability of the cyclic analog <b>6</b>.</div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> <i>In Vivo</i> Brain Uptake Study</h4><div class="NLM_p">To investigate the brain penetration of cyclic analog <b>6</b>, mice were intravenously administered with analog <b>6</b> at a dose of 1 mg/kg. Mice were decapitated at different time points after injection, and the brains and plasma were isolated and quantitated by liquid chromatography–tandem mass spectrometry (LC–MS/MS) analysis. The time course of analog <b>6</b> in the whole brain and plasma are displayed in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. The brain/plasma (B/P) ratio <i>in vivo</i> is a good standard for measuring the extent of brain uptake for drug discovery. In addition, a previous study has indicated that a high B/P (B/P > 0.3) ratio was indicative of brain penetration.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The B/P value of morphine was 0.74, while that of morphine-6 β-glucuronide was 0.05.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The AUCs of the degradation curve of analog <b>6</b> in the whole brain and plasma were 3.87 μg·min/g and 3.78 μg·min/mL, respectively, and the B/P AUC ratio of analog <b>6</b> was 1.02. Therefore, this result indicated a significant BBB permeability of analog <b>6</b> after intravenous administration.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Whole brain (A) and plasma (B) concentration–time curves of analog <b>6</b> measured by LC–MS/MS after i.v. administration to male Kunming mice (6–8 weeks old) at a dose of 1 mg/kg. Data points are average values from three animals per time. Each value represents the mean ± S.E.M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Supraspinal Antinociception Studies</h4><div class="NLM_p">The analgesic activities of all analogs were assessed in the radiant heat tail-flick test. The results of supraspinal antinociceptive ED<sub>50</sub> values are presented in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. In the previous study, <b>0</b> showed nontolerance-forming antinociception with an ED<sub>50</sub> value of 390 pmol after intracerebroventricular (i.c.v.) injection.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In this study, supraspinal administration of fentanyl produced a significant analgesic effect with an ED<sub>50</sub> value of 344 pmol, while analogs <b>1–8</b> produced potent antinociception with ED<sub>50</sub> values ranging from 0.001 to 182 pmol after i.c.v. administration. These data indicated that the antinociceptive potencies of these analogs were more potent than those of the parent peptide <b>0</b> and fentanyl. In addition, the dose- and time-related antinociceptive effects of fentanyl and the analogs after i.c.v. administration are presented in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf" class="ext-link">Supporting Information</a> (Figure S1). The durations of the antinociceptive activities of the fentanyl and peptide <b>0</b> were 1 and 1.5 h, respectively, after supraspinal injection.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In contrast, the supraspinal antinociception induced by most of the analogs (except analogs <b>1</b> and <b>5</b>) lasted at least for 3 h.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Central analgesic effects induced by i.c.v. injection of analogs <b>6</b> and <b>8</b> in male Kunming mice (6–8 weeks old) in the radiant heat tail-flick test. Antinociceptive dose and time effect curves for analogs <b>6</b> [(A) 0.001, 0.03, 1, and 30 pmol] and <b>8</b> [(B) 0.00003, 0.001, 0.03, 1, and 30 pmol] after i.c.v. administration. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 8–13 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to saline group according to one-way ANOVA followed by the Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Antinociception and Tolerance Evaluation After the i.c.v. Administration of Multifunctional Peptide Analogs <i>via</i> the Mouse Tail-Flick Test</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">names</th><th class="colsep0 rowsep0" align="center">ED<sub>50</sub><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> pmol/mouse (95% CI)</th><th class="colsep0 rowsep0" align="center">8 days tolerance</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">fentanyl</td><td class="colsep0 rowsep0" align="left">344 (277–429)</td><td class="colsep0 rowsep0" align="left">tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">BN-9<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">390 (332–464)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">no tolerance<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">OFP001</td><td class="colsep0 rowsep0" align="left">150 (123–184)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">OFP002</td><td class="colsep0 rowsep0" align="left">0.60 (0.45–0.78)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">OFP003</td><td class="colsep0 rowsep0" align="left">6.42 (4.90–8.42)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">OFP004</td><td class="colsep0 rowsep0" align="left">1.13 (0.82–1.56)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">OFP005</td><td class="colsep0 rowsep0" align="left">182 (158–210)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">OFP006</td><td class="colsep0 rowsep0" align="left">0.014 (0.011–0.020)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">OFP007</td><td class="colsep0 rowsep0" align="left">0.21 (0.16–0.28)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">OFP008</td><td class="colsep0 rowsep0" align="left">0.001 (0.0004–0.002)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Analgesic ED<sub>50</sub> is determined by the highest analgesic point.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Data cited from our previous study.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div></div></div><div class="NLM_p">At the supraspinal level, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> showed that analogs <b>6</b> and <b>8</b> exhibited dose-related antinociceptive responses, achieving approximately 90% of the maximal possible effects at a dose of 30 pmol (analog <b>6</b>, <i>F</i><sub>4,53</sub> = 431.1, <i>P</i> < 0.001; analog <b>8</b>, <i>F</i><sub>5,50</sub> = 233.1, <i>P</i> < 0.001). Compared to the μ-opioid receptor selective agonist fentanyl, analogs <b>6–8</b> exhibited more potent antinociception (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Another important feature of analogs <b>6</b> and <b>8</b> was that their antinociceptive effects lasted for 4 h, which was 4-fold longer duration than that produced by fentanyl under the equipotent dose.</div><div class="NLM_p">To evaluate the roles of opioid receptors in the supraspinal antinociception of all analogs, the effects of the selective opioid antagonists on their central antinociceptions are shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,C and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf" class="ext-link">Supporting Information</a> (Figure S2) (analog <b>1</b>, <i>F</i><sub>10,84</sub> = 149.8, <i>P</i> < 0.001; analog <b>2</b>, <i>F</i><sub>10,85</sub> = 85.92, <i>P</i> < 0.001; analog <b>3</b>, <i>F</i><sub>10,86</sub> = 123.8, <i>P</i> < 0.001; analog <b>4</b>, <i>F</i><sub>10,84</sub> = 199.8, <i>P</i> < 0.001; analog <b>5</b>, <i>F</i><sub>10,87</sub> = 240.6, <i>P</i> < 0.001; analog <b>6</b>, <i>F</i><sub>10,89</sub> = 155.4, <i>P</i> < 0.001; analog <b>7</b>, <i>F</i><sub>10,92</sub> = 129.1, <i>P</i> < 0.001; analog <b>8</b>, <i>F</i><sub>10,86</sub> = 229.2, <i>P</i> < 0.001). To our surprise, the supraspinal antinociceptive activities of these four cyclic disulfide peptides were mediated by different opioid receptor subtypes (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). In addition, the linear peptides produced supraspinal antinociception <i>via</i> the mechanisms similar to their corresponding cyclic analogs. It was difficult to explain these exceptional cases. However, the different pharmacological mechanisms involved in the central antinociception of these analogs might partially associate with their different functional selectivities at the opioid receptors in cAMP assays. Both analogs <b>1</b> and <b>5</b> produced central antinociception <i>via</i> δ- and κ-opioid receptors, which were consistent with their improved potencies at the δ- and κ-opioid receptors but a slight loss of μ-opioid activity <i>in vitro</i>. In addition, both analogs <b>4</b> and <b>8</b> produced central antinociception independent of the κ-opioid receptor, which might be due to their reduced κ-opioid receptor agonistic activities in <i>in vitro</i> functional assays.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of central pretreatments with opioid and NPFF receptors antagonists on supraspinal analgesia of analogs <b>6</b> and <b>8</b> in male Kunming mice (6–8 weeks old) in the radiant heat tail-flick test. The effects of supraspinal injection of the opioid receptor antagonist Nal (5 nmol, i.c.v.), the selective opioid receptor antagonists β-FNA (10 nmol, i.c.v.), NTI (10 nmol, i.c.v.), and nor-BNI (10 nmol, i.c.v.) on the central analgesia of analogs <b>6</b> [(A) 30 pmol, i.c.v.] and <b>8</b> [(C) 30 pmol, i.c.v.]. The effects of supraspinal injections of the NPFF receptor antagonist RF9 (10 nmol, i.c.v.) on the central analgesia of analogs <b>6</b> [(B) 0.03 pmol, i.c.v.] and <b>8</b> [(D) 0.03 pmol, i.c.v.]. RF9, 1-adamantanecarbonyl-RF-NH<sub>2</sub>. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–11 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to the saline group. <sup>###</sup><i>P</i> < 0.001 indicates significant differences compared to the saline + drug group, according to one-way ANOVA followed by the Bonferroni’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At the supraspinal level, the high antinociceptive potencies of cyclic peptides <b>6–8</b> might associate with the multifunctional agonism at opioid receptors and their improved enzymatic stabilities in the brain homogenate. As described above, cyclic analogs <b>6–8</b> disappeared in the brain homogenate with half-life values ranging from 173 to 255 min, which might be, at least partially, used to explain their long-lasting antinociception after supraspinal administration. It was notable that the μ-opioid receptor agonistic activity of cyclic analog <b>6</b> exhibited an approximately 7-fold increase than analog <b>0</b>. In addition, analog <b>6</b> had an improved δ- and κ-opioid receptor agonistic activities. In fact, our results also indicated that the analog <b>6</b>-induced supraspinal antinociception was blocked by the μ-opioid receptor antagonist β-funaltrexamine (β-FNA) and partially reduced by the δ- and κ-opioid receptor antagonists (analog <b>6</b>, <i>F</i><sub>10,89</sub> = 155.4, <i>P</i> < 0.001). The synergistic effect of μ-, δ-, and κ-opioid receptor agonists on antinociception has been shown in the previous studies.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> Thus, the multifunctional opioid agonism of analog <b>6</b> might be also used to explain its high antinociceptive potency. However, analog <b>8</b>-induced supraspinal antinociception was partially blocked by the μ-opioid receptor antagonist (analog <b>8</b>, <i>F</i><sub>10,86</sub> = 229.2, <i>P</i> < 0.001), independent of δ- and κ-opioid receptors (<i>P</i> > 0.05). In theory, it was difficult to explain the high antinociceptive potency of analog <b>8</b> because of its low potency at the μ-opioid receptor. Thus, we could not rule out the possibility that other receptors besides opioid receptors might be involved in the potent antinociceptive effect of analog <b>8</b>.</div><div class="NLM_p last">Based on their multifunctional agonistic properties at the opioid and NPFF receptors, we further examined whether NPFF receptors were involved in the central antinociceptive effects of these analogs. A previous study has shown that NPFF exhibited antiopioid activities at the supraspinal level.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Our previous studies have shown that the NPFF pharmacophore of peptide <b>0</b> and DN-9 exhibited antiopioid activities at the supraspinal level.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> As expected, in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B,D and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf" class="ext-link">Supporting Information</a> (Figure S3), the antinociception of all analogs were significantly potentiated by the NPFF receptor antagonist 1-adamantanecarbonyl-Arg-Phe-NH<sub>2</sub> (RF9) (10 nmol, 5 min) after supraspinal administration (analog <b>1</b>, <i>F</i><sub>4,37</sub> = 197.4, <i>P</i> < 0.001; analog <b>2</b>, <i>F</i><sub>4,37</sub> = 254.8, <i>P</i> < 0.001; analog <b>3</b>, <i>F</i><sub>4,37</sub> = 161.1, <i>P</i> < 0.001; analog <b>4</b>, <i>F</i><sub>4,37</sub> = 184.6, <i>P</i> < 0.001; analog <b>5</b>, <i>F</i><sub>4,39</sub> = 179.9, <i>P</i> < 0.001; analog <b>6</b>, <i>F</i><sub>4,38</sub> = 277.8, <i>P</i> < 0.001; analog <b>7</b>, <i>F</i><sub>4,39</sub> = 138.6, <i>P</i> < 0.001; analog <b>8</b>, <i>F</i><sub>4,39</sub> = 215.6, <i>P</i> < 0.001), which further supported NPFF receptor-mediated agonism of these analogs <i>in vivo</i>.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> In our present studies, supraspinal injection of the NPFF receptor antagonist RF9 attenuated the antiopioid activities of the NPFF pharmacophore and further potentiated the μ-opioid-induced analgesia of these compounds after supraspinal injection, which was consistent with our previous studies.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a></div></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Subcutaneous Antinociception Studies</h4><div class="NLM_p">The antinociception of these analogs was also investigated after s.c. injection in the radiant heat tail-flick test. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, our work showed that s.c. administration of fentanyl produced a potent analgesic effect with an ED<sub>50</sub> value of 0.03 μmol/kg, which was consistent with the previous studies.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39−41)</a> After peripheral administration, these analogs produced potent antinociception with ED<sub>50</sub> values ranging from 0.002 to 0.24 μmol/kg, indicating that their antinociceptive potencies were more potent than that of the parent peptide <b>0</b> (1.37 μmol/kg). In addition, the dose- and time-related antinociceptive effects of fentanyl and these analogs after s.c. administration are presented in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf" class="ext-link">Supporting Information</a> (Figure S4). The antinociceptive effects induced by fentanyl and peptide <b>0</b> lasted for 1 h after s.c. injection. Similarly, the antinociceptive effects of analogs <b>1</b> and <b>5</b> lasted for 1.5 h following s.c. administration. In contrast, the antinociception induced by the cyclic analogs <b>6–8</b> and their corresponding linear peptides <b>2–4</b> remained 4 and 3 h, respectively. Notably, after peripheral administration, analogs <b>6</b> and <b>8</b> were more potent than fentanyl. Our results showed that both analogs <b>6</b> and <b>8</b> exhibited dose-dependent antinociceptive responses, achieving approximately 80% of the maximal possible effects at a dose of 0.09 μmol/kg (analog <b>6</b>, <i>F</i><sub>3,34</sub> = 302.9, <i>P</i> < 0.001; analog <b>8</b>, <i>F</i><sub>3,35</sub> = 266.5, <i>P</i> < 0.001). Another important feature of analogs <b>6</b> and <b>8</b> was that their antinociceptive effects lasted for 4 h.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Peripheral analgesic effects induced by s.c. injection of analogs <b>6</b> and <b>8</b> in male Kunming mice (6–8 weeks old) in the radiant heat tail-flick test. Antinociceptive dose and time effect curves for analogs <b>6</b> [(A) 0.0009, 0.009, and 0.09 μmol/kg] and <b>8</b> [(B) 0.0009, 0.009, and 0.09 μmol/kg] after s.c. administration. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–13 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to saline group according to one-way ANOVA followed by the Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Antinociception and Tolerance Evaluation After the s.c. Administration of Multifunctional Peptide Analogs <i>via</i> the Mouse Tail-Flick Test</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">names</th><th class="colsep0 rowsep0" align="center">ED<sub>50</sub><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> μmol/kg (95% CI)</th><th class="colsep0 rowsep0" align="center">8 days tolerance</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">fentanyl</td><td class="colsep0 rowsep0" align="left">0.03 (0.02–0.03)</td><td class="colsep0 rowsep0" align="left">tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">BN-9</td><td class="colsep0 rowsep0" align="left">1.37 (1.16–1.60)</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">OFP001</td><td class="colsep0 rowsep0" align="left">0.24 (0.16–0.35)</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">OFP002</td><td class="colsep0 rowsep0" align="left">0.13 (0.09–0.18)</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">OFP003</td><td class="colsep0 rowsep0" align="left">0.10 (0.07–0.16)</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">OFP004</td><td class="colsep0 rowsep0" align="left">0.06 (0.04–0.09)</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">OFP005</td><td class="colsep0 rowsep0" align="left">0.18 (0.13–0.26)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">OFP006</td><td class="colsep0 rowsep0" align="left">0.003 (0.002–0.004)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">OFP007</td><td class="colsep0 rowsep0" align="left">0.003 (0.002–0.004)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">OFP008</td><td class="colsep0 rowsep0" align="left">0.002 (0.001–0.003)</td><td class="colsep0 rowsep0" align="left">no tolerance</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Analgesic ED<sub>50</sub> is determined by the highest analgesic point.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">The data were not determined.</p></div></div></div><div class="NLM_p">It is well-known that both morphine and fentanyl can pass through the BBB and activate the opioid receptors in the brain after s.c. injection.<a onclick="showRef(event, 'ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45">(42−45)</a> To determine whether the central opioid receptors were involved in the antinociception induced by these novel analogs after s.c. injection, the classical opioid receptor antagonist naloxone (Nal) and the peripherally restricted opioid receptors antagonist naloxone methiodide (NALM) were further used in this study, as shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf" class="ext-link">Supporting Information</a> (Figure S5). Consistent with the previous study,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> our present work demonstrates that the analgesic effect induced by fentanyl after s.c. administration was completely blocked by s.c. injection of Nal (1 mg/kg, 10 min) (<i>F</i><sub>7,60</sub> = 249.7, <i>P</i> < 0.001) but not by s.c. injection of NALM (1 mg/kg, 10 min) (<i>P</i> > 0.05).<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> In contrast, s.c. fentanyl-induced antinociception was also reduced by i.c.v. injection of NALM (5 nmol, 10 min) (<i>F</i><sub>7,60</sub> = 249.7, <i>P</i> < 0.001). These findings supported the BBB permeability of fentanyl. Similar to fentanyl, the four cyclic analogs <b>5–8</b> had improved BBB permeabilities and produced antinociceptive effects through opioid receptors in the brain (analog <b>5</b>, <i>F</i><sub>7,61</sub> = 199.7, <i>P</i> < 0.001; analog <b>6</b>, <i>F</i><sub>7,67</sub> = 92.8, <i>P</i> < 0.001; analog <b>7</b>, <i>F</i><sub>7,65</sub> = 88.6, <i>P</i> < 0.001; analog <b>8</b>, <i>F</i><sub>7,71</sub> = 97.4, <i>P</i> < 0.001). In contrast, the antinociceptive responses induced by the linear peptides including the parent peptide <b>0</b> were inhibited by s.c. injection of Nal and NALM but not by i.c.v. injection of NALM (analog <b>1</b>, <i>F</i><sub>7,62</sub> = 129.6, <i>P</i> < 0.001; analog <b>2</b>, <i>F</i><sub>7,59</sub> = 181.6, <i>P</i> < 0.001; analog <b>3</b>, <i>F</i><sub>7,59</sub> = 142.5, <i>P</i> < 0.001; analog <b>4</b>, <i>F</i><sub>7,62</sub> = 228.0, <i>P</i> < 0.001), implying that these linear peptides produced antinociception <i>via</i> peripheral opioid receptors after s.c. administration. These results were consistent with the recent data that <b>0</b> could not cross the BBB.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of peripheral or central pretreatments with the opioid receptor antagonists Nal (10 mg/kg, s.c.) and NALM (10 mg/kg, s.c.; 5 nmol, i.c.v.) on the peripheral analgesia of fentanyl [(A) 0.19 μmol/kg, s.c.], analog <b>2</b> [(B) 8.94 μmol/kg, s.c.], analog <b>4</b> [(C) 2.68 μmol/kg, s.c.], analog <b>6</b> [(D) 0.09 μmol/kg, s.c.], and analog <b>8</b> [(E) 0.09 μmol/kg, s.c.] in male Kunming mice (6–8 weeks old) in the radiant heat tail-flick test. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 6–17 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to the saline group. <sup>###</sup><i>P</i> < 0.001 indicates significant differences compared to the saline + drug group, according to one-way ANOVA followed by the Bonferroni’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Antinociceptive Profiles of Multifunctional Peptide Analogs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">names</th><th class="colsep0 rowsep0" align="center">opioid antagonism (i.c.v.)</th><th class="colsep0 rowsep0" align="center">effects of RF9 (i.c.v.)</th><th class="colsep0 rowsep0" align="center">BBB permeability</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">fentanyl</td><td class="colsep0 rowsep0" align="left">opioid receptors</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">yes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">BN-9<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">μ-, κ-opioid<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">potentiation<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">no<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">OFP001</td><td class="colsep0 rowsep0" align="left">opioid receptors</td><td class="colsep0 rowsep0" align="left">potentiation</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">OFP002</td><td class="colsep0 rowsep0" align="left">opioid receptors</td><td class="colsep0 rowsep0" align="left">potentiation</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">OFP003</td><td class="colsep0 rowsep0" align="left">opioid receptors</td><td class="colsep0 rowsep0" align="left">potentiation</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">OFP004</td><td class="colsep0 rowsep0" align="left">opioid receptors</td><td class="colsep0 rowsep0" align="left">potentiation</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">OFP005</td><td class="colsep0 rowsep0" align="left">κ-, δ-opioid</td><td class="colsep0 rowsep0" align="left">potentiation</td><td class="colsep0 rowsep0" align="left">yes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">OFP006</td><td class="colsep0 rowsep0" align="left">μ-, κ-, δ-opioid</td><td class="colsep0 rowsep0" align="left">potentiation</td><td class="colsep0 rowsep0" align="left">yes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">OFP007</td><td class="colsep0 rowsep0" align="left">μ-, κ-opioid</td><td class="colsep0 rowsep0" align="left">potentiation</td><td class="colsep0 rowsep0" align="left">yes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">OFP008</td><td class="colsep0 rowsep0" align="left">μ-opioid</td><td class="colsep0 rowsep0" align="left">potentiation</td><td class="colsep0 rowsep0" align="left">yes</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Data cited from our previous study.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20,22)</a></p></div></div></div><div class="NLM_p">In addition, we investigated the role of central and peripheral NPFF receptors in the antinociception induced by these compounds after s.c. administration. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf" class="ext-link">Supporting Information</a> (Figure S6), our present results suggested that the peripheral NPFF system was not involved in the analgesic effects induced by these analogs after s.c. injection (<i>P</i> > 0.05). In fact, our previous results have shown that the antinociceptive effect of s.c. injection of analog <b>0</b> was not affected by peripheral injection of the NPFF receptors antagonist RF9.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Consistent with our results, the previous study has shown that only a small quantity of the NPFF receptors was localized in the peripheral tissues.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, the antinociceptive effects of analogs <b>6</b> and <b>8</b> after s.c. injection were potentiated by supraspinal RF9 (10 nmol, 5 min) (analog <b>6</b>, <i>F</i><sub>4,37</sub> = 190.0, <i>P</i> < 0.001; analog <b>8</b>, <i>F</i><sub>4,37</sub> = 154.8, <i>P</i> < 0.001) but not by s.c. RF9 (5 mg/kg, 5 min), in alignment with the results obtained from NPFF<sub>2</sub><sup>–/–</sup> mice on a C57BL/6 background in which s.c. analog <b>6</b>-induced antinociceptive effects were significantly increased compared to the wild-type (WT) mice on a C57BL/6 background (analog <b>6</b>, <i>F</i><sub>3,26</sub> = 6.7, <i>P</i> < 0.01). However, s.c. administration of the corresponding linear analog <b>2</b> produced antinociception in NPFF<sub>2</sub><sup>–/–</sup> mice with an antinociceptive potency similar to that in WT mice (<i>P</i> > 0.05). These pharmacological data further supported the abilities of analogs <b>6</b> and <b>8</b> but not their corresponding linear peptides to cross the BBB and activate NPFF receptors in the brain. Taken together, the pharmacokinetic and pharmacological studies confirmed the BBB permeability of analog <b>6</b>. These pharmacological data indicated that the cyclization by the disulfide linkage was an effective modification to improve BBB permeabilities of these linear analogs of <b>0</b>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of peripheral or central pretreatments with the NPFF receptor antagonist RF9 on peripheral analgesia of analogs <b>6</b> and <b>8</b> in the radiant heat tail-flick test. The effects of peripheral administration of the NPFF receptor antagonist RF9 (5 mg/kg, s.c.) on the peripheral analgesia of analogs <b>6</b> [(A) 0.009 μmol/kg, s.c.] and <b>8</b> [(B) 0.009 μmol/kg, s.c.] in male Kunming mice (6–8 weeks old). Effects of central administration of the NPFF receptor antagonist RF9 on the peripheral analgesia of analogs <b>6</b> [(C) 0.009 μmol/kg, s.c.] and <b>8</b> [(D) 0.009 μmol/kg, s.c.] in male Kunming mice (6–8 weeks old). (E) The antinociceptive effects of analogs <b>2</b> (0.89 μmol/kg, s.c.) and <b>6</b> (0.09 μmol/kg, s.c.) in WT and NPFF<sub>2</sub><sup>–/–</sup> mice on a C57BL/6 background. RF9, 1-adamantanecarbonyl-RF-NH<sub>2</sub>. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 5–8 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to the saline group. <sup>###</sup><i>P</i> < 0.001 indicates significant differences compared to the saline + drug group, according to one-way ANOVA followed by the Bonferroni’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After s.c. administration, cyclic disulfide analogs <b>6–8</b> exhibited improved antinociceptive potencies and duration of action in comparison to their corresponding linear peptides <b>2–4</b> and the parent peptide <b>0</b> in this study. However, the cyclized peptides possessed improved enzymatic stabilities in the brain homogenate but not in plasma compared to the parent peptide <b>0</b>. The potent antinociceptive effects of s.c. cyclic analogs <b>6–8</b> might be explained by their improved BBB permeabilities, which resulted in the activation of the opioid receptors in the brain following s.c. administration and producing potent antinociceptive effects with improved duration of action of 4 h.</div><div class="NLM_p last">Taken together, based on the data obtained from <i>in vitro</i> pharmacokinetics and <i>in vivo</i> animal behavior experiments, we could conclude that the linear analogs <b>1–4</b> could not pass through the BBB in a manner similar to the parent peptide <b>0</b>. However, the cyclization modification greatly increased the BBB permeabilities of cyclic analogs <b>5–8</b> compared to their corresponding linear analogs and the parent peptide <b>0</b>.</div></div><div id="sec2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Antinociceptive Tolerance Studies</h4><div class="NLM_p">The development of analgesic tolerance of these analogs was further measured in the radiant heat tail-flick test, and analgesic tolerance was evaluated by comparing the daily tail-flick thresholds. At the supraspinal level, the highest analgesic doses of all analogs were i.c.v. injected once daily for 8 consecutive days, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A, and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf" class="ext-link">Supporting Information</a> (Figure S7). Compared to day 1, the analgesic effect induced by i.c.v. administration of fentanyl significantly decreased on the test day 4 (<i>P</i> < 0.001), demonstrating that the tolerance developed to the supraspinal antinociception induced by fentanyl, as described previously.<a onclick="showRef(event, 'ref48 ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51 ref52 ref53">(48−53)</a> In contrast, all analogs produced equivalent antinociceptive effects over 8 days course after i.c.v. administration (<i>P</i> > 0.05). Furthermore, in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B, and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf" class="ext-link">Supporting Information</a> (Figure S8), the tolerance induced by fentanyl began to develop on day 4 following s.c. administration (<i>P</i> < 0.001), while s.c. administration of these cyclic disulfide analogs <b>5–8</b> produced antinociceptive effects without loss of potencies over 8 days (<i>P</i> > 0.05). Indeed, our previous studies have shown that the mixed opioid/NPFF receptor agonists EN-9, <b>0</b> (BN-9), and DN-9 produced potent and nontolerance-forming antinociception after various routes of administration.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Analgesic tolerance evaluations of analogs <b>6</b> and <b>8</b> in male Kunming mice (6–8 weeks old) in the radiant heat tail flick test. Saline, fentanyl (3000 pmol, i.c.v.; 0.19 μmol/kg, s.c.), analogs <b>6</b> (30 pmol, i.c.v.; 0.09 μmol/kg, s.c.), and <b>8</b> (30 pmol, i.c.v.; 0.09 μmol/kg, s.c.) were daily administered for 8 days in mice, and antinociceptive effects were measured once daily after drug administration. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–9 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to day 1 according to one-way ANOVA followed by the Tukey HSD’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Opioid-like Side Effect Studies of Analogs <b>6</b> and <b>8</b></h4><div class="NLM_p">Among these analogs, analogs <b>6</b> and <b>8</b> exhibited the highest antinociceptive potencies compared to the parent peptide <b>0</b> when given at both central and peripheral levels. We further investigated the side effects of analogs <b>6</b> and <b>8</b> at the highest analgesic doses.</div><div class="NLM_p">The effects of the highest analgesic doses of analogs <b>6</b> and <b>8</b> after i.c.v. and s.c. administrations on motor coordination were investigated to rule out the false positive results of analgesic effects. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,B, there were no effect on locomotor activity in mice after i.c.v. and s.c. administrations of analogs <b>6</b> and <b>8</b> in comparison to saline (<i>P</i> > 0.05).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of i.c.v. (A) and s.c. (B) injections of analogs <b>6</b> (30 pmol, i.c.v.; 0.09 μmol/kg, s.c.) and <b>8</b> (30 pmol, i.c.v.; 0.09 μmol/kg, s.c.) on the motor coordination of male Kunming mice (6–8 weeks old) in the rotarod test. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–10 mice per group). There are no significant differences according to one-way ANOVA followed by the Dunnett’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, the behavioral effects of peripheral administration of analogs <b>6</b> and <b>8</b> were evaluated in three experimental paradigms including the classical responses of opioids to acute hyperlocomotion, conditioned place preference (CPP), and Nal-precipitated withdrawal.</div><div class="NLM_p">The activation of the dopaminergic reward circuits plays an important role in the addiction of opioid analgesics and results in an acute hyperlocomotion in mice.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The acute hyperlocomotive responses induced by s.c. administration of fentanyl and analogs <b>6</b> and <b>8</b> were tested using an open field assay. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A,B, s.c. administration of fentanyl significantly increased the total travelled distance (<i>F</i><sub>3,29</sub> = 2.996, <i>P</i> < 0.05) compared to saline, which was consistent with the previous study.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> In contrast, mice treated with analogs <b>6</b> and <b>8</b> produced slight but not statistically significant increases in the locomotor activity after peripheral administration (<i>P</i> > 0.05).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effects of s.c. injections of fentanyl (0.19 μmol/kg), analogs <b>6</b> (0.09 μmol/kg), and <b>8</b> (0.09 μmol/kg) on the rewarding effects and withdrawal reactions in male Kunming mice (6–8 weeks old). (A) The time effect curves of s.c. injections of drugs in the open field test. (B) Effects of s.c. injections of drugs on the total distance in the open field test. (C) Effects of s.c. injections of drugs on CPP in mice. (D) Effects of s.c. injections of drugs on Nal-precipitated withdrawal in mice. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–10 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to the saline group according to the unpaired <i>t</i>-test for CPP or one-way ANOVA followed by the Bonferroni’s post-hot test. <sup>###</sup><i>P</i> < 0.001 indicates significant differences compared to the fentanyl group according to one-way ANOVA followed by the Bonferroni’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C, the effects of fentanyl and analogs <b>6</b> and <b>8</b> on reward effects were investigated with an unbiased CPP equipment. Consistent with the previous reported data,<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> s.c. administration of fentanyl produced significant CPP response after the conditioning exposure compared to saline (<i>F</i><sub>3,35</sub> = 11.95, <i>P</i> < 0.001). In a manner similar to fentanyl, s.c. administration of analog <b>8</b> also produced a significant CPP response (<i>F</i><sub>3,35</sub> = 11.95, <i>P</i> < 0.001). However, analog <b>6</b> did not induce significant CPP response compared to saline at the effective analgesic dose (<i>P</i> > 0.05). These findings indicated that analog <b>6</b> exhibited a reduced activation of reward circuits in comparison to fentanyl and analog <b>8</b>.</div><div class="NLM_p">Behaviors precipitated by the classical opioid antagonist Nal (10 mg/kg, s.c.) in mice previously treated with opioids were evaluated, and Nal precipitated the characteristic withdrawal symptom of jumping. <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>D showed that s.c. injection of fentanyl significantly increased the jumping counts after Nal injection compared to saline (<i>F</i><sub>3,33</sub> = 13.11, <i>P</i> < 0.001), which was consistent with the previous studies.<a onclick="showRef(event, 'ref41 ref57'); return false;" href="javascript:void(0);" class="ref ref41 ref57">(41,57)</a> In contrast, the incidences of jumping induced by analogs <b>6</b> and <b>8</b> had no significant difference compared to saline (<i>P</i> > 0.05), suggesting the reduced withdrawal symptoms of analogs <b>6</b> and <b>8</b>.</div><div class="NLM_p">The constipation is complicated under the use of opioid analgesics for pain control. Lastly, the effects of analogs <b>6</b> and <b>8</b> on gastrointestinal motility were also investigated in mice. As shown in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A,B, s.c. injection of analogs <b>6</b> and <b>8</b> caused dose-dependent inhibition of gastrointestinal motility compared to saline (analog <b>6</b>, <i>F</i><sub>3,29</sub> = 15.92, <i>P</i> < 0.001; analog <b>8</b>, <i>F</i><sub>3,28</sub> = 18.36, <i>P</i> < 0.001). In the gastrointestinal transit (GIT) test, the ED<sub>50</sub> values of analogs <b>6</b> and <b>8</b> were 2.25 and 0.07 μmol/kg after s.c. administration, respectively, and ED<sub>50</sub> values of the gastrointestinal motility inhibition induced by analogs <b>6</b> and <b>8</b> were 750- and 35-fold higher than their analgesic ED<sub>50</sub> values, respectively, when given at the same route. In other words, neither analog <b>6</b> nor analog <b>8</b> exhibited significant gastrointestinal motility inhibition at effective antinociceptive doses.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of s.c. injections of analog <b>6</b> [(A) 0.09, 0.90, and 8.95 μmol/kg] or analog <b>8</b> [(B) 0.009, 0.09, and 0.9 μmol/kg] on gastrointestinal motility in male Kunming mice (6–8 weeks old). Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–8 mice per group). *<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001 indicate significant differences between drugs and saline according to one-way ANOVA followed by the Dunnett’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Taken together, our present data show that the rewarding effects, withdrawal reactions, and constipation of analogs <b>6</b> and <b>8</b> were significantly reduced in comparison to the classical opioid analgesic fentanyl. More importantly, analog <b>6</b> that induced powerful antinociception <i>via</i> the μ-, δ-, and κ-opioid receptors exhibited weaker side effects on rewarding effects and constipation than analog <b>8</b>. In our previous studies, the multifunctional opioid/NPFF receptor agonists EN-9, <b>0</b> (BN-9), and DN-9 induced little inhibition of GIT after various routes of administration.<a onclick="showRef(event, 'ref19 ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref22">(19,20,22)</a> Thus, our present data further support that the multifunctional opioid/NPFF receptor agonists possessed reduced side effects on constipation than the classical opioids. In the previous study, in a manner similar to morphine, the parent peptide <b>0</b> produced dose-related CPP after supraspinal injection.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Similarly, our present work also demonstrates that both fentanyl and analog <b>8</b> induced significant CPP responses after s.c. injection. Based on their BBB permeabilities of fentanyl and analog <b>8</b>, the present results are consistent with the aforementioned studies that they could pass through BBB. Compared to fentanyl, analog <b>6</b> had no significant CPP response. It seemed difficult to explain the conflicting findings between analogs <b>6</b> and <b>8</b> in CPP experiment, which might be due to the different pharmacological mechanisms that were involved in the central antinociception of analogs <b>6</b> and <b>8</b>. The aforementioned results demonstrated that analog <b>6</b> produced supraspinal antinociception <i>via</i> μ-, δ-, and κ-opioid receptors, while analog <b>8</b> exerted μ-opioid receptor-mediated antinociception. Thus, the limited reward activity of analog <b>6</b> might result from its multifunctional agonistic profiles toward μ-, δ-, and κ-opioid receptors <i>in vivo</i>.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31042" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31042" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The parent peptide <b>0</b> (BN-9), a multifunctional opioid/NPFF receptor agonist, produced nontolerance-forming antinociception with limited side effects.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20,22)</a> To improve its therapeutic efficacy for translational-medical development, we synthesized four cyclic disulfide analogs incorporating Cys and/or <span class="smallcaps smallerCapital">d</span>-Cys with the intentions of (1) probing and improving BBB permeability, (2) improving bioavailability and duration of antinociceptive action, and (3) further balancing the efficacies at the opioid and NPFF receptors. In this study, the cyclized analogs and their linear counterparts functioned as multifunctional agonists at both opioid and NPFF receptors <i>in vitro</i>. Among these new analogs, cyclized analog <b>6</b> showed the highest agonist activity at the μ-opioid and NPFF receptors. Compared to the parent peptide <b>0</b>, the μ- and δ-opioid, NPFF<sub>1</sub>, and NPFF<sub>2</sub> receptor activities of the analog <b>6</b> improved approximately 7.1-, 3.4-, 78.8-, and 9.6-fold, respectively.</div><div class="NLM_p">Supraspinal and s.c. administrations of analogs <b>6</b> and <b>8</b> produced more potent and prolonged analgesic actions (4 h) in comparison to fentanyl. As expected, the cyclized analog <b>6</b> had a greater BBB permeability and an improved enzymatic stability in the brain homogenate compared to the parent peptide BN-9. To our surprise, the supraspinal antinociceptive activities of these four cyclic disulfide peptides were mediated by different pharmacological mechanisms.</div><div class="NLM_p last">Based on the antinociceptive efficacy evaluations, analogs <b>6</b> and <b>8</b> were selected for further <i>in vivo</i> side-effect studies. Compared to fentanyl, the side effects of analog <b>6</b> on tolerance, rewarding effect, withdrawal reaction, and constipation were significantly reduced. This work showed that the multifunctional opioid and NPFF receptor agonist analog <b>6</b> was a highly promising compound as a novel analgesic for pain treatment with limited side effects.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51852" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51852" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemicals and Drugs</h3><div class="NLM_p last">All natural amino acids, non-natural amino acids, and coupling reagents were purchased from GL Biochem Ltd. (Shanghai, China). Rink amide 4-methylbenzhydrylamine (MBHA) resin (100–200 mesh, substitution 0.44 mmol/g) was purchased from Nankai Hecheng Science & Technology Co., Ltd. (Tianjin, China). All organic chemicals were purchased from J&K Scientific Ltd. (Beijing, China). [<sup>3</sup>H]cAMP (50 Ci/mmol) was the product of PerkinElmer (Boston, MA, USA). In addition, protein kinase A (PKA), forskolin, 3-isobutyl-1-methylxanthine (IBMX), and the opioid antagonists including Nal, NALM, β-FNA, nor-binaltorphimine (nor-BNI), and naltrindole (NTI) were obtained from Sigma-Aldrich (St. Louis, MO, USA).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Peptide Synthesis</h3><div class="NLM_p">The peptides were synthesized by a well-defined Fmoc solid-phase methodology on Rink amide MBHA resin following our previous report.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> All couplings of amino acids were performed using HBTU/HOBT/DIEA (1:1:2) in DMF as described previously.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> We used 1% piperidine and 1% 1,8-diazabicyclo[5.4.0]undec-7-ene in DMF to deprotect the Fmoc group. Specifically, cyclization reactions of the cyclic peptides were carried out on the resin using an excess of iodine (8 equiv) in DMF and were stirred for 4 h. Upon completion of the oxidation, the resin was washed with dichloromethane (DCM) (2 × 3 min), 2% anti-ascorbic acid in DMF (2 × 3 min), NMP (5 × 3 min), and DCM (2 × 3 min).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Then, the resin was dried in a vacuum at least for 3 h and was cleaved with trifluoroacetic acid (TFA)/triisopropylsilane (Tis)/1,2-ethanedithiol (EDT)/H<sub>2</sub>O (94:1:2.5:2.5) or TFA/Tis/H<sub>2</sub>O (95:2.5:2.5) for 3 h. Subsequently, the evaporated filtrate was precipitated with ice ether and extracted with 10% acetic acid solution and then was lyophilized to get the crude peptides.</div><div class="NLM_p last">The peptides were purified by semipreparative RP-HPLC. Fractions containing the purified peptides were pooled and lyophilized. Molecular weights were measured by the positive ion mode under ESI methods (ESI-Q-TOF maXis-4G, Bruker Daltonics, Germany). The purities of the purified peptides were analyzed by analytical HPLC with the C18 column (XBridge BEH 130 Prep, 5 μm, 250 mm × 4.6 mm) with a linear gradient of 10–80% (system 1) or 10–100% (system 2) of solvent A at a flow rate of 1 mL/min in 30 min (A, acetonitrile with 0.1% TFA; B, water with 0.1% TFA) and confirmed to be of ≥95% purity for all peptides as determined by UV absorption at 220 nm. The purities for analogs: analog <b>1</b>, system 1: 97.4%, system 2: 98.6%; analog <b>2</b>, system 1: 97.2%, system 2: 99.0%; analog <b>3</b>, system 1: 95.1%, system 2: 96.1%; analog <b>4</b>, system 1: 99.5%, system 2: 95.7%; analog <b>5</b>, system 1: 95.5%, system 2: 97.4%; analog <b>6</b>, system 1: 95.8%, system 2: 100.0%; analog <b>7</b>, system 1: 95.4%, system 2: 95.6%; andanalog <b>8</b>, system 1: 96.3%, system 2: 96.7%.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Animals</h3><div class="NLM_p last">Six- to eight-week-old male Kunming and C57BL/6 mice were obtained from the Experimental Animal Centre of Lanzhou University. Six- to eight-week-old male NPFF<sub>2</sub> receptor-deficient (NPFF<sub>2</sub><sup>–/–</sup>) mice on the C57BL/6 background were purchased from Cyagen Biosciences Inc. (Suzhou, China). Mice were maintained on a 12 h light/dark cycle maintained at 22 ± 2 °C and given free access to food and water. All experimental animals were carried out in accordance with the European Community guidelines and performed in accordance with the European Community guidelines (2010/63/EU). The Ethics Committee and Institutional Animal Care and Use Committee of Lanzhou University approved all animal protocols. All mice were used only once in this research.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>In Vitro</i> Functional Assays (cAMP Assays)</h3><div class="NLM_p last">cAMP assays were performed on HEK-293A cells that stably expressed the μ-, κ-, δ-opioid, NPFF<sub>1</sub>, or NPFF<sub>2</sub> receptors as described previously.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> HEK-293A cells were seeded in 24-well microtiter plates and cultured for more than 20 h. The medium contained 10% fetal bovine serum, 100 μg/mL streptomycin, 100 IU/mL penicillin, and 400 mg/mL G418 which was used to maintain cells expressing opioid or NPFF receptors. Cell cultures were kept at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub>. At the beginning of the assay, after removing the culture medium, cells were incubated at 37 °C for 10 min in serum-free medium containing 1 mM IBMX and then were incubated at 37 °C for 30 min after adding various concentrations of drugs and 5 μM forskolin. After the incubation, the final cAMP was extracted and assayed by a competition PKA binding assay. We used the standard curve that was constructed using cAMP standards to calculate the concentration of cAMP.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Drug Administration</h3><div class="NLM_p">i.c.v. administration was similar to the previous report.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In brief, male Kunming mice were anaesthetized with pentobarbital sodium (80 mg/kg, i.p.) and placed in a stereotaxic frame. The stainless-steel guide cannulas were implanted and cemented at 3.0 mm posterior to the bregma, 1.0 mm lateral and 3.0 mm ventral from the surface of the skull. After surgery, the mice were allowed to recover at least for 4 days before use. Drugs were administrated into the lateral ventricle in a volume of 4 μL per mouse followed by 1 μL of saline to flush in the drug at a constant rate of 10 μL/min by using a 25 μL microsyringe.</div><div class="NLM_p">For s.c. administration, drugs or vehicles were given in a volume of 10 mL/kg using a disposable 1 mL syringe at the site of back of the neck for each animal.</div><div class="NLM_p last">For i.v. administration, mice were placed in restrainers and the tail veins were wiped with 75% alcohol to dilate blood vessels. The disposable 1 mL syringe was inserted into the tail vein at an angle of approximately 25°. Drugs were given at a volume of 10 mL/kg.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Stability Studies in Brain and Plasma</h3><div class="NLM_p">The enzymatic stability experiments of analogs were conducted with 15% mouse brain homogenate and 100% mouse plasma as previously described.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The brain homogenate and plasma were prepared following our previous reports.<a onclick="showRef(event, 'ref20 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref22">(20,22)</a> 10 μL of the peptide stock solution (0.01 mM) was added to 190 μL of brain homogenate or plasma. Then, 20 μL volume of solution was quickly removed from the mixture as a 0 min point, and the remaining mixture was then incubated in a water bath at 37 °C. Similarly, 20 μL volume of solution was taken at 5, 10, 15, 30, 60, 90, 120, 240, and 360 min after peptide addition. An equal volume of ice acetonitrile was immediately added to the removed incubation solution, further shaking and maintaining the sample on ice.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> After centrifugation at 13,000<i>g</i> for 15 min, the supernatant was collected and frozen at −80 °C until analyzed by RP-HPLC.</div><div class="NLM_p last">The enzymatic hydrolysis processes of the compounds conformed to the first-order kinetic equation: <i>A</i><sub><i>t</i></sub> = <i>A</i><sub>0</sub> e<sup>–<i>Kt</i></sup>, where <i>A</i><sub>0</sub>: initial peak area, <i>A</i><sub><i>t</i></sub>: <i>t</i> peak area, <i>K</i> represents elimination rate constant, and <i>t</i>: degradation time. From the above formula, ln <i>A</i><sub><i>t</i></sub>/<i>A</i><sub>0</sub> = −<i>Kt</i> is deducted; then, when <i>A</i><sub><i>t</i></sub>/<i>A</i><sub>0</sub> = 0.5, <i>t</i><sub>1/2</sub> = ln 2/<i>K</i> = 0.693/<i>K</i>. The results were further analyzed by linear regression to calculate the linear correlation <i>R</i><sup>2</sup> value.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>In Vivo</i> Brain Uptake Study</h3><div class="NLM_p">Male Kunming mice (6–8 weeks old) were given i.v. injection of 1 mg/kg of analog <b>6</b> dissolved in saline. The brain and plasma samples were obtained by decapitating the animals at 5, 10, 20, 30, 60, 90, 120, and 240 min and frozen on ice. Three mice were used per time point. The brain was weighed and homogenized in 500 μL of ice-cold phosphate buffer saline (pH 7.4). The plasma samples were separated from blood after centrifugation at 1500<i>g</i> for 5 min. The brain and plasma proteins were removed by precipitation after adding 4-fold the volume of ice acetonitrile. The mixture was shaken, then centrifuged at 20,000<i>g</i> for 30 min, and the supernatant was collected and dried in a CentriVap concentrator (Labconco). The samples were reconstituted in 150 μL of 5% (v/v) acetonitrile and then purified by solid-phase extraction C18 spin columns. Finally, the brain and plasma samples were dried in a CentriVap concentrator and dissolved in an equal volume of 10% (v/v) acetonitrile. Standard curves were also made in the mouse brain homogenate and plasma by mixing a stock solution of analog <b>6</b> with the blank brain homogenate and plasma in 1:9 (v/v) ratios and extracted as described for the samples. The samples were stored at −80 °C until further quantitative analysis.</div><div class="NLM_p last">The quantitative analysis was carried out on an Agilent 1260 HPLC LC–tandem 6460 QTRAP mass spectrometer (LC–MS/MS) system. Samples of 5 μL each were injected onto an Agilent Zorbax Eclipse Plus C18 column (2.1 mm × 50 mm, 1.8 μm) in an oven set at 25 °C. The HPLC mobile phase flow was maintained at 0.3 mL/min with a gradient consisting of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B). The gradient elution was started at 90% A and transitioned in a linear gradient to 10% over 5 min.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Antinociceptive Testing</h3><div class="NLM_p last">Acute antinociceptive effects were investigated using the radiant heat tail-flick test following our previous reports, and separate groups of male Kunming mice and NPFF<sub>2</sub><sup>–/–</sup> and WT mice on C57BL/6 background (6–8 weeks old) were used for this test.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> In brief, the mouse was gently restrained by hand, and the tail was placed on a radiant heat source 3 cm from the end. The lamp intensity of the tail-flick apparatus was adjusted to achieve a baseline between 3 and 5 s. The latencies to tail-flick were determined before the experimental animals were treated with saline or drugs (i.c.v. or s.c. administration). The animal threshold after treatment depended on each experiment, and maximal latency was 10 s to minimize tissue damage. Data were expressed as a percentage of the maximum possible effect (MPE %) using the following formula<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_m001.gif" alt="" id="_i31" /></img></span></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Rotarod Test</h3><div class="NLM_p last">The effects of drugs on the coordination of mouse movements were evaluated by a rotarod instrument which was described in our previous papers,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> and separate groups of male Kunming mice (6–8 weeks old) were used for this test. The mice were trained on the rod (16 rpm) three times a day for 2 consecutive days prior to drug injection. The mice that stayed on the rod for no more than 3 min during training were discarded. The maximum cut-off time was 5 min. On the third day, mice were tested at 10, 20, 30, and 40 min after i.c.v. and s.c. injection of saline and analogs <b>6</b> and <b>8</b>. The results were expressed as the time that each mouse stayed on the rod.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Antinociceptive Tolerance Test</h3><div class="NLM_p last">Antinociceptive tolerance test was investigated using the tail-flick apparatus following our previous reports,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> and separate groups of male Kunming mice (6–8 weeks old) were used for this test. The mice were i.c.v. or s.c. injected with the highest analgesic doses of fentanyl and analogs of <b>0</b> once daily for 8 days to evaluate the development of antinociceptive tolerance. The antinociceptive effects were measured once daily after drug administration. The degree of drug tolerance was determined by comparing the changes between the first day and the next few days after drug administration.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Acute Hyperlocomotion Test</h3><div class="NLM_p last">The acute hyperlocomotion was detected by open field assay,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> and separate groups of male Kunming mice (6–8 weeks old) were used for this test. The experimental apparatus consisted of a 50 × 50 × 40 cm nontopped black plexiglass box and a set of motion monitoring system (PMT-100, Chengdu Technology & Market Co., Ltd., China). The room temperature was controlled at 22 ± 1 °C in a sound proof room during the experiment. Before the experiment, the open field should be wiped clean with 75% alcohol to prevent other odors from affecting the locomotor activities of the mice. After the start of the experiment, the mice were first recorded for free exercise within 30 min to confirm the basic activities, and then, the movements of the mice within 150 min were recorded after s.c. injection of analogs <b>6</b> and <b>8</b> and the positive control fentanyl.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Place Conditioning Experiment</h3><div class="NLM_p">The experimental setup of the CPP consisted of three boxes: the two large boxes (20 × 20 × 20 cm) were separated by a small box (5 × 20 × 20 cm) as described previously, and separate groups of male Kunming mice (6–8 weeks old) were used for this test.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> At the bottom of two large plaids, a 5 × 5 cm small door was opened for mice to enter and exit, and the small door could be closed. One of the two large boxes was black, and another one was white. In addition, the two choice boxes were different in vision and tactile sensation (the white walls with a rough floor and the black walls with a smooth floor with 20 lux for blank and 50 lux for white).</div><div class="NLM_p last">To eliminate the strain on the unfamiliar environment of the animals before the experiment, the mice were placed in a CPP box and adapted for 15 min without recording. On the preconditioning day (day 1) of the experiment, the mice were placed in a CPP device and allowed to move freely between the two boxes. Within 15 min of recording, mice spent more than 60% of the time in the same compartment were excluded from the tests. On the conditioning days (day 2–4) of drug treatment, the middle mortal door was closed. Animals were s.c. injected with drugs and placed in one of the choice boxes for 15 min in the morning. Then, mice were s.c. injected with saline approximately 6 h later and placed in the other box for 15 min. On the test day (postconditioning day, day 5), the middle door was opened, and the time that the mice stayed in the drug-associated preference box within 15 min was recorded.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Nal-Precipitated Withdrawal Test</h3><div class="NLM_p last">According to previous studies,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> the withdrawal response of mice to Nal pretreatment was evaluated and separate groups of male Kunming mice (6–8 weeks old) were used for this test. Fentanyl and analogs <b>6</b> and <b>8</b> were s.c. injected every 8 h. The doses of the drugs were gradually increased. The reference was made to the dose of morphine (62, 124, 186, 248, 310, 310, and 310 mg/kg), and the dosage administered was about 10-, 20-, 30-, 40-, and 50-fold that of morphine antinociceptive ED<sub>50</sub> (5.22 μmol/kg).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The ED<sub>50</sub> value of fentanyl was 0.028 μmol/kg, and the dosage administered was 0.28, 0.56, 0.84, 1.12, 1.4, 1.4, and 1.4 μmol/kg. The ED<sub>50</sub> values of analogs <b>6</b> and <b>8</b> were 0.003 and 0.002 μmol/kg, so the reference designs were gradually increasing the doses of injection (analog <b>6</b>, 0.03, 0.06, 0.09, 0.12, 0.15, 0.15, and 0.15 μmol/kg; analog <b>8</b>, 0.02, 0.04, 0.06, 0.08, 0.1, 0.1, and 0.1 μmol/kg). Two hours after the last administration, 10 mg/kg Nal was s.c. injected, and the mice were immediately placed in an opaque barrel structure with an inner diameter of 9 cm and a height of 32 cm. The number of jumps of the mice within 30 min was recorded.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> GIT Test</h3><div class="NLM_p last">The upper gastrointestinal motility experiment was generally used to evaluate the side effect of opioids on constipation as described previously,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and separate groups of male Kunming mice (6–8 weeks old) were used for this test. The mice were fasted for 16 h but were free to drink water. The fasted mice were received s.c. injection of different doses of analogs <b>6</b> and <b>8</b> before an oral suspension. Then, each mouse was orally administered 250 μL of charcoal suspension (0.1 μL/10 g, a physiological saline suspension containing 5% charcoal and 10% gum arabic). After 30 min of oral gavage, mice were sacrificed by cervical dislocation. The mice were immediately dissected, and the small intestines were carefully removed from the stomach pylorus to the cecum. The results were expressed as the percent of GIT (GIT % = the distance travelled by the charcoal/the total distance of small intestine × 100).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Data Analysis</h3><div class="NLM_p last">All data were expressed as means ± standard error of the mean (S.E.M.) from at least three separate experiments (<i>n</i> = 3) for <i>in vitro</i> test and at least 5 animals/group (<i>n</i> = 5) for <i>in vivo</i> test, where <i>n</i> = number of independent values. The EC<sub>50</sub> values for the cAMP test or ED<sub>50</sub> values for antinociceptive experiments and the corresponding 95% confidence limits were calculated with GraphPad Prism 5. Data obtained from our study, excluding the tolerance development test and CPP test, were analyzed using one-way analysis of variance (ANOVA) followed by Dunnett’s or Bonferroni’s post-hoc test. Data from the tolerance development test were analyzed using one-way ANOVA followed by Tukey’s honestly significant difference (HSD) test. Data from the CPP test were analyzed using unpaired <i>t</i>-tests. The criterion of a probability of less than 0.05 was considered statistically significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01367" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53608" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53608" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01367?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01367</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Details of dose- and time-related antinociceptive effects; analgesic mechanism; and antinociceptive tolerance evaluation of analogs after i.c.v. and s.c. injection in the radiant heat tail-flick test (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf">jm0c01367_si_001.pdf (5.81 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01367" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51120" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51120" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Quan Fang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0381-6796" title="Orcid link">http://orcid.org/0000-0003-0381-6796</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1472757a736554786e613a7170613a777a"><span class="__cf_email__" data-cfemail="84e2e5eae3f5c4e8fef1aae1e0f1aae7ea">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mengna Zhang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Biao Xu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ning Li</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuerui Shi</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qinqin Zhang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanbin Shi</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kangtai Xu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Xiao</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan Chen</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hanwen Zhu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yulong Sun</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory for Space Biosciences & Biotechnology, Institute of
Special Environmental Biophysics, School of Life Sciences, Northwestern Polytechnical University, Xi’an 710000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ting Zhang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Run Zhang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Preclinical Study for New Drugs of Gansu Province, and
Institute of Physiology, School of Basic Medical Sciences, Lanzhou University, 199 Donggang West Road, Lanzhou 730000, PR China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.Z., B.X., N.L., H.L., X.S., Q.Z., K.X., J.X., D.C., H.Z., T.Z., and R.Z. performed the research. Q.F. designed the research study. M.Z., B.X., and Q.F. analyzed the data. Yulong Sun provided NPFF2–/– mice. Yanbin Shi provided DAS2.0 software. M.Z. and Q.F. wrote the paper.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43343" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43343" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This study was supported by grants from the National Natural  Science Foundation of China (nos. 81973159, 81673282, and  81903430) and the Funds for Fundamental Research Creative Groups of Gansu Province (20JR5RA310).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ANOVA</td><td class="NLM_def"><p class="first last">analysis of variance</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the concentration–time curve</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">β-FNA</td><td class="NLM_def"><p class="first last">β-funaltrexamine</p></td></tr><tr><td class="NLM_term">BN-9</td><td class="NLM_def"><p class="first last">Tyr-<span class="smallcaps smallerCapital">d</span>-Ala-Gly-Phe-Gln-Pro-Gln-Arg-Phe-NH<sub>2</sub></p></td></tr><tr><td class="NLM_term">CB<sub>1</sub></td><td class="NLM_def"><p class="first last">cannabinoid receptor 1</p></td></tr><tr><td class="NLM_term">CCK<sub>2</sub></td><td class="NLM_def"><p class="first last">cholecystokinin type 2 receptor</p></td></tr><tr><td class="NLM_term">CTAP</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">d</span>-Phe-Cys-Trp-Arg-Thr-Pen-Thr-NH<sub>2</sub></p></td></tr><tr><td class="NLM_term">CTOP</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">d</span>-Pen-Cys-Tyr-<span class="smallcaps smallerCapital">d</span>-Trp-Orn-Thr-Pen-Thr-NH<sub>2</sub></p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DN-9</td><td class="NLM_def"><p class="first last">Tyr-<span class="smallcaps smallerCapital">d</span>-Ala-Gly-<i>NMe</i>-Phe-Gly-Pro-Gln-Arg-Phe-NH<sub>2</sub></p></td></tr><tr><td class="NLM_term">DPDPE</td><td class="NLM_def"><p class="first last">H-Tyr-c[<span class="smallcaps smallerCapital">d</span>-Pen-Gly-Phe-<span class="smallcaps smallerCapital">d</span>-Pen]-OH</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">effective concentration 50% of maximum response</p></td></tr><tr><td class="NLM_term">ED<sub>50</sub></td><td class="NLM_def"><p class="first last">effective dose 50% of maximum response</p></td></tr><tr><td class="NLM_term">EDT</td><td class="NLM_def"><p class="first last">1,2-ethanedithiol</p></td></tr><tr><td class="NLM_term">EN-9</td><td class="NLM_def"><p class="first last">Tyr-Pro-Phe-Phe-Gln-Pro-Gln-Arg-Phe-NH<sub>2</sub></p></td></tr><tr><td class="NLM_term">Fmoc</td><td class="NLM_def"><p class="first last">9-fluorenylmethoxycarbonyl</p></td></tr><tr><td class="NLM_term">GIT</td><td class="NLM_def"><p class="first last">gastrointestinal inhibition</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last">hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">IBMX</td><td class="NLM_def"><p class="first last">3-isobutyl-1-methylxanthine</p></td></tr><tr><td class="NLM_term">i.c.v.</td><td class="NLM_def"><p class="first last">intracerebroventricular</p></td></tr><tr><td class="NLM_term">JOM-13</td><td class="NLM_def"><p class="first last">Tyr-c[<span class="smallcaps smallerCapital">d</span>-Cys-Phe-<span class="smallcaps smallerCapital">d</span>-Pen]-OH</p></td></tr><tr><td class="NLM_term">JOM-6</td><td class="NLM_def"><p class="first last">Tyr-c[<span class="smallcaps smallerCapital">d</span>-Cys-Phe-<span class="smallcaps smallerCapital">d</span>-Pen]-NH<sub>2</sub></p></td></tr><tr><td class="NLM_term">MBHA</td><td class="NLM_def"><p class="first last">4-methylbenzhydrylamine</p></td></tr><tr><td class="NLM_term">LC–MS/MS</td><td class="NLM_def"><p class="first last">liquid chromatography–tandem mass spectrometry</p></td></tr><tr><td class="NLM_term">MD-TOF MS</td><td class="NLM_def"><p class="first last">magnetic deflection time-of-flight mass spectrometry</p></td></tr><tr><td class="NLM_term">mp</td><td class="NLM_def"><p class="first last">melting point</p></td></tr><tr><td class="NLM_term">% MPE</td><td class="NLM_def"><p class="first last">the percent maximum possible effect</p></td></tr><tr><td class="NLM_term">NALM</td><td class="NLM_def"><p class="first last">naloxone methiodide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">nor-BNI</td><td class="NLM_def"><p class="first last">nor-binaltorphimine</p></td></tr><tr><td class="NLM_term">NPFF</td><td class="NLM_def"><p class="first last">Phe-Leu-Phe-Glu-Pro-Gln-Arg-Phe-NH<sub>2</sub></p></td></tr><tr><td class="NLM_term">NTI</td><td class="NLM_def"><p class="first last">naltrindole</p></td></tr><tr><td class="NLM_term">RF9</td><td class="NLM_def"><p class="first last">1-adamantanecarbonyl-Arg-Phe-NH<sub>2</sub></p></td></tr><tr><td class="NLM_term">RP-HPLC</td><td class="NLM_def"><p class="first last">reversed-phase high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">S.E.M.</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">s.c.</td><td class="NLM_def"><p class="first last">subcutaneous</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">Tis</td><td class="NLM_def"><p class="first last">triisopropylsilane</p></td></tr><tr><td class="NLM_term">TY038</td><td class="NLM_def"><p class="first last">Tyr-cyclo[<span class="smallcaps smallerCapital">d</span>-Cys-Gly-Phe-Met-Pro-<span class="smallcaps smallerCapital">d</span>-Cys]-Trp-NH-[3′,5′-(CF<sub>3</sub>)<sub>2</sub>Bzl]</p></td></tr><tr><td class="NLM_term">TY027</td><td class="NLM_def"><p class="first last">Tyr-<span class="smallcaps smallerCapital">d</span>-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-[3′,5′-(CF<sub>3</sub>)<sub>2</sub>Bzl]</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 63 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zöllner, C.</span>; <span class="NLM_string-name">Stein, C.</span></span> <span> </span><span class="NLM_article-title">Opioids</span>.  <i>Analgesia</i>; <span class="NLM_series">Handbook of Experimental Pharmacology</span>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_year">2007</span>; Vol.  <span class="NLM_volume">177</span>, pp  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">63</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=31-63&author=C.+Z%C3%B6llner&author=C.+Stein&title=Analgesia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DZ%25C3%25B6llner%26aufirst%3DC.%26atitle%3DOpioids%26btitle%3DAnalgesia%26pub%3DSpringer%26date%3D2007%26volume%3D177%26spage%3D31%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldhoer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whistler, J. L.</span></span> <span> </span><span class="NLM_article-title">Opioid receptors</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">990</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1146%2Fannurev.biochem.73.011303.073940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=15189164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=953-990&author=M.+Waldhoerauthor=S.+E.+Bartlettauthor=J.+L.+Whistler&title=Opioid+receptors&doi=10.1146%2Fannurev.biochem.73.011303.073940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptors</span></div><div class="casAuthors">Waldhoer, Maria; Bartlett, Selena E.; Whistler, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">953-990</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Opioid receptors belong to the large superfamily of 7 transmembrane-spanning (7TM) G protein-coupled receptors (GPCRs).  As a class, GPCRs are of fundamental physiol. importance mediating the actions of the majority of known neurotransmitters and hormones.  Opioid receptors are particularly intriguing members of this receptor family.  They are activated both by endogenously produced opioid peptides and by exogenously administered opiate compds., some of which are not only among the most effective analgesics known but also highly addictive drugs of abuse.  A fundamental question in addiction biol. is why exogenous opioid drugs, such as morphine and heroin, have a high liability for inducing tolerance, dependence, and addiction.  This review focuses on many aspects of opioid receptors with the aim of gaining a greater insight into mechanisms of opioid tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSV3Nl3WDHrVg90H21EOLACvtfcHk0ljBn6H1zzGAxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D&md5=9f865544116a6dac76c80432587180a3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073940%26sid%3Dliteratum%253Aachs%26aulast%3DWaldhoer%26aufirst%3DM.%26aulast%3DBartlett%26aufirst%3DS.%2BE.%26aulast%3DWhistler%26aufirst%3DJ.%2BL.%26atitle%3DOpioid%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D953%26epage%3D990%26doi%3D10.1146%2Fannurev.biochem.73.011303.073940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, C.</span></span> <span> </span><span class="NLM_article-title">Opioids, sensory systems and chronic pain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>716</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2013.01.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ejphar.2013.01.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=23500206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtValsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=716&publication_year=2013&pages=179-187&author=C.+Stein&title=Opioids%2C+sensory+systems+and+chronic+pain&doi=10.1016%2Fj.ejphar.2013.01.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Opioids, sensory systems and chronic pain</span></div><div class="casAuthors">Stein, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">716</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">179-187</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Opioids are the oldest and most potent drugs for the treatment of severe pain.  Their clin. application is undisputed in acute pain (e.g. assocd. with trauma or surgery) but their long-term use in chronic pain has met increasing scrutiny.  Therefore, this article will review sensory mechanisms related to opioid analgesia and side effects with a special emphasis on chronic pain.  Central and peripheral sites of analgesic actions and side effects, as well as conventional and novel opioid compds. will be discussed.  Since pain is a complex bio-psycho-social phenomenon, non-pharmacol. considerations important for the understanding of opioid analgesic efficacy are also included.  Finally, examples of challenging clin. situations such as the perioperative management of patients receiving long-term opioid treatment are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtVfvmEPZOzLVg90H21EOLACvtfcHk0ljBn6H1zzGAxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtValsb0%253D&md5=d2e6ca840fccc49b2b96c9407530348e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.01.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.01.076%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DC.%26atitle%3DOpioids%252C%2520sensory%2520systems%2520and%2520chronic%2520pain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D716%26spage%3D179%26epage%3D187%26doi%3D10.1016%2Fj.ejphar.2013.01.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benyamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trescot, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buenaventura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adlaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehgal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallejo, R.</span></span> <span> </span><span class="NLM_article-title">Opioid complications and side effects</span>. <i>Pain Physician</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S105</span>– <span class="NLM_lpage">S120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=18443635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A280%3ADC%252BD1czosVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=S105-S120&author=R.+Benyaminauthor=A.+M.+Trescotauthor=S.+Dattaauthor=R.+Buenaventuraauthor=R.+Adlakaauthor=N.+Sehgalauthor=S.+E.+Glaserauthor=R.+Vallejo&title=Opioid+complications+and+side+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid complications and side effects</span></div><div class="casAuthors">Benyamin Ramsin; Trescot Andrea M; Datta Sukdeb; Buenaventura Ricardo; Adlaka Rajive; Sehgal Nalini; Glaser Scott E; Vallejo Ricardo</div><div class="citationInfo"><span class="NLM_cas:title">Pain physician</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2 Suppl</span>),
    <span class="NLM_cas:pages">S105-20</span>
        ISSN:<span class="NLM_cas:issn">1533-3159</span>.
    </div><div class="casAbstract">Medications which bind to opioid receptors are increasingly being prescribed for the treatment of multiple and diverse chronic painful conditions.  Their use for acute pain or terminal pain is well accepted.  Their role in the long-term treatment of chronic noncancer pain is, however, controversial for many reasons.  One of the primary reasons is the well-known phenomenon of psychological addiction that can occur with the use of these medications.  Abuse and diversion of these medications is a growing problem as the availability of these medications increases and this public health issue confounds their clinical utility.  Also, the extent of their efficacy in the treatment of pain when utilized on a chronic basis has not been definitively proven.  Lastly, the role of opioids in the treatment of chronic pain is also influenced by the fact that these potent analgesics are associated with a significant number of side effects and complications.  It is these phenomena that are the focus of this review.  Common side effects of opioid administration include sedation, dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and respiratory depression.  Physical dependence and addiction are clinical concerns that may prevent proper prescribing and in turn inadequate pain management.  Less common side effects may include delayed gastric emptying, hyperalgesia, immunologic and hormonal dysfunction, muscle rigidity, and myoclonus.  The most common side effects of opioid usage are constipation (which has a very high incidence) and nausea.  These 2 side effects can be difficult to manage and frequently tolerance to them does not develop; this is especially true for constipation.  They may be severe enough to require opioid discontinuation, and contribute to under-dosing and inadequate analgesia.  Several clinical trials are underway to identify adjunct therapies that may mitigate these side effects.  Switching opioids and/or routes of administration may also provide benefits for patients.  Proper patient screening, education, and preemptive treatment of potential side effects may aid in maximizing effectiveness while reducing the severity of side effects and adverse events.  Opioids can be considered broad spectrum analgesic agents, affecting a wide number of organ systems and influencing a large number of body functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS-eBn7Ppy6vx2phytoz6_fW6udTcc2ebhkjs3N9Ngrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czosVSjsQ%253D%253D&md5=26196f3cc302b1cad86e32477bb52e18</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenyamin%26aufirst%3DR.%26aulast%3DTrescot%26aufirst%3DA.%2BM.%26aulast%3DDatta%26aufirst%3DS.%26aulast%3DBuenaventura%26aufirst%3DR.%26aulast%3DAdlaka%26aufirst%3DR.%26aulast%3DSehgal%26aufirst%3DN.%26aulast%3DGlaser%26aufirst%3DS.%2BE.%26aulast%3DVallejo%26aufirst%3DR.%26atitle%3DOpioid%2520complications%2520and%2520side%2520effects%26jtitle%3DPain%2520Physician%26date%3D2008%26volume%3D11%26spage%3DS105%26epage%3DS120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, P. W.</span></span> <span> </span><span class="NLM_article-title">Bi- or multifunctional opioid peptide drugs</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2009.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.lfs.2009.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19285088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlChs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2010&pages=598-603&author=P.+W.+Schiller&title=Bi-+or+multifunctional+opioid+peptide+drugs&doi=10.1016%2Fj.lfs.2009.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bi- or multifunctional opioid peptide drugs</span></div><div class="casAuthors">Schiller, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">598-603</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Strategies for the design of bi- or multifunctional drugs are reviewed.  A distinction is made between bifunctional drugs interacting in a monovalent fashion with two targets and ligands contg. two distinct pharmacophores binding in a bivalent mode to the two binding sites in a receptor heterodimer.  Arguments are presented to indicate that some of the so-called "bivalent" ligands reported in the literature are unlikely to simultaneously interact with two binding sites.  Aspects related to the development of bi- or multifunctional drugs are illustrated with examples from the field of opioid analgesics.  The drug-like properties of the tetrapeptide Dmt1[DALDA] with triple action as a μ opioid agonist, norepinephrine uptake inhibitor and releaser of endogenous opioid peptides to produce potent spinal analgesia are reviewed.  Rationales for the development of opioid peptides with mixed agonist/antagonist profiles as analgesics with reduced side effects are presented.  Progress in the development of mixed μ opioid agonist/δ opioid antagonists with low propensity to produce tolerance and phys. dependence is reviewed.  Efforts to develop bifunctional peptides contg. a μ opioid agonist and a cholecystokinin antagonist or an NK1 receptor antagonist as analgesics expected to produce less tolerance and dependence are also reviewed.  A strategy to improve the drug-like properties of bifunctional opioid peptide analgesics is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo51QVXgJVx6LVg90H21EOLACvtfcHk0liGvl9YgzBBSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlChs7o%253D&md5=6bb5b32b59f9d2bbd12763c1c32cd641</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2009.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2009.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DSchiller%26aufirst%3DP.%2BW.%26atitle%3DBi-%2520or%2520multifunctional%2520opioid%2520peptide%2520drugs%26jtitle%3DLife%2520Sci.%26date%3D2010%26volume%3D86%26spage%3D598%26epage%3D603%26doi%3D10.1016%2Fj.lfs.2009.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0liGvl9YgzBBSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, A.</span></span> <span> </span><span class="NLM_article-title">Multiple ligands in opioid research</span>. <i>Protein Pept. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.2174/092986608785133672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.2174%2F092986608785133672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=18782061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=668-682&author=S.+Balletauthor=M.+Pietschauthor=A.+Abell&title=Multiple+ligands+in+opioid+research&doi=10.2174%2F092986608785133672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple ligands in opioid research</span></div><div class="casAuthors">Ballet, Steven; Pietsch, Markus; Abell, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Peptide Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">668-682</span>CODEN:
                <span class="NLM_cas:coden">PPELEN</span>;
        ISSN:<span class="NLM_cas:issn">0929-8665</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The observation in 1979 that opioid receptors interact, led to the design of bivalent ligands in an attempt to improve selectivity and affinity towards the different subtypes (i.e. μ, δ, and κ).  Dimers of monovalent "parent" opioid structures were evaluated and include: (a) endogenous (e.g. enkephalins) or exogenous (e.g. dermorphin) peptide dimer analogs (b) mixed peptidic-non-peptidic bivalent ligands and (c) dual non-peptidic dimers.  Chimeric structures, using an opioid pharmacophore in combination with a non-opioid pharmacophore, were also prepd.  The common aim in all these studies is to improve the pharmacol. profile of potential analgesics to minimize common opioid-induced side-effects, such as phys. dependence and tolerance.  Here we present a brief overview of efforts to develop bivalent opioid ligands for use in pain-related research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqqggOwEwoZ7Vg90H21EOLACvtfcHk0liGvl9YgzBBSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyguro%253D&md5=e5222fb145da6472a7c9477ba8ba60c7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986608785133672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986608785133672%26sid%3Dliteratum%253Aachs%26aulast%3DBallet%26aufirst%3DS.%26aulast%3DPietsch%26aufirst%3DM.%26aulast%3DAbell%26aufirst%3DA.%26atitle%3DMultiple%2520ligands%2520in%2520opioid%2520research%26jtitle%3DProtein%2520Pept.%2520Lett.%26date%3D2008%26volume%3D15%26spage%3D668%26epage%3D682%26doi%3D10.2174%2F092986608785133672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foran, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipkowski, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maszczynska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinborn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kream, R. M.</span></span> <span> </span><span class="NLM_article-title">A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">7621</span>– <span class="NLM_lpage">7626</span>, <span class="refDoi"> DOI: 10.1073/pnas.130181897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.130181897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10852965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=7621-7626&author=S.+E.+Foranauthor=D.+B.+Carrauthor=A.+W.+Lipkowskiauthor=I.+Maszczynskaauthor=J.+E.+Marchandauthor=A.+Misickaauthor=M.+Beinbornauthor=A.+S.+Kopinauthor=R.+M.+Kream&title=A+substance+P-opioid+chimeric+peptide+as+a+unique+nontolerance-forming+analgesic&doi=10.1073%2Fpnas.130181897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic</span></div><div class="casAuthors">Foran, Stacy E.; Carr, Daniel B.; Lipkowski, Andrzej W.; Maszczynska, Iwona; Marchand, James E.; Misicka, Aleksandra; Beinborn, Martin; Kopin, Alan S.; Kream, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7621-7626</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">To elucidate mechanisms of acute and chronic pain, it is important to understand how spinal excitatory systems influence opioid analgesia.  The tachykinin substance P (SP) represents the prototypic spinal excitatory peptide neurotransmitter/neuromodulator, acting in concert with endogenous opioid systems to regulate analgesic responses to nociceptive stimuli.  We have synthesized and pharmacol. characterized a chimeric peptide contg. overlapping NH2- and COOH-terminal functional domains of the endogenous opioid endomorphin-2 (EM-2) and the tachykinin SP, resp.  Repeated administration of the chimeric mol. YPFFGLM-NH2, designated ESP7, into the rat spinal cord produces opioid-dependent analgesia without loss of potency over 5 days.  In contrast, repeated administration of ESP7 with concurrent SP receptor (SPR) blockade results in a progressive loss of analgesic potency, consistent with the development of tolerance.  Furthermore, tolerant animals completely regain opioid sensitivity after post hoc administration of ESP7 alone, suggesting that coactivation of SPRs is essential to maintaining opioid responsiveness.  Radioligand binding and signaling assays, using recombinant receptors, confirm that ESP7 can coactivate μ-opioid receptors (MOR) and SPRs in vitro.  We hypothesize that coincidental activation of the MOR- and SPR-expressing systems in the spinal cord mimics an ongoing state of reciprocal excitation and inhibition, which is normally encountered in nociceptive processing.  Due to the ability of ESP7 to interact with both MOR and SPRs, it represents a unique prototypic, anti-tolerance-forming analgesic with future therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwpOaxyG994LVg90H21EOLACvtfcHk0lj45AhIXy5pZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKhsbs%253D&md5=3500b41c38bbaef0375aea4413a0a490</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.130181897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.130181897%26sid%3Dliteratum%253Aachs%26aulast%3DForan%26aufirst%3DS.%2BE.%26aulast%3DCarr%26aufirst%3DD.%2BB.%26aulast%3DLipkowski%26aufirst%3DA.%2BW.%26aulast%3DMaszczynska%26aufirst%3DI.%26aulast%3DMarchand%26aufirst%3DJ.%2BE.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DBeinborn%26aufirst%3DM.%26aulast%3DKopin%26aufirst%3DA.%2BS.%26aulast%3DKream%26aufirst%3DR.%2BM.%26atitle%3DA%2520substance%2520P-opioid%2520chimeric%2520peptide%2520as%2520a%2520unique%2520nontolerance-forming%2520analgesic%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D7621%26epage%3D7626%26doi%3D10.1073%2Fpnas.130181897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span> <span> </span><span class="NLM_article-title">The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7337</span>– <span class="NLM_lpage">7343</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.bmc.2009.08.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19762245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ais7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7337-7343&author=T.+Yamamotoauthor=P.+Nairauthor=S.-w.+Maauthor=P.+Davisauthor=H.+I.+Yamamuraauthor=T.+W.+Vanderahauthor=F.+Porrecaauthor=J.+Laiauthor=V.+J.+Hruby&title=The+biological+activity+and+metabolic+stability+of+peptidic+bifunctional+compounds+that+are+opioid+receptor+agonists+and+neurokinin-1+receptor+antagonists+with+a+cystine+moiety&doi=10.1016%2Fj.bmc.2009.08.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety</span></div><div class="casAuthors">Yamamoto, Takashi; Nair, Padma; Ma, Shou-wu; Davis, Peg; Yamamura, Henry I.; Vanderah, Todd W.; Porreca, Frank; Lai, Josephine; Hruby, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7337-7343</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to improve metabolic stability, a ring structure with a cystine moiety was introduced into TY027 (Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-[3',5'-(CF3)2Bzl]), which is a lead compd. of our developing bifunctional peptide possessing opioid agonist and NK1 antagonist activities.  TY038 (Tyr-cyclo[D-Cys-Gly-Phe-Met-Pro-D-Cys]-Trp-NH-[3',5'-(CF3)2Bzl]) was found as a highly selective δ opioid agonist over μ receptor in conventional tissue-based assays, together with an effective NK1 antagonist activity and good metabolic stability with more than 24 h half life in rat plasma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGparHxQyFibhbVg90H21EOLACvtfcHk0lj45AhIXy5pZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ais7nL&md5=61567a71476cf64f45d354d7be6cec53</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNair%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DS.-w.%26aulast%3DDavis%26aufirst%3DP.%26aulast%3DYamamura%26aufirst%3DH.%2BI.%26aulast%3DVanderah%26aufirst%3DT.%2BW.%26aulast%3DPorreca%26aufirst%3DF.%26aulast%3DLai%26aufirst%3DJ.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DThe%2520biological%2520activity%2520and%2520metabolic%2520stability%2520of%2520peptidic%2520bifunctional%2520compounds%2520that%2520are%2520opioid%2520receptor%2520agonists%2520and%2520neurokinin-1%2520receptor%2520antagonists%2520with%2520a%2520cystine%2520moiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D7337%26epage%3D7343%26doi%3D10.1016%2Fj.bmc.2009.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Largent-Milnes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T.</span></span> <span> </span><span class="NLM_article-title">Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00824.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1111%2Fj.1476-5381.2010.00824.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=20977451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2ms7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=986-1001&author=T.+Largent-Milnesauthor=T.+Yamamotoauthor=P.+Nairauthor=J.+Moultonauthor=V.+Hrubyauthor=J.+Laiauthor=F.+Porrecaauthor=T.+Vanderah&title=Spinal+or+systemic+TY005%2C+a+peptidic+opioid+agonist%2Fneurokinin+1+antagonist%2C+attenuates+pain+with+reduced+tolerance&doi=10.1111%2Fj.1476-5381.2010.00824.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance</span></div><div class="casAuthors">Largent-Milnes, T. M.; Yamamoto, T.; Nair, P.; Moulton, J. W.; Hruby, V. J.; Lai, J.; Porreca, F.; Vanderah, T. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">986-1001</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The use of opioids in treating pain is limited due to significant side effects including somnolence, constipation, analgesic tolerance, addiction and respiratory depression.  Pre-clin. studies have shown that neurokinin 1 (NK1) receptor antagonists block opioid-induced antinociceptive tolerance and may inhibit opioid-induced rewarding behaviors.  Here, we have characterized a bifunctional peptide with both opioid agonist and NK1 antagonist pharmacophores in a rodent model of neuropathic pain.  Rats were evaluated for behavioral responses to both tactile and thermal stimuli in either an uninjured, sham- or nerve-injured state.  TY005 (Tyr-DAla-Gly-Phe-Met-Pro-Leu-Trp-O-3,5-Bn(CF3)2) was delivered spinally or systemically to assess the antinociceptive effects after acute exposure.  Motor skills were evaluated using the rotarod test to det. potential sedative effects.  Spinal TY005 was given chronically to sham- or nerve-injured animals to det. the development of tolerance.  Bolus injections of TY005 produced dose-dependent antinociception in non-injured animals and alleviated nerve injury-induced thermal and tactile hypersensitivities (i.e. antihyperalgesia) more effectively than morphine.  Sedative effects were not evident from the rotarod test at doses that were antihyperalgesic, nor at doses 3-fold higher.  Repeated administration of TY005 did not lead to the development of antihyperalgesic tolerance or alter sensory thresholds.  Collectively, the data suggest that opioid agonist/NK1 antagonist bifunctional peptides represent a promising novel approach to the management of chronic pain without the development of tolerance, reducing the need for escalation of doses and unwanted side effects assocd. with opiates alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmIZV-rESBFrVg90H21EOLACvtfcHk0lj30gSxICL_uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2ms7jN&md5=5ea51d658f8678e93d8e19a5f20802c1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00824.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00824.x%26sid%3Dliteratum%253Aachs%26aulast%3DLargent-Milnes%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNair%26aufirst%3DP.%26aulast%3DMoulton%26aufirst%3DJ.%26aulast%3DHruby%26aufirst%3DV.%26aulast%3DLai%26aufirst%3DJ.%26aulast%3DPorreca%26aufirst%3DF.%26aulast%3DVanderah%26aufirst%3DT.%26atitle%3DSpinal%2520or%2520systemic%2520TY005%252C%2520a%2520peptidic%2520opioid%2520agonist%252Fneurokinin%25201%2520antagonist%252C%2520attenuates%2520pain%2520with%2520reduced%2520tolerance%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D986%26epage%3D1001%26doi%3D10.1111%2Fj.1476-5381.2010.00824.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Naour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akgün, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yekkirala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunzer, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyuzhny, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5505</span>– <span class="NLM_lpage">5513</span>, <span class="refDoi"> DOI: 10.1021/jm4005219</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4005219" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5505-5513&author=M.+Le%0ANaourauthor=E.+Akg%C3%BCnauthor=A.+Yekkiralaauthor=M.+M.+Lunzerauthor=M.+D.+Powersauthor=A.+E.+Kalyuzhnyauthor=P.+S.+Portoghese&title=Bivalent+Ligands+That+Target+%CE%BC+Opioid+%28MOP%29+and+Cannabinoid1+%28CB1%29+Receptors+Are+Potent+Analgesics+Devoid+of+Tolerance&doi=10.1021%2Fjm4005219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid 1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance</span></div><div class="casAuthors">Le Naour, Morgan; Akgun, Eyup; Yekkirala, Ajay; Lunzer, Mary M.; Powers, Mike D.; Kalyuzhny, Alexander E.; Portoghese, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5505-5513</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given that μ opioid (MOP) and cannabinoid (CB1) receptors are colocalized in various regions of the central nervous system and have been reported to assoc. as heteromer (MOP-CB1) in cultured cells, the possibility of functional, endogenous MOP-CB1 in nociception and other pharmacol. effects has been raised.  As a first step in investigating this possibility, we have synthesized a series of bivalent ligands 1-5 that contain both μ agonist and CB1 antagonist pharmacophores for use as tools to study the functional interaction between MOP and CB1 receptors in vivo.  Immunofluorescent studies on HEK293 cells coexpressing both receptors suggested 5 (20-atom spacer) to be the only member of the series that bridges the protomers of the heteromer.  Antinociceptive testing in mice revealed 5 to be the most potent member of the series.  As neither a mixt. of monovalent ligands 9+10 nor bivalents 2-5 produced tolerance in mice, MOR-CB1 apparently is not an important target for reducing tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdqGOG4RA1RLVg90H21EOLACvtfcHk0lj30gSxICL_uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSqtLc%253D&md5=b3df3237bfebc84448056724c3cfca4d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm4005219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4005219%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BNaour%26aufirst%3DM.%26aulast%3DAkg%25C3%25BCn%26aufirst%3DE.%26aulast%3DYekkirala%26aufirst%3DA.%26aulast%3DLunzer%26aufirst%3DM.%2BM.%26aulast%3DPowers%26aufirst%3DM.%2BD.%26aulast%3DKalyuzhny%26aufirst%3DA.%2BE.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DBivalent%2520Ligands%2520That%2520Target%2520%25CE%25BC%2520Opioid%2520%2528MOP%2529%2520and%2520Cannabinoid1%2520%2528CB1%2529%2520Receptors%2520Are%2520Potent%2520Analgesics%2520Devoid%2520of%2520Tolerance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5505%26epage%3D5513%26doi%3D10.1021%2Fjm4005219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhtankar, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.-C.</span></span> <span> </span><span class="NLM_article-title">A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E5511</span>– <span class="NLM_lpage">E5518</span>, <span class="refDoi"> DOI: 10.1073/pnas.1605295113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.1605295113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27573832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWks7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E5511-E5518&author=H.+Dingauthor=P.+W.+Czotyauthor=N.+Kiguchiauthor=G.+Cami-Kobeciauthor=D.+D.+Sukhtankarauthor=M.+A.+Naderauthor=S.+M.+Husbandsauthor=M.-C.+Ko&title=A+novel+orvinol+analog%2C+BU08028%2C+as+a+safe+opioid+analgesic+without+abuse+liability+in+primates&doi=10.1073%2Fpnas.1605295113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates</span></div><div class="casAuthors">Ding, Huiping; Czoty, Paul W.; Kiguchi, Norikazu; Cami-Kobeci, Gerta; Sukhtankar, Devki D.; Nader, Michael A.; Husbands, Stephen M.; Ko, Mei-Chuan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">E5511-E5518</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite the crit. need, no previous research has substantiated safe opioid analgesics without abuse liability in primates.  Recent advances in medicinal chem. have led to the development of ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist activity to achieve this objective.  BU08028 is a novel orvinol analog that displays a similar binding profile to buprenorphine with improved affinity and efficacy at NOP receptors.  The aim of this preclin. study was to establish the functional profile of BU08028 in monkeys using clin. used MOP receptor agonists for side-by-side comparisons in various well-honed behavioral and physiol. assays.  Systemic BU08028 (0.001-0.01 mg/kg) produced potent long-lasting (i.e., >24 h) antinociceptive and antiallodynic effects, which were blocked by MOP or NOP receptor antagonists.  More importantly, the reinforcing strength of BU08028 was significantly lower than that of cocaine, remifentanil, or buprenorphine in monkeys responding under a progressive-ratio schedule of drug self-administration.  Unlike MOP receptor agonists, BU08028 at antinociceptive doses and ∼10- to 30-fold higher doses did not cause respiratory depression or cardiovascular adverse events as measured by telemetry devices.  After repeated administration, the monkeys developed acute phys. dependence on morphine, as manifested by pptd. withdrawal signs, such as increased respiratory rate, heart rate, and blood pressure.  In contrast, monkeys did not show phys. dependence on BU08028.  These in vivo findings in primates not only document the efficacy and tolerability profile of bifunctional MOP/NOP receptor agonists, but also provide a means of translating such ligands into therapies as safe and potentially abuse-free opioid analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh-uGrYC0W5rVg90H21EOLACvtfcHk0lj30gSxICL_uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWks7nM&md5=f4d19b2246e87706b906c2cf8ddfdea6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1605295113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1605295113%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DKiguchi%26aufirst%3DN.%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DSukhtankar%26aufirst%3DD.%2BD.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DKo%26aufirst%3DM.-C.%26atitle%3DA%2520novel%2520orvinol%2520analog%252C%2520BU08028%252C%2520as%2520a%2520safe%2520opioid%2520analgesic%2520without%2520abuse%2520liability%2520in%2520primates%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3DE5511%26epage%3DE5518%26doi%3D10.1073%2Fpnas.1605295113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-X.</span></span> <span> </span><span class="NLM_article-title">Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">10225</span>– <span class="NLM_lpage">10227</span>, <span class="refDoi"> DOI: 10.1073/pnas.1612752113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.1612752113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27573851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSltLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=10225-10227&author=J.-X.+Li&title=Buprenorphine+analogue+BU08028+is+one+step+closer+to+the+Holy+Grail+of+opioid+research&doi=10.1073%2Fpnas.1612752113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research</span></div><div class="casAuthors">Li, Jun-Xu</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">10225-10227</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKPmz5i_R2pbVg90H21EOLACvtfcHk0liBCG7iezAr0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSltLbK&md5=c74f8a1e0a6dd6b27e71354e5a94364b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1612752113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1612752113%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-X.%26atitle%3DBuprenorphine%2520analogue%2520BU08028%2520is%2520one%2520step%2520closer%2520to%2520the%2520Holy%2520Grail%2520of%2520opioid%2520research%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3D10225%26epage%3D10227%26doi%3D10.1073%2Fpnas.1612752113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daga, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishioka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.-C.</span></span> <span> </span><span class="NLM_article-title">A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">eaar3483</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aar3483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1126%2Fscitranslmed.aar3483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30158150" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&author=H.+Dingauthor=N.+Kiguchiauthor=D.+Yasudaauthor=P.+R.+Dagaauthor=W.+E.+Polgarauthor=J.+J.+Luauthor=P.+W.+Czotyauthor=S.+Kishiokaauthor=N.+T.+Zaveriauthor=M.-C.+Ko&title=A+bifunctional+nociceptin+and+mu+opioid+receptor+agonist+is+analgesic+without+opioid+side+effects+in+nonhuman+primates&doi=10.1126%2Fscitranslmed.aar3483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aar3483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aar3483%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DKiguchi%26aufirst%3DN.%26aulast%3DYasuda%26aufirst%3DD.%26aulast%3DDaga%26aufirst%3DP.%2BR.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DLu%26aufirst%3DJ.%2BJ.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DKishioka%26aufirst%3DS.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DKo%26aufirst%3DM.-C.%26atitle%3DA%2520bifunctional%2520nociceptin%2520and%2520mu%2520opioid%2520receptor%2520agonist%2520is%2520analgesic%2520without%2520opioid%2520side%2520effects%2520in%2520nonhuman%2520primates%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26doi%3D10.1126%2Fscitranslmed.aar3483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhtankar, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLoid, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, F.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.-C.</span></span> <span> </span><span class="NLM_article-title">BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">e146</span>– <span class="NLM_lpage">e156</span>, <span class="refDoi"> DOI: 10.1016/j.bja.2018.10.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.bja.2018.10.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30916003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFOrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2019&pages=e146-e156&author=N.+Kiguchiauthor=H.+Dingauthor=G.+Cami-Kobeciauthor=D.+D.+Sukhtankarauthor=P.+W.+Czotyauthor=H.+B.+DeLoidauthor=F.-C.+Hsuauthor=L.+Tollauthor=S.+M.+Husbandsauthor=M.-C.+Ko&title=BU10038+as+a+safe+opioid+analgesic+with+fewer+side-effects+after+systemic+and+intrathecal+administration+in+primates&doi=10.1016%2Fj.bja.2018.10.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates</span></div><div class="casAuthors">Kiguchi, Norikazu; Ding, Huiping; Cami-Kobeci, Gerta; Sukhtankar, Devki D.; Czoty, Paul W.; DeLoid, Heather B.; Hsu, Fang-Chi; Toll, Lawrence; Husbands, Stephen M.; Ko, Mei-Chuan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e146-e156</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">1471-6771</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The marked increase in mis-use of prescription opioids has greatly affected our society.  One potential soln. is to develop improved analgesics which have agonist action at both mu opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptors.  BU10038 is a recently identified bifunctional MOP/NOP partial agonist.  The aim of this study was to det. the functional profile of systemic or spinal delivery of BU10038 in primates after acute and chronic administration.  A series of behavioral and physiol. assays have been established specifically to reflect the therapeutic (analgesia) and side-effects (abuse potential, respiratory depression, itch, phys. dependence, and tolerance) of opioid analgesics in rhesus monkeys.  After systemic administration, BU10038 (0.001-0.01 mg kg-1) dose-dependently produced long-lasting antinociceptive and antihypersensitive effects.  Unlike the MOP agonist oxycodone, BU10038 lacked reinforcing effects (i.e. little or no abuse liability), and BU10038 did not compromise the physiol. functions of primates including respiration, cardiovascular activities, and body temp. at antinociceptive doses and a 10-30-fold higher dose (0.01-0.1 mg kg-1).  After intrathecal administration, BU10038 (3 μg) exerted morphine-comparable antinociception and antihypersensitivity without itch scratching responses.  Unlike morphine, BU10038 did not cause the development of phys. dependence and tolerance after repeated and chronic administration.  These in vivo findings demonstrate the translational potential of bifunctional MOP/NOP receptor agonists such as BU10038 as a safe, non-addictive analgesic with fewer side-effects in primates.  This study strongly supports that bifunctional MOP/NOP agonists may provide improved analgesics and an alternative soln. for the ongoing prescription opioid crisis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVLOISUSOFbVg90H21EOLACvtfcHk0liBCG7iezAr0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFOrtr8%253D&md5=77bae3bd7f251e8a5db31de871acca02</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bja.2018.10.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bja.2018.10.065%26sid%3Dliteratum%253Aachs%26aulast%3DKiguchi%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DSukhtankar%26aufirst%3DD.%2BD.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DDeLoid%26aufirst%3DH.%2BB.%26aulast%3DHsu%26aufirst%3DF.-C.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DKo%26aufirst%3DM.-C.%26atitle%3DBU10038%2520as%2520a%2520safe%2520opioid%2520analgesic%2520with%2520fewer%2520side-effects%2520after%2520systemic%2520and%2520intrathecal%2520administration%2520in%2520primates%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2019%26volume%3D122%26spage%3De146%26epage%3De156%26doi%3D10.1016%2Fj.bja.2018.10.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quelven, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlet-Schiltz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouardères, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafani, J.-A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazarguil, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J.-M.</span></span> <span> </span><span class="NLM_article-title">Dissociation of pharmacological pro- and anti-opioid effects by neuropeptide FF analogs</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>449</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/s0014-2999(02)01983-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2FS0014-2999%2802%2901983-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=12163111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVWlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=449&publication_year=2002&pages=91-98&author=I.+Quelvenauthor=A.+Roussinauthor=O.+Burlet-Schiltzauthor=C.+Gouard%C3%A8resauthor=J.-A.+M.+Tafaniauthor=H.+Mazarguilauthor=J.-M.+Zajac&title=Dissociation+of+pharmacological+pro-+and+anti-opioid+effects+by+neuropeptide+FF+analogs&doi=10.1016%2Fs0014-2999%2802%2901983-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociation of pharmacological pro- and anti-opioid effects by neuropeptide FF analogs</span></div><div class="casAuthors">Quelven, Isabelle; Roussin, Anne; Burlet-Schiltz, Odile; Gouarderes, Christine; Tafani, Jean-Andre Mathieu; Mazarguil, Honore; Zajac, Jean-Marie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">449</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">91-98</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Neuropeptide FF (NPFF) and its analog 1DMe ([D-Tyr1,(NMe)Phe3]NPFF) have been shown to reverse or potentiate morphine analgesia in rat depending on the supraspinal or spinal site of injection.  The properties, in the mouse tail-flick test, of 1DMe and its related compd. Nic-1DMe (Nicotinoyl-Pro-1DMe) were investigated after their local (i.c.v. and i.t.) and systemic administration.  Whereas Nic-1DMe and 1DMe exhibit the same affinity and selectivity towards NPFF1 and NPFF2 receptors, Nic-1DMe, in contrast to 1DMe, is unable to inhibit morphine-induced analgesia after i.c.v. and i.p. administration.  Conversely, after i.t. and i.p. administration, both neuropeptide FF analogs could potentiate morphine analgesia.  Differences in disposition parameters between 1DMe and Nic-1DMe are evidenced, suggesting that the two neuropeptide FF analogs could stimulate differentially supraspinal neuropeptide FF receptors.  The predominant activation of spinal neuronal pathways by Nic-1DMe could explain the selective pro-opioid action of this compd. after i.t., i.c.v. and i.p. administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcbVL00N4qR7Vg90H21EOLACvtfcHk0liBCG7iezAr0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVWlt7s%253D&md5=6247bf2f6606ba8765bc4d902bbcda52</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2901983-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252901983-0%26sid%3Dliteratum%253Aachs%26aulast%3DQuelven%26aufirst%3DI.%26aulast%3DRoussin%26aufirst%3DA.%26aulast%3DBurlet-Schiltz%26aufirst%3DO.%26aulast%3DGouard%25C3%25A8res%26aufirst%3DC.%26aulast%3DTafani%26aufirst%3DJ.-A.%2BM.%26aulast%3DMazarguil%26aufirst%3DH.%26aulast%3DZajac%26aufirst%3DJ.-M.%26atitle%3DDissociation%2520of%2520pharmacological%2520pro-%2520and%2520anti-opioid%2520effects%2520by%2520neuropeptide%2520FF%2520analogs%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D449%26spage%3D91%26epage%3D98%26doi%3D10.1016%2Fs0014-2999%2802%2901983-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mollereau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roumy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J.-M.</span></span> <span> </span><span class="NLM_article-title">Opioid-modulating peptides: mechanisms of action</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.2174/1568026053544515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.2174%2F1568026053544515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=15857316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFaqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-355&author=C.+Mollereauauthor=M.+Roumyauthor=J.-M.+Zajac&title=Opioid-modulating+peptides%3A+mechanisms+of+action&doi=10.2174%2F1568026053544515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid-modulating peptides: mechanisms of action</span></div><div class="casAuthors">Mollereau, Catherine; Roumy, Michel; Zajac, Jean-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-355</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Opioids are involved in the physiol. control of numerous functions of the central nervous system, particularly nociception.  It appears that some endogenous neuropeptides, called anti-opioids, participate in an homeostatic system tending to reduce the effects of opioids.  Neuropeptide FF (NPFF) and cholecystokinin (CCK) possess these properties and, paradoxically, the opioid peptides nociceptin and dynorphin display some anti-opioid activity.  All these peptides exhibit complex properties as they are able to both counteract and potentiate opioid activity, acting rather as modulators of opioid functions.  The purpose of this review is to highlight that 2 different mechanisms are clearly involved in the control of opioid functions by opioid-modulating peptides: a circuitry-induced mechanism for nociceptin and dynorphin, and a cellular anti-opioid mechanism for NPFF and CCK.  The knowledge of these mechanisms has potential therapeutic interest in the control of opioid functions, notably for alleviating pain and(or) for the treatment of opioid abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZw2fMuWKMaLVg90H21EOLACvtfcHk0ljS03x-7nuw_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFaqu70%253D&md5=f4a866b30e48dd49e4599405b8f1dab1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1568026053544515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026053544515%26sid%3Dliteratum%253Aachs%26aulast%3DMollereau%26aufirst%3DC.%26aulast%3DRoumy%26aufirst%3DM.%26aulast%3DZajac%26aufirst%3DJ.-M.%26atitle%3DOpioid-modulating%2520peptides%253A%2520mechanisms%2520of%2520action%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D355%26doi%3D10.2174%2F1568026053544515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elhabazi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trigo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollereau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulédous, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meziane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit-demoulière, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, F.</span></span> <span> </span><span class="NLM_article-title">Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01563.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1111%2Fj.1476-5381.2011.01563.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=21718302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1yksLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=424-435&author=K.+Elhabaziauthor=J.+Trigoauthor=C.+Mollereauauthor=L.+Moul%C3%A9dousauthor=J.-M.+Zajacauthor=F.+Bihelauthor=M.+Schmittauthor=J.+Bourguignonauthor=H.+Mezianeauthor=B.+Petit-demouli%C3%A8reauthor=F.+Bockelauthor=R.+Maldonadoauthor=F.+Simonin&title=Involvement+of+neuropeptide+FF+receptors+in+neuroadaptive+responses+to+acute+and+chronic+opiate+treatments&doi=10.1111%2Fj.1476-5381.2011.01563.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments</span></div><div class="casAuthors">Elhabazi, K.; Trigo, J. M.; Mollereau, C.; Mouledous, L.; Zajac, J.-M.; Bihel, F.; Schmitt, M.; Bourguignon, J. J.; Meziane, H.; Petit-demouliere, B.; Bockel, F.; Maldonado, R.; Simonin, F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">424-435</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Opiates remain the most effective compds. for alleviating severe pain across a wide range of conditions.  However, their use is assocd. with significant side effects.  Neuropeptide FF (NPFF) receptors have been implicated in several opiate-induced neuroadaptive changes including the development of tolerance.  In this study, we investigated the consequences of NPFF receptor blockade on acute and chronic stimulation of opioid receptors in mice by using RF9, a potent and selective antagonist of NPFF receptors that can be administered systemically.  Exptl. Approach The effects of RF9 were investigated on opioid pharmacol. responses including locomotor activity, antinociception, opioid-induced hyperalgesia, rewarding properties and phys. dependence.  Key Results RF9 had no effect on morphine-induced horizontal hyperlocomotion and slightly attenuated the decrease induced in vertical activity.  Furthermore, RF9 dose-dependently blocked the long-lasting hyperalgesia produced by either acute fentanyl or chronic morphine administration.  RF9 also potentiated opiate early analgesic effects and prevented the development of morphine tolerance.  Finally, RF9 increased morphine-induced conditioned place preference without producing any rewarding effect by itself and decreased naltrexone-pptd. withdrawal syndrome following chronic morphine treatment.  Conclusion and Implications The NPFF system is involved in the development of two major undesirable effects: tolerance and dependence, which are clin. assocd. with prolonged exposure to opiates.  Our findings suggest that NPFF receptors are interesting therapeutic targets to improve the analgesic efficacy of opiates by limiting the development of tolerance, and for the treatment of opioid dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIbIwFL47xALVg90H21EOLACvtfcHk0ljS03x-7nuw_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1yksLfN&md5=ebef9a66eea11441638e60fa0f617eb8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01563.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01563.x%26sid%3Dliteratum%253Aachs%26aulast%3DElhabazi%26aufirst%3DK.%26aulast%3DTrigo%26aufirst%3DJ.%26aulast%3DMollereau%26aufirst%3DC.%26aulast%3DMoul%25C3%25A9dous%26aufirst%3DL.%26aulast%3DZajac%26aufirst%3DJ.-M.%26aulast%3DBihel%26aufirst%3DF.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DBourguignon%26aufirst%3DJ.%26aulast%3DMeziane%26aufirst%3DH.%26aulast%3DPetit-demouli%25C3%25A8re%26aufirst%3DB.%26aulast%3DBockel%26aufirst%3DF.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DSimonin%26aufirst%3DF.%26atitle%3DInvolvement%2520of%2520neuropeptide%2520FF%2520receptors%2520in%2520neuroadaptive%2520responses%2520to%2520acute%2520and%2520chronic%2520opiate%2520treatments%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D424%26epage%3D435%26doi%3D10.1111%2Fj.1476-5381.2011.01563.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.-p.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-n.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2016.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.neuropharm.2016.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=26970017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Shsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=364-372&author=Z.-l.+Wangauthor=N.+Liauthor=P.+Wangauthor=H.-h.+Tangauthor=Z.-l.+Hanauthor=J.-j.+Songauthor=X.-h.+Liauthor=H.-p.+Yuauthor=T.+Zhangauthor=R.+Zhangauthor=B.+Xuauthor=M.-n.+Zhangauthor=Q.+Fangauthor=R.+Wang&title=Pharmacological+characterization+of+EN-9%2C+a+novel+chimeric+peptide+of+endomorphin-2+and+neuropeptide+FF+that+produces+potent+antinociceptive+activity+and+limited+tolerance&doi=10.1016%2Fj.neuropharm.2016.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance</span></div><div class="casAuthors">Wang, Zi-long; Li, Ning; Wang, Pei; Tang, Hong-hai; Han, Zheng-lan; Song, Jing-jing; Li, Xu-hui; Yu, Hong-ping; Zhang, Ting; Zhang, Run; Xu, Biao; Zhang, Meng-na; Fang, Quan; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">364-372</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mounting evidences indicate the functional interactions between neuropeptide FF (NPFF) and opioids, including the endogenous opioids.  In the present work, EN-9, a chimeric peptide contg. the functional domains of the endogenous opioid endomorphin-2 (EM-2) and NPFF, was synthesized and pharmacol. characterized.  In vitro cAMP assay demonstrated that EN-9 was a multifunctional agonist of κ-opioid, NPFF1 and NPFF2 receptors.  In the mouse tail-flick test, intracerebroventricularly (i.c.v.) administration of EN-9 produced significant antinociception with an ED50 value of 13.44 nmol, which lasted longer than that of EM-2.  In addn., EN-9 induced potent antinociception after both i.v. (i.v.) and s.c. (s.c.) injection.  Furthermore, the expts. using the antagonists of opioid and NPFF receptors indicated that the central antinociception of EN-9 was mainly mediated by κ-opioid receptor, independently on NPFF receptors.  Notably, the central antinociception of EN-9 was not reduced over a period of 6 days repeated i.c.v. injection.  Repeated i.c.v. administration of EN-9 with the NPFF1 and NPFF2 receptors antagonist RF9 resulted in a progressive loss of analgesic potency, consistent with the development of tolerance.  Moreover, central administration of EN-9 induced the place conditioning aversion only at a high dose of 60 nmol, but not at low doses.  At supraspinal level, only high dose of EN-9 (60 nmol, i.c.v.) inhibited gastrointestinal transit via NPFF receptors.  Similarly, systemic administration of EN-9 also inhibited gastrointestinal transit at high doses (10 and 30 mg/kg, i.v.).  Taken together, the multifunctional agonist of κ-opioid and NPFF receptors EN-9 produced a potent, non-tolerance forming antinociception with limited side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoby4T7pGme6bVg90H21EOLACvtfcHk0ljw2BwKoaD7lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Shsbo%253D&md5=0b9dd9d2bdeba08a9b0248c7a0c68296</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.-l.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DH.-h.%26aulast%3DHan%26aufirst%3DZ.-l.%26aulast%3DSong%26aufirst%3DJ.-j.%26aulast%3DLi%26aufirst%3DX.-h.%26aulast%3DYu%26aufirst%3DH.-p.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.-n.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DPharmacological%2520characterization%2520of%2520EN-9%252C%2520a%2520novel%2520chimeric%2520peptide%2520of%2520endomorphin-2%2520and%2520neuropeptide%2520FF%2520that%2520produces%2520potent%2520antinociceptive%2520activity%2520and%2520limited%2520tolerance%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D108%26spage%3D364%26epage%3D372%26doi%3D10.1016%2Fj.neuropharm.2016.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-n.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1864</span>– <span class="NLM_lpage">1880</span>, <span class="refDoi"> DOI: 10.1111/bph.13489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1111%2Fbph.13489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27018797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmtlenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=1864-1880&author=N.+Liauthor=Z.-l.+Hanauthor=Z.-l.+Wangauthor=Y.-h.+Xingauthor=Y.-l.+Sunauthor=X.-h.+Liauthor=J.-j.+Songauthor=T.+Zhangauthor=R.+Zhangauthor=M.-n.+Zhangauthor=B.+Xuauthor=Q.+Fangauthor=R.+Wang&title=BN-9%2C+a+chimeric+peptide+with+mixed+opioid+and+neuropeptide+FF+receptor+agonistic+properties%2C+produces+nontolerance-forming+antinociception+in+mice&doi=10.1111%2Fbph.13489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice</span></div><div class="casAuthors">Li, Ning; Han, Zheng-lan; Wang, Zi-long; Xing, Yan-hong; Sun, Yu-long; Li, Xu-hui; Song, Jing-jing; Zhang, Ting; Zhang, Run; Zhang, Meng-na; Xu, Biao; Fang, Quan; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1864-1880</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Neuropeptide FF (NPFF) behaves as an endogenous opioid-modulating peptide.  In the present study, the opioid and NPFF pharmacophore-contg. chimeric peptide BN-9 was synthesized and pharmacol. characterized.  Exptl. Approach : Agonist activities of BN-9 at opioid and NPFF receptors were characterized in in vitro cAMP assays.  Antinociceptive activities of BN-9 were evaluated in the mouse tail-flick and formalin tests.  Furthermore, its side effects were investigated in rotarod, antinociceptive tolerance, reward and gastrointestinal transit tests.  Key Results : BN-9 acted as a novel multifunctional agonist at μ, δ, κ, NPFF1 and NPFF2 receptors in cAMP assays.  In the tail-flick test, BN-9 produced dose-related antinociception and was approx. equipotent to morphine; this antinociception was blocked by μ and κ receptor antagonists, but not by the δ receptor antagonist.  In the formalin test, supraspinal administration of BN-9 produced significant analgesia.  Notably, repeated administration of BN-9 produced analgesia without loss of potency over 8 days.  In contrast, repeated i.c.v. co-administration of BN-9 with the NPFF receptor antagonist RF9 produced significant antinociceptive tolerance.  Furthermore, i.c.v.  BN-9 induced conditioned place preference.  When given by the same routes, BN-9 had a more than eightfold higher ED50 value for gastrointestinal transit inhibition compared with the ED50 values for antinociception.  Conclusions and Implications : BN-9 produced a robust, nontolerance-forming analgesia with limited inhibition of gastrointestinal transit.  As BN-9 is able to activate both opioid and NPFF systems, this provides an interesting approach for the development of novel analgesics with minimal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpicXFgT8DcO7Vg90H21EOLACvtfcHk0ljw2BwKoaD7lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmtlenu7Y%253D&md5=90dce7f015555e141e30a0e82d8bdfd7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fbph.13489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13489%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DZ.-l.%26aulast%3DWang%26aufirst%3DZ.-l.%26aulast%3DXing%26aufirst%3DY.-h.%26aulast%3DSun%26aufirst%3DY.-l.%26aulast%3DLi%26aufirst%3DX.-h.%26aulast%3DSong%26aufirst%3DJ.-j.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DM.-n.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DBN-9%252C%2520a%2520chimeric%2520peptide%2520with%2520mixed%2520opioid%2520and%2520neuropeptide%2520FF%2520receptor%2520agonistic%2520properties%252C%2520produces%2520nontolerance-forming%2520antinociception%2520in%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D1864%26epage%3D1880%26doi%3D10.1111%2Fbph.13489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Structure-based optimization of multifunctional agonists for opioid and Neuropeptide FF receptors with potent nontolerance forming analgesic activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10198</span>– <span class="NLM_lpage">10208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01181</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01181" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKgtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10198-10208&author=Z.-L.+Wangauthor=J.-X.+Panauthor=J.-J.+Songauthor=H.-H.+Tangauthor=H.-P.+Yuauthor=X.-H.+Liauthor=N.+Liauthor=T.+Zhangauthor=R.+Zhangauthor=M.-N.+Zhangauthor=B.+Xuauthor=Q.+Fangauthor=R.+Wang&title=Structure-based+optimization+of+multifunctional+agonists+for+opioid+and+Neuropeptide+FF+receptors+with+potent+nontolerance+forming+analgesic+activities&doi=10.1021%2Facs.jmedchem.6b01181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities</span></div><div class="casAuthors">Wang, Zi-Long; Pan, Jia-Xin; Song, Jing-Jing; Tang, Hong-Hai; Yu, Hong-Ping; Li, Xu-Hui; Li, Ning; Zhang, Ting; Zhang, Run; Zhang, Meng-Na; Xu, Biao; Fang, Quan; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10198-10208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The opioid and neuropeptide FF pharmacophore-contg. chimeric peptide 0 (BN-9) was recently developed and produced potent nontolerance forming analgesia.  In this study, 11 analogs of 0 were designed and synthesized.  An in vitro cAMP assay demonstrated that these analogs behaved as multifunctional agonists at both opioid and NPFF receptors.  In mouse tail-flick test, most of the analogs produced potent nontolerance forming antinociception.  Notably, 11 (DN-9) was 33-fold more potent than 0 at analgesic effects, which was mediated by μ- and κ-opioid receptors.  In addn., 11 also produced powerful analgesic effects in the formalin pain and CFA-induced chronic inflammatory pain models.  Strikingly, following its repeated administration for 6 days, 11 did not produce antinociceptive tolerance in the tail-flick test and CFA-induced pain model.  The present work indicates that it is reasonable to design multifunctional peptide ligands for opioid and NPFF receptors in a single mol. producing effective nontolerance forming antinociception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr397Dq_Czk37Vg90H21EOLACvtfcHk0ljw2BwKoaD7lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKgtrbP&md5=d67570b5cb6d804532180bf50dd3532f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01181%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.-L.%26aulast%3DPan%26aufirst%3DJ.-X.%26aulast%3DSong%26aufirst%3DJ.-J.%26aulast%3DTang%26aufirst%3DH.-H.%26aulast%3DYu%26aufirst%3DH.-P.%26aulast%3DLi%26aufirst%3DX.-H.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DM.-N.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DStructure-based%2520optimization%2520of%2520multifunctional%2520agonists%2520for%2520opioid%2520and%2520Neuropeptide%2520FF%2520receptors%2520with%2520potent%2520nontolerance%2520forming%2520analgesic%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10198%26epage%3D10208%26doi%3D10.1021%2Facs.jmedchem.6b01181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span> <span> </span><span class="NLM_article-title">Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>837</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2018.08.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ejphar.2018.08.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30172787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ClsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=837&publication_year=2018&pages=53-63&author=N.+Liauthor=Z.-L.+Hanauthor=B.+Xuauthor=M.-N.+Zhangauthor=T.+Zhangauthor=X.-R.+Shiauthor=W.-D.+Zhaoauthor=Y.-Y.+Guoauthor=Q.-Q.+Zhangauthor=Q.+Fang&title=Systemic+administration+of+the+bifunctional+opioid%2Fneuropeptide+FF+receptors+agonist+BN-9+produced+peripheral+antinociception+in+preclinical+mouse+models+of+pain&doi=10.1016%2Fj.ejphar.2018.08.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain</span></div><div class="casAuthors">Li, Ning; Han, Zheng-Lan; Xu, Biao; Zhang, Meng-Na; Zhang, Ting; Shi, Xue-Rui; Zhao, Wei-Dong; Guo, Yuan-Yuan; Zhang, Qin-Qin; Fang, Quan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">837</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-63</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We recently characterized a novel bifunctional agonist for opioid and neuropeptide FF receptors, named BN-9, which exhibited potent analgesia in the mouse tail-flick test when given centrally.  To further evaluate its potential therapeutic efficacy for translational-medical development, the current work was performed to explore the antinociceptive activities of i.p. (i.p.) administration of BN-9 in mouse models of tail-flick assay, formalin pain, visceral pain and post-operative pain.  In the tail-flick test, BN-9 induced a dose-related antinociceptive effect, which was fully blocked by systemic pretreatment with the peripheral acting opioid receptor antagonist naloxone methiodide, but not supraspinal naloxone methiodide, implying the involvement of the peripheral opioid receptors.  In addn., the systemic antinociception of BN-9 was antagonized by the selective antagonists of the μ- and κ-opioid receptors, independently of the δ-opioid and neuropeptide FF receptors.  Similarly, dose-dependent analgesia was also produced by systemic BN-9 in different pain models via the peripheral opioid receptors, independently of the neuropeptide FF receptors.  Furthermore, the side-effects of systemic BN-9 on motor performance, tolerance development and gastrointestinal transit inhibition were also evaluated.  Repeated systemic injection of BN-9 produced non-tolerance analgesia over 8 days.  Compared with morphine, i.p. administration of BN-9 exerted less inhibition of gastrointestinal transit.  These data show that BN-9 induced systemic analgesia with reduced side-effects on tolerance and constipation.  This article suggests that systemic injection of BN-9 causes effective antinociception in different preclin. pain models via the peripheral opioid receptors, providing an attractive approach to develop peripherally acting opioid analgesics with multiple targeting properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoJmldygEisLVg90H21EOLACvtfcHk0liMJrmiP_2I0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ClsLrO&md5=06c8c7cf2e41dd9f792196eeff49da8d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2018.08.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2018.08.039%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DZ.-L.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.-N.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DX.-R.%26aulast%3DZhao%26aufirst%3DW.-D.%26aulast%3DGuo%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DQ.-Q.%26aulast%3DFang%26aufirst%3DQ.%26atitle%3DSystemic%2520administration%2520of%2520the%2520bifunctional%2520opioid%252Fneuropeptide%2520FF%2520receptors%2520agonist%2520BN-9%2520produced%2520peripheral%2520antinociception%2520in%2520preclinical%2520mouse%2520models%2520of%2520pain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D837%26spage%3D53%26epage%3D63%26doi%3D10.1016%2Fj.ejphar.2018.08.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-n.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>813</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.07.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ejphar.2017.07.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=28755985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1CrsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=813&publication_year=2017&pages=122-129&author=R.+Zhangauthor=B.+Xuauthor=M.-n.+Zhangauthor=T.+Zhangauthor=Z.-l.+Wangauthor=G.+Zhaoauthor=G.-h.+Zhaoauthor=N.+Liauthor=Q.+Fangauthor=R.+Wang&title=Peripheral+and+central+sites+of+action+for+anti-allodynic+activity+induced+by+the+bifunctional+opioid%2FNPFF+receptors+agonist+BN-9+in+inflammatory+pain+model&doi=10.1016%2Fj.ejphar.2017.07.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/npff receptors agonist bn-9 in inflammatory pain model</span></div><div class="casAuthors">Zhang, Run; Xu, Biao; Zhang, Meng-na; Zhang, Ting; Wang, Zi-long; Zhao, Geng; Zhao, Guang-hai; Li, Ning; Fang, Quan; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">813</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-129</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The activation of opioid and neuropeptide FF (NPFF) receptors plays important roles to modulate nociceptive signal in inflammatory pain states.  Recently, BN-9 (Tyr-D. Ala-Gly-Phe-Gln-Pro-Gln-Arg-Phe-NH2) was pharmacol. characterized as a novel bifunctional agonist at both opioid and NPFF receptors.  In the present study, the anti-allodynic activity and site(s) of action of BN-9 were assessed in a mouse model of carrageenan-induced inflammatory pain.  In mice, BN-9 induced a dose-dependent anti-allodinic effect through opioid receptor at supraspinal or spinal level, and this effect was augmented by pretreatment with the NPFF receptor antagonist at the same level.  In contrast, peripheral administration of BN-9 produced opioid receptor-mediated anti-allodynia, which was insensitive of the NPFF receptor antagonist.  In addn., systemic BN-9 produced anti-allodynic effect via opioid receptors, independent of NPFF system.  Therefore, these data indicate that central, peripheral or systemic administrations of BN-9 exert potent analgesic activities in inflammatory pain model via opioid receptor, and central effects of BN-9 are assocd. with NPFF system.  Interestingly, systemic anti-allodynia of BN-9 was blocked by i.p. administration of the opioid receptor antagonists, naloxone and naloxone methiodide, but not by intracerebroventricular injection of the peripherally acting opioid antagonist naloxone methiodide.  Furthermore, BN-9-induced systemic anti-allodynia was reversed by intraplantar administration of naloxone, but not by peripheral administration of the NPFF receptor antagonist.  Taken together, our data further suggest that systemic BN-9-induced anti-allodynic effect is mainly mediated by peripheral opioid receptors, independent of NPFF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofvqw6PBkmZ7Vg90H21EOLACvtfcHk0liMJrmiP_2I0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1CrsrvO&md5=9325a59bdfb697a36269e59e89e7b009</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.07.044%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.-n.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.-l.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DG.-h.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DPeripheral%2520and%2520central%2520sites%2520of%2520action%2520for%2520anti-allodynic%2520activity%2520induced%2520by%2520the%2520bifunctional%2520opioid%252FNPFF%2520receptors%2520agonist%2520BN-9%2520in%2520inflammatory%2520pain%2520model%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D813%26spage%3D122%26epage%3D129%26doi%3D10.1016%2Fj.ejphar.2017.07.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollny, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokkar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mieres-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Garcia, E.</span></span> <span> </span><span class="NLM_article-title">Solvent-enhanced conformational flexibility of cyclic tetrapeptides</span>. <i>ChemPhysChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1664</span>– <span class="NLM_lpage">1670</span>, <span class="refDoi"> DOI: 10.1002/cphc.201900345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1002%2Fcphc.201900345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=31045298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1664-1670&author=N.+Bergerauthor=L.+Wollnyauthor=P.+Sokkarauthor=S.+Mittalauthor=J.+Mieres-Perezauthor=R.+Stollauthor=W.+Sanderauthor=E.+Sanchez-Garcia&title=Solvent-enhanced+conformational+flexibility+of+cyclic+tetrapeptides&doi=10.1002%2Fcphc.201900345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Solvent-Enhanced Conformational Flexibility of Cyclic Tetrapeptides</span></div><div class="casAuthors">Berger, Nadja; Wollny, Laura J. B.; Sokkar, Pandian; Mittal, Sumit; Mieres-Perez, Joel; Stoll, Raphael; Sander, Wolfram; Sanchez-Garcia, Elsa</div><div class="citationInfo"><span class="NLM_cas:title">ChemPhysChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1664-1670</span>CODEN:
                <span class="NLM_cas:coden">CPCHFT</span>;
        ISSN:<span class="NLM_cas:issn">1439-4235</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Solvent and temp. can affect the structural properties of cyclic peptides by controlling their flexibility.  Here, we investigate two cyclic peptides, featuring beta turns.  Using temp.-dependent NMR and FT-IR, we obsd. a pronounced temp. effect on the conformation of the cyclic peptide D-1 in CHCl3 but a much smaller effect in CH3CN.  Almost no effect was obsd. for its diastereomer L-1 within a similar temp. range and using the same solvents.  With the aid of Replica Exchange Mol. Dynamics simulations and Quantum Mechanics/Mol. Mechanics calcns., we were able to explain this behavior based on the increased flexibility of D-1 (in CHCl3) in terms of intramol. hydrogen bonding.  The largest temp. dependence is obsd. for D-1 in CHCl3, while the temp. effect is less pronounced for L-1 in CHCl3 and for both peptides in CH3CN.  This work provides new insights into the role of the environment and temp. on the conformations of cyclic peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBkdiukqRh6rVg90H21EOLACvtfcHk0liMJrmiP_2I0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsrzF&md5=fbdeff8938e6e29d4651c8f65031140e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fcphc.201900345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcphc.201900345%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DN.%26aulast%3DWollny%26aufirst%3DL.%26aulast%3DSokkar%26aufirst%3DP.%26aulast%3DMittal%26aufirst%3DS.%26aulast%3DMieres-Perez%26aufirst%3DJ.%26aulast%3DStoll%26aufirst%3DR.%26aulast%3DSander%26aufirst%3DW.%26aulast%3DSanchez-Garcia%26aufirst%3DE.%26atitle%3DSolvent-enhanced%2520conformational%2520flexibility%2520of%2520cyclic%2520tetrapeptides%26jtitle%3DChemPhysChem%26date%3D2019%26volume%3D20%26spage%3D1664%26epage%3D1670%26doi%3D10.1002%2Fcphc.201900345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deyle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Phage selection of cyclic peptides for application in research and drug development</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1866</span>– <span class="NLM_lpage">1874</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.7b00184</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.7b00184" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOqt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1866-1874&author=K.+Deyleauthor=X.-D.+Kongauthor=C.+Heinis&title=Phage+selection+of+cyclic+peptides+for+application+in+research+and+drug+development&doi=10.1021%2Facs.accounts.7b00184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phage Selection of Cyclic Peptides for Application in Research and Drug Development</span></div><div class="casAuthors">Deyle, Kaycie; Kong, Xu-Dong; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1866-1874</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic peptides can bind to protein targets with high affinities and selectivities, which makes them an attractive modality for the development of research reagents and therapeutics.  Addnl. properties, including low inherent toxicity, efficient chem. synthesis, and facile modification with labels or immobilization reagents, increase their attractiveness.  Cyclic peptide ligands against a wide range of protein targets have been isolated from natural sources such as bacteria, fungi, plants, and animals.  Many of them are currently used as research tools, and several have found application as therapeutics, such as the peptide hormones oxytocin and vasopressin and the antibiotics vancomycin and daptomycin, proving the utility of cyclic peptides in research and medicine.With the advent of phage display and other in vitro evolution techniques, it has become possible to generate cyclic peptide binders to diverse protein targets for which no natural peptides have been discovered.  A highly robust and widely applied approach is based on the cyclization of peptides displayed on phage via a disulfide bridge.  Disulfide-cyclized peptide ligands to more than a hundred different proteins have been reported in the literature.  Technol. advances achieved over the last three decades, including methods for generating larger phage display libraries, improved phage panning protocols, new cyclic peptide formats, and high-throughput sequencing, have enabled the generation of cyclic peptides with ever better binding affinities to more challenging targets.A relatively new cyclic peptide format developed using phage display involves bicyclic peptides.  These mols. consist of two macrocyclic peptide rings cyclized through a chem. linker.  Compared to monocyclic peptides of comparable mol. mass, bicyclic peptides are more constrained in their conformation.  As a result, they can bind to their targets with a higher affinity and are more resistant to proteolytic degrdn.  Phage-encoded bicyclic peptides are generated by chem. cyclizing random peptide libraries on phage.  Binders are identified by conventional phage panning and DNA sequencing.  Next-generation sequencing and new sequence alignment tools have enabled the rapid identification of bicyclic peptides.Bicyclic peptide ligands were developed against a range of diverse target classes including enzymes, receptors, and cytokines.  Most ligands bind with nanomolar affinities, with some reaching the picomolar range.  To date, several bicyclic peptides have been pos. evaluated in preclin. studies, and the first clin. tests are in sight.  While bicyclic peptide phage display was developed with therapeutic applications in mind, these peptides are increasingly used as research tools for target evaluation or as basic research probes as well.  Given the efficient development method, the ease of synthesis and handling, and the favorable binding and biophys. properties, bicyclic peptides are being developed against more and more targets, ever increasing their potential applications in research and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtQln3dL6wo7Vg90H21EOLACvtfcHk0lgSu_Ny16K3aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOqt7zP&md5=416350a497d5f8811ac0a52cc441a03e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.7b00184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.7b00184%26sid%3Dliteratum%253Aachs%26aulast%3DDeyle%26aufirst%3DK.%26aulast%3DKong%26aufirst%3DX.-D.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPhage%2520selection%2520of%2520cyclic%2520peptides%2520for%2520application%2520in%2520research%2520and%2520drug%2520development%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2017%26volume%3D50%26spage%3D1866%26epage%3D1874%26doi%3D10.1021%2Facs.accounts.7b00184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucke, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoermer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">Orally absorbed cyclic peptides</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">8094</span>– <span class="NLM_lpage">8128</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.6b00838</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00838" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot12lurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=8094-8128&author=D.+S.+Nielsenauthor=N.+E.+Shepherdauthor=W.+Xuauthor=A.+J.+Luckeauthor=M.+J.+Stoermerauthor=D.+P.+Fairlie&title=Orally+absorbed+cyclic+peptides&doi=10.1021%2Facs.chemrev.6b00838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Absorbed Cyclic Peptides</span></div><div class="casAuthors">Nielsen, Daniel S.; Shepherd, Nicholas E.; Xu, Weijun; Lucke, Andrew J.; Stoermer, Martin J.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">8094-8128</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Peptides and proteins are not orally bioavailable in mammals, although a few peptides are intestinally absorbed in small amts.  Polypeptides are generally too large and polar to passively diffuse through lipid membranes, while most known active transport mechanisms facilitate cell uptake of only very small peptides.  Systematic evaluations of peptides with mol. wts. above 500 Da are needed to identify parameters that influence oral bioavailability.  Here we describe 125 cyclic peptides contg. four to thirty-seven amino acids that are orally absorbed by mammals.  Cyclization minimizes degrdn. in the gut, blood and tissues by removing cleavable N- and C-termini and by shielding components from metabolic enzymes.  Cyclization also folds peptides into bioactive conformations that det. exposure of polar atoms to solvation by water and lipids, and therefore should influence oral bioavailability.  Key chem. properties thought to influence oral absorption and bioavailability are analyzed, including mol. wt., octanol-water partitioning, hydrogen bond donors/acceptors, rotatable bonds and polar surface area.  The cyclic peptides violated to different degrees all of the limits traditionally considered to be important for oral bioavailability of drug-like small mols., although fewer hydrogen bond donors and reduced flexibility generally favored oral absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprHf1YVkf7ErVg90H21EOLACvtfcHk0lgSu_Ny16K3aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot12lurY%253D&md5=38af1945471e5ddffd3ae630ebbe129b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00838%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DD.%2BS.%26aulast%3DShepherd%26aufirst%3DN.%2BE.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLucke%26aufirst%3DA.%2BJ.%26aulast%3DStoermer%26aufirst%3DM.%2BJ.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DOrally%2520absorbed%2520cyclic%2520peptides%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D8094%26epage%3D8128%26doi%3D10.1021%2Facs.chemrev.6b00838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span> <span> </span><span class="NLM_article-title">Targeting intracellular protein-protein interactions with cell-permeable cyclic peptides</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2017.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.cbpa.2017.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=28388463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1KlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=80-86&author=Z.+Qianauthor=P.+G.+Doughertyauthor=D.+Pei&title=Targeting+intracellular+protein-protein+interactions+with+cell-permeable+cyclic+peptides&doi=10.1016%2Fj.cbpa.2017.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting intracellular protein-protein interactions with cell-permeable cyclic peptides</span></div><div class="casAuthors">Qian, Ziqing; Dougherty, Patrick G.; Pei, Dehua</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-86</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Intracellular protein-protein interactions (PPIs) are challenging targets for conventional drug modalities, because small mols. generally do not bind to their large, flat binding sites with high affinity, whereas monoclonal antibodies cannot cross the cell membrane to reach the targets.  Cyclic peptides in the 700-2000 mol.-wt. range have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat PPI interfaces with antibody-like affinity and specificity.  Several powerful cyclic peptide library technologies were developed over the past decade to rapidly discover potent, specific cyclic peptide ligands against proteins of interest including those involved in PPIs.  Methods are also being developed to enhance the membrane permeability of cyclic peptides through both passive diffusion and active transport mechanisms.  Integration of the permeability-enhancing elements into cyclic peptide design has led to an increasing no. of cell-permeable and biol. active cyclic peptides against intracellular PPIs.  In this account, we review the recent developments in the design and synthesis of cell-permeable cyclic peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_IPrrU8rcMbVg90H21EOLACvtfcHk0lgSu_Ny16K3aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1KlsLg%253D&md5=2ea4ac695ee1f1651e5da4ed0bb7cf0b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2017.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2017.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DDougherty%26aufirst%3DP.%2BG.%26aulast%3DPei%26aufirst%3DD.%26atitle%3DTargeting%2520intracellular%2520protein-protein%2520interactions%2520with%2520cell-permeable%2520cyclic%2520peptides%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D38%26spage%3D80%26epage%3D86%26doi%3D10.1016%2Fj.cbpa.2017.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remesic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span> <span> </span><span class="NLM_article-title">Cyclic opioid peptides</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.2174/0929867323666160427123005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.2174%2F0929867323666160427123005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27117332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFags7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1288-1303&author=M.+Remesicauthor=Y.+Sun+Leeauthor=V.+J.+Hruby&title=Cyclic+opioid+peptides&doi=10.2174%2F0929867323666160427123005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic Opioid Peptides</span></div><div class="casAuthors">Remesic, Michael; Lee, Yeon Sun; Hruby, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1288-1303</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">For decades the opioid receptors have been an attractive therapeutic target for the treatment of pain.  Since the first discovery of enkephalin, approx. a dozen endogenous opioid peptides have been known to produce opioid activity and analgesia, but their therapeutics have been limited mainly due to low blood brain barrier penetration and poor resistance to proteolytic degrdn.  One versatile approach to overcome these drawbacks is the cyclization of linear peptides to cyclic peptides with constrained topog. structure.  Compared to their linear parents, cyclic analogs exhibit better metabolic stability, lower offtarget toxicity, and improved bioavailability.  Extensive structure-activity relationship studies have uncovered promising compds. for the treatment of pain as well as further elucidate structural elements required for selective opioid receptor activity.  The benefits that come with employing cyclization can be further enhanced through the generation of polycyclic derivs.  Opioid ligands generally have a short peptide chain and thus the realm of polycyclic peptides has yet to be explored.  In this review, a brief history of designing ligands for the opioid receptors, including classic linear and cyclic ligands, is discussed along with recent approaches and successes of cyclic peptide ligands for the receptors.  Various scaffolds and approaches to improve bioavailability are elaborated and concluded with a discourse towards polycyclic peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVqRd2N_Fx-LVg90H21EOLACvtfcHk0ljCrZzraqNu5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFags7w%253D&md5=3a1df6a45b331fa5d7c78f0c34eccfe9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F0929867323666160427123005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666160427123005%26sid%3Dliteratum%253Aachs%26aulast%3DRemesic%26aufirst%3DM.%26aulast%3DSun%2BLee%26aufirst%3DY.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DCyclic%2520opioid%2520peptides%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D1288%26epage%3D1303%26doi%3D10.2174%2F0929867323666160427123005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galligan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, T. F.</span></span> <span> </span><span class="NLM_article-title">Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">5871</span>– <span class="NLM_lpage">5874</span>, <span class="refDoi"> DOI: 10.1073/pnas.80.19.5871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.80.19.5871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=6310598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaL2cXivFOqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1983&pages=5871-5874&author=H.+I.+Mosbergauthor=R.+Hurstauthor=V.+J.+Hrubyauthor=K.+Geeauthor=H.+I.+Yamamuraauthor=J.+J.+Galliganauthor=T.+F.+Burks&title=Bis-penicillamine+enkephalins+possess+highly+improved+specificity+toward+delta+opioid+receptors&doi=10.1073%2Fpnas.80.19.5871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-penicillamine enkephalins possess highly improved specificity toward δ opioid receptors</span></div><div class="casAuthors">Mosberg, Henry I.; Hurst, Robin; Hruby, Victor J.; Gee, Kelvin; Yamamura, Henry I.; Galligan, James J.; Burks, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5871-4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The conformationally restricted, cyclic, disulfide-contg., enkephalin analogs [2-D-penicillamine, 5-L-penicillamine]enkephalin ([D-Pen2,L-Pen5]enkephalin)(I)  [88373-72-2] and [2-D-penicillamine, 5-D-penicillamine]enkephalin ([D-Pen2,D-Pen5]enkephalin)  [88373-73-3] were synthesized by solid-phase methods and selectivities of these analogs for a single class of opioid receptor investigated by examg. relative potencies in the mouse vas deferens assay (δ receptor), vs. the guinea pig ileum assay (μ receptor), and by detg. their relative abilities to displace the prototypical δ receptor ligand [D-Ala2,D-Leu5]enkephalin  [63631-40-3] and the prototypical μ receptor ligand naloxone from rat brain membrane prepns.  Based on these comparisons [D-Pen2,L-Pen5]- and [D-Pen2,D-Pen5]enkephalin exhibited δ receptor selectivities of 1088 and 3164, resp., in the bioassays, and 371 and 175, resp., in the binding assays.  Compared with the previously reported δ receptor selective analogs, [D-Ala2,D-Leu5]enkephalin  [63631-40-3], [D-Ser2,Leu5,Thr6]enkephalin  [75644-90-5], and [D-Thr2,Leu5,Thr6]enkephalin  [466-97-7], the bis-Pen-contg. analogs provide an order of magnitude increase in δ receptor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Z8bMlV-VgLVg90H21EOLACvtfcHk0ljCrZzraqNu5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXivFOqsA%253D%253D&md5=1c17f2fb1638bf23739c667b75b8e27b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.80.19.5871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.80.19.5871%26sid%3Dliteratum%253Aachs%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DHurst%26aufirst%3DR.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGee%26aufirst%3DK.%26aulast%3DYamamura%26aufirst%3DH.%2BI.%26aulast%3DGalligan%26aufirst%3DJ.%2BJ.%26aulast%3DBurks%26aufirst%3DT.%2BF.%26atitle%3DBis-penicillamine%2520enkephalins%2520possess%2520highly%2520improved%2520specificity%2520toward%2520delta%2520opioid%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1983%26volume%3D80%26spage%3D5871%26epage%3D5874%26doi%3D10.1073%2Fpnas.80.19.5871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lomize, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flippen-Anderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Conformational analysis of the .delta. receptor-selective, cyclic opioid peptide, Tyr-cyclo[D-Cys-Phe-D-Pen]OH (JOM-13). Comparison of x-ray crystallographic structures, molecular mechanics simulations, and proton NMR data</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1021/ja00081a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00081a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK2cXhtlGisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=429-436&author=A.+L.+Lomizeauthor=J.+L.+Flippen-Andersonauthor=C.+Georgeauthor=H.+I.+Mosberg&title=Conformational+analysis+of+the+.delta.+receptor-selective%2C+cyclic+opioid+peptide%2C+Tyr-cyclo%5BD-Cys-Phe-D-Pen%5DOH+%28JOM-13%29.+Comparison+of+x-ray+crystallographic+structures%2C+molecular+mechanics+simulations%2C+and+proton+NMR+data&doi=10.1021%2Fja00081a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational analysis of the δ receptor-selective, cyclic opioid peptide, Tyr-cyclo[D-Cys-Phe-D-Pen]OH (JOM-13). Comparison of x-ray crystallographic structures, molecular mechanics simulations, and proton NMR data</span></div><div class="casAuthors">Lomize, Andrei L.; Flippen-Anderson, Judith L.; George, Clifford; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">429-36</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The conformational features of the title δ-selective, cyclic opioid peptide I (Pen = penicillamine) (JOM-13) were investigated using a combination of exptl. (x-ray crystallog., 1H NMR) and theor. (mol. mechanics computations) techniques.  Energy calcns. with the CHARMm force field show the existence of a single energetically preferred backbone conformation for the cyclic tripeptide portion of the mol.  Several distinct low-energy conformations were calcd., however, for the disulfide bridge linking the D-Cys and D-Pen residues, for the single Tyr residue outside the cycle, and for the Tyr and Phe side chains.  The two calcd. lowest-energy conformers of the D-Cys, D-Pen disulfide bridge (A and B) differ in values of D-Cys χ and χ3 (S-S) torsion angles.  This is consistent with the observation of two 1H NMR signal sets in aq. soln. (in the ratio 68:32) with distinctly different vicinal coupling consts. for protons H-CαCβ-H that correspond to a D-Cys χ1 angle of about -60° for the first set and ∼180° or +60° for the second.  X-ray crystallog. anal. of crystals grown from aq. soln. also revealed two independent conformers which are in excellent agreement with the computational and NMR data for the rigid, cyclic part of the mol. including the disulfide bridge.  However, 1H NMR data and computational results indicate that the flexible elements of JOM-13 (the exocyclic Tyr residue and the Tyr and Phe side chains) have no fixed structure in water soln.  In the cryst. environment they adopt conformations that are stabilized mainly by intermol. interactions and which do not correspond exactly to any local energy min. identified in the mol. mechanics calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsisCOYsRfX7Vg90H21EOLACvtfcHk0ljCrZzraqNu5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtlGisLw%253D&md5=44b5a3fc074b0803d1c8360d3a21b102</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja00081a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00081a001%26sid%3Dliteratum%253Aachs%26aulast%3DLomize%26aufirst%3DA.%2BL.%26aulast%3DFlippen-Anderson%26aufirst%3DJ.%2BL.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DConformational%2520analysis%2520of%2520the%2520.delta.%2520receptor-selective%252C%2520cyclic%2520opioid%2520peptide%252C%2520Tyr-cyclo%255BD-Cys-Phe-D-Pen%255DOH%2520%2528JOM-13%2529.%2520Comparison%2520of%2520x-ray%2520crystallographic%2520structures%252C%2520molecular%2520mechanics%2520simulations%252C%2520and%2520proton%2520NMR%2520data%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D429%26epage%3D436%26doi%3D10.1021%2Fja00081a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Przydzial, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tharp, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor</span>. <i>J. Pept. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.2005.00220.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1111%2Fj.1399-3011.2005.00220.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=15787963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVCjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=333-342&author=M.+J.+Przydzialauthor=I.+D.+Pogozhevaauthor=K.+E.+Bosseauthor=S.+M.+Andrewsauthor=T.+A.+Tharpauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Roles+of+residues+3+and+4+in+cyclic+tetrapeptide+ligand+recognition+by+the+kappa-opioid+receptor&doi=10.1111%2Fj.1399-3011.2005.00220.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the κ-opioid receptor</span></div><div class="casAuthors">Przydzial, M. J.; Pogozheva, I. D.; Bosse, K. E.; Andrews, S. M.; Tharp, T. A.; Traynor, J. R.; Mosberg, H. I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-342</span>CODEN:
                <span class="NLM_cas:coden">JPERFA</span>;
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A series of cyclic, disulfide- or dithioether-contg. tetrapeptides based on previously reported potent μ- and δ-selective analogs has been explored with the aim of improving their poor affinity to the κ-opioid receptor.  Specifically targeted were modifications of tetrapeptide residues 3 and 4, as they presumably interact with residues from transmembrane helixes 6 and 7 and extracellular loop 3 that differ among the three receptors.  Accordingly, tetrapeptides were synthesized with Phe3 replaced by aliph. (Gly, Ala, Aib, Cha), basic (Lys, Arg, homo-Arg), or arom. sides chains (Trp, Tyr, p-NH2Phe), and with D-Pen4 replaced by D-Cys4, and binding affinities to stably expressed μ-, δ-, and κ-receptors were detd.  In general, the resulting analogs failed to exhibit appreciable affinity for the κ-receptor, with the exception of the tetrapeptide Tyr-c[D-Cys-Phe-D-Cys]-NH2, cyclized via a disulfide bond, which demonstrated high binding affinity toward all opioid receptors (Kiμ = 1.26 nM, Kiδ = 16.1 nM, Kiκ = 38.7 nM).  Modeling of the κ-receptor/ligand complex in the active state reveals that the receptor-binding pocket for residues 3 and 4 of the tetrapeptide ligands is smaller than that in the μ-receptor and requires, for optimal fit, that the tripeptide cycle of the ligand assume a higher energy conformation.  The magnitude of this energy penalty depends on the nature of the fourth residue of the peptide (D-Pen or D-Cys) and correlates well with the obsd. κ-receptor binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqpaJjquUBDrVg90H21EOLACvtfcHk0liIieLOf3yyOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVCjtbw%253D&md5=62f2c2c4946da1a922d23310f1d933b2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.2005.00220.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.2005.00220.x%26sid%3Dliteratum%253Aachs%26aulast%3DPrzydzial%26aufirst%3DM.%2BJ.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DBosse%26aufirst%3DK.%2BE.%26aulast%3DAndrews%26aufirst%3DS.%2BM.%26aulast%3DTharp%26aufirst%3DT.%2BA.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DRoles%2520of%2520residues%25203%2520and%25204%2520in%2520cyclic%2520tetrapeptide%2520ligand%2520recognition%2520by%2520the%2520kappa-opioid%2520receptor%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D2005%26volume%3D65%26spage%3D333%26epage%3D342%26doi%3D10.1111%2Fj.1399-3011.2005.00220.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chieng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span> <span> </span><span class="NLM_article-title">The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K<sup>+</sup> conductance of rat locus ceruleus neurons</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">655</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=8794906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK28XlslSgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=650-655&author=B.+Chiengauthor=M.+Connorauthor=M.+J.+Christie&title=The+mu-opioid+receptor+antagonist+D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2+%28CTOP%29+%5Bbut+not+D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2+%28CTAP%29%5D+produces+a+nonopioid+receptor-mediated+increase+in+K%2B+conductance+of+rat+locus+ceruleus+neurons"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The μ-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-The-NH2 (CTOP) but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP) produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons</span></div><div class="casAuthors">Chieng, Billy; Connor, Mark; Christie, MacDonald J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">650-655</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The somatostatin analogs CTOP and CTAP have been used widely as selective antagonists of μ-opioid receptors.  Actions of CTOP and CTAP on the membrane properties of rat locus ceruleus neurons were studied using intracellular recordings of membrane currents in superfused brain slices.  CTOP increased a K+ conductance with an EC50 of 560 nM.  The maximal conductance increase produced by CTOP (10 μm) was similar to that produced by high concns. of the μ-opioid agonists D-Ala-Met-enkephalinglycol (1 μM) and Met-enkephalin (10 μM), as well as an α2-adrenoceptor agonist (UK14304, 3 μM) and somatostatin (1 μM).  The K+ current produced by CTOP was not antagonized by naloxone (1 μM), suggesting it was not mediated by μ-opioid receptors.  The K+ currents induced by high concns. of CTOP desensitized to 42% of the initial max. after prolonged superfusion (t1/2 = 247 s).  In the presence of fully desensitized CTOP responses, somatostatin (1 μM) still produced near-maximal K+ currents; i.e. there was no cross-desensitization, which suggests that CTOP might act on a receptor distinct from somatostatin receptors.  However, the converse did not apply; high concns. of CTOP did not produce any addnl. current in the presence of desensitized somatostatin responses.  No cross-desensitization was obsd. between CTOP (10-30 μM) and Met-enkephalin (30 μM) or nociceptin (3 μM) regardless of the order of drug application.  Cyclo-(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[Bzl]), antagonized both somatostatin-(KD = 10 μM) and CTOP-(KK = 8 μM) induced K+ currents with similar potency.  Concns. of CTOP (100 nm) that produced a small K+ current partially antagonized the actions of Met-enkephalin (10- μM) on μ-opioid receptors.  In contrast to CTOP, CTAP produced no K+ current at concns. of 300 nm and 1 μM and little current at 10 μm.  CTAP potently antagonized K+ currents produced by the μ-opioid receptor agonist D-Ala-Met-enkephalin-glyol, with an equil. dissocn. const. of 4 nM (Schlid anal.).  CTAP did not antagonize K+ currents produced by CTOP or somatostatin.  These results demonstrated that CTOP is a potent and efficacious agonist at nonopioid receptors, whereas CTAP is a potent μ-opioid receptor antagonist with little nonopioid agonist activity in rat locus ceruleus neurons.  The receptor activated by CTOP has yet to be fully resolved but seems to be similar to the somatostatin type 2 receptor or perhaps to a receptor closely related to somatostatin or opioid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosJmtqteaBEbVg90H21EOLACvtfcHk0liIieLOf3yyOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlslSgsr0%253D&md5=b1f38bf9df7b66897934250f3a4b3aa4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChieng%26aufirst%3DB.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520mu-opioid%2520receptor%2520antagonist%2520D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2%2520%2528CTOP%2529%2520%255Bbut%2520not%2520D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2%2520%2528CTAP%2529%255D%2520produces%2520a%2520nonopioid%2520receptor-mediated%2520increase%2520in%2520K%252B%2520conductance%2520of%2520rat%2520locus%2520ceruleus%2520neurons%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D50%26spage%3D650%26epage%3D655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patkar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span> <span> </span><span class="NLM_article-title">Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">18396</span>– <span class="NLM_lpage">18401</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910180106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.0910180106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19841255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18396-18401&author=J.+V.+Aldrichauthor=K.+A.+Patkarauthor=J.+P.+McLaughlin&title=Zyklophin%2C+a+systemically+active+selective+kappa+opioid+receptor+peptide+antagonist+with+short+duration+of+action&doi=10.1073%2Fpnas.0910180106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action</span></div><div class="casAuthors">Aldrich, Jane V.; Patkar, Kshitij A.; McLaughlin, Jay P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">18396-18401</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The cyclic peptide zyklophin is a selective peptide kappa opioid receptor (KOR) antagonist that shows activity following systemic administration.  Systemic (1-3 mg/kg s.c.) as well as central (0.3-3 nmol intracerebroventricular, i.c.v.) administration of this peptide dose-dependently antagonizes the antinociception induced by the selective KOR agonist U50,488 in C57BU6J mice tested in the 55 warm water tail withdrawal assay.  Zyklophin administration had no effect on morphine- or SNC-80-mediated antinociception, suggesting that zyklophin selectively antagonizes KOR in vivo.  Addnl., the antagonism of antinociception induced by centrally (i.c.v.) administered U50,488 following peripheral administration of zyklophin strongly suggests that the peptide crosses the blood-brain barrier to antagonize KOR in the CNS.  Most importantly, the antagonist activity of zyklophin (3 mg/kg s.c.) lasts less than 12 h, which contrasts sharply with the exceptionally long duration of antagonism reported for the established small-mol. selective KOR antagonists such as norbinaltorphimine (nor-BNI) that last weeks after a single administration.  Systemically administered zyklophin (3 mg/kg s.c.) also prevented stress-induced reinstatement of cocaine-seeking behavior in a conditioned place preference assay.  In conclusion, the peptide zyklophin is a KOR-selective antagonist that exhibits the desired shorter duration of action, and represents a significant advance in the development of KOR-selective antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl_X3b-nZo-LVg90H21EOLACvtfcHk0liIieLOf3yyOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3F&md5=af15f86e709f6127d56e027aff38c967</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910180106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910180106%26sid%3Dliteratum%253Aachs%26aulast%3DAldrich%26aufirst%3DJ.%2BV.%26aulast%3DPatkar%26aufirst%3DK.%2BA.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26atitle%3DZyklophin%252C%2520a%2520systemically%2520active%2520selective%2520kappa%2520opioid%2520receptor%2520peptide%2520antagonist%2520with%2520short%2520duration%2520of%2520action%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D18396%26epage%3D18401%26doi%3D10.1073%2Fpnas.0910180106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mansfeld, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and plasma stability of disulfide-bridged cyclic endomorphin-1 derivatives</span>. <i>Int. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.4236/ijoc.2012.21001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.4236%2Fijoc.2012.21001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSlsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1-6&author=F.+M.+Mansfeldauthor=I.+Toth&title=Synthesis+and+plasma+stability+of+disulfide-bridged+cyclic+endomorphin-1+derivatives&doi=10.4236%2Fijoc.2012.21001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and plasma stability of disulfide-bridged cyclic endomorphin-1 derivatives</span></div><div class="casAuthors">Mansfeld, Friederike M.; Toth, Istvan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">IJOCCR</span>;
        ISSN:<span class="NLM_cas:issn">2161-4687</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">Endomorphin-1 is an endogenous opioid peptide that mediates pain relief through interaction with the μ-opioid receptor in the central nervous system.  To enhance the metabolic stability of this tetrapeptide, cyclization through the formation of a disulfide bridge between the side chains of cysteine residues added to the sequence was explored.  A further increase in stability was achieved through N-terminal modification with lipoamino acid and lactose succinamic acid, and the inclusion of D-amino acids.  The latter also provided an alternative spatial arrangement of the arom. side chains.  The lipidated cyclic derivs. were insol. in aq. buffer, however, the cyclic peptides and glycopeptides showed greatly improved stability towards enzymic degrdn. in human plasma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwfyEhqlCilbVg90H21EOLACvtfcHk0liIieLOf3yyOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSlsrfK&md5=7f419ea0e4764b3876c8a50a790b3b70</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.4236%2Fijoc.2012.21001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fijoc.2012.21001%26sid%3Dliteratum%253Aachs%26aulast%3DMansfeld%26aufirst%3DF.%2BM.%26aulast%3DToth%26aufirst%3DI.%26atitle%3DSynthesis%2520and%2520plasma%2520stability%2520of%2520disulfide-bridged%2520cyclic%2520endomorphin-1%2520derivatives%26jtitle%3DInt.%2520J.%2520Org.%2520Chem.%26date%3D2012%26volume%3D2%26spage%3D1%26epage%3D6%26doi%3D10.4236%2Fijoc.2012.21001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">Strategies to assess blood-brain barrier penetration</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1517/17460441.3.6.677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1517%2F17460441.3.6.677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=23506148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVyrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=677-687&author=L.+Diauthor=E.+H.+Kernsauthor=G.+T.+Carter&title=Strategies+to+assess+blood-brain+barrier+penetration&doi=10.1517%2F17460441.3.6.677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to assess blood-brain barrier penetration</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-687</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: The principles and screening strategies for brain penetration in drug discovery are important in identifying drug candidates with desirable CNS properties.  Objective: Define key variables and assays that are essential for detg. brain penetration.  Methods: This review covers issues, methods, and strategies for assessing brain penetration of small mols. in drug discovery.  Results/conclusion: Brain penetration is assessed using both initial rate and extent at steady-state.  Unbound drug is the active species that exerts pharmacol. effects.  Low brain penetration can be due to low blood-brain barrier (BBB) permeability, P-glycoprotein (Pgp) efflux, or high plasma protein binding.  Successful methods include: parallel artificial membrane permeability assay (PAMPA)-BBB permeability, MDR1-MDCKII for Pgp efflux, B-P dialysis for fraction unbound, and in vivo B/P ratio to extrapolate unbound brain drug concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOHHdHc1xH7LVg90H21EOLACvtfcHk0lj23_4yvax7ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVyrtL0%253D&md5=8186d3a972120691aebb3dba4810f7f8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F17460441.3.6.677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.3.6.677%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DStrategies%2520to%2520assess%2520blood-brain%2520barrier%2520penetration%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D677%26epage%3D687%26doi%3D10.1517%2F17460441.3.6.677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stain-Texier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandouk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrmann, J.-M.</span></span> <span> </span><span class="NLM_article-title">Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fsj.bjp.0702873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10556926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK1MXntFCiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=917-924&author=F.+Stain-Texierauthor=G.+Boschiauthor=P.+Sandoukauthor=J.-M.+Scherrmann&title=Elevated+concentrations+of+morphine+6-beta-D-glucuronide+in+brain+extracellular+fluid+despite+low+blood-brain+barrier+permeability&doi=10.1038%2Fsj.bjp.0702873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood - brain barrier permeability</span></div><div class="casAuthors">Stain-Texier, Frederique; Boschi, Gabrielle; Sandouk, Pierre; Scherrmann, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">917-924</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">This study was done to find out how morphine 6-beta-D-glucuronide (M6G) induces more potent central analgesia than morphine, despite its poor blood-brain barrier (BBB) permeability.  The brain uptake and disposition of these compds. were investigated in plasma and in various brain compartments: extracellular fluid (ECF), intracellular space (ICS) and cerebrospinal fluid (CSF).  Morphine or M6G was given to rats at 10 mg kg-1 s.c.  Transcortical microdialysis was used to assess their distributions in the brain ECF.  Conventional tissue homogenization was used to det. the distribution in the cortex and whole brain.  These two procedures were combined to est. drug distribution in the brain ICS.  The blood and CSF pharmacokinetics were also detd.  Plasma concn. data for M6G were much higher than those of morphine, with Cmax and AUC 4-5 times more higher, Tmax shorter, and VZf-1 (vol. of distribution) and CL f-1 (clearance) 4-6 times lower.  The concns. of the compds. in various brain compartments also differed: AUC values for M6G were lower than those of morphine in tissue and CSF and higher in brain ECF.  AUC values in brain show that morphine levels were four times higher in ICS than in ECF, whereas M6G levels were 125 higher in ECF than in ICS.  Morphine entered brain cells, whereas M6G was almost exclusively extracellular.  This high extracellular concn., coupled with extremely slow diffusion into the CSF, indicates that M6G was predominantly trapped in the extracellular fluid and therefore durably available to bind at opioid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4m4joGsaYsLVg90H21EOLACvtfcHk0lj23_4yvax7ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFCiu7g%253D&md5=5c21b08e2b1099a8fe5b3e5b32ae0d39</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702873%26sid%3Dliteratum%253Aachs%26aulast%3DStain-Texier%26aufirst%3DF.%26aulast%3DBoschi%26aufirst%3DG.%26aulast%3DSandouk%26aufirst%3DP.%26aulast%3DScherrmann%26aufirst%3DJ.-M.%26atitle%3DElevated%2520concentrations%2520of%2520morphine%25206-beta-D-glucuronide%2520in%2520brain%2520extracellular%2520fluid%2520despite%2520low%2520blood-brain%2520barrier%2520permeability%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D917%26epage%3D924%26doi%3D10.1038%2Fsj.bjp.0702873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gengo, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNutt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-J.</span></span> <span> </span><span class="NLM_article-title">DPI-3290 [(+)-3-((α-R)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A Mixed Opioid Agonist with Potent Antinociceptive Activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.054361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1124%2Fjpet.103.054361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=14534368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslSht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=1221-1226&author=P.+J.+Gengoauthor=H.+O.+Pettitauthor=S.+J.+O%E2%80%99Neillauthor=K.+Weiauthor=R.+McNuttauthor=M.+J.+Bishopauthor=K.-J.+Chang&title=DPI-3290+%5B%28%2B%29-3-%28%28%CE%B1-R%29-%CE%B1-%28%282S%2C5R%29-4-Allyl-2%2C5-dimethyl-1-piperazinyl%29-3-hydroxybenzyl%29-N-%283-fluorophenyl%29-N-methylbenzamide%5D.+I.+A+Mixed+Opioid+Agonist+with+Potent+Antinociceptive+Activity&doi=10.1124%2Fjpet.103.054361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">DPI-3290 [(+)-3-((α-R)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity</span></div><div class="casAuthors">Gengo, Peter J.; Pettit, Hugh O.; O'Neill, Scott J.; Wei, Ke; McNutt, Robert; Bishop, Michael J.; Chang, Kwen-jen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1221-1226</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">DPI-3290 is one of a series of novel centrally acting agents with potent antinociceptive activity that binds specifically and with high affinity to opioid receptors.  In satn. equil. binding studies performed at 25°C using membranes from rat brain or guinea pig cerebellum, the Ki values measured for DPI-3290 at δ-, μ-, and κ-opioid receptors were 0.18 ± 0.02, 0.46 ± 0.05, and 0.62 ± 0.09 nM, resp.  In vas deferens isolated from lab. mice, DPI-3290 decreased elec. induced tension development in a concn.-dependent manner with corresponding IC50 values of 1.0 ± 0.3, 6.2 ± 2.0, and 25.0 ± 3.3 nM at δ-, μ-, and κ-receptors, resp.  The activity of DPI-3290 in isolated vas deferens tissue was approx. 20,000, 175.8, and 1500 times more efficacious than morphine, and 492, 2.5, and 35 times more efficacious than fentanyl at δ-, μ-, and κ-receptors, resp.  In ileal strips isolated from guinea pigs, DPI-3290 inhibited tension development with a corresponding IC50 value of 3.4 ± 1.6 nM at μ-opioid receptors and 6.7 ± 1.6 nM at κ-opioid receptors.  I.v. administration of 0.05 ± 0.007 mg/kg DPI-3290 produced a 50% antinociceptive response in rats.  The antinociceptive properties of DPI-3290 were blocked by naloxone (0.5 mg/kg s.c.).  Compared with morphine, this study demonstrated that DPI-3290 is more potent and elicited a similar magnitude of antinociceptive activity in the rat, actions mediated by its mixed opioid receptor agonist activity.  The marked antinociceptive activity of DPI-3290 will likely provide a means for relieving severe pain in patients that require analgesic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLw--VdDEU6LVg90H21EOLACvtfcHk0lj23_4yvax7ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslSht7Y%253D&md5=4ec14513152f2d0f517c6ac1bfc4d7bd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.054361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.054361%26sid%3Dliteratum%253Aachs%26aulast%3DGengo%26aufirst%3DP.%2BJ.%26aulast%3DPettit%26aufirst%3DH.%2BO.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DS.%2BJ.%26aulast%3DWei%26aufirst%3DK.%26aulast%3DMcNutt%26aufirst%3DR.%26aulast%3DBishop%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DK.-J.%26atitle%3DDPI-3290%2520%255B%2528%252B%2529-3-%2528%2528%25CE%25B1-R%2529-%25CE%25B1-%2528%25282S%252C5R%2529-4-Allyl-2%252C5-dimethyl-1-piperazinyl%2529-3-hydroxybenzyl%2529-N-%25283-fluorophenyl%2529-N-methylbenzamide%255D.%2520I.%2520A%2520Mixed%2520Opioid%2520Agonist%2520with%2520Potent%2520Antinociceptive%2520Activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D307%26spage%3D1221%26epage%3D1226%26doi%3D10.1124%2Fjpet.103.054361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, S.-p.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Q.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Z.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, R.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-j.</span></span> <span> </span><span class="NLM_article-title">The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">977</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1038/aps.2017.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Faps.2017.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=28502978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFanu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=977-989&author=S.-p.+Yiauthor=Q.-h.+Kongauthor=Y.-l.+Liauthor=C.-l.+Panauthor=J.+Yuauthor=B.-q.+Cuiauthor=Y.-f.+Wangauthor=G.-l.+Wangauthor=P.-l.+Zhouauthor=L.-l.+Wangauthor=Z.-h.+Gongauthor=R.-b.+Suauthor=Y.-h.+Shenauthor=G.+Yuauthor=K.-j.+Chang&title=The+opioid+receptor+triple+agonist+DPI-125+produces+analgesia+with+less+respiratory+depression+and+reduced+abuse+liability&doi=10.1038%2Faps.2017.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability</span></div><div class="casAuthors">Yi, Shou-pu; Kong, Qing-hong; Li, Yu-lei; Pan, Chen-ling; Yu, Jie; Cui, Ben-qiang; Wang, Ying-fei; Wang, Guan-lin; Zhou, Pei-lan; Wang, Li-li; Gong, Ze-hui; Su, Rui-bin; Shen, Yue-hai; Yu, Gang; Chang, Kwen-jen</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">977-989</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Opioid analgesics remain the first choice for the treatment of moderate to severe pain, but they are also notorious for their respiratory depression and addictive effects.  This study focused on the pharmacol. of a novel opioid receptor mixed agonist DPI-125 and attempted to elucidate the relationship between the δ-, μ- and κ-receptor potency ratio and respiratory depression and abuse liability.  Five diarylmethylpiperazine compds. (DPI-125, DPI-3290, DPI-130, KUST202 and KUST13T02) were selected for this study.  PKA fluorescence redistribution assays in CHO cells individually expressing δ-, μ- or κ-receptors were used to measure the agonist potency.  The respiratory safety profiles were estd. in rats by the ratio of ED50 (pCO2 increase)/ED50 (antinociception).  The abuse liability of DPI-125 was evaluated with a self-administration model in rhesus monkeys.  The obsd. agonist potencies of DPI-125 for δ-, μ- and κ-opioid receptors were 4.29±0.36, 11.10±3.04, and 16.57±4.14 nmol/L, resp.  The other four compds. were also mixed agonists with varying potencies.  DPI-125 exhibited a high respiratory safety profile, clearly related to its high δ-receptor potency.  The ratio of the EC50 potencies for the μ- and δ-receptors was found to be pos. correlated with the respiratory safety ratio.  DPI-125 has similar potencies for μ- and κ-receptors, which is likely the reason for its reduced abuse potential.  Our results demonstrate that the opioid receptor mixed agonist DPI-125 is safer and less addictive than traditional μ-agonist analgesics.  These findings suggest that the development of δ>μ∼κ opioid receptor mixed agonists is feasible, and such compds. could represent a promising class of potent analgesics with wider therapeutic windows.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJPFKpBtgRMLVg90H21EOLACvtfcHk0lg3L4LLL_eY5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFanu77I&md5=2d646c2c1d38012deaaeda208c9abcf5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Faps.2017.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2017.14%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DS.-p.%26aulast%3DKong%26aufirst%3DQ.-h.%26aulast%3DLi%26aufirst%3DY.-l.%26aulast%3DPan%26aufirst%3DC.-l.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DB.-q.%26aulast%3DWang%26aufirst%3DY.-f.%26aulast%3DWang%26aufirst%3DG.-l.%26aulast%3DZhou%26aufirst%3DP.-l.%26aulast%3DWang%26aufirst%3DL.-l.%26aulast%3DGong%26aufirst%3DZ.-h.%26aulast%3DSu%26aufirst%3DR.-b.%26aulast%3DShen%26aufirst%3DY.-h.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DK.-j.%26atitle%3DThe%2520opioid%2520receptor%2520triple%2520agonist%2520DPI-125%2520produces%2520analgesia%2520with%2520less%2520respiratory%2520depression%2520and%2520reduced%2520abuse%2520liability%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2017%26volume%3D38%26spage%3D977%26epage%3D989%26doi%3D10.1038%2Faps.2017.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanemasa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, A.</span></span> <span> </span><span class="NLM_article-title">Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1254/jphs.09139fp</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1254%2Fjphs.09139FP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19729873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ert7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2009&pages=60-72&author=K.+Minamiauthor=M.+Hasegawaauthor=H.+Itoauthor=A.+Nakamuraauthor=T.+Tomiiauthor=M.+Matsumotoauthor=S.+Oritaauthor=S.+Matsushimaauthor=T.+Miyoshiauthor=K.+Masunoauthor=M.+Toriiauthor=K.+Koikeauthor=S.+Shimadaauthor=T.+Kanemasaauthor=T.+Kiharaauthor=M.+Naritaauthor=T.+Suzukiauthor=A.+Kato&title=Morphine%2C+oxycodone%2C+and+fentanyl+exhibit+different+analgesic+profiles+in+mouse+pain+models&doi=10.1254%2Fjphs.09139fp"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models</span></div><div class="casAuthors">Minami, Kazuhisa; Hasegawa, Minoru; Ito, Hisanori; Nakamura, Atsushi; Tomii, Takako; Matsumoto, Mitsunobu; Orita, Satoshi; Matsushima, Syuichi; Miyoshi, Takako; Masuno, Koichi; Torii, Mikinori; Koike, Katsumi; Shimada, Shinji; Kanemasa, Toshiyuki; Kihara, Tsuyoshi; Narita, Minoru; Suzuki, Tsutomu; Kato, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-72</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">Morphine, oxycodone, and fentanyl are clin. prescribed drugs for the management of severe pain.  We investigated whether these opioids possess different efficacy profiles on several types of pain in mouse pain models.  When the three opioids were tested in the femur bone cancer model, all of them significantly reversed guarding behavior, whereas the effects on limb-use abnormality and allodynia-like behavior differed among the opioids.  Particularly, although oxycodone (5-20 mg/kg) and fentanyl (0.2 mg/kg) significantly reversed limb-use abnormality, not even a high dose of morphine (50 mg/kg) could reverse it.  When the effects of these opioids were examd. in a sciatic nerve ligation (SNL) model of neuropathic pain, oxycodone was the most effective, producing an antinociceptive effect without affecting the withdrawal threshold of sham-treated animals.  When the effects of these opioids were examd. with the tail-flick test using naive animals, oxycodone, morphine, and fentanyl exhibited antinociceptive effects on thermal nociception.  These results show that the three opioids exhibit different efficacy outcomes in multiple pain models and that the efficacy profile of oxycodone does not overlap those of morphine and fentanyl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXmVdmAiwZZrVg90H21EOLACvtfcHk0lg3L4LLL_eY5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ert7jM&md5=3830bf7a680b3278c1be1e02a1a3c3ff</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1254%2Fjphs.09139FP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.09139FP%26sid%3Dliteratum%253Aachs%26aulast%3DMinami%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DTomii%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DOrita%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DS.%26aulast%3DMiyoshi%26aufirst%3DT.%26aulast%3DMasuno%26aufirst%3DK.%26aulast%3DTorii%26aufirst%3DM.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DS.%26aulast%3DKanemasa%26aufirst%3DT.%26aulast%3DKihara%26aufirst%3DT.%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DA.%26atitle%3DMorphine%252C%2520oxycodone%252C%2520and%2520fentanyl%2520exhibit%2520different%2520analgesic%2520profiles%2520in%2520mouse%2520pain%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D111%26spage%3D60%26epage%3D72%26doi%3D10.1254%2Fjphs.09139fp" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moncada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendán, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Pozo, E.</span></span> <span> </span><span class="NLM_article-title">Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/s0014-2999(03)01461-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2FS0014-2999%2803%2901461-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=12650833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitV2nt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2003&pages=53-60&author=A.+Moncadaauthor=C.+M.+Cend%C3%A1nauthor=J.+M.+Baeyensauthor=E.+Del+Pozo&title=Effects+of+serine%2Fthreonine+protein+phosphatase+inhibitors+on+morphine-induced+antinociception+in+the+tail+flick+test+in+mice&doi=10.1016%2Fs0014-2999%2803%2901461-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice</span></div><div class="casAuthors">Moncada, Ana; Cendan, Cruz Miguel; Baeyens, Jose M.; Del Pozo, Esperanza</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">53-60</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the effects of serine/threonine protein phosphatase (PP) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction.  Neither okadaic acid nor cantharidin (1-10 000 nM) displaced [3H]naloxone from its specific binding sites, which indicates that they do not interact at the opioid receptor level.  The i.c.v. administration of very low doses of okadaic acid (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit PP2A, produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.).  However, L-nor-okadaone (0.001 pg/mouse-1 ng/mouse, i.c.v.), an analog of okadaic acid lacking activity against protein phosphatases, did not affect the antinociceptive effect of morphine.  On the other hand, high doses of okadaic acid (10 ng/mouse, i.c.v.) and cantharidin (1 μg/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception.  These results suggest that the activation of type 2A serine/threonine protein phosphatases may play a role in the antinociceptive effect of morphine, and that PP1 might counterbalance this activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrynBkEXFNhALVg90H21EOLACvtfcHk0lg_Rjpn-1xA2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitV2nt7g%253D&md5=0299389efd988d0d91b20738e314f033</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2901461-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252901461-4%26sid%3Dliteratum%253Aachs%26aulast%3DMoncada%26aufirst%3DA.%26aulast%3DCend%25C3%25A1n%26aufirst%3DC.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DDel%2BPozo%26aufirst%3DE.%26atitle%3DEffects%2520of%2520serine%252Fthreonine%2520protein%2520phosphatase%2520inhibitors%2520on%2520morphine-induced%2520antinociception%2520in%2520the%2520tail%2520flick%2520test%2520in%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D465%26spage%3D53%26epage%3D60%26doi%3D10.1016%2Fs0014-2999%2803%2901461-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sianati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">367</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-08162-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fs41467-018-08162-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30664663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFeks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=367&author=A.+Kliewerauthor=F.+Schmiedelauthor=S.+Sianatiauthor=A.+Baileyauthor=J.+T.+Batemanauthor=E.+S.+Levittauthor=J.+T.+Williamsauthor=M.+J.+Christieauthor=S.+Schulz&title=Phosphorylation-deficient+G-protein-biased+mu-opioid+receptors+improve+analgesia+and+diminish+tolerance+but+worsen+opioid+side+effects&doi=10.1038%2Fs41467-018-08162-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects</span></div><div class="casAuthors">Kliewer, A.; Schmiedel, F.; Sianati, S.; Bailey, A.; Bateman, J. T.; Levitt, E. S.; Williams, J. T.; Christie, M. J.; Schulz, S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">367</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Opioid analgesics are powerful pain relievers; however, over time, pain control diminishes as analgesic tolerance develops.  The mol. mechanisms initiating tolerance have remained unresolved to date.  We have previously shown that desensitization of the mu-opioid receptor and interaction with beta-arrestins is controlled by carboxyl-terminal phosphorylation.  Here we created knockin mice with a series of serine- and threonine-to-alanine mutations that render the receptor increasingly unable to recruit beta-arrestins.  Desensitization is inhibited in locus coeruleus neurons of mutant mice.  Opioid-induced analgesia is strongly enhanced and analgesic tolerance is greatly diminished.  Surprisingly, respiratory depression, constipation, and opioid withdrawal signs are unchanged or exacerbated, indicating that beta-arrestin recruitment does not contribute to the severity of opioid side effects and, hence, predicting that G-protein-biased mu-agonists are still likely to elicit severe adverse effects.  In conclusion, our findings identify carboxyl-terminal multisite phosphorylation as key step that drives acute mu-opioid receptor desensitization and long-term tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaEj4ARbzSS7Vg90H21EOLACvtfcHk0lg_Rjpn-1xA2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFeks7k%253D&md5=19fa2354d75d29b28503d21f63754d45</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08162-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08162-1%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DA.%26aulast%3DSchmiedel%26aufirst%3DF.%26aulast%3DSianati%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBateman%26aufirst%3DJ.%2BT.%26aulast%3DLevitt%26aufirst%3DE.%2BS.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DSchulz%26aufirst%3DS.%26atitle%3DPhosphorylation-deficient%2520G-protein-biased%2520mu-opioid%2520receptors%2520improve%2520analgesia%2520and%2520diminish%2520tolerance%2520but%2520worsen%2520opioid%2520side%2520effects%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D367%26doi%3D10.1038%2Fs41467-018-08162-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armenian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vo, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr-Walker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. L.</span></span> <span> </span><span class="NLM_article-title">Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.neuropharm.2017.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=29042317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSktbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2018&pages=121-132&author=P.+Armenianauthor=K.+T.+Voauthor=J.+Barr-Walkerauthor=K.+L.+Lynch&title=Fentanyl%2C+fentanyl+analogs+and+novel+synthetic+opioids%3A+A+comprehensive+review&doi=10.1016%2Fj.neuropharm.2017.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review</span></div><div class="casAuthors">Armenian, Patil; Vo, Kathy T.; Barr-Walker, Jill; Lynch, Kara L.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">121-132</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Deaths from opioid use are increasing in the US, with a growing proportion due to synthetic opioids.  Until 2013, sporadic outbreaks of fentanyl and fentanyl analogs contaminating the heroin supply caused some deaths in heroin users.  Since then, fentanyl has caused deaths in every state and fentanyl and its analogs have completely infiltrated the North American heroin supply.  In 2014, the first illicit pills contg. fentanyl, fentanyl analogs, and other novel synthetic opioids such as U-47700 were detected.  These pills, which look like known opioids or benzodiazepines, have introduced synthetic opioids to more unsuspecting customers.  As soon as these drugs are regulated by various countries, new compds. quickly appear on the market, making detection difficult and the no. of cases likely underreported.  Std. targeted anal. techniques such as GC-MS (gas chromatog. mass spectrometry) and LC-MS/MS (liq. chromatog. tandem mass spectrometry) can detect these drugs, but novel compd. identification is aided by nontargeted testing with LC-HRMS (liq. chromatog. high resoln. mass spectrometry).  Fentanyl, fentanyl analogs and other novel synthetic opioids are all full agonists of varying potencies at the μ-opioid receptor, leading to typical clin. effects of miosis and respiratory and central nervous system depression.  Due to their high affinity for μ-opioid receptors, larger doses of naloxone are required to reverse the effects than are commonly used.  Synthetic opioids are an increasingly major public health threat requiring vigilance from multiple fields including law enforcement, government agencies, clin. chemists, pharmacists, and physicians, to name a few, in order to stem its tide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxtCmdklHXLbVg90H21EOLACvtfcHk0lg_Rjpn-1xA2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSktbrM&md5=10085cfb511f8fd6316ffba4d39dcdef</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DArmenian%26aufirst%3DP.%26aulast%3DVo%26aufirst%3DK.%2BT.%26aulast%3DBarr-Walker%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DK.%2BL.%26atitle%3DFentanyl%252C%2520fentanyl%2520analogs%2520and%2520novel%2520synthetic%2520opioids%253A%2520A%2520comprehensive%2520review%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D134%26spage%3D121%26epage%3D132%26doi%3D10.1016%2Fj.neuropharm.2017.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherebillo, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elizarov, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polegaev, A. V.</span></span> <span> </span><span class="NLM_article-title">Membrane-introduction mass spectrometry analysis of desflurane, propofol and fentanyl in plasma and cerebrospinal fluid for estimation BBB properties</span>. <i>Exp. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.5607/en.2015.24.3.206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.5607%2Fen.2015.24.3.206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=26412969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A280%3ADC%252BC283msFagsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=206-210&author=V.+Y.+Cherebilloauthor=A.+Y.+Elizarovauthor=A.+V.+Polegaev&title=Membrane-introduction+mass+spectrometry+analysis+of+desflurane%2C+propofol+and+fentanyl+in+plasma+and+cerebrospinal+fluid+for+estimation+BBB+properties&doi=10.5607%2Fen.2015.24.3.206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane-Introduction Mass Spectrometry Analysis of Desflurane, Propofol and Fentanyl in Plasma and Cerebrospinal Fluid for Estimation BBB Properties</span></div><div class="casAuthors">Cherebillo Vyacheslav Yu; Polegaev Andrei V; Elizarov Andrei Yu</div><div class="citationInfo"><span class="NLM_cas:title">Experimental neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-10</span>
        ISSN:<span class="NLM_cas:issn">1226-2560</span>.
    </div><div class="casAbstract">A possibility to use the Membrane-Introduction Mass Spectrometry (MIMS) with membrane separator interface has evolved into a powerful method for measurement of anaesthetic agents absolute concentration in blood plasma and cerebrospinal fluid for the study of blood-brain barrier (BBB) properties.  Recent advanced a new membrane material was used for drug concentration measurement in biologic fluids.  A hydrophobic membrane was used in the interface to separate anaesthetic agents from biological fluids: inhalational anaesthetic desflurane,hypnotic propofol, analgesic fentanyl.  The selective detection of volatile anesthetic agents in blood does not require long-term sample processing before injecting the sample into mass-spectrometer interface, in contrast to chromatographic methods.  Mass-spectrometric interface for the measurement of anaesthetic agent concentration in biological fluids (blood plasma and cerebrospinal fluid) is described.  Sampling of biological fluids was performed during balanced inhalational (desflurane, fentanyl) anaesthesia and total intravenous (propofol, fentanyl) anaesthesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPmBbWtac9RbjnyZkbE8yXfW6udTcc2eYm-lQKr-sZ87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283msFagsg%253D%253D&md5=46e9839d6b0284252f013aa1ac4191fd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.5607%2Fen.2015.24.3.206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5607%252Fen.2015.24.3.206%26sid%3Dliteratum%253Aachs%26aulast%3DCherebillo%26aufirst%3DV.%2BY.%26aulast%3DElizarov%26aufirst%3DA.%2BY.%26aulast%3DPolegaev%26aufirst%3DA.%2BV.%26atitle%3DMembrane-introduction%2520mass%2520spectrometry%2520analysis%2520of%2520desflurane%252C%2520propofol%2520and%2520fentanyl%2520in%2520plasma%2520and%2520cerebrospinal%2520fluid%2520for%2520estimation%2520BBB%2520properties%26jtitle%3DExp.%2520Neurobiol.%26date%3D2015%26volume%3D24%26spage%3D206%26epage%3D210%26doi%3D10.5607%2Fen.2015.24.3.206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fürst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tímar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khrasani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makuch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przewlocki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przewlocka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidhammer, H.</span></span> <span> </span><span class="NLM_article-title">Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">618</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.075176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1124%2Fjpet.104.075176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=15383636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVCnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=609-618&author=S.+F%C3%BCrstauthor=P.+Ribaauthor=T.+Friedmannauthor=J.+T%C3%ADmarauthor=M.+Al-Khrasaniauthor=I.+Obaraauthor=W.+Makuchauthor=M.+Speteaauthor=J.+Sch%C3%BCtzauthor=R.+Przewlockiauthor=B.+Przewlockaauthor=H.+Schmidhammer&title=Peripheral+versus+central+antinociceptive+actions+of+6-amino+acid-substituted+derivatives+of+14-O-methyloxymorphone+in+acute+and+inflammatory+pain+in+the+rat&doi=10.1124%2Fjpet.104.075176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat</span></div><div class="casAuthors">Fuerst, Susanna; Riba, Pal; Friedmann, Tamas; Timar, Julia; Al-Khrasani, Mahmoud; Obara, Ilona; Makuch, Wioletta; Spetea, Mariana; Schuetz, Johannes; Przewlocki, Ryszard; Przewlocka, Barbara; Schmidhammer, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-618</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Opioid analgesics with restricted access to the central nervous system represent a new approach to the treatment of severe pain with an improved safety profile.  The objective of this study was to investigate the peripheral and central components of the antinociceptive actions of the 6-amino acid conjugates (glycine, alanine, and phenylalanine) of 14-O-methyloxymorphone.  Their antinociceptive activities were compared with those of the centrally penetrating μ-opioid agonists morphine, fentanyl, and 14-O-methyloxymorphone.  In the tail-flick test in rats, the 6-amino acid conjugates were 45- to 1170-fold more potent than morphine after i.c.v. administration and 19- to 209-fold after s.c. administration.  They showed potencies similar to fentanyl after s.c. administration and were more potent after i.c.v. application.  The time course of action was different between s.c. and i.c.v. administration, with significant long-lasting effects after i.c.v. administration.  Systemic administration of the peripherally selective opioid antagonist naloxone methiodide antagonized the effects after s.c. but not after i.c.v. administration in the tail-flick test.  S.c. 6-amino acid derivs. also elicited antihyperalgesic effects in the formalin test in rats, which were reversed by systemically administered naloxone methiodide.  Although morphine exerts its analgesic effects by central and peripheral mechanisms, the investigated new opioids interact primarily with peripheral opioid receptors after s.c. administration.  The present data indicate that the 6-amino acid conjugates of 14-O-methyloxymorphone have limited access to the central nervous system and can mediate antinociception at peripheral sites.  Also, they might find clin. application when the central actions of opioids are unwanted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPp43K4DtnyLVg90H21EOLACvtfcHk0ljf0_7tb0JG0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVCnsbg%253D&md5=28a8bf615e51d49f4746b35e58a956f3</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.075176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.075176%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCrst%26aufirst%3DS.%26aulast%3DRiba%26aufirst%3DP.%26aulast%3DFriedmann%26aufirst%3DT.%26aulast%3DT%25C3%25ADmar%26aufirst%3DJ.%26aulast%3DAl-Khrasani%26aufirst%3DM.%26aulast%3DObara%26aufirst%3DI.%26aulast%3DMakuch%26aufirst%3DW.%26aulast%3DSpetea%26aufirst%3DM.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DJ.%26aulast%3DPrzewlocki%26aufirst%3DR.%26aulast%3DPrzewlocka%26aufirst%3DB.%26aulast%3DSchmidhammer%26aufirst%3DH.%26atitle%3DPeripheral%2520versus%2520central%2520antinociceptive%2520actions%2520of%25206-amino%2520acid-substituted%2520derivatives%2520of%252014-O-methyloxymorphone%2520in%2520acute%2520and%2520inflammatory%2520pain%2520in%2520the%2520rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D609%26epage%3D618%26doi%3D10.1124%2Fjpet.104.075176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giricz, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balogh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiraly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csekő, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosztafi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadori, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helyes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferdinandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khrasani, M.</span></span> <span> </span><span class="NLM_article-title">New morphine analogs produce peripheral antinociception within a certain dose range of their systemic administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.233551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1124%2Fjpet.116.233551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27435180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2jt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2016&pages=171-181&author=E.+Lackoauthor=P.+Ribaauthor=Z.+Giriczauthor=A.+Varadiauthor=L.+Cornicauthor=M.+Baloghauthor=K.+Kiralyauthor=K.+Csek%C5%91author=S.+A.+Mousaauthor=S.+Hosztafiauthor=M.+Schaferauthor=Z.+S.+Zadoriauthor=Z.+Helyesauthor=P.+Ferdinandyauthor=S.+Furstauthor=M.+Al-Khrasani&title=New+morphine+analogs+produce+peripheral+antinociception+within+a+certain+dose+range+of+their+systemic+administration&doi=10.1124%2Fjpet.116.233551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New morphine analogs produce peripheral antinociception within a certain dose range of their systemic administration</span></div><div class="casAuthors">Lacko, Erzsebet; Riba, Pal; Giricz, Zoltan; Varadi, Andras; Cornic, Laura; Balogh, Mihaly; Kiraly, Kornel; Cseko, Kata; Mousa, Shaaban A.; Hosztafi, Sandor; Schafer, Michael; Zadori, Zoltan Sandor; Helyes, Zsuzsanna; Ferdinandy, Peter; Furst, Susanna; Al-Khrasani, Mahmoud</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Growing data support peripheral opioid antinociceptive effects, particularly in inflammatory pain models.  Here, we examd. the antinociceptive effects of s.c. administered, recently synthesized 14-O-methylmorphine-6-O-sulfate (14-OMeM6SU) compared withmorphine-6-O-sulfate (M6SU) in a rat model of inflammatory pain induced by an injection of complete Freund's adjuvant and in a mouse model of visceral pain evoked by acetic acid.  S.c. doses of 14-O-MeM6SU and M6SU up to 126 and 547 nmol/kg, resp., produced significant and s.c. or intraplantar naloxone methiodide (NAL-M)-reversible antinociception in inflamed paws compared with noninflamed paws.  Neither of these doses significantly affected thiobutabarbital-induced sleeping time or rat pulmonary parameters.  However, the antinociceptive effects of higher doses were only partially reversed by NAL-M, indicating contribution of the central nervous system.  In the mouse writhing test, 14-O-MeM6SU was more potent than M6SU after s.c. or intracerebroventricular injections.  Both displayed high s.c./intracerebroventricular ED50 ratios.  The antinociceptive effects of s.c. 14-O-MeM6SU and M6SU up to 136 and 3043 nmol/kg, resp., were fully antagonized by s.c. NAL-M.  In addn., the test compds. inhibited mouse gastrointestinal transit in antinociceptive doses.  Taken together, these findings suggest that systemic administration of the novel compd. 14-O-MeM6SU similar to M6SU in specific dose ranges shows peripheral antinociception in rat and mouse inflammatory pain models without central adverse effects.  These findings apply to male animals and must be confirmed in female animals.  Therefore, titrn. of systemic doses of opioid compds. with limited access to the brain might offer peripheral antinociception of clin. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovZ9vZSEuG87Vg90H21EOLACvtfcHk0ljf0_7tb0JG0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2jt7fE&md5=280db8d78c6888984aa8195e5d6e1434</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.233551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.233551%26sid%3Dliteratum%253Aachs%26aulast%3DLacko%26aufirst%3DE.%26aulast%3DRiba%26aufirst%3DP.%26aulast%3DGiricz%26aufirst%3DZ.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DCornic%26aufirst%3DL.%26aulast%3DBalogh%26aufirst%3DM.%26aulast%3DKiraly%26aufirst%3DK.%26aulast%3DCsek%25C5%2591%26aufirst%3DK.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26aulast%3DHosztafi%26aufirst%3DS.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DZadori%26aufirst%3DZ.%2BS.%26aulast%3DHelyes%26aufirst%3DZ.%26aulast%3DFerdinandy%26aufirst%3DP.%26aulast%3DFurst%26aufirst%3DS.%26aulast%3DAl-Khrasani%26aufirst%3DM.%26atitle%3DNew%2520morphine%2520analogs%2520produce%2520peripheral%2520antinociception%2520within%2520a%2520certain%2520dose%2520range%2520of%2520their%2520systemic%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D359%26spage%3D171%26epage%3D181%26doi%3D10.1124%2Fjpet.116.233551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khalefa, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaqura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khrasani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span> <span> </span><span class="NLM_article-title">Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids</span>. <i>Eur. J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1002/j.1532-2149.2011.00070.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1002%2Fj.1532-2149.2011.00070.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=22337491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVClurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=690-705&author=B.+I.+Khalefaauthor=M.+Shaquraauthor=M.+Al-Khrasaniauthor=S.+F%C3%BCrstauthor=S.+A.+Mousaauthor=M.+Sch%C3%A4fer&title=Relative+contributions+of+peripheral+versus+supraspinal+or+spinal+opioid+receptors+to+the+antinociception+of+systemic+opioids&doi=10.1002%2Fj.1532-2149.2011.00070.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids</span></div><div class="casAuthors">Khalefa, B. I.; Shaqura, M.; Al-Khrasani, M.; Fuerst, S.; Mousa, S. A.; Schaefer, M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pain (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">690-705</span>CODEN:
                <span class="NLM_cas:coden">EJPAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1090-3801</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The contribution of supraspinal, spinal or peripheral mu-opioid receptors (MORs) to the overall antinociception of systemic centrally penetrating vs. peripherally restricted opioids has not been thoroughly investigated.  Therefore, we examd. paw pressure thresholds in Wistar rats with complete Freund's adjuvant hindpaw inflammation following different doses of intraplantar (i.pl.) as well as i.v. (i.v.) fentanyl (6.25-50 μg/kg), morphine (1-7.5 mg/kg) or loperamide (1-7.5 mg/kg).  Antagonism of the i.v. mu-opioid agonists by intracerebroventricular (i.c.v.), intrathecal (i.t.) or i.pl. naloxone-methiodide (NLXM) revealed the relative contributions of supraspinal, spinal and peripheral MOR to the overall antinociceptive effects.  In parallel, the MOR d. at these three levels of pain transmission was assessed by radioligand binding.  Antinociceptive effects of i.v. fentanyl and morphine, but not of the peripherally restricted loperamide were two- to threefold greater and longer lasting compared with their i.pl. administration.  I.c.v. but not i.pl.  NLXM significantly antagonized fentanyl's and morphine's antinociception by 70-80%, whereas i.t.  NLXM reduced it by 20-30%.  In contrast, antinociception of i.v. loperamide was abolished by i.pl. but not by i.c.v. or i.t.  NLXM. In parallel, a resp. 32- and sixfold higher MOR d. in supraspinal and spinal vs. peripheral sensory neurons was detected.  In conclusion, in comparison with supraspinal and spinal opioid receptors, peripheral opioid receptors do not significantly contribute to the antinociception of systemic fentanyl and morphine during inflammatory pain.  Antinociception of their i.v. administration was superior over both i.v and i.pl. loperamide, acting exclusively via peripheral MOR.  These findings may guide the future development of novel peripherally restricted opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRpcUA5UdgNbVg90H21EOLACvtfcHk0lh2eUbowlvgvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVClurw%253D&md5=5db72309db5880bd7322a44a23302ac9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fj.1532-2149.2011.00070.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1532-2149.2011.00070.x%26sid%3Dliteratum%253Aachs%26aulast%3DKhalefa%26aufirst%3DB.%2BI.%26aulast%3DShaqura%26aufirst%3DM.%26aulast%3DAl-Khrasani%26aufirst%3DM.%26aulast%3DF%25C3%25BCrst%26aufirst%3DS.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26atitle%3DRelative%2520contributions%2520of%2520peripheral%2520versus%2520supraspinal%2520or%2520spinal%2520opioid%2520receptors%2520to%2520the%2520antinociception%2520of%2520systemic%2520opioids%26jtitle%3DEur.%2520J.%2520Pain%26date%3D2012%26volume%3D16%26spage%3D690%26epage%3D705%26doi%3D10.1002%2Fj.1532-2149.2011.00070.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artymyshyn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boteju, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhlani, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raddatz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogozalek, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouranova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysse, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branchek, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowsky, B.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of two G protein-coupled receptors for neuropeptide FF</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">39324</span>– <span class="NLM_lpage">39331</span>, <span class="refDoi"> DOI: 10.1074/jbc.m004385200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1074%2Fjbc.M004385200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=11024015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptFSrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=39324-39331&author=J.+A.+Boniniauthor=K.+A.+Jonesauthor=N.+Adhamauthor=C.+Forrayauthor=R.+Artymyshynauthor=M.+M.+Durkinauthor=K.+E.+Smithauthor=J.+A.+Tammauthor=L.+W.+Botejuauthor=P.+P.+Lakhlaniauthor=R.+Raddatzauthor=W.-J.+Yaoauthor=K.+L.+Ogozalekauthor=N.+Boyleauthor=E.+V.+Kouranovaauthor=Y.+Quanauthor=P.+J.+Vaysseauthor=J.+M.+Wetzelauthor=T.+A.+Branchekauthor=C.+Geraldauthor=B.+Borowsky&title=Identification+and+characterization+of+two+G+protein-coupled+receptors+for+neuropeptide+FF&doi=10.1074%2Fjbc.m004385200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of two G protein-coupled receptors for neuropeptide FF</span></div><div class="casAuthors">Bonini, James A.; Jones, Kenneth A.; Adham, Nika; Forray, Carlos; Artymyshyn, Roman; Durkin, Margaret M.; Smith, Kelli E.; Tamm, Joseph A.; Boteju, Lakmal W.; Lakhlani, Parul P.; Raddatz, Rita; Yao, Wen-Jeng; Ogozalek, Kristine L.; Boyle, Noel; Kouranova, Evguenia V.; Quan, Yong; Vaysse, Pierre J.; Wetzel, John M.; Branchek, Theresa A.; Gerald, Christophe; Borowsky, Beth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">39324-39331</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The central nervous system octapeptide, neuropeptide FF (NPFF),is believed to play a role in pain modulation and opiate tolerance.  Two G protein-coupled receptors, NPFF1 and NPFF2, were isolated from human and rat central nervous system tissues.  NPFF specifically bound to NPFF1 (Kd = 1.13 nM) and NPFF2 (Kd = 0.37 nM), and both receptors were activated by NPFF in a variety of heterologous expression systems.  The localization of mRNA and binding sites of these receptors in the dorsal horn of the spinal cord, the lateral hypothalamus, the spinal trigeminal nuclei, and the thalamic nuclei supports a role for NPFF in pain modulation.  Among the receptors with the highest amino acid sequence homol. to NPFF1 and NPFF2 are members of the orexin, NPY, and cholecystokinin families, which have been implicated in feeding.  These similarities together with the finding that BIBP3226, an anorexigenic Y1 receptor ligand, also binds to NPFF1 suggest a potential role for NPFF1 in feeding.  The identification of NPFF1 and NPFF2 will help delineate their roles in these and other physiol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgOaVTwhLRnbVg90H21EOLACvtfcHk0lh2eUbowlvgvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptFSrsLc%253D&md5=1cad618e8e4b53a1be848f2979ec7cc7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M004385200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M004385200%26sid%3Dliteratum%253Aachs%26aulast%3DBonini%26aufirst%3DJ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BA.%26aulast%3DAdham%26aufirst%3DN.%26aulast%3DForray%26aufirst%3DC.%26aulast%3DArtymyshyn%26aufirst%3DR.%26aulast%3DDurkin%26aufirst%3DM.%2BM.%26aulast%3DSmith%26aufirst%3DK.%2BE.%26aulast%3DTamm%26aufirst%3DJ.%2BA.%26aulast%3DBoteju%26aufirst%3DL.%2BW.%26aulast%3DLakhlani%26aufirst%3DP.%2BP.%26aulast%3DRaddatz%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DW.-J.%26aulast%3DOgozalek%26aufirst%3DK.%2BL.%26aulast%3DBoyle%26aufirst%3DN.%26aulast%3DKouranova%26aufirst%3DE.%2BV.%26aulast%3DQuan%26aufirst%3DY.%26aulast%3DVaysse%26aufirst%3DP.%2BJ.%26aulast%3DWetzel%26aufirst%3DJ.%2BM.%26aulast%3DBranchek%26aufirst%3DT.%2BA.%26aulast%3DGerald%26aufirst%3DC.%26aulast%3DBorowsky%26aufirst%3DB.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520two%2520G%2520protein-coupled%2520receptors%2520for%2520neuropeptide%2520FF%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D39324%26epage%3D39331%26doi%3D10.1074%2Fjbc.m004385200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawfik, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sypek, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotoudeh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barres, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span> <span> </span><span class="NLM_article-title">Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1038/nm.4262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fnm.4262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=28092666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=164-173&author=G.+Corderauthor=V.+L.+Tawfikauthor=D.+Wangauthor=E.+I.+Sypekauthor=S.+A.+Lowauthor=J.+R.+Dickinsonauthor=C.+Sotoudehauthor=J.+D.+Clarkauthor=B.+A.+Barresauthor=C.+J.+Bohlenauthor=G.+Scherrer&title=Loss+of+%CE%BC+opioid+receptor+signaling+in+nociceptors%2C+but+not+microglia%2C+abrogates+morphine+tolerance+without+disrupting+analgesia&doi=10.1038%2Fnm.4262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia</span></div><div class="casAuthors">Corder, Gregory; Tawfik, Vivianne L.; Wang, Dong; Sypek, Elizabeth I.; Low, Sarah A.; Dickinson, Jasmine R.; Sotoudeh, Chaudy; Clark, J. David; Barres, Ben A.; Bohlen, Christopher J.; Scherrer, Gregory</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">164-173</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Opioid pain medications have detrimental side effects including analgesic tolerance and opioid-induced hyperalgesia (OIH).  Tolerance and OIH counteract opioid analgesia and drive dose escalation.  The cell types and receptors on which opioids act to initiate these maladaptive processes remain disputed, which has prevented the development of therapies to maximize and sustain opioid analgesic efficacy.  We found that μ opioid receptors (MORs) expressed by primary afferent nociceptors initiate tolerance and OIH development.  RNA sequencing and histol. anal. revealed that MORs are expressed by nociceptors, but not by spinal microglia.  Deletion of MORs specifically in nociceptors eliminated morphine tolerance, OIH and pronociceptive synaptic long-term potentiation without altering antinociception.  Furthermore, we found that co-administration of methylnaltrexone bromide, a peripherally restricted MOR antagonist, was sufficient to abrogate morphine tolerance and OIH without diminishing antinociception in perioperative and chronic pain models.  Collectively, our data support the idea that opioid agonists can be combined with peripheral MOR antagonists to limit analgesic tolerance and OIH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqkX7EcqLR_LVg90H21EOLACvtfcHk0lh2eUbowlvgvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCls74%253D&md5=d65fbed56aa56dce619b2c6401ddc850</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnm.4262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4262%26sid%3Dliteratum%253Aachs%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DTawfik%26aufirst%3DV.%2BL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSypek%26aufirst%3DE.%2BI.%26aulast%3DLow%26aufirst%3DS.%2BA.%26aulast%3DDickinson%26aufirst%3DJ.%2BR.%26aulast%3DSotoudeh%26aufirst%3DC.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DBarres%26aufirst%3DB.%2BA.%26aulast%3DBohlen%26aufirst%3DC.%2BJ.%26aulast%3DScherrer%26aufirst%3DG.%26atitle%3DLoss%2520of%2520%25CE%25BC%2520opioid%2520receptor%2520signaling%2520in%2520nociceptors%252C%2520but%2520not%2520microglia%252C%2520abrogates%2520morphine%2520tolerance%2520without%2520disrupting%2520analgesia%26jtitle%3DNat.%2520Med.%26date%3D2017%26volume%3D23%26spage%3D164%26epage%3D173%26doi%3D10.1038%2Fnm.4262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-H.</span></span> <span> </span><span class="NLM_article-title">Selective blockade of spinal D2DR by levo-corydalmine attenuates morphine tolerance via suppressing PI3K/Akt-MAPK signaling in a MOR-dependent manner</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s12276-018-0175-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fs12276-018-0175-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30429454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Snsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=1-12&author=W.-L.+Daiauthor=X.-T.+Liuauthor=Y.-N.+Baoauthor=B.+Yanauthor=N.+Jiangauthor=B.-Y.+Yuauthor=J.-H.+Liu&title=Selective+blockade+of+spinal+D2DR+by+levo-corydalmine+attenuates+morphine+tolerance+via+suppressing+PI3K%2FAkt-MAPK+signaling+in+a+MOR-dependent+manner&doi=10.1038%2Fs12276-018-0175-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of spinal D2DR by levo-corydalmine attenuates morphine tolerance via suppressing PI3K/Akt-MAPK signaling in a MOR-dependent manner</span></div><div class="casAuthors">Dai, Wen-Ling; Liu, Xin-Tong; Bao, Yi-Ni; Yan, Bing; Jiang, Nan; Yu, Bo-Yang; Liu, Ji-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Molecular Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">2092-6413</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Morphine tolerance remains a challenge in the management of chronic pain in the clinic.  As shown in our previous study, the dopamine D2 receptor (D2DR) expressed in spinal cord neurons might be involved in morphine tolerance, but the underlying mechanisms remain to be elucidated.  In the present study, selective spinal D2DR blockade attenuated morphine tolerance in mice by inhibiting phosphatidylinositol 3 kinase (PI3K)/serine-threonine kinase (Akt)-mitogen activated protein kinase (MAPK) signaling in a μ opioid receptor (MOR)-dependent manner.  Levo-corydalmine (l-CDL), which exhibited micromolar affinity for D2DR in D2/CHO-K1 cell lines in this report and effectively alleviated bone cancer pain in our previous study, attenuated morphine tolerance in rats with chronic bone cancer pain at nonanalgesic doses.  Furthermore, the intrathecal administration of l-CDL obviously attenuated morphine tolerance, and the effect was reversed by a D2DR agonist in mice.  Spinal D2DR inhibition and l-CDL also inhibited tolerance induced by the MOR agonist DAMGO.  L-CDLand a D2DR small interfering RNA (siRNA) decreased the increase in levels of phosphorylated Akt and MAPK in the spinal cord; these changes were abolished by a PI3K inhibitor.  In addn., the activated Akt and MAPK proteins in mice exhibiting morphine tolerance were inhibited by a MOR antagonist.  Intrathecal administration of a PI3K inhibitor also attenuated DAMGO-induced tolerance.  Based on these results, l-CDL antagonized spinal D2DR to attenuate morphine tolerance by inhibiting PI3K/Akt-dependent MAPK phosphorylation through MOR.  These findings provide insights into a more versatile treatment for morphine tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7UeLw7xq8MLVg90H21EOLACvtfcHk0liOkg8z_RKGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Snsb%252FL&md5=5824ed7d69443034743d2fdcf6e6bd09</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fs12276-018-0175-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-018-0175-1%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DW.-L.%26aulast%3DLiu%26aufirst%3DX.-T.%26aulast%3DBao%26aufirst%3DY.-N.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DB.-Y.%26aulast%3DLiu%26aufirst%3DJ.-H.%26atitle%3DSelective%2520blockade%2520of%2520spinal%2520D2DR%2520by%2520levo-corydalmine%2520attenuates%2520morphine%2520tolerance%2520via%2520suppressing%2520PI3K%252FAkt-MAPK%2520signaling%2520in%2520a%2520MOR-dependent%2520manner%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2018%26volume%3D50%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs12276-018-0175-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.-x.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-x.</span></span> <span> </span><span class="NLM_article-title">NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.neulet.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19818835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyltr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2009&pages=95-99&author=R.-x.+Guoauthor=M.+Zhangauthor=W.+Liuauthor=C.-m.+Zhaoauthor=Y.+Cuiauthor=C.-h.+Wangauthor=J.-q.+Fengauthor=P.-x.+Chen&title=NMDA+receptors+are+involved+in+upstream+of+the+spinal+JNK+activation+in+morphine+antinociceptive+tolerance&doi=10.1016%2Fj.neulet.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance</span></div><div class="casAuthors">Guo, Rui-Xian; Zhang, Mei; Liu, Wei; Zhao, Chun-Mei; Cui, Yu; Wang, Chu-Huai; Feng, Jian-Qiang; Chen, Pei-Xi</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-99</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">N-methyl-D-aspartate (NMDA) receptors and c-Jun N-terminal kinase (JNK) have been shown to be involved in morphine antinociceptive tolerance.  However, whether chronic morphine-induced activation of the spinal JNK is NMDA receptor-dependent is unknown.  The present study investigated the link between the spinal NMDA receptor NR2B subunit and the JNK activation during morphine antinociceptive tolerance in rats.  Our results showed that chronic morphine treatment induced upregulation of the NR2B expression and activation of JNK in the spinal cord.  Moreover, the increased NR2B-immunoreactivity (IR) and phosphorylated JNK-IR were obsd. mainly at the superficial dorsal horn laminae of the spinal cord; the spinal p-JNK was mainly expressed in astrocytes and NR2B in neurons.  SP600125, a selective inhibitor of JNK, significantly attenuated morphine tolerance.  MK-801, a noncompetitive NMDA receptor antagonist, not only suppressed morphine antinociceptive tolerance and the increase in NR2B, but also reduced the spinal JNK activation induced by chronic morphine treatment.  These findings demonstrated for the first time that NMDA receptor-dependent activation of the spinal JNK contributes to morphine antinociceptive tolerance and that MK-801 attenuates morphine tolerance partly due to its inhibition on the spinal JNK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-l5kyzb1qprVg90H21EOLACvtfcHk0liOkg8z_RKGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyltr%252FJ&md5=9dbc322620f749f78e098a547051b68e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DR.-x.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DC.-m.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.-h.%26aulast%3DFeng%26aufirst%3DJ.-q.%26aulast%3DChen%26aufirst%3DP.-x.%26atitle%3DNMDA%2520receptors%2520are%2520involved%2520in%2520upstream%2520of%2520the%2520spinal%2520JNK%2520activation%2520in%2520morphine%2520antinociceptive%2520tolerance%26jtitle%3DNeurosci.%2520Lett.%26date%3D2009%26volume%3D467%26spage%3D95%26epage%3D99%26doi%3D10.1016%2Fj.neulet.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Healy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezawada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coop, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Modeling, and Pharmacological Evaluation of UMB 425, a Mixed μ Agonist/δ Antagonist Opioid Analgesic with Reduced Tolerance Liabilities</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1266</span>, <span class="refDoi"> DOI: 10.1021/cn4000428</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn4000428" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Sqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1256-1266&author=J.+R.+Healyauthor=P.+Bezawadaauthor=J.+Shimauthor=J.+W.+Jonesauthor=M.+A.+Kaneauthor=A.+D.+MacKerellauthor=A.+Coopauthor=R.+R.+Matsumoto&title=Synthesis%2C+Modeling%2C+and+Pharmacological+Evaluation+of+UMB+425%2C+a+Mixed+%CE%BC+Agonist%2F%CE%B4+Antagonist+Opioid+Analgesic+with+Reduced+Tolerance+Liabilities&doi=10.1021%2Fcn4000428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Modeling, and Pharmacological Evaluation of UMB 425, a Mixed μ Agonist/δ Antagonist Opioid Analgesic with Reduced Tolerance Liabilities</span></div><div class="casAuthors">Healy, Jason R.; Bezawada, Padmavani; Shim, Jihyun; Jones, Jace W.; Kane, Maureen A.; MacKerell, Alexander D.; Coop, Andrew; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1256-1266</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opioid narcotics are used for the treatment of moderate-to-severe pain and primarily exert their analgesic effects through μ receptors.  Although traditional μ agonists can cause undesired side effects, including tolerance, addn. of δ antagonists can attenuate said side effects.  Herein, the authors report 4a,9-dihydroxy-7a-(hydroxymethyl)-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one (UMB 425) a 5,14-bridged morphinan-based orvinol precursor synthesized from thebaine.  Although UMB 425 lacks δ-specific motifs, conformationally sampled pharmacophore models for μ and δ receptors predict it to have efficacy similar to morphine at μ receptors and similar to naltrexone at δ receptors, due to the compd. sampling conformations in which the hydroxyl moiety interacts with the receptors similar to orvinols.  As predicted, UMB 425 exhibits a mixed μ agonist/δ antagonist profile as detd. in receptor binding and [35S]GTPγS functional assays in CHO cells.  In vivo studies in mice show that UMB 425 displays potent antinociception in the hot plate and tail-flick assays.  The antinociceptive effects of UMB 425 are blocked by naloxone, but not by the κ-selective antagonist norbinaltorphimine.  During a 6-day tolerance paradigm, UMB 425 maintains significantly greater antinociception compared to morphine.  These studies thus indicate that, even in the absence of δ-specific motifs fused to the C-ring, UMB 425 has mixed μ agonist/δ antagonist properties in vitro that translate to reduced tolerance liabilities in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6OgV4pm0lbVg90H21EOLACvtfcHk0liOkg8z_RKGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Sqtbk%253D&md5=6949bbfec033537662cfa64b7d281df5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fcn4000428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn4000428%26sid%3Dliteratum%253Aachs%26aulast%3DHealy%26aufirst%3DJ.%2BR.%26aulast%3DBezawada%26aufirst%3DP.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%2BW.%26aulast%3DKane%26aufirst%3DM.%2BA.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DCoop%26aufirst%3DA.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSynthesis%252C%2520Modeling%252C%2520and%2520Pharmacological%2520Evaluation%2520of%2520UMB%2520425%252C%2520a%2520Mixed%2520%25CE%25BC%2520Agonist%252F%25CE%25B4%2520Antagonist%2520Opioid%2520Analgesic%2520with%2520Reduced%2520Tolerance%2520Liabilities%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2013%26volume%3D4%26spage%3D1256%26epage%3D1266%26doi%3D10.1021%2Fcn4000428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Moreno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Espinosa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León-Olea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, S. L.</span></span> <span> </span><span class="NLM_article-title">Synergistic antinociceptive actions and tolerance development produced by morphine-fentanyl coadministration: Correlation with μ-opioid receptor internalization</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>674</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.10.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ejphar.2011.10.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=22079772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1KisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=674&publication_year=2012&pages=239-247&author=A.+Silva-Morenoauthor=C.+Gonzalez-Espinosaauthor=M.+Le%C3%B3n-Oleaauthor=S.+L.+Cruz&title=Synergistic+antinociceptive+actions+and+tolerance+development+produced+by+morphine-fentanyl+coadministration%3A+Correlation+with+%CE%BC-opioid+receptor+internalization&doi=10.1016%2Fj.ejphar.2011.10.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antinociceptive actions and tolerance development produced by morphine-fentanyl coadministration: Correlation with μ-opioid receptor internalization</span></div><div class="casAuthors">Silva-Moreno, Arturo; Gonzalez-Espinosa, Claudia; Leon-Olea, Martha; Cruz, Silvia L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">674</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">239-247</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It was described that coadministration of opioids with low doses of other analgesics can reduce adverse effects and increase antinociception, but combinations of 2 μ-opioid receptor agonists were poorly explored.  The objective of this work was 3-fold: (1) to evaluate the antinociceptive combination of i.c.v. morphine and fentanyl at different doses; (2) to compare the antinociception produced by acute or repeated administration of an effective morphine dose (1 μg) alone, or combined with a low fentanyl dose (1 ng); and (3) to correlate these effects with μ-opioid receptor internalization in periaqueductal gray matter and locus coeruleus.  Antinociception was evaluated by the tail-flick test and receptor internalization was analyzed by confocal microscopy in Wistar rats.  Drug interactions were examd. by administering combinations of opioids in 1:3, 1:1, and 3:1 ratios of their resp. ED50 fractions.  For tolerance and internalization studies, animals were i.c.v. injected only once (acute treatment) or twice a day until 5 administrations were completed.  Our results show that morphine and fentanyl have synergistic effects.  The combination of 1 ng fentanyl with 1 μg morphine increases the magnitude and duration of antinociception not only after a single injection, but also after 5 administrations when tolerance develops to morphine alone.  Increased and long-lasting antinociception correlates pos. with increased β-arrestin 2 activity and μ-opioid receptor internalization in periaqueductal gray matter and locus coeruleus.  These results suggest that combined administration of morphine and fentanyl increases long-lasting antinociception and β-arrestin 2 signaling contributes to the combination effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8DcrSowlozrVg90H21EOLACvtfcHk0lj1EyKzzeZyRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1KisQ%253D%253D&md5=ba207836ad00734f1b5488b8d26bb0ed</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.10.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.10.034%26sid%3Dliteratum%253Aachs%26aulast%3DSilva-Moreno%26aufirst%3DA.%26aulast%3DGonzalez-Espinosa%26aufirst%3DC.%26aulast%3DLe%25C3%25B3n-Olea%26aufirst%3DM.%26aulast%3DCruz%26aufirst%3DS.%2BL.%26atitle%3DSynergistic%2520antinociceptive%2520actions%2520and%2520tolerance%2520development%2520produced%2520by%2520morphine-fentanyl%2520coadministration%253A%2520Correlation%2520with%2520%25CE%25BC-opioid%2520receptor%2520internalization%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D674%26spage%3D239%26epage%3D247%26doi%3D10.1016%2Fj.ejphar.2011.10.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, F. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of neonatal rat fentanyl tolerance and dependence</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">521</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=9103539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK2sXislWnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1997&pages=514-521&author=S.+R.+Thorntonauthor=F.+L.+Smith&title=Characterization+of+neonatal+rat+fentanyl+tolerance+and+dependence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of neonatal rat fentanyl tolerance and dependence</span></div><div class="casAuthors">Thornton, Suzanne R.; Smith, Forrest L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">514-521</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Fentanyl and morphine are administered to human neonates and infants to provide analgesia and sedation during painful and stressful procedures.  These opioids have often been shown to produce tolerance and dependence during continuous i.v. infusion.  In neonatal animals, morphine produces tolerance and dependence, yet little is known about fentanyl.  This report describes the first model for studying opioid tolerance and dependence in neonatal animals with use of osmotic minipumps.  Postnatal day 6 rat pups were anesthetized and then remained naive or were surgically implanted s.c. with Alzet osmotic minipumps contg. either saline or fentanyl (100 μg/kg/h).  Tolerance and dependence were assessed 72 h after implantation.  The ED50 values for fentanyl antinociception in the tail-flick test were not different between naive and saline pump-implanted animals.  However, the fentanyl pump-implanted animals were tolerant to fentanyl.  The tolerance obsd. was not the result of gender, developmental changes, fentanyl distribution or changes in fentanyl metab.  These results indicate that continuous administration of fentanyl via osmotic minipump can render normal neonatal rats tolerant and phys. dependent on fentanyl in 72 h.  Withdrawal pptd. by naloxone (5 mg/kg s.c.) in the fentanyl pump-implanted animals was characterized by increased spontaneous activity, micturition/defecation, wall climbing, abdominal stretching, tremors, scream on touch and spontaneous vocalization.  This new model may provide a tool for studying the long-term consequences of neonatal opioid exposure in juvenile and adult animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-AJIIX3-8LVg90H21EOLACvtfcHk0lj1EyKzzeZyRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislWnsr8%253D&md5=4ea61a41bcfd203614766abb22653802</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThornton%26aufirst%3DS.%2BR.%26aulast%3DSmith%26aufirst%3DF.%2BL.%26atitle%3DCharacterization%2520of%2520neonatal%2520rat%2520fentanyl%2520tolerance%2520and%2520dependence%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D281%26spage%3D514%26epage%3D521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitanaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, M.</span></span> <span> </span><span class="NLM_article-title">Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2018.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.pbb.2018.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30017858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGlu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=9-16&author=N.+Kitanakaauthor=J.+Kitanakaauthor=F.+S.+Hallauthor=T.+Kandoriauthor=A.+Murakamiauthor=K.+Murataniauthor=T.+Nakanoauthor=G.+R.+Uhlauthor=M.+Takemura&title=Tetrabenazine%2C+a+vesicular+monoamine+transporter-2+inhibitor%2C+attenuates+morphine-induced+hyperlocomotion+in+mice+through+alteration+of+dopamine+and+5-hydroxytryptamine+turnover+in+the+cerebral+cortex&doi=10.1016%2Fj.pbb.2018.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex</span></div><div class="casAuthors">Kitanaka, Nobue; Kitanaka, Junichi; Hall, F. Scott; Kandori, Takashi; Murakami, Ayaka; Muratani, Kazuki; Nakano, Tae; Uhl, George R.; Takemura, Motohiko</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-16</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A single administration with morphine (30 mg/kg, i.p.) induced long-lasting hyperlocomotion in male ICR mice.  Pretreatment of mice with a benzoquinolizine deriv. tetrabenazine (TBZ; a reversible vesicular monoamine transporter-2 inhibitor) (1 mg/kg, i.p.) for 30 min significantly attenuated the hyperlocomotion induced by morphine, as compared with vehicle (saline)-pretreated mice.  No significant change in locomotion was obsd. in mice pretreated with TBZ (1 mg/kg) alone.  Mice treated with TBZ (1 mg/kg) showed an increase in immobility time in a tail suspension test, as compared with saline-treated mice.  Pretreatment with TBZ (1 mg/kg) had no effect on morphine (1-30 mg/kg)-induced antinociception.  TBZ at a dose of 1 mg/kg inhibited dopamine turnover (the ratio of 3,4-dihydroxyphenylacetic acid/dopamine) and 5-hydroxytryptamine turnover (the ratio of 5-hydroxyindoleacetic acid/5-hydroxytryptamine) in the cerebral cortex of mice challenged with morphine, as compared with saline-pretreated mice challenged with morphine.  No stereotypic behavior was obsd. in mice treated with morphine (30 mg/kg) in combination with TBZ (1 mg/kg), so the redn. in obsd. locomotion did not result from induction of stereotypical behavior.  Moreover, TBZ (1 and 2 mg/kg) pretreatment had no effect on stereotyped behaviors obsd. in mice challenged with 10 mg/kg methamphetamine.  These data support the potential antagonistic actions of TBZ on some opiate actions, and encourage further exploration of potential effects on morphine reinforcement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrShbDPlcN6dbVg90H21EOLACvtfcHk0lj1EyKzzeZyRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGlu7rN&md5=ffecdee9a12fe72ab2ab5e9a5520328b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2018.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2018.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DKitanaka%26aufirst%3DN.%26aulast%3DKitanaka%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DF.%2BS.%26aulast%3DKandori%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DA.%26aulast%3DMuratani%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DUhl%26aufirst%3DG.%2BR.%26aulast%3DTakemura%26aufirst%3DM.%26atitle%3DTetrabenazine%252C%2520a%2520vesicular%2520monoamine%2520transporter-2%2520inhibitor%252C%2520attenuates%2520morphine-induced%2520hyperlocomotion%2520in%2520mice%2520through%2520alteration%2520of%2520dopamine%2520and%25205-hydroxytryptamine%2520turnover%2520in%2520the%2520cerebral%2520cortex%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2018%26volume%3D172%26spage%3D9%26epage%3D16%26doi%3D10.1016%2Fj.pbb.2018.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culbertson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanselow, M. S.</span></span> <span> </span><span class="NLM_article-title">Pavlovian conditioning of multiple opioid-like responses in mice</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2009.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.drugalcdep.2009.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19419821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2009&pages=74-83&author=C.+D.+Bryantauthor=K.+W.+Robertsauthor=C.+S.+Culbertsonauthor=A.+Leauthor=C.+J.+Evansauthor=M.+S.+Fanselow&title=Pavlovian+conditioning+of+multiple+opioid-like+responses+in+mice&doi=10.1016%2Fj.drugalcdep.2009.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pavlovian conditioning of multiple opioid-like responses in mice</span></div><div class="casAuthors">Bryant, Camron D.; Roberts, Kristofer W.; Culbertson, Christopher S.; Le, Alan; Evans, Christopher J.; Fanselow, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">74-83</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Conditional responses in rodents such as locomotion have been reported for drugs of abuse and similar to the placebo response in humans, may be assocd. with the expectation of reward.  We examd. several conditional opioid-like responses and the influence of drug expectation on conditioned place preference and concomitant conditional locomotion.  Male C57BL/6J mice were conditioned with the selective mu opioid receptor agonist fentanyl (0.2 mg/kg, i.p.) in a novel context and subsequently given a vehicle injection.  In sep. expts., locomotor activity, Straub tail, hot plate sensitivity, and conditioned place preference (CPP) were measured.  Mice exhibited multiple conditional opioid-like responses including conditional hyperlocomotion, a conditional pattern of opioid-like locomotion, Straub tail, analgesia, and place preference.  Modulating drug expectation via administration of fentanyl to "demonstrator" mice in the home cage did not affect the expression of conditioned place preference or the concomitant locomotor activity in "observer" mice.  In summary, Pavlovian conditioning of an opioid in a novel context induced multiple conditional opioid-like behaviors and provides a model for studying the neurobiol. mechanisms of the placebo response in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSqmCtFwbgdLVg90H21EOLACvtfcHk0liKZSdFo0PjyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKksLc%253D&md5=b1c4d278907f5ecbc75bb79a98458832</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2009.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2009.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DC.%2BD.%26aulast%3DRoberts%26aufirst%3DK.%2BW.%26aulast%3DCulbertson%26aufirst%3DC.%2BS.%26aulast%3DLe%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DC.%2BJ.%26aulast%3DFanselow%26aufirst%3DM.%2BS.%26atitle%3DPavlovian%2520conditioning%2520of%2520multiple%2520opioid-like%2520responses%2520in%2520mice%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2009%26volume%3D103%26spage%3D74%26epage%3D83%26doi%3D10.1016%2Fj.drugalcdep.2009.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fibiger, H. C.</span></span> <span> </span><span class="NLM_article-title">Fentanyl-induced conditional place preference: lack of associated conditional neurochemical events</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1007/bf02180036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1007%2FBF02180036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=3149777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaL1MXjtlKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1988&pages=534-540&author=J.+M.+Finlayauthor=A.+Jakubovicauthor=A.+G.+Phillipsauthor=H.+C.+Fibiger&title=Fentanyl-induced+conditional+place+preference%3A+lack+of+associated+conditional+neurochemical+events&doi=10.1007%2Fbf02180036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Fentanyl-induced conditional place preference:  lack of associated conditional neurochemical events</span></div><div class="casAuthors">Finlay, J. M.; Jakubovic, A.; Phillips, A. G.; Fibiger, H. C.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">534-40</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">The unconditional effects of fentanyl (0.04 mg/kg, s.c.) were characterized on neurochem. indexes of dopaminergic activity in rats.  Both acute and repeated fentanyl injections (5 injections administered at 48-h intervals) increased the concns. of the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) within the striatum (STR), nucleus accumbens (NAS), and olfactory tubercle (OT).  Acute injections elicited a greater increase in metabolite concns. in the NAS than in the STR, suggesting that there are regional differences in the sensitivity of dopaminergic neurons to fentanyl.  In expts. 2 and 3, fentanyl (5 injections; 0.04 mg/kg, s.c.) was paired with environmental stimuli using a place-preference conditioning paradigm.  The fentanyl-paired stimuli failed to elicit conditional changes in DOPAC or HVA concns. within the STR, NAS, or OT even though rats exhibited a preference for the drug-paired compartment of the shuttle box.  Thus, the secondary reinforcing effects of stimuli previously paired with fentanyl may not reflect the ability of these stimuli to elicit measurable changes in the activity of mesolimbic or nigrostriatal dopaminergic neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY_nu9bsqZjbVg90H21EOLACvtfcHk0liKZSdFo0PjyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXjtlKrtA%253D%253D&md5=37596b0caef77cb1da57e7afc2165b2f</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2FBF02180036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02180036%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DJ.%2BM.%26aulast%3DJakubovic%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DA.%2BG.%26aulast%3DFibiger%26aufirst%3DH.%2BC.%26atitle%3DFentanyl-induced%2520conditional%2520place%2520preference%253A%2520lack%2520of%2520associated%2520conditional%2520neurochemical%2520events%26jtitle%3DPsychopharmacology%26date%3D1988%26volume%3D96%26spage%3D534%26epage%3D540%26doi%3D10.1007%2Fbf02180036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruijnzeel, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajpai, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morey, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M.</span></span> <span> </span><span class="NLM_article-title">Severe deficit in brain reward function associated with fentanyl withdrawal in rats</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2005.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.biopsych.2005.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=16169528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVehu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=477-480&author=A.+W.+Bruijnzeelauthor=B.+Lewisauthor=L.+K.+Bajpaiauthor=T.+E.+Moreyauthor=D.+M.+Dennisauthor=M.+Gold&title=Severe+deficit+in+brain+reward+function+associated+with+fentanyl+withdrawal+in+rats&doi=10.1016%2Fj.biopsych.2005.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Severe Deficit in Brain Reward Function Associated with Fentanyl Withdrawal in Rats</span></div><div class="casAuthors">Bruijnzeel, Adrie W.; Lewis, Ben; Bajpai, Lakshmi K.; Morey, Timothy E.; Dennis, Donn M.; Gold, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">477-480</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: During the last decade, there has been a strong increase in the use of the mu-opioid receptor agonist fentanyl.  The aim of these studies was to investigate the effects of fentanyl withdrawal on brain reward function and somatic withdrawal signs.  Methods: Fentanyl and saline were chronically administered via minipumps.  An intracranial self-stimulation procedure was used to provide a measure of brain reward function.  Somatic signs were recorded from a checklist of opioid abstinence signs.  Results: The opioid receptor antagonist naloxone induced a dose-dependent elevation in brain reward thresholds and somatic withdrawal signs in fentanyl-treated rats.  Discontinuation of fentanyl administration resulted in a time-dependent elevation of brain reward thresholds and somatic withdrawal signs.  Conclusions: These findings indicate that fentanyl withdrawal is assocd. with affective and somatic withdrawal signs.  The severity of the deficit in brain reward function in this animal model suggests that affective fentanyl withdrawal symptoms may be a strong deterrent to abstinence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN_1ODBEITebVg90H21EOLACvtfcHk0liKZSdFo0PjyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVehu7g%253D&md5=dd93f42ba48b04209cc3a051b681f755</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DBruijnzeel%26aufirst%3DA.%2BW.%26aulast%3DLewis%26aufirst%3DB.%26aulast%3DBajpai%26aufirst%3DL.%2BK.%26aulast%3DMorey%26aufirst%3DT.%2BE.%26aulast%3DDennis%26aufirst%3DD.%2BM.%26aulast%3DGold%26aufirst%3DM.%26atitle%3DSevere%2520deficit%2520in%2520brain%2520reward%2520function%2520associated%2520with%2520fentanyl%2520withdrawal%2520in%2520rats%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D477%26epage%3D480%26doi%3D10.1016%2Fj.biopsych.2005.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gazal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellerman, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel protected Nα (ω-thioalkyl) amino acid building units and their incorporation in backbone cyclic disulfide and thioetheric bridged peptides</span>. <i>J. Pept. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1034/j.1399-3011.2001.00936.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1034%2Fj.1399-3011.2001.00936.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=12005422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVentrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2001&pages=527-539&author=S.+Gazalauthor=E.+Glukhovauthor=C.+Gilonauthor=G.+Gellerman&title=Synthesis+of+novel+protected+N%CE%B1+%28%CF%89-thioalkyl%29+amino+acid+building+units+and+their+incorporation+in+backbone+cyclic+disulfide+and+thioetheric+bridged+peptides&doi=10.1034%2Fj.1399-3011.2001.00936.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel protected Nα(ω-thioalkyl) amino acid building units and their incorporation in backbone cyclic disulfide and thioetheric bridged peptides</span></div><div class="casAuthors">Gazal, S.; Gellerman, G.; Glukhov, E.; Gilon, C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">527-539</span>CODEN:
                <span class="NLM_cas:coden">JPERFA</span>;
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">General methods for the prepn. of protected Nα(ω-thioalkyl) amino acids building units for backbone cyclization using reductive alkylation and on-resin prepn. are described.  The synthesis of non-Gly Fmoc-protected S-functionalized N-alkylated amino acids is based on the reaction of readily prepd. protected ω-thio aldehyde with the appropriate amino acid.  Prepn. of Fmoc-protected S-functionalized N-alkylated Gly building units was carried out using two methods: reaction of glyoxylic acid with Acm-thioalkylamine and an on-resin reaction of bromoacetyl resin with Trt-thioalkylamines.  Three model peptides were prepd. using these building units.  The GlyS2 building unit was incorporated into a backbone cyclic analog of somatostatin that contains a disulfide bridge.  Formation of the disulfide bridge was performed by on-resin oxidn. using I2 or TI(CF3COO-)3.  Both methods resulted in the desired product in a high degree of purity in the crude.  The AspS3 building unit was also successfully incorporated into a model peptide.  In addn., the in situ generation of sulfur contg. Gly building units was demonstrated on a Substance P backbone cyclic analog contg. a thioether bridge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8BYlx2DhlZ7Vg90H21EOLACvtfcHk0lgV9la7nBUHlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVentrs%253D&md5=deb33953af8d60438a9a14b9e8f47e85</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1034%2Fj.1399-3011.2001.00936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1399-3011.2001.00936.x%26sid%3Dliteratum%253Aachs%26aulast%3DGazal%26aufirst%3DS.%26aulast%3DGlukhov%26aufirst%3DE.%26aulast%3DGilon%26aufirst%3DC.%26aulast%3DGellerman%26aufirst%3DG.%26atitle%3DSynthesis%2520of%2520novel%2520protected%2520N%25CE%25B1%2520%2528%25CF%2589-thioalkyl%2529%2520amino%2520acid%2520building%2520units%2520and%2520their%2520incorporation%2520in%2520backbone%2520cyclic%2520disulfide%2520and%2520thioetheric%2520bridged%2520peptides%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D2001%26volume%3D58%26spage%3D527%26epage%3D539%26doi%3D10.1034%2Fj.1399-3011.2001.00936.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>476</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2014.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ijpharm.2014.08.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=25245547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Shsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=476&publication_year=2014&pages=1-8&author=H.+Liuauthor=W.+Zhangauthor=L.+Maauthor=L.+Fanauthor=F.+Gaoauthor=J.+Niauthor=R.+Wang&title=The+improved+blood-brain+barrier+permeability+of+endomorphin-1+using+the+cell-penetrating+peptide+synB3+with+three+different+linkages&doi=10.1016%2Fj.ijpharm.2014.08.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages</span></div><div class="casAuthors">Liu, Hui; Zhang, Wei; Ma, Linnan; Fan, Linlan; Gao, Feiyun; Ni, Jingman; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">476</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Endomorphins, although they have high analgesic activity and few undesirable side effects, are not in clin. use because of the blood-brain barrier (BBB).  One promising soln. is to use cell-penetrating peptides (CPPs).  CPPs have the ability to translocate cell membranes and have been successfully applied for delivery of therapeutic mols. across the BBB.  However, little is known about the transport efficiency of different conjugation strategies between cargo and CPPs.  In this study, endomorphin-1 (EM-1) was conjugated with SynB3, an efficient CPP-carrier, via amide, maleimide and disulfide linkages.  The delivery efficiency of three linkers was compared in terms of pharmacodynamics and in vitro metabolic stability.  Near-IR fluorescent and fluorescent microscopy expts. were applied to detect the brain uptake and distribution of CPP delivery qual. and quant.  After the most successful linkage was screened out, the further mechanisms were discussed.  We concluded that compared with the other two linkages, the disulfide bond was the most efficient linkage to deliver EM-1 across the BBB and confirmed that it could be reduced at physiol. conditions in the brain and release its active form.  These findings indicate that for those who need to release a free drug in the brain and maintain activity, a disulfide bond might be the most efficient linkage across the BBB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd-m2iE0KhOLVg90H21EOLACvtfcHk0lgV9la7nBUHlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Shsb3F&md5=48e7b5d5fbec399015bc56d0059a6cc0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2014.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2014.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DThe%2520improved%2520blood-brain%2520barrier%2520permeability%2520of%2520endomorphin-1%2520using%2520the%2520cell-penetrating%2520peptide%2520synB3%2520with%2520three%2520different%2520linkages%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2014%26volume%3D476%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.ijpharm.2014.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egleton, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruscato, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechowski, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T. P.</span></span> <span> </span><span class="NLM_article-title">The effect of halogenation on blood-brain barrier permeability of a novel peptide drug</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1238</span>, <span class="refDoi"> DOI: 10.1016/s0196-9781(99)00127-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2FS0196-9781%2899%2900127-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10573295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK1MXntVCnsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=1229-1238&author=C.+L.+Gentryauthor=R.+D.+Egletonauthor=T.+Gillespieauthor=T.+J.+Abbruscatoauthor=H.+B.+Bechowskiauthor=V.+J.+Hrubyauthor=T.+P.+Davis&title=The+effect+of+halogenation+on+blood-brain+barrier+permeability+of+a+novel+peptide+drug&doi=10.1016%2Fs0196-9781%2899%2900127-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of halogenation on blood-brain barrier permeability of a novel peptide drug</span></div><div class="casAuthors">Gentry, C. L.; Egleton, R. D.; Gillespie, T.; Abbruscato, T. J.; Bechowski, H. B.; Hruby, V. J.; Davis, T. P.</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1229-1238</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The utility of a drug depends on its ability to reach appropriate receptors at the target tissue and remain metabolically stable to produce the desired effect.  To improve central nervous system entry of the opioid analgesic [d-Pen2, l-Pen5, Phe6]Enkephalin (DPLEPe-Phe), our research group synthesized analogs that had chloro, brome, fluoro, and iodo halogens on the para positions of the phenylalanine-4 residue.  This study reports on investigation of the effect of halogenation on stability , lipophilicity, an in vitro blood-brain barrier permeability of a novel enkephalin analog DPLPE-Phe.  The stability of each halogenated DPLPE-Phe analog as well as the amidated and nonamidated parent peptide was tested in plasma and brain.  All peptides tested had a half-time disappearance >300 min except for DPLPE-Phe-NH2, which was found to have a half-life of 30 min in plasma.  Octanol/saline distribution studies indicated addn. of halogens to DPLPE-Phe-OH significantly increased lipophilicity except for p-[F-Phe4]DPLPE-Phe-OH.  P-[Cl-Phe4]DPLPE-Phe-OH exhibited the most pronounced increase in lipophilicity.  Para-bromo and para-chloro halogen addns. significantly enhanced in vitro blood-brain barrier permeability, providing evidence for improved delivery to the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3ejPXyxyHkrVg90H21EOLACvtfcHk0lgV9la7nBUHlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVCnsrg%253D&md5=5c78027002239f8700bb4c52d27ce33c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS0196-9781%2899%2900127-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0196-9781%252899%252900127-8%26sid%3Dliteratum%253Aachs%26aulast%3DGentry%26aufirst%3DC.%2BL.%26aulast%3DEgleton%26aufirst%3DR.%2BD.%26aulast%3DGillespie%26aufirst%3DT.%26aulast%3DAbbruscato%26aufirst%3DT.%2BJ.%26aulast%3DBechowski%26aufirst%3DH.%2BB.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DDavis%26aufirst%3DT.%2BP.%26atitle%3DThe%2520effect%2520of%2520halogenation%2520on%2520blood-brain%2520barrier%2520permeability%2520of%2520a%2520novel%2520peptide%2520drug%26jtitle%3DPeptides%26date%3D1999%26volume%3D20%26spage%3D1229%26epage%3D1238%26doi%3D10.1016%2Fs0196-9781%2899%2900127-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aryal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguère, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Duan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of opioid analgesics with reduced side effects</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1038/nature19112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fnature19112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27533032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=185-190&author=A.+Manglikauthor=H.+Linauthor=D.+K.+Aryalauthor=J.+D.+McCorvyauthor=D.+Denglerauthor=G.+Corderauthor=A.+Levitauthor=R.+C.+Klingauthor=V.+Bernatauthor=H.+H%C3%BCbnerauthor=X.-P.+Huangauthor=M.+F.+Sassanoauthor=P.+M.+Gigu%C3%A8reauthor=S.+L%C3%B6berauthor=D.+Da+Duanauthor=G.+Scherrerauthor=B.+K.+Kobilkaauthor=P.+Gmeinerauthor=B.+L.+Rothauthor=B.+K.+Shoichet&title=Structure-based+discovery+of+opioid+analgesics+with+reduced+side+effects&doi=10.1038%2Fnature19112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of opioid analgesics with reduced side effects</span></div><div class="casAuthors">Manglik, Aashish; Lin, Henry; Aryal, Dipendra K.; McCorvy, John D.; Dengler, Daniela; Corder, Gregory; Levit, Anat; Kling, Ralf C.; Bernat, Viachaslau; Hubner, Harald; Huang, Xi-Ping; Sassano, Maria F.; Giguere, Patrick M.; Lober, Stefan; Da Duan; Scherrer, Gregory; Kobilka, Brian K.; Gmeiner, Peter; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">185-190</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Morphine is an alkaloid from the opium poppy used to treat pain.  The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors.  Conversely, G-protein μOR signalling is thought to confer analgesia.  Here we computationally dock over 3 million mols. against the μOR structure and identify new scaffolds unrelated to known opioids.  Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment.  Unlike morphine, PZM21 is more efficacious for the affective component of analgesia vs. the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses.  PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCff2w3U8iLVg90H21EOLACvtfcHk0liY_Of3vRn2fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI&md5=b8bb2d8575dadf4a6dc74d94c26d2c1a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnature19112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19112%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DAryal%26aufirst%3DD.%2BK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DP.%2BM.%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DDa%2BDuan%26aufirst%3DD.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DStructure-based%2520discovery%2520of%2520opioid%2520analgesics%2520with%2520reduced%2520side%2520effects%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D185%26epage%3D190%26doi%3D10.1038%2Fnature19112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirohi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dighe, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madia, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoburn, B. C.</span></span> <span> </span><span class="NLM_article-title">The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.152678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1124%2Fjpet.109.152678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19435929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFClsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=513-519&author=S.+Sirohiauthor=S.+V.+Digheauthor=P.+A.+Madiaauthor=B.+C.+Yoburn&title=The+relative+potency+of+inverse+opioid+agonists+and+a+neutral+opioid+antagonist+in+precipitated+withdrawal+and+antagonism+of+analgesia+and+toxicity&doi=10.1124%2Fjpet.109.152678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity</span></div><div class="casAuthors">Sirohi, Sunil; Dighe, Shveta V.; Madia, Priyanka A.; Yoburn, Byron C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">513-519</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Opioid antagonists can be classified as inverse agonists and neutral antagonists.  In the opioid-dependent state, neutral antagonists are significantly less potent in pptg. withdrawal than inverse agonists.  Consequently, neutral opioid antagonists may offer advantages over inverse agonists in the management of opioid overdose.  In this study, the relative potency of three opioid antagonists to block opioid analgesia and toxicity and ppt. withdrawal was examd.  First, the potency of two opioid inverse agonists (naltrexone and naloxone) and a neutral antagonist (6β-naltrexol) to antagonize fentanyl-induced analgesia and lethality was detd.  The order of potency to block analgesia was naltrexone > naloxone > 6β-naltrexol (17, 4, 1), which was similar to that to block lethality (13, 2, 1).  Next, the antagonists were compared using withdrawal jumping in fentanyl-dependent mice.  The order of potency to ppt. withdrawal jumping was naltrexone > naloxone >>> 6β-naltrexol (1107, 415, 1).  The relative potencies to ppt. withdrawal for the inverse agonists compared with the neutral antagonist were dramatically different from that for antagonism of analgesia and lethality.  Finally, the effect of 6β-naltrexol pretreatment on naloxone-pptd. jumping was detd. in morphine and fentanyl-dependent mice.  6β-Naltrexol pretreatment decreased naloxone pptd. withdrawal, indicating that 6β-naltrexol is a neutral antagonist.  These data demonstrate that inverse agonists and neutral antagonists have generally comparable potencies to block opioid analgesia and lethality, whereas the neutral opioid antagonist is substantially less potent in pptg. opioid withdrawal.  These results support suggestions that neutral antagonists may have advantages over inverse agonists in the management of opioid overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw-j4cGjagnbVg90H21EOLACvtfcHk0liuGeyNvzkkZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFClsLc%253D&md5=dcba0f30d77c82cf8a83b83903d37f37</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152678%26sid%3Dliteratum%253Aachs%26aulast%3DSirohi%26aufirst%3DS.%26aulast%3DDighe%26aufirst%3DS.%2BV.%26aulast%3DMadia%26aufirst%3DP.%2BA.%26aulast%3DYoburn%26aufirst%3DB.%2BC.%26atitle%3DThe%2520relative%2520potency%2520of%2520inverse%2520opioid%2520agonists%2520and%2520a%2520neutral%2520opioid%2520antagonist%2520in%2520precipitated%2520withdrawal%2520and%2520antagonism%2520of%2520analgesia%2520and%2520toxicity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D513%26epage%3D519%26doi%3D10.1124%2Fjpet.109.152678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maadani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farahanikia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eftekhari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifzadeh, M.</span></span> <span> </span><span class="NLM_article-title">Effect of the methanolic extracts of different parts of Ferula assa-foetida on naloxone-induced withdrawal behavior in morphine-dependent mice</span>. <i>Avicenna J. Phytomed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=29062804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVGqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=426-435&author=M.+Khanaviauthor=S.+Maadaniauthor=B.+Farahanikiaauthor=M.+Eftekhariauthor=M.+Sharifzadeh&title=Effect+of+the+methanolic+extracts+of+different+parts+of+Ferula+assa-foetida+on+naloxone-induced+withdrawal+behavior+in+morphine-dependent+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the methanolic extracts of different parts of Ferula assa-foetida on naloxone-induced withdrawal behavior in morphine-dependent mice</span></div><div class="casAuthors">Khanavi, Mahnaz; Maadani, Sajad; Farahanikia, Behnaz; Eftekhari, Mahdieh; Sharifzadeh, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Avicenna Journal of Phytomedicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-435</span>CODEN:
                <span class="NLM_cas:coden">AJPVAX</span>;
        ISSN:<span class="NLM_cas:issn">2228-7949</span>.
    
            (<span class="NLM_cas:orgname">Mashhad University of Medical Sciences</span>)
        </div><div class="casAbstract">Objective:Ferula assa-foetida, a native species in Iran, is used for treatment of several diseases particularly for neurol. disorders in Iranian Traditional Medicine.  The aim of this study is to investigate the effect of methanolic roots, fruits, and aerial parts exts. of Ferula assa-foetida on withdrawal syndrome in morphine-dependent mice.  Materials and Methods: Aerial parts, roots, and fruits of the plant were sep. extd. with 80% MeOH.  For induction of dependence, morphine (50, 50 and 75 mg/kg) was injected s.c. three times daily (10 am, 1 pm and 4 pm) for three days and a last dose of morphine (50 mg/kg) was administrated on the fourth day.  Withdrawal syndrome was induced by injection of naloxone (5 mg/kg, i.p.) 2 h after the final dose of morphine.  Different doses of the exts. were administered i.p. 60 min before naloxone injection and withdrawal sign was recorded 2 min after naloxone injection for a period of 60 min.  Results: Pre-treatment of animals with different doses (2.5, 5, 10, 20 mg/kg) of methanolic ext. of the aerial parts of F. assafoetida caused a significant decrease in naloxone-induced behavior.  I.p. administration of different doses (10, 15, 20, 25 mg/kg) of methanolic ext. of the fruit significantly reduced the naloxone-induced withdrawal behavior (p<0.001).  Conclusion: It might be concluded that the exts. of Ferula assa-foetida affect morphine withdrawal syndrome possibly via interference with the neurotransmitters in nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_mKf86XIV6bVg90H21EOLACvtfcHk0liuGeyNvzkkZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVGqs7g%253D&md5=75f1f3e9ca9b68150f9ec8cb30ffe4f5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhanavi%26aufirst%3DM.%26aulast%3DMaadani%26aufirst%3DS.%26aulast%3DFarahanikia%26aufirst%3DB.%26aulast%3DEftekhari%26aufirst%3DM.%26aulast%3DSharifzadeh%26aufirst%3DM.%26atitle%3DEffect%2520of%2520the%2520methanolic%2520extracts%2520of%2520different%2520parts%2520of%2520Ferula%2520assa-foetida%2520on%2520naloxone-induced%2520withdrawal%2520behavior%2520in%2520morphine-dependent%2520mice%26jtitle%3DAvicenna%2520J.%2520Phytomed.%26date%3D2017%26volume%3D7%26spage%3D426%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Whole brain (A) and plasma (B) concentration–time curves of analog <b>6</b> measured by LC–MS/MS after i.v. administration to male Kunming mice (6–8 weeks old) at a dose of 1 mg/kg. Data points are average values from three animals per time. Each value represents the mean ± S.E.M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Central analgesic effects induced by i.c.v. injection of analogs <b>6</b> and <b>8</b> in male Kunming mice (6–8 weeks old) in the radiant heat tail-flick test. Antinociceptive dose and time effect curves for analogs <b>6</b> [(A) 0.001, 0.03, 1, and 30 pmol] and <b>8</b> [(B) 0.00003, 0.001, 0.03, 1, and 30 pmol] after i.c.v. administration. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 8–13 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to saline group according to one-way ANOVA followed by the Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of central pretreatments with opioid and NPFF receptors antagonists on supraspinal analgesia of analogs <b>6</b> and <b>8</b> in male Kunming mice (6–8 weeks old) in the radiant heat tail-flick test. The effects of supraspinal injection of the opioid receptor antagonist Nal (5 nmol, i.c.v.), the selective opioid receptor antagonists β-FNA (10 nmol, i.c.v.), NTI (10 nmol, i.c.v.), and nor-BNI (10 nmol, i.c.v.) on the central analgesia of analogs <b>6</b> [(A) 30 pmol, i.c.v.] and <b>8</b> [(C) 30 pmol, i.c.v.]. The effects of supraspinal injections of the NPFF receptor antagonist RF9 (10 nmol, i.c.v.) on the central analgesia of analogs <b>6</b> [(B) 0.03 pmol, i.c.v.] and <b>8</b> [(D) 0.03 pmol, i.c.v.]. RF9, 1-adamantanecarbonyl-RF-NH<sub>2</sub>. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–11 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to the saline group. <sup>###</sup><i>P</i> < 0.001 indicates significant differences compared to the saline + drug group, according to one-way ANOVA followed by the Bonferroni’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Peripheral analgesic effects induced by s.c. injection of analogs <b>6</b> and <b>8</b> in male Kunming mice (6–8 weeks old) in the radiant heat tail-flick test. Antinociceptive dose and time effect curves for analogs <b>6</b> [(A) 0.0009, 0.009, and 0.09 μmol/kg] and <b>8</b> [(B) 0.0009, 0.009, and 0.09 μmol/kg] after s.c. administration. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–13 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to saline group according to one-way ANOVA followed by the Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of peripheral or central pretreatments with the opioid receptor antagonists Nal (10 mg/kg, s.c.) and NALM (10 mg/kg, s.c.; 5 nmol, i.c.v.) on the peripheral analgesia of fentanyl [(A) 0.19 μmol/kg, s.c.], analog <b>2</b> [(B) 8.94 μmol/kg, s.c.], analog <b>4</b> [(C) 2.68 μmol/kg, s.c.], analog <b>6</b> [(D) 0.09 μmol/kg, s.c.], and analog <b>8</b> [(E) 0.09 μmol/kg, s.c.] in male Kunming mice (6–8 weeks old) in the radiant heat tail-flick test. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 6–17 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to the saline group. <sup>###</sup><i>P</i> < 0.001 indicates significant differences compared to the saline + drug group, according to one-way ANOVA followed by the Bonferroni’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of peripheral or central pretreatments with the NPFF receptor antagonist RF9 on peripheral analgesia of analogs <b>6</b> and <b>8</b> in the radiant heat tail-flick test. The effects of peripheral administration of the NPFF receptor antagonist RF9 (5 mg/kg, s.c.) on the peripheral analgesia of analogs <b>6</b> [(A) 0.009 μmol/kg, s.c.] and <b>8</b> [(B) 0.009 μmol/kg, s.c.] in male Kunming mice (6–8 weeks old). Effects of central administration of the NPFF receptor antagonist RF9 on the peripheral analgesia of analogs <b>6</b> [(C) 0.009 μmol/kg, s.c.] and <b>8</b> [(D) 0.009 μmol/kg, s.c.] in male Kunming mice (6–8 weeks old). (E) The antinociceptive effects of analogs <b>2</b> (0.89 μmol/kg, s.c.) and <b>6</b> (0.09 μmol/kg, s.c.) in WT and NPFF<sub>2</sub><sup>–/–</sup> mice on a C57BL/6 background. RF9, 1-adamantanecarbonyl-RF-NH<sub>2</sub>. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 5–8 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to the saline group. <sup>###</sup><i>P</i> < 0.001 indicates significant differences compared to the saline + drug group, according to one-way ANOVA followed by the Bonferroni’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Analgesic tolerance evaluations of analogs <b>6</b> and <b>8</b> in male Kunming mice (6–8 weeks old) in the radiant heat tail flick test. Saline, fentanyl (3000 pmol, i.c.v.; 0.19 μmol/kg, s.c.), analogs <b>6</b> (30 pmol, i.c.v.; 0.09 μmol/kg, s.c.), and <b>8</b> (30 pmol, i.c.v.; 0.09 μmol/kg, s.c.) were daily administered for 8 days in mice, and antinociceptive effects were measured once daily after drug administration. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–9 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to day 1 according to one-way ANOVA followed by the Tukey HSD’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of i.c.v. (A) and s.c. (B) injections of analogs <b>6</b> (30 pmol, i.c.v.; 0.09 μmol/kg, s.c.) and <b>8</b> (30 pmol, i.c.v.; 0.09 μmol/kg, s.c.) on the motor coordination of male Kunming mice (6–8 weeks old) in the rotarod test. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–10 mice per group). There are no significant differences according to one-way ANOVA followed by the Dunnett’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effects of s.c. injections of fentanyl (0.19 μmol/kg), analogs <b>6</b> (0.09 μmol/kg), and <b>8</b> (0.09 μmol/kg) on the rewarding effects and withdrawal reactions in male Kunming mice (6–8 weeks old). (A) The time effect curves of s.c. injections of drugs in the open field test. (B) Effects of s.c. injections of drugs on the total distance in the open field test. (C) Effects of s.c. injections of drugs on CPP in mice. (D) Effects of s.c. injections of drugs on Nal-precipitated withdrawal in mice. Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–10 mice per group). ***<i>P</i> < 0.001 indicates significant differences compared to the saline group according to the unpaired <i>t</i>-test for CPP or one-way ANOVA followed by the Bonferroni’s post-hot test. <sup>###</sup><i>P</i> < 0.001 indicates significant differences compared to the fentanyl group according to one-way ANOVA followed by the Bonferroni’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/medium/jm0c01367_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effects of s.c. injections of analog <b>6</b> [(A) 0.09, 0.90, and 8.95 μmol/kg] or analog <b>8</b> [(B) 0.009, 0.09, and 0.9 μmol/kg] on gastrointestinal motility in male Kunming mice (6–8 weeks old). Each value represents the mean ± S.E.M. Group sizes are shown in the figures (<i>n</i> = 7–8 mice per group). *<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001 indicate significant differences between drugs and saline according to one-way ANOVA followed by the Dunnett’s post-hoc test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01367/20201218/images/large/jm0c01367_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01367&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15785" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15785" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 63 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zöllner, C.</span>; <span class="NLM_string-name">Stein, C.</span></span> <span> </span><span class="NLM_article-title">Opioids</span>.  <i>Analgesia</i>; <span class="NLM_series">Handbook of Experimental Pharmacology</span>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_year">2007</span>; Vol.  <span class="NLM_volume">177</span>, pp  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">63</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=31-63&author=C.+Z%C3%B6llner&author=C.+Stein&title=Analgesia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DZ%25C3%25B6llner%26aufirst%3DC.%26atitle%3DOpioids%26btitle%3DAnalgesia%26pub%3DSpringer%26date%3D2007%26volume%3D177%26spage%3D31%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waldhoer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whistler, J. L.</span></span> <span> </span><span class="NLM_article-title">Opioid receptors</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">953</span>– <span class="NLM_lpage">990</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.73.011303.073940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1146%2Fannurev.biochem.73.011303.073940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=15189164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2004&pages=953-990&author=M.+Waldhoerauthor=S.+E.+Bartlettauthor=J.+L.+Whistler&title=Opioid+receptors&doi=10.1146%2Fannurev.biochem.73.011303.073940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid receptors</span></div><div class="casAuthors">Waldhoer, Maria; Bartlett, Selena E.; Whistler, Jennifer L.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">953-990</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Opioid receptors belong to the large superfamily of 7 transmembrane-spanning (7TM) G protein-coupled receptors (GPCRs).  As a class, GPCRs are of fundamental physiol. importance mediating the actions of the majority of known neurotransmitters and hormones.  Opioid receptors are particularly intriguing members of this receptor family.  They are activated both by endogenously produced opioid peptides and by exogenously administered opiate compds., some of which are not only among the most effective analgesics known but also highly addictive drugs of abuse.  A fundamental question in addiction biol. is why exogenous opioid drugs, such as morphine and heroin, have a high liability for inducing tolerance, dependence, and addiction.  This review focuses on many aspects of opioid receptors with the aim of gaining a greater insight into mechanisms of opioid tolerance and dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSV3Nl3WDHrVg90H21EOLACvtfcHk0lhbFTsqfsBcdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslagsbs%253D&md5=9f865544116a6dac76c80432587180a3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.73.011303.073940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.73.011303.073940%26sid%3Dliteratum%253Aachs%26aulast%3DWaldhoer%26aufirst%3DM.%26aulast%3DBartlett%26aufirst%3DS.%2BE.%26aulast%3DWhistler%26aufirst%3DJ.%2BL.%26atitle%3DOpioid%2520receptors%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2004%26volume%3D73%26spage%3D953%26epage%3D990%26doi%3D10.1146%2Fannurev.biochem.73.011303.073940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stein, C.</span></span> <span> </span><span class="NLM_article-title">Opioids, sensory systems and chronic pain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>716</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2013.01.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ejphar.2013.01.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=23500206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtValsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=716&publication_year=2013&pages=179-187&author=C.+Stein&title=Opioids%2C+sensory+systems+and+chronic+pain&doi=10.1016%2Fj.ejphar.2013.01.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Opioids, sensory systems and chronic pain</span></div><div class="casAuthors">Stein, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">716</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">179-187</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Opioids are the oldest and most potent drugs for the treatment of severe pain.  Their clin. application is undisputed in acute pain (e.g. assocd. with trauma or surgery) but their long-term use in chronic pain has met increasing scrutiny.  Therefore, this article will review sensory mechanisms related to opioid analgesia and side effects with a special emphasis on chronic pain.  Central and peripheral sites of analgesic actions and side effects, as well as conventional and novel opioid compds. will be discussed.  Since pain is a complex bio-psycho-social phenomenon, non-pharmacol. considerations important for the understanding of opioid analgesic efficacy are also included.  Finally, examples of challenging clin. situations such as the perioperative management of patients receiving long-term opioid treatment are illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtVfvmEPZOzLVg90H21EOLACvtfcHk0lgC-7l8H1Eipw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtValsb0%253D&md5=d2e6ca840fccc49b2b96c9407530348e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2013.01.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2013.01.076%26sid%3Dliteratum%253Aachs%26aulast%3DStein%26aufirst%3DC.%26atitle%3DOpioids%252C%2520sensory%2520systems%2520and%2520chronic%2520pain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D716%26spage%3D179%26epage%3D187%26doi%3D10.1016%2Fj.ejphar.2013.01.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benyamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trescot, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buenaventura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adlaka, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehgal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallejo, R.</span></span> <span> </span><span class="NLM_article-title">Opioid complications and side effects</span>. <i>Pain Physician</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S105</span>– <span class="NLM_lpage">S120</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=18443635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A280%3ADC%252BD1czosVSjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=S105-S120&author=R.+Benyaminauthor=A.+M.+Trescotauthor=S.+Dattaauthor=R.+Buenaventuraauthor=R.+Adlakaauthor=N.+Sehgalauthor=S.+E.+Glaserauthor=R.+Vallejo&title=Opioid+complications+and+side+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid complications and side effects</span></div><div class="casAuthors">Benyamin Ramsin; Trescot Andrea M; Datta Sukdeb; Buenaventura Ricardo; Adlaka Rajive; Sehgal Nalini; Glaser Scott E; Vallejo Ricardo</div><div class="citationInfo"><span class="NLM_cas:title">Pain physician</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2 Suppl</span>),
    <span class="NLM_cas:pages">S105-20</span>
        ISSN:<span class="NLM_cas:issn">1533-3159</span>.
    </div><div class="casAbstract">Medications which bind to opioid receptors are increasingly being prescribed for the treatment of multiple and diverse chronic painful conditions.  Their use for acute pain or terminal pain is well accepted.  Their role in the long-term treatment of chronic noncancer pain is, however, controversial for many reasons.  One of the primary reasons is the well-known phenomenon of psychological addiction that can occur with the use of these medications.  Abuse and diversion of these medications is a growing problem as the availability of these medications increases and this public health issue confounds their clinical utility.  Also, the extent of their efficacy in the treatment of pain when utilized on a chronic basis has not been definitively proven.  Lastly, the role of opioids in the treatment of chronic pain is also influenced by the fact that these potent analgesics are associated with a significant number of side effects and complications.  It is these phenomena that are the focus of this review.  Common side effects of opioid administration include sedation, dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and respiratory depression.  Physical dependence and addiction are clinical concerns that may prevent proper prescribing and in turn inadequate pain management.  Less common side effects may include delayed gastric emptying, hyperalgesia, immunologic and hormonal dysfunction, muscle rigidity, and myoclonus.  The most common side effects of opioid usage are constipation (which has a very high incidence) and nausea.  These 2 side effects can be difficult to manage and frequently tolerance to them does not develop; this is especially true for constipation.  They may be severe enough to require opioid discontinuation, and contribute to under-dosing and inadequate analgesia.  Several clinical trials are underway to identify adjunct therapies that may mitigate these side effects.  Switching opioids and/or routes of administration may also provide benefits for patients.  Proper patient screening, education, and preemptive treatment of potential side effects may aid in maximizing effectiveness while reducing the severity of side effects and adverse events.  Opioids can be considered broad spectrum analgesic agents, affecting a wide number of organ systems and influencing a large number of body functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS-eBn7Ppy6vx2phytoz6_fW6udTcc2ebd-nMEBQfINbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1czosVSjsQ%253D%253D&md5=26196f3cc302b1cad86e32477bb52e18</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBenyamin%26aufirst%3DR.%26aulast%3DTrescot%26aufirst%3DA.%2BM.%26aulast%3DDatta%26aufirst%3DS.%26aulast%3DBuenaventura%26aufirst%3DR.%26aulast%3DAdlaka%26aufirst%3DR.%26aulast%3DSehgal%26aufirst%3DN.%26aulast%3DGlaser%26aufirst%3DS.%2BE.%26aulast%3DVallejo%26aufirst%3DR.%26atitle%3DOpioid%2520complications%2520and%2520side%2520effects%26jtitle%3DPain%2520Physician%26date%3D2008%26volume%3D11%26spage%3DS105%26epage%3DS120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, P. W.</span></span> <span> </span><span class="NLM_article-title">Bi- or multifunctional opioid peptide drugs</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">603</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2009.02.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.lfs.2009.02.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19285088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktlChs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2010&pages=598-603&author=P.+W.+Schiller&title=Bi-+or+multifunctional+opioid+peptide+drugs&doi=10.1016%2Fj.lfs.2009.02.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Bi- or multifunctional opioid peptide drugs</span></div><div class="casAuthors">Schiller, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">598-603</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Strategies for the design of bi- or multifunctional drugs are reviewed.  A distinction is made between bifunctional drugs interacting in a monovalent fashion with two targets and ligands contg. two distinct pharmacophores binding in a bivalent mode to the two binding sites in a receptor heterodimer.  Arguments are presented to indicate that some of the so-called "bivalent" ligands reported in the literature are unlikely to simultaneously interact with two binding sites.  Aspects related to the development of bi- or multifunctional drugs are illustrated with examples from the field of opioid analgesics.  The drug-like properties of the tetrapeptide Dmt1[DALDA] with triple action as a μ opioid agonist, norepinephrine uptake inhibitor and releaser of endogenous opioid peptides to produce potent spinal analgesia are reviewed.  Rationales for the development of opioid peptides with mixed agonist/antagonist profiles as analgesics with reduced side effects are presented.  Progress in the development of mixed μ opioid agonist/δ opioid antagonists with low propensity to produce tolerance and phys. dependence is reviewed.  Efforts to develop bifunctional peptides contg. a μ opioid agonist and a cholecystokinin antagonist or an NK1 receptor antagonist as analgesics expected to produce less tolerance and dependence are also reviewed.  A strategy to improve the drug-like properties of bifunctional opioid peptide analgesics is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo51QVXgJVx6LVg90H21EOLACvtfcHk0ligdOZkn0dMFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktlChs7o%253D&md5=6bb5b32b59f9d2bbd12763c1c32cd641</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2009.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2009.02.025%26sid%3Dliteratum%253Aachs%26aulast%3DSchiller%26aufirst%3DP.%2BW.%26atitle%3DBi-%2520or%2520multifunctional%2520opioid%2520peptide%2520drugs%26jtitle%3DLife%2520Sci.%26date%3D2010%26volume%3D86%26spage%3D598%26epage%3D603%26doi%3D10.1016%2Fj.lfs.2009.02.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0ligdOZkn0dMFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, A.</span></span> <span> </span><span class="NLM_article-title">Multiple ligands in opioid research</span>. <i>Protein Pept. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">682</span>, <span class="refDoi"> DOI: 10.2174/092986608785133672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.2174%2F092986608785133672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=18782061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnsVyguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=668-682&author=S.+Balletauthor=M.+Pietschauthor=A.+Abell&title=Multiple+ligands+in+opioid+research&doi=10.2174%2F092986608785133672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple ligands in opioid research</span></div><div class="casAuthors">Ballet, Steven; Pietsch, Markus; Abell, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Peptide Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">668-682</span>CODEN:
                <span class="NLM_cas:coden">PPELEN</span>;
        ISSN:<span class="NLM_cas:issn">0929-8665</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The observation in 1979 that opioid receptors interact, led to the design of bivalent ligands in an attempt to improve selectivity and affinity towards the different subtypes (i.e. μ, δ, and κ).  Dimers of monovalent "parent" opioid structures were evaluated and include: (a) endogenous (e.g. enkephalins) or exogenous (e.g. dermorphin) peptide dimer analogs (b) mixed peptidic-non-peptidic bivalent ligands and (c) dual non-peptidic dimers.  Chimeric structures, using an opioid pharmacophore in combination with a non-opioid pharmacophore, were also prepd.  The common aim in all these studies is to improve the pharmacol. profile of potential analgesics to minimize common opioid-induced side-effects, such as phys. dependence and tolerance.  Here we present a brief overview of efforts to develop bivalent opioid ligands for use in pain-related research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqqggOwEwoZ7Vg90H21EOLACvtfcHk0ligdOZkn0dMFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnsVyguro%253D&md5=e5222fb145da6472a7c9477ba8ba60c7</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F092986608785133672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986608785133672%26sid%3Dliteratum%253Aachs%26aulast%3DBallet%26aufirst%3DS.%26aulast%3DPietsch%26aufirst%3DM.%26aulast%3DAbell%26aufirst%3DA.%26atitle%3DMultiple%2520ligands%2520in%2520opioid%2520research%26jtitle%3DProtein%2520Pept.%2520Lett.%26date%3D2008%26volume%3D15%26spage%3D668%26epage%3D682%26doi%3D10.2174%2F092986608785133672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foran, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipkowski, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maszczynska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinborn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopin, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kream, R. M.</span></span> <span> </span><span class="NLM_article-title">A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">7621</span>– <span class="NLM_lpage">7626</span>, <span class="refDoi"> DOI: 10.1073/pnas.130181897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.130181897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10852965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVKhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=7621-7626&author=S.+E.+Foranauthor=D.+B.+Carrauthor=A.+W.+Lipkowskiauthor=I.+Maszczynskaauthor=J.+E.+Marchandauthor=A.+Misickaauthor=M.+Beinbornauthor=A.+S.+Kopinauthor=R.+M.+Kream&title=A+substance+P-opioid+chimeric+peptide+as+a+unique+nontolerance-forming+analgesic&doi=10.1073%2Fpnas.130181897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic</span></div><div class="casAuthors">Foran, Stacy E.; Carr, Daniel B.; Lipkowski, Andrzej W.; Maszczynska, Iwona; Marchand, James E.; Misicka, Aleksandra; Beinborn, Martin; Kopin, Alan S.; Kream, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7621-7626</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">To elucidate mechanisms of acute and chronic pain, it is important to understand how spinal excitatory systems influence opioid analgesia.  The tachykinin substance P (SP) represents the prototypic spinal excitatory peptide neurotransmitter/neuromodulator, acting in concert with endogenous opioid systems to regulate analgesic responses to nociceptive stimuli.  We have synthesized and pharmacol. characterized a chimeric peptide contg. overlapping NH2- and COOH-terminal functional domains of the endogenous opioid endomorphin-2 (EM-2) and the tachykinin SP, resp.  Repeated administration of the chimeric mol. YPFFGLM-NH2, designated ESP7, into the rat spinal cord produces opioid-dependent analgesia without loss of potency over 5 days.  In contrast, repeated administration of ESP7 with concurrent SP receptor (SPR) blockade results in a progressive loss of analgesic potency, consistent with the development of tolerance.  Furthermore, tolerant animals completely regain opioid sensitivity after post hoc administration of ESP7 alone, suggesting that coactivation of SPRs is essential to maintaining opioid responsiveness.  Radioligand binding and signaling assays, using recombinant receptors, confirm that ESP7 can coactivate μ-opioid receptors (MOR) and SPRs in vitro.  We hypothesize that coincidental activation of the MOR- and SPR-expressing systems in the spinal cord mimics an ongoing state of reciprocal excitation and inhibition, which is normally encountered in nociceptive processing.  Due to the ability of ESP7 to interact with both MOR and SPRs, it represents a unique prototypic, anti-tolerance-forming analgesic with future therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwpOaxyG994LVg90H21EOLACvtfcHk0lgBPxNjJ5mLMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVKhsbs%253D&md5=3500b41c38bbaef0375aea4413a0a490</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.130181897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.130181897%26sid%3Dliteratum%253Aachs%26aulast%3DForan%26aufirst%3DS.%2BE.%26aulast%3DCarr%26aufirst%3DD.%2BB.%26aulast%3DLipkowski%26aufirst%3DA.%2BW.%26aulast%3DMaszczynska%26aufirst%3DI.%26aulast%3DMarchand%26aufirst%3DJ.%2BE.%26aulast%3DMisicka%26aufirst%3DA.%26aulast%3DBeinborn%26aufirst%3DM.%26aulast%3DKopin%26aufirst%3DA.%2BS.%26aulast%3DKream%26aufirst%3DR.%2BM.%26atitle%3DA%2520substance%2520P-opioid%2520chimeric%2520peptide%2520as%2520a%2520unique%2520nontolerance-forming%2520analgesic%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2000%26volume%3D97%26spage%3D7621%26epage%3D7626%26doi%3D10.1073%2Fpnas.130181897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span> <span> </span><span class="NLM_article-title">The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7337</span>– <span class="NLM_lpage">7343</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.bmc.2009.08.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19762245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ais7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7337-7343&author=T.+Yamamotoauthor=P.+Nairauthor=S.-w.+Maauthor=P.+Davisauthor=H.+I.+Yamamuraauthor=T.+W.+Vanderahauthor=F.+Porrecaauthor=J.+Laiauthor=V.+J.+Hruby&title=The+biological+activity+and+metabolic+stability+of+peptidic+bifunctional+compounds+that+are+opioid+receptor+agonists+and+neurokinin-1+receptor+antagonists+with+a+cystine+moiety&doi=10.1016%2Fj.bmc.2009.08.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety</span></div><div class="casAuthors">Yamamoto, Takashi; Nair, Padma; Ma, Shou-wu; Davis, Peg; Yamamura, Henry I.; Vanderah, Todd W.; Porreca, Frank; Lai, Josephine; Hruby, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7337-7343</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to improve metabolic stability, a ring structure with a cystine moiety was introduced into TY027 (Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-[3',5'-(CF3)2Bzl]), which is a lead compd. of our developing bifunctional peptide possessing opioid agonist and NK1 antagonist activities.  TY038 (Tyr-cyclo[D-Cys-Gly-Phe-Met-Pro-D-Cys]-Trp-NH-[3',5'-(CF3)2Bzl]) was found as a highly selective δ opioid agonist over μ receptor in conventional tissue-based assays, together with an effective NK1 antagonist activity and good metabolic stability with more than 24 h half life in rat plasma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGparHxQyFibhbVg90H21EOLACvtfcHk0lhlx9ecIdMmZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ais7nL&md5=61567a71476cf64f45d354d7be6cec53</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNair%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DS.-w.%26aulast%3DDavis%26aufirst%3DP.%26aulast%3DYamamura%26aufirst%3DH.%2BI.%26aulast%3DVanderah%26aufirst%3DT.%2BW.%26aulast%3DPorreca%26aufirst%3DF.%26aulast%3DLai%26aufirst%3DJ.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DThe%2520biological%2520activity%2520and%2520metabolic%2520stability%2520of%2520peptidic%2520bifunctional%2520compounds%2520that%2520are%2520opioid%2520receptor%2520agonists%2520and%2520neurokinin-1%2520receptor%2520antagonists%2520with%2520a%2520cystine%2520moiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D7337%26epage%3D7343%26doi%3D10.1016%2Fj.bmc.2009.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Largent-Milnes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porreca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderah, T.</span></span> <span> </span><span class="NLM_article-title">Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">986</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.00824.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1111%2Fj.1476-5381.2010.00824.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=20977451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2ms7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2010&pages=986-1001&author=T.+Largent-Milnesauthor=T.+Yamamotoauthor=P.+Nairauthor=J.+Moultonauthor=V.+Hrubyauthor=J.+Laiauthor=F.+Porrecaauthor=T.+Vanderah&title=Spinal+or+systemic+TY005%2C+a+peptidic+opioid+agonist%2Fneurokinin+1+antagonist%2C+attenuates+pain+with+reduced+tolerance&doi=10.1111%2Fj.1476-5381.2010.00824.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance</span></div><div class="casAuthors">Largent-Milnes, T. M.; Yamamoto, T.; Nair, P.; Moulton, J. W.; Hruby, V. J.; Lai, J.; Porreca, F.; Vanderah, T. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">986-1001</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The use of opioids in treating pain is limited due to significant side effects including somnolence, constipation, analgesic tolerance, addiction and respiratory depression.  Pre-clin. studies have shown that neurokinin 1 (NK1) receptor antagonists block opioid-induced antinociceptive tolerance and may inhibit opioid-induced rewarding behaviors.  Here, we have characterized a bifunctional peptide with both opioid agonist and NK1 antagonist pharmacophores in a rodent model of neuropathic pain.  Rats were evaluated for behavioral responses to both tactile and thermal stimuli in either an uninjured, sham- or nerve-injured state.  TY005 (Tyr-DAla-Gly-Phe-Met-Pro-Leu-Trp-O-3,5-Bn(CF3)2) was delivered spinally or systemically to assess the antinociceptive effects after acute exposure.  Motor skills were evaluated using the rotarod test to det. potential sedative effects.  Spinal TY005 was given chronically to sham- or nerve-injured animals to det. the development of tolerance.  Bolus injections of TY005 produced dose-dependent antinociception in non-injured animals and alleviated nerve injury-induced thermal and tactile hypersensitivities (i.e. antihyperalgesia) more effectively than morphine.  Sedative effects were not evident from the rotarod test at doses that were antihyperalgesic, nor at doses 3-fold higher.  Repeated administration of TY005 did not lead to the development of antihyperalgesic tolerance or alter sensory thresholds.  Collectively, the data suggest that opioid agonist/NK1 antagonist bifunctional peptides represent a promising novel approach to the management of chronic pain without the development of tolerance, reducing the need for escalation of doses and unwanted side effects assocd. with opiates alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmIZV-rESBFrVg90H21EOLACvtfcHk0lhlx9ecIdMmZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2ms7jN&md5=5ea51d658f8678e93d8e19a5f20802c1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.00824.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.00824.x%26sid%3Dliteratum%253Aachs%26aulast%3DLargent-Milnes%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNair%26aufirst%3DP.%26aulast%3DMoulton%26aufirst%3DJ.%26aulast%3DHruby%26aufirst%3DV.%26aulast%3DLai%26aufirst%3DJ.%26aulast%3DPorreca%26aufirst%3DF.%26aulast%3DVanderah%26aufirst%3DT.%26atitle%3DSpinal%2520or%2520systemic%2520TY005%252C%2520a%2520peptidic%2520opioid%2520agonist%252Fneurokinin%25201%2520antagonist%252C%2520attenuates%2520pain%2520with%2520reduced%2520tolerance%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2010%26volume%3D161%26spage%3D986%26epage%3D1001%26doi%3D10.1111%2Fj.1476-5381.2010.00824.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Naour, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akgün, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yekkirala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunzer, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalyuzhny, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portoghese, P. S.</span></span> <span> </span><span class="NLM_article-title">Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5505</span>– <span class="NLM_lpage">5513</span>, <span class="refDoi"> DOI: 10.1021/jm4005219</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4005219" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3sXoslSqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5505-5513&author=M.+Le%0ANaourauthor=E.+Akg%C3%BCnauthor=A.+Yekkiralaauthor=M.+M.+Lunzerauthor=M.+D.+Powersauthor=A.+E.+Kalyuzhnyauthor=P.+S.+Portoghese&title=Bivalent+Ligands+That+Target+%CE%BC+Opioid+%28MOP%29+and+Cannabinoid1+%28CB1%29+Receptors+Are+Potent+Analgesics+Devoid+of+Tolerance&doi=10.1021%2Fjm4005219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Bivalent Ligands That Target μ Opioid (MOP) and Cannabinoid 1 (CB1) Receptors Are Potent Analgesics Devoid of Tolerance</span></div><div class="casAuthors">Le Naour, Morgan; Akgun, Eyup; Yekkirala, Ajay; Lunzer, Mary M.; Powers, Mike D.; Kalyuzhny, Alexander E.; Portoghese, Philip S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5505-5513</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given that μ opioid (MOP) and cannabinoid (CB1) receptors are colocalized in various regions of the central nervous system and have been reported to assoc. as heteromer (MOP-CB1) in cultured cells, the possibility of functional, endogenous MOP-CB1 in nociception and other pharmacol. effects has been raised.  As a first step in investigating this possibility, we have synthesized a series of bivalent ligands 1-5 that contain both μ agonist and CB1 antagonist pharmacophores for use as tools to study the functional interaction between MOP and CB1 receptors in vivo.  Immunofluorescent studies on HEK293 cells coexpressing both receptors suggested 5 (20-atom spacer) to be the only member of the series that bridges the protomers of the heteromer.  Antinociceptive testing in mice revealed 5 to be the most potent member of the series.  As neither a mixt. of monovalent ligands 9+10 nor bivalents 2-5 produced tolerance in mice, MOR-CB1 apparently is not an important target for reducing tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdqGOG4RA1RLVg90H21EOLACvtfcHk0lhlx9ecIdMmZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXoslSqtLc%253D&md5=b3df3237bfebc84448056724c3cfca4d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm4005219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4005219%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BNaour%26aufirst%3DM.%26aulast%3DAkg%25C3%25BCn%26aufirst%3DE.%26aulast%3DYekkirala%26aufirst%3DA.%26aulast%3DLunzer%26aufirst%3DM.%2BM.%26aulast%3DPowers%26aufirst%3DM.%2BD.%26aulast%3DKalyuzhny%26aufirst%3DA.%2BE.%26aulast%3DPortoghese%26aufirst%3DP.%2BS.%26atitle%3DBivalent%2520Ligands%2520That%2520Target%2520%25CE%25BC%2520Opioid%2520%2528MOP%2529%2520and%2520Cannabinoid1%2520%2528CB1%2529%2520Receptors%2520Are%2520Potent%2520Analgesics%2520Devoid%2520of%2520Tolerance%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5505%26epage%3D5513%26doi%3D10.1021%2Fjm4005219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhtankar, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nader, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.-C.</span></span> <span> </span><span class="NLM_article-title">A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">E5511</span>– <span class="NLM_lpage">E5518</span>, <span class="refDoi"> DOI: 10.1073/pnas.1605295113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.1605295113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27573832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWks7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=E5511-E5518&author=H.+Dingauthor=P.+W.+Czotyauthor=N.+Kiguchiauthor=G.+Cami-Kobeciauthor=D.+D.+Sukhtankarauthor=M.+A.+Naderauthor=S.+M.+Husbandsauthor=M.-C.+Ko&title=A+novel+orvinol+analog%2C+BU08028%2C+as+a+safe+opioid+analgesic+without+abuse+liability+in+primates&doi=10.1073%2Fpnas.1605295113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates</span></div><div class="casAuthors">Ding, Huiping; Czoty, Paul W.; Kiguchi, Norikazu; Cami-Kobeci, Gerta; Sukhtankar, Devki D.; Nader, Michael A.; Husbands, Stephen M.; Ko, Mei-Chuan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">E5511-E5518</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite the crit. need, no previous research has substantiated safe opioid analgesics without abuse liability in primates.  Recent advances in medicinal chem. have led to the development of ligands with mixed mu opioid peptide (MOP)/nociceptin-orphanin FQ peptide (NOP) receptor agonist activity to achieve this objective.  BU08028 is a novel orvinol analog that displays a similar binding profile to buprenorphine with improved affinity and efficacy at NOP receptors.  The aim of this preclin. study was to establish the functional profile of BU08028 in monkeys using clin. used MOP receptor agonists for side-by-side comparisons in various well-honed behavioral and physiol. assays.  Systemic BU08028 (0.001-0.01 mg/kg) produced potent long-lasting (i.e., >24 h) antinociceptive and antiallodynic effects, which were blocked by MOP or NOP receptor antagonists.  More importantly, the reinforcing strength of BU08028 was significantly lower than that of cocaine, remifentanil, or buprenorphine in monkeys responding under a progressive-ratio schedule of drug self-administration.  Unlike MOP receptor agonists, BU08028 at antinociceptive doses and ∼10- to 30-fold higher doses did not cause respiratory depression or cardiovascular adverse events as measured by telemetry devices.  After repeated administration, the monkeys developed acute phys. dependence on morphine, as manifested by pptd. withdrawal signs, such as increased respiratory rate, heart rate, and blood pressure.  In contrast, monkeys did not show phys. dependence on BU08028.  These in vivo findings in primates not only document the efficacy and tolerability profile of bifunctional MOP/NOP receptor agonists, but also provide a means of translating such ligands into therapies as safe and potentially abuse-free opioid analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh-uGrYC0W5rVg90H21EOLACvtfcHk0ljaX3dmlZUN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWks7nM&md5=f4d19b2246e87706b906c2cf8ddfdea6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1605295113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1605295113%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DKiguchi%26aufirst%3DN.%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DSukhtankar%26aufirst%3DD.%2BD.%26aulast%3DNader%26aufirst%3DM.%2BA.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DKo%26aufirst%3DM.-C.%26atitle%3DA%2520novel%2520orvinol%2520analog%252C%2520BU08028%252C%2520as%2520a%2520safe%2520opioid%2520analgesic%2520without%2520abuse%2520liability%2520in%2520primates%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3DE5511%26epage%3DE5518%26doi%3D10.1073%2Fpnas.1605295113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-X.</span></span> <span> </span><span class="NLM_article-title">Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">10225</span>– <span class="NLM_lpage">10227</span>, <span class="refDoi"> DOI: 10.1073/pnas.1612752113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.1612752113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27573851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSltLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=10225-10227&author=J.-X.+Li&title=Buprenorphine+analogue+BU08028+is+one+step+closer+to+the+Holy+Grail+of+opioid+research&doi=10.1073%2Fpnas.1612752113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research</span></div><div class="casAuthors">Li, Jun-Xu</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">10225-10227</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKPmz5i_R2pbVg90H21EOLACvtfcHk0ljaX3dmlZUN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSltLbK&md5=c74f8a1e0a6dd6b27e71354e5a94364b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1612752113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1612752113%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-X.%26atitle%3DBuprenorphine%2520analogue%2520BU08028%2520is%2520one%2520step%2520closer%2520to%2520the%2520Holy%2520Grail%2520of%2520opioid%2520research%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2016%26volume%3D113%26spage%3D10225%26epage%3D10227%26doi%3D10.1073%2Fpnas.1612752113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daga, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishioka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaveri, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.-C.</span></span> <span> </span><span class="NLM_article-title">A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">eaar3483</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aar3483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1126%2Fscitranslmed.aar3483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30158150" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&author=H.+Dingauthor=N.+Kiguchiauthor=D.+Yasudaauthor=P.+R.+Dagaauthor=W.+E.+Polgarauthor=J.+J.+Luauthor=P.+W.+Czotyauthor=S.+Kishiokaauthor=N.+T.+Zaveriauthor=M.-C.+Ko&title=A+bifunctional+nociceptin+and+mu+opioid+receptor+agonist+is+analgesic+without+opioid+side+effects+in+nonhuman+primates&doi=10.1126%2Fscitranslmed.aar3483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aar3483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aar3483%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DKiguchi%26aufirst%3DN.%26aulast%3DYasuda%26aufirst%3DD.%26aulast%3DDaga%26aufirst%3DP.%2BR.%26aulast%3DPolgar%26aufirst%3DW.%2BE.%26aulast%3DLu%26aufirst%3DJ.%2BJ.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DKishioka%26aufirst%3DS.%26aulast%3DZaveri%26aufirst%3DN.%2BT.%26aulast%3DKo%26aufirst%3DM.-C.%26atitle%3DA%2520bifunctional%2520nociceptin%2520and%2520mu%2520opioid%2520receptor%2520agonist%2520is%2520analgesic%2520without%2520opioid%2520side%2520effects%2520in%2520nonhuman%2520primates%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26doi%3D10.1126%2Fscitranslmed.aar3483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cami-Kobeci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhtankar, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czoty, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLoid, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, F.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husbands, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.-C.</span></span> <span> </span><span class="NLM_article-title">BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">e146</span>– <span class="NLM_lpage">e156</span>, <span class="refDoi"> DOI: 10.1016/j.bja.2018.10.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.bja.2018.10.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30916003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktFOrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2019&pages=e146-e156&author=N.+Kiguchiauthor=H.+Dingauthor=G.+Cami-Kobeciauthor=D.+D.+Sukhtankarauthor=P.+W.+Czotyauthor=H.+B.+DeLoidauthor=F.-C.+Hsuauthor=L.+Tollauthor=S.+M.+Husbandsauthor=M.-C.+Ko&title=BU10038+as+a+safe+opioid+analgesic+with+fewer+side-effects+after+systemic+and+intrathecal+administration+in+primates&doi=10.1016%2Fj.bja.2018.10.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates</span></div><div class="casAuthors">Kiguchi, Norikazu; Ding, Huiping; Cami-Kobeci, Gerta; Sukhtankar, Devki D.; Czoty, Paul W.; DeLoid, Heather B.; Hsu, Fang-Chi; Toll, Lawrence; Husbands, Stephen M.; Ko, Mei-Chuan</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e146-e156</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">1471-6771</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The marked increase in mis-use of prescription opioids has greatly affected our society.  One potential soln. is to develop improved analgesics which have agonist action at both mu opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptors.  BU10038 is a recently identified bifunctional MOP/NOP partial agonist.  The aim of this study was to det. the functional profile of systemic or spinal delivery of BU10038 in primates after acute and chronic administration.  A series of behavioral and physiol. assays have been established specifically to reflect the therapeutic (analgesia) and side-effects (abuse potential, respiratory depression, itch, phys. dependence, and tolerance) of opioid analgesics in rhesus monkeys.  After systemic administration, BU10038 (0.001-0.01 mg kg-1) dose-dependently produced long-lasting antinociceptive and antihypersensitive effects.  Unlike the MOP agonist oxycodone, BU10038 lacked reinforcing effects (i.e. little or no abuse liability), and BU10038 did not compromise the physiol. functions of primates including respiration, cardiovascular activities, and body temp. at antinociceptive doses and a 10-30-fold higher dose (0.01-0.1 mg kg-1).  After intrathecal administration, BU10038 (3 μg) exerted morphine-comparable antinociception and antihypersensitivity without itch scratching responses.  Unlike morphine, BU10038 did not cause the development of phys. dependence and tolerance after repeated and chronic administration.  These in vivo findings demonstrate the translational potential of bifunctional MOP/NOP receptor agonists such as BU10038 as a safe, non-addictive analgesic with fewer side-effects in primates.  This study strongly supports that bifunctional MOP/NOP agonists may provide improved analgesics and an alternative soln. for the ongoing prescription opioid crisis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlVLOISUSOFbVg90H21EOLACvtfcHk0ljCDhYlCp2I1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktFOrtr8%253D&md5=77bae3bd7f251e8a5db31de871acca02</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bja.2018.10.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bja.2018.10.065%26sid%3Dliteratum%253Aachs%26aulast%3DKiguchi%26aufirst%3DN.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DCami-Kobeci%26aufirst%3DG.%26aulast%3DSukhtankar%26aufirst%3DD.%2BD.%26aulast%3DCzoty%26aufirst%3DP.%2BW.%26aulast%3DDeLoid%26aufirst%3DH.%2BB.%26aulast%3DHsu%26aufirst%3DF.-C.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DHusbands%26aufirst%3DS.%2BM.%26aulast%3DKo%26aufirst%3DM.-C.%26atitle%3DBU10038%2520as%2520a%2520safe%2520opioid%2520analgesic%2520with%2520fewer%2520side-effects%2520after%2520systemic%2520and%2520intrathecal%2520administration%2520in%2520primates%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2019%26volume%3D122%26spage%3De146%26epage%3De156%26doi%3D10.1016%2Fj.bja.2018.10.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quelven, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlet-Schiltz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouardères, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafani, J.-A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazarguil, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J.-M.</span></span> <span> </span><span class="NLM_article-title">Dissociation of pharmacological pro- and anti-opioid effects by neuropeptide FF analogs</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>449</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/s0014-2999(02)01983-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2FS0014-2999%2802%2901983-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=12163111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtVWlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=449&publication_year=2002&pages=91-98&author=I.+Quelvenauthor=A.+Roussinauthor=O.+Burlet-Schiltzauthor=C.+Gouard%C3%A8resauthor=J.-A.+M.+Tafaniauthor=H.+Mazarguilauthor=J.-M.+Zajac&title=Dissociation+of+pharmacological+pro-+and+anti-opioid+effects+by+neuropeptide+FF+analogs&doi=10.1016%2Fs0014-2999%2802%2901983-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociation of pharmacological pro- and anti-opioid effects by neuropeptide FF analogs</span></div><div class="casAuthors">Quelven, Isabelle; Roussin, Anne; Burlet-Schiltz, Odile; Gouarderes, Christine; Tafani, Jean-Andre Mathieu; Mazarguil, Honore; Zajac, Jean-Marie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">449</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">91-98</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Neuropeptide FF (NPFF) and its analog 1DMe ([D-Tyr1,(NMe)Phe3]NPFF) have been shown to reverse or potentiate morphine analgesia in rat depending on the supraspinal or spinal site of injection.  The properties, in the mouse tail-flick test, of 1DMe and its related compd. Nic-1DMe (Nicotinoyl-Pro-1DMe) were investigated after their local (i.c.v. and i.t.) and systemic administration.  Whereas Nic-1DMe and 1DMe exhibit the same affinity and selectivity towards NPFF1 and NPFF2 receptors, Nic-1DMe, in contrast to 1DMe, is unable to inhibit morphine-induced analgesia after i.c.v. and i.p. administration.  Conversely, after i.t. and i.p. administration, both neuropeptide FF analogs could potentiate morphine analgesia.  Differences in disposition parameters between 1DMe and Nic-1DMe are evidenced, suggesting that the two neuropeptide FF analogs could stimulate differentially supraspinal neuropeptide FF receptors.  The predominant activation of spinal neuronal pathways by Nic-1DMe could explain the selective pro-opioid action of this compd. after i.t., i.c.v. and i.p. administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcbVL00N4qR7Vg90H21EOLACvtfcHk0lhc2-fql6jsqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtVWlt7s%253D&md5=6247bf2f6606ba8765bc4d902bbcda52</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2802%2901983-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252802%252901983-0%26sid%3Dliteratum%253Aachs%26aulast%3DQuelven%26aufirst%3DI.%26aulast%3DRoussin%26aufirst%3DA.%26aulast%3DBurlet-Schiltz%26aufirst%3DO.%26aulast%3DGouard%25C3%25A8res%26aufirst%3DC.%26aulast%3DTafani%26aufirst%3DJ.-A.%2BM.%26aulast%3DMazarguil%26aufirst%3DH.%26aulast%3DZajac%26aufirst%3DJ.-M.%26atitle%3DDissociation%2520of%2520pharmacological%2520pro-%2520and%2520anti-opioid%2520effects%2520by%2520neuropeptide%2520FF%2520analogs%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D449%26spage%3D91%26epage%3D98%26doi%3D10.1016%2Fs0014-2999%2802%2901983-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mollereau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roumy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J.-M.</span></span> <span> </span><span class="NLM_article-title">Opioid-modulating peptides: mechanisms of action</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.2174/1568026053544515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.2174%2F1568026053544515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=15857316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvFaqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-355&author=C.+Mollereauauthor=M.+Roumyauthor=J.-M.+Zajac&title=Opioid-modulating+peptides%3A+mechanisms+of+action&doi=10.2174%2F1568026053544515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid-modulating peptides: mechanisms of action</span></div><div class="casAuthors">Mollereau, Catherine; Roumy, Michel; Zajac, Jean-Marie</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-355</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Opioids are involved in the physiol. control of numerous functions of the central nervous system, particularly nociception.  It appears that some endogenous neuropeptides, called anti-opioids, participate in an homeostatic system tending to reduce the effects of opioids.  Neuropeptide FF (NPFF) and cholecystokinin (CCK) possess these properties and, paradoxically, the opioid peptides nociceptin and dynorphin display some anti-opioid activity.  All these peptides exhibit complex properties as they are able to both counteract and potentiate opioid activity, acting rather as modulators of opioid functions.  The purpose of this review is to highlight that 2 different mechanisms are clearly involved in the control of opioid functions by opioid-modulating peptides: a circuitry-induced mechanism for nociceptin and dynorphin, and a cellular anti-opioid mechanism for NPFF and CCK.  The knowledge of these mechanisms has potential therapeutic interest in the control of opioid functions, notably for alleviating pain and(or) for the treatment of opioid abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZw2fMuWKMaLVg90H21EOLACvtfcHk0lhc2-fql6jsqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvFaqu70%253D&md5=f4a866b30e48dd49e4599405b8f1dab1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F1568026053544515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026053544515%26sid%3Dliteratum%253Aachs%26aulast%3DMollereau%26aufirst%3DC.%26aulast%3DRoumy%26aufirst%3DM.%26aulast%3DZajac%26aufirst%3DJ.-M.%26atitle%3DOpioid-modulating%2520peptides%253A%2520mechanisms%2520of%2520action%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D355%26doi%3D10.2174%2F1568026053544515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elhabazi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trigo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mollereau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulédous, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bihel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourguignon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meziane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit-demoulière, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, F.</span></span> <span> </span><span class="NLM_article-title">Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01563.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1111%2Fj.1476-5381.2011.01563.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=21718302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1yksLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=424-435&author=K.+Elhabaziauthor=J.+Trigoauthor=C.+Mollereauauthor=L.+Moul%C3%A9dousauthor=J.-M.+Zajacauthor=F.+Bihelauthor=M.+Schmittauthor=J.+Bourguignonauthor=H.+Mezianeauthor=B.+Petit-demouli%C3%A8reauthor=F.+Bockelauthor=R.+Maldonadoauthor=F.+Simonin&title=Involvement+of+neuropeptide+FF+receptors+in+neuroadaptive+responses+to+acute+and+chronic+opiate+treatments&doi=10.1111%2Fj.1476-5381.2011.01563.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments</span></div><div class="casAuthors">Elhabazi, K.; Trigo, J. M.; Mollereau, C.; Mouledous, L.; Zajac, J.-M.; Bihel, F.; Schmitt, M.; Bourguignon, J. J.; Meziane, H.; Petit-demouliere, B.; Bockel, F.; Maldonado, R.; Simonin, F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">424-435</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Opiates remain the most effective compds. for alleviating severe pain across a wide range of conditions.  However, their use is assocd. with significant side effects.  Neuropeptide FF (NPFF) receptors have been implicated in several opiate-induced neuroadaptive changes including the development of tolerance.  In this study, we investigated the consequences of NPFF receptor blockade on acute and chronic stimulation of opioid receptors in mice by using RF9, a potent and selective antagonist of NPFF receptors that can be administered systemically.  Exptl. Approach The effects of RF9 were investigated on opioid pharmacol. responses including locomotor activity, antinociception, opioid-induced hyperalgesia, rewarding properties and phys. dependence.  Key Results RF9 had no effect on morphine-induced horizontal hyperlocomotion and slightly attenuated the decrease induced in vertical activity.  Furthermore, RF9 dose-dependently blocked the long-lasting hyperalgesia produced by either acute fentanyl or chronic morphine administration.  RF9 also potentiated opiate early analgesic effects and prevented the development of morphine tolerance.  Finally, RF9 increased morphine-induced conditioned place preference without producing any rewarding effect by itself and decreased naltrexone-pptd. withdrawal syndrome following chronic morphine treatment.  Conclusion and Implications The NPFF system is involved in the development of two major undesirable effects: tolerance and dependence, which are clin. assocd. with prolonged exposure to opiates.  Our findings suggest that NPFF receptors are interesting therapeutic targets to improve the analgesic efficacy of opiates by limiting the development of tolerance, and for the treatment of opioid dependence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIbIwFL47xALVg90H21EOLACvtfcHk0lgllAakAa_P2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1yksLfN&md5=ebef9a66eea11441638e60fa0f617eb8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01563.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01563.x%26sid%3Dliteratum%253Aachs%26aulast%3DElhabazi%26aufirst%3DK.%26aulast%3DTrigo%26aufirst%3DJ.%26aulast%3DMollereau%26aufirst%3DC.%26aulast%3DMoul%25C3%25A9dous%26aufirst%3DL.%26aulast%3DZajac%26aufirst%3DJ.-M.%26aulast%3DBihel%26aufirst%3DF.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DBourguignon%26aufirst%3DJ.%26aulast%3DMeziane%26aufirst%3DH.%26aulast%3DPetit-demouli%25C3%25A8re%26aufirst%3DB.%26aulast%3DBockel%26aufirst%3DF.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DSimonin%26aufirst%3DF.%26atitle%3DInvolvement%2520of%2520neuropeptide%2520FF%2520receptors%2520in%2520neuroadaptive%2520responses%2520to%2520acute%2520and%2520chronic%2520opiate%2520treatments%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26spage%3D424%26epage%3D435%26doi%3D10.1111%2Fj.1476-5381.2011.01563.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.-p.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-n.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2016.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.neuropharm.2016.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=26970017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Shsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=364-372&author=Z.-l.+Wangauthor=N.+Liauthor=P.+Wangauthor=H.-h.+Tangauthor=Z.-l.+Hanauthor=J.-j.+Songauthor=X.-h.+Liauthor=H.-p.+Yuauthor=T.+Zhangauthor=R.+Zhangauthor=B.+Xuauthor=M.-n.+Zhangauthor=Q.+Fangauthor=R.+Wang&title=Pharmacological+characterization+of+EN-9%2C+a+novel+chimeric+peptide+of+endomorphin-2+and+neuropeptide+FF+that+produces+potent+antinociceptive+activity+and+limited+tolerance&doi=10.1016%2Fj.neuropharm.2016.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of EN-9, a novel chimeric peptide of endomorphin-2 and neuropeptide FF that produces potent antinociceptive activity and limited tolerance</span></div><div class="casAuthors">Wang, Zi-long; Li, Ning; Wang, Pei; Tang, Hong-hai; Han, Zheng-lan; Song, Jing-jing; Li, Xu-hui; Yu, Hong-ping; Zhang, Ting; Zhang, Run; Xu, Biao; Zhang, Meng-na; Fang, Quan; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">364-372</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mounting evidences indicate the functional interactions between neuropeptide FF (NPFF) and opioids, including the endogenous opioids.  In the present work, EN-9, a chimeric peptide contg. the functional domains of the endogenous opioid endomorphin-2 (EM-2) and NPFF, was synthesized and pharmacol. characterized.  In vitro cAMP assay demonstrated that EN-9 was a multifunctional agonist of κ-opioid, NPFF1 and NPFF2 receptors.  In the mouse tail-flick test, intracerebroventricularly (i.c.v.) administration of EN-9 produced significant antinociception with an ED50 value of 13.44 nmol, which lasted longer than that of EM-2.  In addn., EN-9 induced potent antinociception after both i.v. (i.v.) and s.c. (s.c.) injection.  Furthermore, the expts. using the antagonists of opioid and NPFF receptors indicated that the central antinociception of EN-9 was mainly mediated by κ-opioid receptor, independently on NPFF receptors.  Notably, the central antinociception of EN-9 was not reduced over a period of 6 days repeated i.c.v. injection.  Repeated i.c.v. administration of EN-9 with the NPFF1 and NPFF2 receptors antagonist RF9 resulted in a progressive loss of analgesic potency, consistent with the development of tolerance.  Moreover, central administration of EN-9 induced the place conditioning aversion only at a high dose of 60 nmol, but not at low doses.  At supraspinal level, only high dose of EN-9 (60 nmol, i.c.v.) inhibited gastrointestinal transit via NPFF receptors.  Similarly, systemic administration of EN-9 also inhibited gastrointestinal transit at high doses (10 and 30 mg/kg, i.v.).  Taken together, the multifunctional agonist of κ-opioid and NPFF receptors EN-9 produced a potent, non-tolerance forming antinociception with limited side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoby4T7pGme6bVg90H21EOLACvtfcHk0lgllAakAa_P2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Shsbo%253D&md5=0b9dd9d2bdeba08a9b0248c7a0c68296</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2016.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2016.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.-l.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DH.-h.%26aulast%3DHan%26aufirst%3DZ.-l.%26aulast%3DSong%26aufirst%3DJ.-j.%26aulast%3DLi%26aufirst%3DX.-h.%26aulast%3DYu%26aufirst%3DH.-p.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.-n.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DPharmacological%2520characterization%2520of%2520EN-9%252C%2520a%2520novel%2520chimeric%2520peptide%2520of%2520endomorphin-2%2520and%2520neuropeptide%2520FF%2520that%2520produces%2520potent%2520antinociceptive%2520activity%2520and%2520limited%2520tolerance%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D108%26spage%3D364%26epage%3D372%26doi%3D10.1016%2Fj.neuropharm.2016.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-n.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1864</span>– <span class="NLM_lpage">1880</span>, <span class="refDoi"> DOI: 10.1111/bph.13489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1111%2Fbph.13489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27018797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmtlenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=1864-1880&author=N.+Liauthor=Z.-l.+Hanauthor=Z.-l.+Wangauthor=Y.-h.+Xingauthor=Y.-l.+Sunauthor=X.-h.+Liauthor=J.-j.+Songauthor=T.+Zhangauthor=R.+Zhangauthor=M.-n.+Zhangauthor=B.+Xuauthor=Q.+Fangauthor=R.+Wang&title=BN-9%2C+a+chimeric+peptide+with+mixed+opioid+and+neuropeptide+FF+receptor+agonistic+properties%2C+produces+nontolerance-forming+antinociception+in+mice&doi=10.1111%2Fbph.13489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice</span></div><div class="casAuthors">Li, Ning; Han, Zheng-lan; Wang, Zi-long; Xing, Yan-hong; Sun, Yu-long; Li, Xu-hui; Song, Jing-jing; Zhang, Ting; Zhang, Run; Zhang, Meng-na; Xu, Biao; Fang, Quan; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1864-1880</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Neuropeptide FF (NPFF) behaves as an endogenous opioid-modulating peptide.  In the present study, the opioid and NPFF pharmacophore-contg. chimeric peptide BN-9 was synthesized and pharmacol. characterized.  Exptl. Approach : Agonist activities of BN-9 at opioid and NPFF receptors were characterized in in vitro cAMP assays.  Antinociceptive activities of BN-9 were evaluated in the mouse tail-flick and formalin tests.  Furthermore, its side effects were investigated in rotarod, antinociceptive tolerance, reward and gastrointestinal transit tests.  Key Results : BN-9 acted as a novel multifunctional agonist at μ, δ, κ, NPFF1 and NPFF2 receptors in cAMP assays.  In the tail-flick test, BN-9 produced dose-related antinociception and was approx. equipotent to morphine; this antinociception was blocked by μ and κ receptor antagonists, but not by the δ receptor antagonist.  In the formalin test, supraspinal administration of BN-9 produced significant analgesia.  Notably, repeated administration of BN-9 produced analgesia without loss of potency over 8 days.  In contrast, repeated i.c.v. co-administration of BN-9 with the NPFF receptor antagonist RF9 produced significant antinociceptive tolerance.  Furthermore, i.c.v.  BN-9 induced conditioned place preference.  When given by the same routes, BN-9 had a more than eightfold higher ED50 value for gastrointestinal transit inhibition compared with the ED50 values for antinociception.  Conclusions and Implications : BN-9 produced a robust, nontolerance-forming analgesia with limited inhibition of gastrointestinal transit.  As BN-9 is able to activate both opioid and NPFF systems, this provides an interesting approach for the development of novel analgesics with minimal side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpicXFgT8DcO7Vg90H21EOLACvtfcHk0lgI75Zgb9zOrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmtlenu7Y%253D&md5=90dce7f015555e141e30a0e82d8bdfd7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fbph.13489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13489%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DZ.-l.%26aulast%3DWang%26aufirst%3DZ.-l.%26aulast%3DXing%26aufirst%3DY.-h.%26aulast%3DSun%26aufirst%3DY.-l.%26aulast%3DLi%26aufirst%3DX.-h.%26aulast%3DSong%26aufirst%3DJ.-j.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DM.-n.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DBN-9%252C%2520a%2520chimeric%2520peptide%2520with%2520mixed%2520opioid%2520and%2520neuropeptide%2520FF%2520receptor%2520agonistic%2520properties%252C%2520produces%2520nontolerance-forming%2520antinociception%2520in%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D1864%26epage%3D1880%26doi%3D10.1111%2Fbph.13489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, J.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Structure-based optimization of multifunctional agonists for opioid and Neuropeptide FF receptors with potent nontolerance forming analgesic activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10198</span>– <span class="NLM_lpage">10208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01181</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01181" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKgtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10198-10208&author=Z.-L.+Wangauthor=J.-X.+Panauthor=J.-J.+Songauthor=H.-H.+Tangauthor=H.-P.+Yuauthor=X.-H.+Liauthor=N.+Liauthor=T.+Zhangauthor=R.+Zhangauthor=M.-N.+Zhangauthor=B.+Xuauthor=Q.+Fangauthor=R.+Wang&title=Structure-based+optimization+of+multifunctional+agonists+for+opioid+and+Neuropeptide+FF+receptors+with+potent+nontolerance+forming+analgesic+activities&doi=10.1021%2Facs.jmedchem.6b01181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities</span></div><div class="casAuthors">Wang, Zi-Long; Pan, Jia-Xin; Song, Jing-Jing; Tang, Hong-Hai; Yu, Hong-Ping; Li, Xu-Hui; Li, Ning; Zhang, Ting; Zhang, Run; Zhang, Meng-Na; Xu, Biao; Fang, Quan; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10198-10208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The opioid and neuropeptide FF pharmacophore-contg. chimeric peptide 0 (BN-9) was recently developed and produced potent nontolerance forming analgesia.  In this study, 11 analogs of 0 were designed and synthesized.  An in vitro cAMP assay demonstrated that these analogs behaved as multifunctional agonists at both opioid and NPFF receptors.  In mouse tail-flick test, most of the analogs produced potent nontolerance forming antinociception.  Notably, 11 (DN-9) was 33-fold more potent than 0 at analgesic effects, which was mediated by μ- and κ-opioid receptors.  In addn., 11 also produced powerful analgesic effects in the formalin pain and CFA-induced chronic inflammatory pain models.  Strikingly, following its repeated administration for 6 days, 11 did not produce antinociceptive tolerance in the tail-flick test and CFA-induced pain model.  The present work indicates that it is reasonable to design multifunctional peptide ligands for opioid and NPFF receptors in a single mol. producing effective nontolerance forming antinociception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr397Dq_Czk37Vg90H21EOLACvtfcHk0lgI75Zgb9zOrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKgtrbP&md5=d67570b5cb6d804532180bf50dd3532f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01181%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.-L.%26aulast%3DPan%26aufirst%3DJ.-X.%26aulast%3DSong%26aufirst%3DJ.-J.%26aulast%3DTang%26aufirst%3DH.-H.%26aulast%3DYu%26aufirst%3DH.-P.%26aulast%3DLi%26aufirst%3DX.-H.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DM.-N.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DStructure-based%2520optimization%2520of%2520multifunctional%2520agonists%2520for%2520opioid%2520and%2520Neuropeptide%2520FF%2520receptors%2520with%2520potent%2520nontolerance%2520forming%2520analgesic%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10198%26epage%3D10208%26doi%3D10.1021%2Facs.jmedchem.6b01181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Z.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span> <span> </span><span class="NLM_article-title">Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>837</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2018.08.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ejphar.2018.08.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30172787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ClsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=837&publication_year=2018&pages=53-63&author=N.+Liauthor=Z.-L.+Hanauthor=B.+Xuauthor=M.-N.+Zhangauthor=T.+Zhangauthor=X.-R.+Shiauthor=W.-D.+Zhaoauthor=Y.-Y.+Guoauthor=Q.-Q.+Zhangauthor=Q.+Fang&title=Systemic+administration+of+the+bifunctional+opioid%2Fneuropeptide+FF+receptors+agonist+BN-9+produced+peripheral+antinociception+in+preclinical+mouse+models+of+pain&doi=10.1016%2Fj.ejphar.2018.08.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain</span></div><div class="casAuthors">Li, Ning; Han, Zheng-Lan; Xu, Biao; Zhang, Meng-Na; Zhang, Ting; Shi, Xue-Rui; Zhao, Wei-Dong; Guo, Yuan-Yuan; Zhang, Qin-Qin; Fang, Quan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">837</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53-63</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We recently characterized a novel bifunctional agonist for opioid and neuropeptide FF receptors, named BN-9, which exhibited potent analgesia in the mouse tail-flick test when given centrally.  To further evaluate its potential therapeutic efficacy for translational-medical development, the current work was performed to explore the antinociceptive activities of i.p. (i.p.) administration of BN-9 in mouse models of tail-flick assay, formalin pain, visceral pain and post-operative pain.  In the tail-flick test, BN-9 induced a dose-related antinociceptive effect, which was fully blocked by systemic pretreatment with the peripheral acting opioid receptor antagonist naloxone methiodide, but not supraspinal naloxone methiodide, implying the involvement of the peripheral opioid receptors.  In addn., the systemic antinociception of BN-9 was antagonized by the selective antagonists of the μ- and κ-opioid receptors, independently of the δ-opioid and neuropeptide FF receptors.  Similarly, dose-dependent analgesia was also produced by systemic BN-9 in different pain models via the peripheral opioid receptors, independently of the neuropeptide FF receptors.  Furthermore, the side-effects of systemic BN-9 on motor performance, tolerance development and gastrointestinal transit inhibition were also evaluated.  Repeated systemic injection of BN-9 produced non-tolerance analgesia over 8 days.  Compared with morphine, i.p. administration of BN-9 exerted less inhibition of gastrointestinal transit.  These data show that BN-9 induced systemic analgesia with reduced side-effects on tolerance and constipation.  This article suggests that systemic injection of BN-9 causes effective antinociception in different preclin. pain models via the peripheral opioid receptors, providing an attractive approach to develop peripherally acting opioid analgesics with multiple targeting properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoJmldygEisLVg90H21EOLACvtfcHk0liRwSe4bTfdIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ClsLrO&md5=06c8c7cf2e41dd9f792196eeff49da8d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2018.08.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2018.08.039%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DZ.-L.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.-N.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DX.-R.%26aulast%3DZhao%26aufirst%3DW.-D.%26aulast%3DGuo%26aufirst%3DY.-Y.%26aulast%3DZhang%26aufirst%3DQ.-Q.%26aulast%3DFang%26aufirst%3DQ.%26atitle%3DSystemic%2520administration%2520of%2520the%2520bifunctional%2520opioid%252Fneuropeptide%2520FF%2520receptors%2520agonist%2520BN-9%2520produced%2520peripheral%2520antinociception%2520in%2520preclinical%2520mouse%2520models%2520of%2520pain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D837%26spage%3D53%26epage%3D63%26doi%3D10.1016%2Fj.ejphar.2018.08.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.-n.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>813</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2017.07.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ejphar.2017.07.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=28755985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1CrsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=813&publication_year=2017&pages=122-129&author=R.+Zhangauthor=B.+Xuauthor=M.-n.+Zhangauthor=T.+Zhangauthor=Z.-l.+Wangauthor=G.+Zhaoauthor=G.-h.+Zhaoauthor=N.+Liauthor=Q.+Fangauthor=R.+Wang&title=Peripheral+and+central+sites+of+action+for+anti-allodynic+activity+induced+by+the+bifunctional+opioid%2FNPFF+receptors+agonist+BN-9+in+inflammatory+pain+model&doi=10.1016%2Fj.ejphar.2017.07.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/npff receptors agonist bn-9 in inflammatory pain model</span></div><div class="casAuthors">Zhang, Run; Xu, Biao; Zhang, Meng-na; Zhang, Ting; Wang, Zi-long; Zhao, Geng; Zhao, Guang-hai; Li, Ning; Fang, Quan; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">813</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">122-129</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The activation of opioid and neuropeptide FF (NPFF) receptors plays important roles to modulate nociceptive signal in inflammatory pain states.  Recently, BN-9 (Tyr-D. Ala-Gly-Phe-Gln-Pro-Gln-Arg-Phe-NH2) was pharmacol. characterized as a novel bifunctional agonist at both opioid and NPFF receptors.  In the present study, the anti-allodynic activity and site(s) of action of BN-9 were assessed in a mouse model of carrageenan-induced inflammatory pain.  In mice, BN-9 induced a dose-dependent anti-allodinic effect through opioid receptor at supraspinal or spinal level, and this effect was augmented by pretreatment with the NPFF receptor antagonist at the same level.  In contrast, peripheral administration of BN-9 produced opioid receptor-mediated anti-allodynia, which was insensitive of the NPFF receptor antagonist.  In addn., systemic BN-9 produced anti-allodynic effect via opioid receptors, independent of NPFF system.  Therefore, these data indicate that central, peripheral or systemic administrations of BN-9 exert potent analgesic activities in inflammatory pain model via opioid receptor, and central effects of BN-9 are assocd. with NPFF system.  Interestingly, systemic anti-allodynia of BN-9 was blocked by i.p. administration of the opioid receptor antagonists, naloxone and naloxone methiodide, but not by intracerebroventricular injection of the peripherally acting opioid antagonist naloxone methiodide.  Furthermore, BN-9-induced systemic anti-allodynia was reversed by intraplantar administration of naloxone, but not by peripheral administration of the NPFF receptor antagonist.  Taken together, our data further suggest that systemic BN-9-induced anti-allodynic effect is mainly mediated by peripheral opioid receptors, independent of NPFF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofvqw6PBkmZ7Vg90H21EOLACvtfcHk0liRwSe4bTfdIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1CrsrvO&md5=9325a59bdfb697a36269e59e89e7b009</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2017.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2017.07.044%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DM.-n.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.-l.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DG.-h.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DPeripheral%2520and%2520central%2520sites%2520of%2520action%2520for%2520anti-allodynic%2520activity%2520induced%2520by%2520the%2520bifunctional%2520opioid%252FNPFF%2520receptors%2520agonist%2520BN-9%2520in%2520inflammatory%2520pain%2520model%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D813%26spage%3D122%26epage%3D129%26doi%3D10.1016%2Fj.ejphar.2017.07.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollny, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokkar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mieres-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Garcia, E.</span></span> <span> </span><span class="NLM_article-title">Solvent-enhanced conformational flexibility of cyclic tetrapeptides</span>. <i>ChemPhysChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1664</span>– <span class="NLM_lpage">1670</span>, <span class="refDoi"> DOI: 10.1002/cphc.201900345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1002%2Fcphc.201900345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=31045298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1664-1670&author=N.+Bergerauthor=L.+Wollnyauthor=P.+Sokkarauthor=S.+Mittalauthor=J.+Mieres-Perezauthor=R.+Stollauthor=W.+Sanderauthor=E.+Sanchez-Garcia&title=Solvent-enhanced+conformational+flexibility+of+cyclic+tetrapeptides&doi=10.1002%2Fcphc.201900345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Solvent-Enhanced Conformational Flexibility of Cyclic Tetrapeptides</span></div><div class="casAuthors">Berger, Nadja; Wollny, Laura J. B.; Sokkar, Pandian; Mittal, Sumit; Mieres-Perez, Joel; Stoll, Raphael; Sander, Wolfram; Sanchez-Garcia, Elsa</div><div class="citationInfo"><span class="NLM_cas:title">ChemPhysChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1664-1670</span>CODEN:
                <span class="NLM_cas:coden">CPCHFT</span>;
        ISSN:<span class="NLM_cas:issn">1439-4235</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Solvent and temp. can affect the structural properties of cyclic peptides by controlling their flexibility.  Here, we investigate two cyclic peptides, featuring beta turns.  Using temp.-dependent NMR and FT-IR, we obsd. a pronounced temp. effect on the conformation of the cyclic peptide D-1 in CHCl3 but a much smaller effect in CH3CN.  Almost no effect was obsd. for its diastereomer L-1 within a similar temp. range and using the same solvents.  With the aid of Replica Exchange Mol. Dynamics simulations and Quantum Mechanics/Mol. Mechanics calcns., we were able to explain this behavior based on the increased flexibility of D-1 (in CHCl3) in terms of intramol. hydrogen bonding.  The largest temp. dependence is obsd. for D-1 in CHCl3, while the temp. effect is less pronounced for L-1 in CHCl3 and for both peptides in CH3CN.  This work provides new insights into the role of the environment and temp. on the conformations of cyclic peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBkdiukqRh6rVg90H21EOLACvtfcHk0liRwSe4bTfdIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsrzF&md5=fbdeff8938e6e29d4651c8f65031140e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fcphc.201900345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcphc.201900345%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DN.%26aulast%3DWollny%26aufirst%3DL.%26aulast%3DSokkar%26aufirst%3DP.%26aulast%3DMittal%26aufirst%3DS.%26aulast%3DMieres-Perez%26aufirst%3DJ.%26aulast%3DStoll%26aufirst%3DR.%26aulast%3DSander%26aufirst%3DW.%26aulast%3DSanchez-Garcia%26aufirst%3DE.%26atitle%3DSolvent-enhanced%2520conformational%2520flexibility%2520of%2520cyclic%2520tetrapeptides%26jtitle%3DChemPhysChem%26date%3D2019%26volume%3D20%26spage%3D1664%26epage%3D1670%26doi%3D10.1002%2Fcphc.201900345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deyle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinis, C.</span></span> <span> </span><span class="NLM_article-title">Phage selection of cyclic peptides for application in research and drug development</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1866</span>– <span class="NLM_lpage">1874</span>, <span class="refDoi"> DOI: 10.1021/acs.accounts.7b00184</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.accounts.7b00184" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOqt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1866-1874&author=K.+Deyleauthor=X.-D.+Kongauthor=C.+Heinis&title=Phage+selection+of+cyclic+peptides+for+application+in+research+and+drug+development&doi=10.1021%2Facs.accounts.7b00184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Phage Selection of Cyclic Peptides for Application in Research and Drug Development</span></div><div class="casAuthors">Deyle, Kaycie; Kong, Xu-Dong; Heinis, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1866-1874</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic peptides can bind to protein targets with high affinities and selectivities, which makes them an attractive modality for the development of research reagents and therapeutics.  Addnl. properties, including low inherent toxicity, efficient chem. synthesis, and facile modification with labels or immobilization reagents, increase their attractiveness.  Cyclic peptide ligands against a wide range of protein targets have been isolated from natural sources such as bacteria, fungi, plants, and animals.  Many of them are currently used as research tools, and several have found application as therapeutics, such as the peptide hormones oxytocin and vasopressin and the antibiotics vancomycin and daptomycin, proving the utility of cyclic peptides in research and medicine.With the advent of phage display and other in vitro evolution techniques, it has become possible to generate cyclic peptide binders to diverse protein targets for which no natural peptides have been discovered.  A highly robust and widely applied approach is based on the cyclization of peptides displayed on phage via a disulfide bridge.  Disulfide-cyclized peptide ligands to more than a hundred different proteins have been reported in the literature.  Technol. advances achieved over the last three decades, including methods for generating larger phage display libraries, improved phage panning protocols, new cyclic peptide formats, and high-throughput sequencing, have enabled the generation of cyclic peptides with ever better binding affinities to more challenging targets.A relatively new cyclic peptide format developed using phage display involves bicyclic peptides.  These mols. consist of two macrocyclic peptide rings cyclized through a chem. linker.  Compared to monocyclic peptides of comparable mol. mass, bicyclic peptides are more constrained in their conformation.  As a result, they can bind to their targets with a higher affinity and are more resistant to proteolytic degrdn.  Phage-encoded bicyclic peptides are generated by chem. cyclizing random peptide libraries on phage.  Binders are identified by conventional phage panning and DNA sequencing.  Next-generation sequencing and new sequence alignment tools have enabled the rapid identification of bicyclic peptides.Bicyclic peptide ligands were developed against a range of diverse target classes including enzymes, receptors, and cytokines.  Most ligands bind with nanomolar affinities, with some reaching the picomolar range.  To date, several bicyclic peptides have been pos. evaluated in preclin. studies, and the first clin. tests are in sight.  While bicyclic peptide phage display was developed with therapeutic applications in mind, these peptides are increasingly used as research tools for target evaluation or as basic research probes as well.  Given the efficient development method, the ease of synthesis and handling, and the favorable binding and biophys. properties, bicyclic peptides are being developed against more and more targets, ever increasing their potential applications in research and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtQln3dL6wo7Vg90H21EOLACvtfcHk0ljrUHXivKGExQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOqt7zP&md5=416350a497d5f8811ac0a52cc441a03e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.accounts.7b00184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.accounts.7b00184%26sid%3Dliteratum%253Aachs%26aulast%3DDeyle%26aufirst%3DK.%26aulast%3DKong%26aufirst%3DX.-D.%26aulast%3DHeinis%26aufirst%3DC.%26atitle%3DPhage%2520selection%2520of%2520cyclic%2520peptides%2520for%2520application%2520in%2520research%2520and%2520drug%2520development%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2017%26volume%3D50%26spage%3D1866%26epage%3D1874%26doi%3D10.1021%2Facs.accounts.7b00184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucke, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoermer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">Orally absorbed cyclic peptides</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">8094</span>– <span class="NLM_lpage">8128</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.6b00838</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.6b00838" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot12lurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=8094-8128&author=D.+S.+Nielsenauthor=N.+E.+Shepherdauthor=W.+Xuauthor=A.+J.+Luckeauthor=M.+J.+Stoermerauthor=D.+P.+Fairlie&title=Orally+absorbed+cyclic+peptides&doi=10.1021%2Facs.chemrev.6b00838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Absorbed Cyclic Peptides</span></div><div class="casAuthors">Nielsen, Daniel S.; Shepherd, Nicholas E.; Xu, Weijun; Lucke, Andrew J.; Stoermer, Martin J.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">8094-8128</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Peptides and proteins are not orally bioavailable in mammals, although a few peptides are intestinally absorbed in small amts.  Polypeptides are generally too large and polar to passively diffuse through lipid membranes, while most known active transport mechanisms facilitate cell uptake of only very small peptides.  Systematic evaluations of peptides with mol. wts. above 500 Da are needed to identify parameters that influence oral bioavailability.  Here we describe 125 cyclic peptides contg. four to thirty-seven amino acids that are orally absorbed by mammals.  Cyclization minimizes degrdn. in the gut, blood and tissues by removing cleavable N- and C-termini and by shielding components from metabolic enzymes.  Cyclization also folds peptides into bioactive conformations that det. exposure of polar atoms to solvation by water and lipids, and therefore should influence oral bioavailability.  Key chem. properties thought to influence oral absorption and bioavailability are analyzed, including mol. wt., octanol-water partitioning, hydrogen bond donors/acceptors, rotatable bonds and polar surface area.  The cyclic peptides violated to different degrees all of the limits traditionally considered to be important for oral bioavailability of drug-like small mols., although fewer hydrogen bond donors and reduced flexibility generally favored oral absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprHf1YVkf7ErVg90H21EOLACvtfcHk0ljrUHXivKGExQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot12lurY%253D&md5=38af1945471e5ddffd3ae630ebbe129b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.6b00838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.6b00838%26sid%3Dliteratum%253Aachs%26aulast%3DNielsen%26aufirst%3DD.%2BS.%26aulast%3DShepherd%26aufirst%3DN.%2BE.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLucke%26aufirst%3DA.%2BJ.%26aulast%3DStoermer%26aufirst%3DM.%2BJ.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DOrally%2520absorbed%2520cyclic%2520peptides%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D8094%26epage%3D8128%26doi%3D10.1021%2Facs.chemrev.6b00838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span> <span> </span><span class="NLM_article-title">Targeting intracellular protein-protein interactions with cell-permeable cyclic peptides</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2017.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.cbpa.2017.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=28388463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1KlsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=80-86&author=Z.+Qianauthor=P.+G.+Doughertyauthor=D.+Pei&title=Targeting+intracellular+protein-protein+interactions+with+cell-permeable+cyclic+peptides&doi=10.1016%2Fj.cbpa.2017.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting intracellular protein-protein interactions with cell-permeable cyclic peptides</span></div><div class="casAuthors">Qian, Ziqing; Dougherty, Patrick G.; Pei, Dehua</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80-86</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Intracellular protein-protein interactions (PPIs) are challenging targets for conventional drug modalities, because small mols. generally do not bind to their large, flat binding sites with high affinity, whereas monoclonal antibodies cannot cross the cell membrane to reach the targets.  Cyclic peptides in the 700-2000 mol.-wt. range have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat PPI interfaces with antibody-like affinity and specificity.  Several powerful cyclic peptide library technologies were developed over the past decade to rapidly discover potent, specific cyclic peptide ligands against proteins of interest including those involved in PPIs.  Methods are also being developed to enhance the membrane permeability of cyclic peptides through both passive diffusion and active transport mechanisms.  Integration of the permeability-enhancing elements into cyclic peptide design has led to an increasing no. of cell-permeable and biol. active cyclic peptides against intracellular PPIs.  In this account, we review the recent developments in the design and synthesis of cell-permeable cyclic peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_IPrrU8rcMbVg90H21EOLACvtfcHk0ljrUHXivKGExQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1KlsLg%253D&md5=2ea4ac695ee1f1651e5da4ed0bb7cf0b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2017.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2017.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DZ.%26aulast%3DDougherty%26aufirst%3DP.%2BG.%26aulast%3DPei%26aufirst%3DD.%26atitle%3DTargeting%2520intracellular%2520protein-protein%2520interactions%2520with%2520cell-permeable%2520cyclic%2520peptides%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D38%26spage%3D80%26epage%3D86%26doi%3D10.1016%2Fj.cbpa.2017.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remesic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span> <span> </span><span class="NLM_article-title">Cyclic opioid peptides</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.2174/0929867323666160427123005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.2174%2F0929867323666160427123005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27117332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFags7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=1288-1303&author=M.+Remesicauthor=Y.+Sun+Leeauthor=V.+J.+Hruby&title=Cyclic+opioid+peptides&doi=10.2174%2F0929867323666160427123005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclic Opioid Peptides</span></div><div class="casAuthors">Remesic, Michael; Lee, Yeon Sun; Hruby, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1288-1303</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">For decades the opioid receptors have been an attractive therapeutic target for the treatment of pain.  Since the first discovery of enkephalin, approx. a dozen endogenous opioid peptides have been known to produce opioid activity and analgesia, but their therapeutics have been limited mainly due to low blood brain barrier penetration and poor resistance to proteolytic degrdn.  One versatile approach to overcome these drawbacks is the cyclization of linear peptides to cyclic peptides with constrained topog. structure.  Compared to their linear parents, cyclic analogs exhibit better metabolic stability, lower offtarget toxicity, and improved bioavailability.  Extensive structure-activity relationship studies have uncovered promising compds. for the treatment of pain as well as further elucidate structural elements required for selective opioid receptor activity.  The benefits that come with employing cyclization can be further enhanced through the generation of polycyclic derivs.  Opioid ligands generally have a short peptide chain and thus the realm of polycyclic peptides has yet to be explored.  In this review, a brief history of designing ligands for the opioid receptors, including classic linear and cyclic ligands, is discussed along with recent approaches and successes of cyclic peptide ligands for the receptors.  Various scaffolds and approaches to improve bioavailability are elaborated and concluded with a discourse towards polycyclic peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVqRd2N_Fx-LVg90H21EOLACvtfcHk0ljcXeW3D_lhmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFags7w%253D&md5=3a1df6a45b331fa5d7c78f0c34eccfe9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2174%2F0929867323666160427123005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666160427123005%26sid%3Dliteratum%253Aachs%26aulast%3DRemesic%26aufirst%3DM.%26aulast%3DSun%2BLee%26aufirst%3DY.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26atitle%3DCyclic%2520opioid%2520peptides%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D1288%26epage%3D1303%26doi%3D10.2174%2F0929867323666160427123005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galligan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burks, T. F.</span></span> <span> </span><span class="NLM_article-title">Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">5871</span>– <span class="NLM_lpage">5874</span>, <span class="refDoi"> DOI: 10.1073/pnas.80.19.5871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.80.19.5871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=6310598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaL2cXivFOqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1983&pages=5871-5874&author=H.+I.+Mosbergauthor=R.+Hurstauthor=V.+J.+Hrubyauthor=K.+Geeauthor=H.+I.+Yamamuraauthor=J.+J.+Galliganauthor=T.+F.+Burks&title=Bis-penicillamine+enkephalins+possess+highly+improved+specificity+toward+delta+opioid+receptors&doi=10.1073%2Fpnas.80.19.5871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Bis-penicillamine enkephalins possess highly improved specificity toward δ opioid receptors</span></div><div class="casAuthors">Mosberg, Henry I.; Hurst, Robin; Hruby, Victor J.; Gee, Kelvin; Yamamura, Henry I.; Galligan, James J.; Burks, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5871-4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The conformationally restricted, cyclic, disulfide-contg., enkephalin analogs [2-D-penicillamine, 5-L-penicillamine]enkephalin ([D-Pen2,L-Pen5]enkephalin)(I)  [88373-72-2] and [2-D-penicillamine, 5-D-penicillamine]enkephalin ([D-Pen2,D-Pen5]enkephalin)  [88373-73-3] were synthesized by solid-phase methods and selectivities of these analogs for a single class of opioid receptor investigated by examg. relative potencies in the mouse vas deferens assay (δ receptor), vs. the guinea pig ileum assay (μ receptor), and by detg. their relative abilities to displace the prototypical δ receptor ligand [D-Ala2,D-Leu5]enkephalin  [63631-40-3] and the prototypical μ receptor ligand naloxone from rat brain membrane prepns.  Based on these comparisons [D-Pen2,L-Pen5]- and [D-Pen2,D-Pen5]enkephalin exhibited δ receptor selectivities of 1088 and 3164, resp., in the bioassays, and 371 and 175, resp., in the binding assays.  Compared with the previously reported δ receptor selective analogs, [D-Ala2,D-Leu5]enkephalin  [63631-40-3], [D-Ser2,Leu5,Thr6]enkephalin  [75644-90-5], and [D-Thr2,Leu5,Thr6]enkephalin  [466-97-7], the bis-Pen-contg. analogs provide an order of magnitude increase in δ receptor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5Z8bMlV-VgLVg90H21EOLACvtfcHk0ljcXeW3D_lhmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXivFOqsA%253D%253D&md5=1c17f2fb1638bf23739c667b75b8e27b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.80.19.5871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.80.19.5871%26sid%3Dliteratum%253Aachs%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DHurst%26aufirst%3DR.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DGee%26aufirst%3DK.%26aulast%3DYamamura%26aufirst%3DH.%2BI.%26aulast%3DGalligan%26aufirst%3DJ.%2BJ.%26aulast%3DBurks%26aufirst%3DT.%2BF.%26atitle%3DBis-penicillamine%2520enkephalins%2520possess%2520highly%2520improved%2520specificity%2520toward%2520delta%2520opioid%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1983%26volume%3D80%26spage%3D5871%26epage%3D5874%26doi%3D10.1073%2Fpnas.80.19.5871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lomize, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flippen-Anderson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Conformational analysis of the .delta. receptor-selective, cyclic opioid peptide, Tyr-cyclo[D-Cys-Phe-D-Pen]OH (JOM-13). Comparison of x-ray crystallographic structures, molecular mechanics simulations, and proton NMR data</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1021/ja00081a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00081a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK2cXhtlGisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=429-436&author=A.+L.+Lomizeauthor=J.+L.+Flippen-Andersonauthor=C.+Georgeauthor=H.+I.+Mosberg&title=Conformational+analysis+of+the+.delta.+receptor-selective%2C+cyclic+opioid+peptide%2C+Tyr-cyclo%5BD-Cys-Phe-D-Pen%5DOH+%28JOM-13%29.+Comparison+of+x-ray+crystallographic+structures%2C+molecular+mechanics+simulations%2C+and+proton+NMR+data&doi=10.1021%2Fja00081a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational analysis of the δ receptor-selective, cyclic opioid peptide, Tyr-cyclo[D-Cys-Phe-D-Pen]OH (JOM-13). Comparison of x-ray crystallographic structures, molecular mechanics simulations, and proton NMR data</span></div><div class="casAuthors">Lomize, Andrei L.; Flippen-Anderson, Judith L.; George, Clifford; Mosberg, Henry I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">429-36</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The conformational features of the title δ-selective, cyclic opioid peptide I (Pen = penicillamine) (JOM-13) were investigated using a combination of exptl. (x-ray crystallog., 1H NMR) and theor. (mol. mechanics computations) techniques.  Energy calcns. with the CHARMm force field show the existence of a single energetically preferred backbone conformation for the cyclic tripeptide portion of the mol.  Several distinct low-energy conformations were calcd., however, for the disulfide bridge linking the D-Cys and D-Pen residues, for the single Tyr residue outside the cycle, and for the Tyr and Phe side chains.  The two calcd. lowest-energy conformers of the D-Cys, D-Pen disulfide bridge (A and B) differ in values of D-Cys χ and χ3 (S-S) torsion angles.  This is consistent with the observation of two 1H NMR signal sets in aq. soln. (in the ratio 68:32) with distinctly different vicinal coupling consts. for protons H-CαCβ-H that correspond to a D-Cys χ1 angle of about -60° for the first set and ∼180° or +60° for the second.  X-ray crystallog. anal. of crystals grown from aq. soln. also revealed two independent conformers which are in excellent agreement with the computational and NMR data for the rigid, cyclic part of the mol. including the disulfide bridge.  However, 1H NMR data and computational results indicate that the flexible elements of JOM-13 (the exocyclic Tyr residue and the Tyr and Phe side chains) have no fixed structure in water soln.  In the cryst. environment they adopt conformations that are stabilized mainly by intermol. interactions and which do not correspond exactly to any local energy min. identified in the mol. mechanics calcns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsisCOYsRfX7Vg90H21EOLACvtfcHk0ljcXeW3D_lhmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtlGisLw%253D&md5=44b5a3fc074b0803d1c8360d3a21b102</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fja00081a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00081a001%26sid%3Dliteratum%253Aachs%26aulast%3DLomize%26aufirst%3DA.%2BL.%26aulast%3DFlippen-Anderson%26aufirst%3DJ.%2BL.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DConformational%2520analysis%2520of%2520the%2520.delta.%2520receptor-selective%252C%2520cyclic%2520opioid%2520peptide%252C%2520Tyr-cyclo%255BD-Cys-Phe-D-Pen%255DOH%2520%2528JOM-13%2529.%2520Comparison%2520of%2520x-ray%2520crystallographic%2520structures%252C%2520molecular%2520mechanics%2520simulations%252C%2520and%2520proton%2520NMR%2520data%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D429%26epage%3D436%26doi%3D10.1021%2Fja00081a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Przydzial, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosse, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tharp, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span> <span> </span><span class="NLM_article-title">Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor</span>. <i>J. Pept. Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1111/j.1399-3011.2005.00220.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1111%2Fj.1399-3011.2005.00220.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=15787963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtVCjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=333-342&author=M.+J.+Przydzialauthor=I.+D.+Pogozhevaauthor=K.+E.+Bosseauthor=S.+M.+Andrewsauthor=T.+A.+Tharpauthor=J.+R.+Traynorauthor=H.+I.+Mosberg&title=Roles+of+residues+3+and+4+in+cyclic+tetrapeptide+ligand+recognition+by+the+kappa-opioid+receptor&doi=10.1111%2Fj.1399-3011.2005.00220.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the κ-opioid receptor</span></div><div class="casAuthors">Przydzial, M. J.; Pogozheva, I. D.; Bosse, K. E.; Andrews, S. M.; Tharp, T. A.; Traynor, J. R.; Mosberg, H. I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-342</span>CODEN:
                <span class="NLM_cas:coden">JPERFA</span>;
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A series of cyclic, disulfide- or dithioether-contg. tetrapeptides based on previously reported potent μ- and δ-selective analogs has been explored with the aim of improving their poor affinity to the κ-opioid receptor.  Specifically targeted were modifications of tetrapeptide residues 3 and 4, as they presumably interact with residues from transmembrane helixes 6 and 7 and extracellular loop 3 that differ among the three receptors.  Accordingly, tetrapeptides were synthesized with Phe3 replaced by aliph. (Gly, Ala, Aib, Cha), basic (Lys, Arg, homo-Arg), or arom. sides chains (Trp, Tyr, p-NH2Phe), and with D-Pen4 replaced by D-Cys4, and binding affinities to stably expressed μ-, δ-, and κ-receptors were detd.  In general, the resulting analogs failed to exhibit appreciable affinity for the κ-receptor, with the exception of the tetrapeptide Tyr-c[D-Cys-Phe-D-Cys]-NH2, cyclized via a disulfide bond, which demonstrated high binding affinity toward all opioid receptors (Kiμ = 1.26 nM, Kiδ = 16.1 nM, Kiκ = 38.7 nM).  Modeling of the κ-receptor/ligand complex in the active state reveals that the receptor-binding pocket for residues 3 and 4 of the tetrapeptide ligands is smaller than that in the μ-receptor and requires, for optimal fit, that the tripeptide cycle of the ligand assume a higher energy conformation.  The magnitude of this energy penalty depends on the nature of the fourth residue of the peptide (D-Pen or D-Cys) and correlates well with the obsd. κ-receptor binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqpaJjquUBDrVg90H21EOLACvtfcHk0ljK8DhtlQZlPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtVCjtbw%253D&md5=62f2c2c4946da1a922d23310f1d933b2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fj.1399-3011.2005.00220.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1399-3011.2005.00220.x%26sid%3Dliteratum%253Aachs%26aulast%3DPrzydzial%26aufirst%3DM.%2BJ.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DBosse%26aufirst%3DK.%2BE.%26aulast%3DAndrews%26aufirst%3DS.%2BM.%26aulast%3DTharp%26aufirst%3DT.%2BA.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26atitle%3DRoles%2520of%2520residues%25203%2520and%25204%2520in%2520cyclic%2520tetrapeptide%2520ligand%2520recognition%2520by%2520the%2520kappa-opioid%2520receptor%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D2005%26volume%3D65%26spage%3D333%26epage%3D342%26doi%3D10.1111%2Fj.1399-3011.2005.00220.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chieng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span> <span> </span><span class="NLM_article-title">The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K<sup>+</sup> conductance of rat locus ceruleus neurons</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">650</span>– <span class="NLM_lpage">655</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=8794906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK28XlslSgsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=650-655&author=B.+Chiengauthor=M.+Connorauthor=M.+J.+Christie&title=The+mu-opioid+receptor+antagonist+D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2+%28CTOP%29+%5Bbut+not+D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2+%28CTAP%29%5D+produces+a+nonopioid+receptor-mediated+increase+in+K%2B+conductance+of+rat+locus+ceruleus+neurons"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The μ-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-The-NH2 (CTOP) but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP) produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons</span></div><div class="casAuthors">Chieng, Billy; Connor, Mark; Christie, MacDonald J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">650-655</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The somatostatin analogs CTOP and CTAP have been used widely as selective antagonists of μ-opioid receptors.  Actions of CTOP and CTAP on the membrane properties of rat locus ceruleus neurons were studied using intracellular recordings of membrane currents in superfused brain slices.  CTOP increased a K+ conductance with an EC50 of 560 nM.  The maximal conductance increase produced by CTOP (10 μm) was similar to that produced by high concns. of the μ-opioid agonists D-Ala-Met-enkephalinglycol (1 μM) and Met-enkephalin (10 μM), as well as an α2-adrenoceptor agonist (UK14304, 3 μM) and somatostatin (1 μM).  The K+ current produced by CTOP was not antagonized by naloxone (1 μM), suggesting it was not mediated by μ-opioid receptors.  The K+ currents induced by high concns. of CTOP desensitized to 42% of the initial max. after prolonged superfusion (t1/2 = 247 s).  In the presence of fully desensitized CTOP responses, somatostatin (1 μM) still produced near-maximal K+ currents; i.e. there was no cross-desensitization, which suggests that CTOP might act on a receptor distinct from somatostatin receptors.  However, the converse did not apply; high concns. of CTOP did not produce any addnl. current in the presence of desensitized somatostatin responses.  No cross-desensitization was obsd. between CTOP (10-30 μM) and Met-enkephalin (30 μM) or nociceptin (3 μM) regardless of the order of drug application.  Cyclo-(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[Bzl]), antagonized both somatostatin-(KD = 10 μM) and CTOP-(KK = 8 μM) induced K+ currents with similar potency.  Concns. of CTOP (100 nm) that produced a small K+ current partially antagonized the actions of Met-enkephalin (10- μM) on μ-opioid receptors.  In contrast to CTOP, CTAP produced no K+ current at concns. of 300 nm and 1 μM and little current at 10 μm.  CTAP potently antagonized K+ currents produced by the μ-opioid receptor agonist D-Ala-Met-enkephalin-glyol, with an equil. dissocn. const. of 4 nM (Schlid anal.).  CTAP did not antagonize K+ currents produced by CTOP or somatostatin.  These results demonstrated that CTOP is a potent and efficacious agonist at nonopioid receptors, whereas CTAP is a potent μ-opioid receptor antagonist with little nonopioid agonist activity in rat locus ceruleus neurons.  The receptor activated by CTOP has yet to be fully resolved but seems to be similar to the somatostatin type 2 receptor or perhaps to a receptor closely related to somatostatin or opioid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosJmtqteaBEbVg90H21EOLACvtfcHk0ljK8DhtlQZlPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlslSgsr0%253D&md5=b1f38bf9df7b66897934250f3a4b3aa4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChieng%26aufirst%3DB.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520mu-opioid%2520receptor%2520antagonist%2520D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2%2520%2528CTOP%2529%2520%255Bbut%2520not%2520D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2%2520%2528CTAP%2529%255D%2520produces%2520a%2520nonopioid%2520receptor-mediated%2520increase%2520in%2520K%252B%2520conductance%2520of%2520rat%2520locus%2520ceruleus%2520neurons%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D50%26spage%3D650%26epage%3D655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patkar, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span> <span> </span><span class="NLM_article-title">Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">18396</span>– <span class="NLM_lpage">18401</span>, <span class="refDoi"> DOI: 10.1073/pnas.0910180106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1073%2Fpnas.0910180106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19841255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=18396-18401&author=J.+V.+Aldrichauthor=K.+A.+Patkarauthor=J.+P.+McLaughlin&title=Zyklophin%2C+a+systemically+active+selective+kappa+opioid+receptor+peptide+antagonist+with+short+duration+of+action&doi=10.1073%2Fpnas.0910180106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action</span></div><div class="casAuthors">Aldrich, Jane V.; Patkar, Kshitij A.; McLaughlin, Jay P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">18396-18401</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The cyclic peptide zyklophin is a selective peptide kappa opioid receptor (KOR) antagonist that shows activity following systemic administration.  Systemic (1-3 mg/kg s.c.) as well as central (0.3-3 nmol intracerebroventricular, i.c.v.) administration of this peptide dose-dependently antagonizes the antinociception induced by the selective KOR agonist U50,488 in C57BU6J mice tested in the 55 warm water tail withdrawal assay.  Zyklophin administration had no effect on morphine- or SNC-80-mediated antinociception, suggesting that zyklophin selectively antagonizes KOR in vivo.  Addnl., the antagonism of antinociception induced by centrally (i.c.v.) administered U50,488 following peripheral administration of zyklophin strongly suggests that the peptide crosses the blood-brain barrier to antagonize KOR in the CNS.  Most importantly, the antagonist activity of zyklophin (3 mg/kg s.c.) lasts less than 12 h, which contrasts sharply with the exceptionally long duration of antagonism reported for the established small-mol. selective KOR antagonists such as norbinaltorphimine (nor-BNI) that last weeks after a single administration.  Systemically administered zyklophin (3 mg/kg s.c.) also prevented stress-induced reinstatement of cocaine-seeking behavior in a conditioned place preference assay.  In conclusion, the peptide zyklophin is a KOR-selective antagonist that exhibits the desired shorter duration of action, and represents a significant advance in the development of KOR-selective antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl_X3b-nZo-LVg90H21EOLACvtfcHk0ligJh2QtuD6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3F&md5=af15f86e709f6127d56e027aff38c967</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0910180106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0910180106%26sid%3Dliteratum%253Aachs%26aulast%3DAldrich%26aufirst%3DJ.%2BV.%26aulast%3DPatkar%26aufirst%3DK.%2BA.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26atitle%3DZyklophin%252C%2520a%2520systemically%2520active%2520selective%2520kappa%2520opioid%2520receptor%2520peptide%2520antagonist%2520with%2520short%2520duration%2520of%2520action%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D18396%26epage%3D18401%26doi%3D10.1073%2Fpnas.0910180106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mansfeld, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and plasma stability of disulfide-bridged cyclic endomorphin-1 derivatives</span>. <i>Int. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.4236/ijoc.2012.21001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.4236%2Fijoc.2012.21001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSlsrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1-6&author=F.+M.+Mansfeldauthor=I.+Toth&title=Synthesis+and+plasma+stability+of+disulfide-bridged+cyclic+endomorphin-1+derivatives&doi=10.4236%2Fijoc.2012.21001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and plasma stability of disulfide-bridged cyclic endomorphin-1 derivatives</span></div><div class="casAuthors">Mansfeld, Friederike M.; Toth, Istvan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">IJOCCR</span>;
        ISSN:<span class="NLM_cas:issn">2161-4687</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">Endomorphin-1 is an endogenous opioid peptide that mediates pain relief through interaction with the μ-opioid receptor in the central nervous system.  To enhance the metabolic stability of this tetrapeptide, cyclization through the formation of a disulfide bridge between the side chains of cysteine residues added to the sequence was explored.  A further increase in stability was achieved through N-terminal modification with lipoamino acid and lactose succinamic acid, and the inclusion of D-amino acids.  The latter also provided an alternative spatial arrangement of the arom. side chains.  The lipidated cyclic derivs. were insol. in aq. buffer, however, the cyclic peptides and glycopeptides showed greatly improved stability towards enzymic degrdn. in human plasma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwfyEhqlCilbVg90H21EOLACvtfcHk0ligJh2QtuD6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSlsrfK&md5=7f419ea0e4764b3876c8a50a790b3b70</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.4236%2Fijoc.2012.21001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fijoc.2012.21001%26sid%3Dliteratum%253Aachs%26aulast%3DMansfeld%26aufirst%3DF.%2BM.%26aulast%3DToth%26aufirst%3DI.%26atitle%3DSynthesis%2520and%2520plasma%2520stability%2520of%2520disulfide-bridged%2520cyclic%2520endomorphin-1%2520derivatives%26jtitle%3DInt.%2520J.%2520Org.%2520Chem.%26date%3D2012%26volume%3D2%26spage%3D1%26epage%3D6%26doi%3D10.4236%2Fijoc.2012.21001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">Strategies to assess blood-brain barrier penetration</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1517/17460441.3.6.677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1517%2F17460441.3.6.677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=23506148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVyrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=677-687&author=L.+Diauthor=E.+H.+Kernsauthor=G.+T.+Carter&title=Strategies+to+assess+blood-brain+barrier+penetration&doi=10.1517%2F17460441.3.6.677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to assess blood-brain barrier penetration</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-687</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: The principles and screening strategies for brain penetration in drug discovery are important in identifying drug candidates with desirable CNS properties.  Objective: Define key variables and assays that are essential for detg. brain penetration.  Methods: This review covers issues, methods, and strategies for assessing brain penetration of small mols. in drug discovery.  Results/conclusion: Brain penetration is assessed using both initial rate and extent at steady-state.  Unbound drug is the active species that exerts pharmacol. effects.  Low brain penetration can be due to low blood-brain barrier (BBB) permeability, P-glycoprotein (Pgp) efflux, or high plasma protein binding.  Successful methods include: parallel artificial membrane permeability assay (PAMPA)-BBB permeability, MDR1-MDCKII for Pgp efflux, B-P dialysis for fraction unbound, and in vivo B/P ratio to extrapolate unbound brain drug concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOHHdHc1xH7LVg90H21EOLACvtfcHk0li_JD-7_qyFtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVyrtL0%253D&md5=8186d3a972120691aebb3dba4810f7f8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F17460441.3.6.677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.3.6.677%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DStrategies%2520to%2520assess%2520blood-brain%2520barrier%2520penetration%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D677%26epage%3D687%26doi%3D10.1517%2F17460441.3.6.677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stain-Texier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandouk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrmann, J.-M.</span></span> <span> </span><span class="NLM_article-title">Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">924</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fsj.bjp.0702873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10556926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK1MXntFCiu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=917-924&author=F.+Stain-Texierauthor=G.+Boschiauthor=P.+Sandoukauthor=J.-M.+Scherrmann&title=Elevated+concentrations+of+morphine+6-beta-D-glucuronide+in+brain+extracellular+fluid+despite+low+blood-brain+barrier+permeability&doi=10.1038%2Fsj.bjp.0702873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood - brain barrier permeability</span></div><div class="casAuthors">Stain-Texier, Frederique; Boschi, Gabrielle; Sandouk, Pierre; Scherrmann, Jean-Michel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">917-924</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">This study was done to find out how morphine 6-beta-D-glucuronide (M6G) induces more potent central analgesia than morphine, despite its poor blood-brain barrier (BBB) permeability.  The brain uptake and disposition of these compds. were investigated in plasma and in various brain compartments: extracellular fluid (ECF), intracellular space (ICS) and cerebrospinal fluid (CSF).  Morphine or M6G was given to rats at 10 mg kg-1 s.c.  Transcortical microdialysis was used to assess their distributions in the brain ECF.  Conventional tissue homogenization was used to det. the distribution in the cortex and whole brain.  These two procedures were combined to est. drug distribution in the brain ICS.  The blood and CSF pharmacokinetics were also detd.  Plasma concn. data for M6G were much higher than those of morphine, with Cmax and AUC 4-5 times more higher, Tmax shorter, and VZf-1 (vol. of distribution) and CL f-1 (clearance) 4-6 times lower.  The concns. of the compds. in various brain compartments also differed: AUC values for M6G were lower than those of morphine in tissue and CSF and higher in brain ECF.  AUC values in brain show that morphine levels were four times higher in ICS than in ECF, whereas M6G levels were 125 higher in ECF than in ICS.  Morphine entered brain cells, whereas M6G was almost exclusively extracellular.  This high extracellular concn., coupled with extremely slow diffusion into the CSF, indicates that M6G was predominantly trapped in the extracellular fluid and therefore durably available to bind at opioid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4m4joGsaYsLVg90H21EOLACvtfcHk0li_JD-7_qyFtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFCiu7g%253D&md5=5c21b08e2b1099a8fe5b3e5b32ae0d39</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702873%26sid%3Dliteratum%253Aachs%26aulast%3DStain-Texier%26aufirst%3DF.%26aulast%3DBoschi%26aufirst%3DG.%26aulast%3DSandouk%26aufirst%3DP.%26aulast%3DScherrmann%26aufirst%3DJ.-M.%26atitle%3DElevated%2520concentrations%2520of%2520morphine%25206-beta-D-glucuronide%2520in%2520brain%2520extracellular%2520fluid%2520despite%2520low%2520blood-brain%2520barrier%2520permeability%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D917%26epage%3D924%26doi%3D10.1038%2Fsj.bjp.0702873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gengo, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNutt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-J.</span></span> <span> </span><span class="NLM_article-title">DPI-3290 [(+)-3-((α-R)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A Mixed Opioid Agonist with Potent Antinociceptive Activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.054361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1124%2Fjpet.103.054361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=14534368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslSht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=1221-1226&author=P.+J.+Gengoauthor=H.+O.+Pettitauthor=S.+J.+O%E2%80%99Neillauthor=K.+Weiauthor=R.+McNuttauthor=M.+J.+Bishopauthor=K.-J.+Chang&title=DPI-3290+%5B%28%2B%29-3-%28%28%CE%B1-R%29-%CE%B1-%28%282S%2C5R%29-4-Allyl-2%2C5-dimethyl-1-piperazinyl%29-3-hydroxybenzyl%29-N-%283-fluorophenyl%29-N-methylbenzamide%5D.+I.+A+Mixed+Opioid+Agonist+with+Potent+Antinociceptive+Activity&doi=10.1124%2Fjpet.103.054361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">DPI-3290 [(+)-3-((α-R)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A mixed opioid agonist with potent antinociceptive activity</span></div><div class="casAuthors">Gengo, Peter J.; Pettit, Hugh O.; O'Neill, Scott J.; Wei, Ke; McNutt, Robert; Bishop, Michael J.; Chang, Kwen-jen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1221-1226</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">DPI-3290 is one of a series of novel centrally acting agents with potent antinociceptive activity that binds specifically and with high affinity to opioid receptors.  In satn. equil. binding studies performed at 25°C using membranes from rat brain or guinea pig cerebellum, the Ki values measured for DPI-3290 at δ-, μ-, and κ-opioid receptors were 0.18 ± 0.02, 0.46 ± 0.05, and 0.62 ± 0.09 nM, resp.  In vas deferens isolated from lab. mice, DPI-3290 decreased elec. induced tension development in a concn.-dependent manner with corresponding IC50 values of 1.0 ± 0.3, 6.2 ± 2.0, and 25.0 ± 3.3 nM at δ-, μ-, and κ-receptors, resp.  The activity of DPI-3290 in isolated vas deferens tissue was approx. 20,000, 175.8, and 1500 times more efficacious than morphine, and 492, 2.5, and 35 times more efficacious than fentanyl at δ-, μ-, and κ-receptors, resp.  In ileal strips isolated from guinea pigs, DPI-3290 inhibited tension development with a corresponding IC50 value of 3.4 ± 1.6 nM at μ-opioid receptors and 6.7 ± 1.6 nM at κ-opioid receptors.  I.v. administration of 0.05 ± 0.007 mg/kg DPI-3290 produced a 50% antinociceptive response in rats.  The antinociceptive properties of DPI-3290 were blocked by naloxone (0.5 mg/kg s.c.).  Compared with morphine, this study demonstrated that DPI-3290 is more potent and elicited a similar magnitude of antinociceptive activity in the rat, actions mediated by its mixed opioid receptor agonist activity.  The marked antinociceptive activity of DPI-3290 will likely provide a means for relieving severe pain in patients that require analgesic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLw--VdDEU6LVg90H21EOLACvtfcHk0li_JD-7_qyFtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslSht7Y%253D&md5=4ec14513152f2d0f517c6ac1bfc4d7bd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.054361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.054361%26sid%3Dliteratum%253Aachs%26aulast%3DGengo%26aufirst%3DP.%2BJ.%26aulast%3DPettit%26aufirst%3DH.%2BO.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DS.%2BJ.%26aulast%3DWei%26aufirst%3DK.%26aulast%3DMcNutt%26aufirst%3DR.%26aulast%3DBishop%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DK.-J.%26atitle%3DDPI-3290%2520%255B%2528%252B%2529-3-%2528%2528%25CE%25B1-R%2529-%25CE%25B1-%2528%25282S%252C5R%2529-4-Allyl-2%252C5-dimethyl-1-piperazinyl%2529-3-hydroxybenzyl%2529-N-%25283-fluorophenyl%2529-N-methylbenzamide%255D.%2520I.%2520A%2520Mixed%2520Opioid%2520Agonist%2520with%2520Potent%2520Antinociceptive%2520Activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D307%26spage%3D1221%26epage%3D1226%26doi%3D10.1124%2Fjpet.103.054361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, S.-p.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, Q.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Z.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, R.-b.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-j.</span></span> <span> </span><span class="NLM_article-title">The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">977</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1038/aps.2017.14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Faps.2017.14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=28502978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFanu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=977-989&author=S.-p.+Yiauthor=Q.-h.+Kongauthor=Y.-l.+Liauthor=C.-l.+Panauthor=J.+Yuauthor=B.-q.+Cuiauthor=Y.-f.+Wangauthor=G.-l.+Wangauthor=P.-l.+Zhouauthor=L.-l.+Wangauthor=Z.-h.+Gongauthor=R.-b.+Suauthor=Y.-h.+Shenauthor=G.+Yuauthor=K.-j.+Chang&title=The+opioid+receptor+triple+agonist+DPI-125+produces+analgesia+with+less+respiratory+depression+and+reduced+abuse+liability&doi=10.1038%2Faps.2017.14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability</span></div><div class="casAuthors">Yi, Shou-pu; Kong, Qing-hong; Li, Yu-lei; Pan, Chen-ling; Yu, Jie; Cui, Ben-qiang; Wang, Ying-fei; Wang, Guan-lin; Zhou, Pei-lan; Wang, Li-li; Gong, Ze-hui; Su, Rui-bin; Shen, Yue-hai; Yu, Gang; Chang, Kwen-jen</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">977-989</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Opioid analgesics remain the first choice for the treatment of moderate to severe pain, but they are also notorious for their respiratory depression and addictive effects.  This study focused on the pharmacol. of a novel opioid receptor mixed agonist DPI-125 and attempted to elucidate the relationship between the δ-, μ- and κ-receptor potency ratio and respiratory depression and abuse liability.  Five diarylmethylpiperazine compds. (DPI-125, DPI-3290, DPI-130, KUST202 and KUST13T02) were selected for this study.  PKA fluorescence redistribution assays in CHO cells individually expressing δ-, μ- or κ-receptors were used to measure the agonist potency.  The respiratory safety profiles were estd. in rats by the ratio of ED50 (pCO2 increase)/ED50 (antinociception).  The abuse liability of DPI-125 was evaluated with a self-administration model in rhesus monkeys.  The obsd. agonist potencies of DPI-125 for δ-, μ- and κ-opioid receptors were 4.29±0.36, 11.10±3.04, and 16.57±4.14 nmol/L, resp.  The other four compds. were also mixed agonists with varying potencies.  DPI-125 exhibited a high respiratory safety profile, clearly related to its high δ-receptor potency.  The ratio of the EC50 potencies for the μ- and δ-receptors was found to be pos. correlated with the respiratory safety ratio.  DPI-125 has similar potencies for μ- and κ-receptors, which is likely the reason for its reduced abuse potential.  Our results demonstrate that the opioid receptor mixed agonist DPI-125 is safer and less addictive than traditional μ-agonist analgesics.  These findings suggest that the development of δ>μ∼κ opioid receptor mixed agonists is feasible, and such compds. could represent a promising class of potent analgesics with wider therapeutic windows.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJPFKpBtgRMLVg90H21EOLACvtfcHk0ljNWRDzCL6xhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFanu77I&md5=2d646c2c1d38012deaaeda208c9abcf5</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Faps.2017.14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2017.14%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DS.-p.%26aulast%3DKong%26aufirst%3DQ.-h.%26aulast%3DLi%26aufirst%3DY.-l.%26aulast%3DPan%26aufirst%3DC.-l.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DB.-q.%26aulast%3DWang%26aufirst%3DY.-f.%26aulast%3DWang%26aufirst%3DG.-l.%26aulast%3DZhou%26aufirst%3DP.-l.%26aulast%3DWang%26aufirst%3DL.-l.%26aulast%3DGong%26aufirst%3DZ.-h.%26aulast%3DSu%26aufirst%3DR.-b.%26aulast%3DShen%26aufirst%3DY.-h.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DChang%26aufirst%3DK.-j.%26atitle%3DThe%2520opioid%2520receptor%2520triple%2520agonist%2520DPI-125%2520produces%2520analgesia%2520with%2520less%2520respiratory%2520depression%2520and%2520reduced%2520abuse%2520liability%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2017%26volume%3D38%26spage%3D977%26epage%3D989%26doi%3D10.1038%2Faps.2017.14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanemasa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, A.</span></span> <span> </span><span class="NLM_article-title">Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models</span>. <i>J. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1254/jphs.09139fp</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1254%2Fjphs.09139FP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19729873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ert7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2009&pages=60-72&author=K.+Minamiauthor=M.+Hasegawaauthor=H.+Itoauthor=A.+Nakamuraauthor=T.+Tomiiauthor=M.+Matsumotoauthor=S.+Oritaauthor=S.+Matsushimaauthor=T.+Miyoshiauthor=K.+Masunoauthor=M.+Toriiauthor=K.+Koikeauthor=S.+Shimadaauthor=T.+Kanemasaauthor=T.+Kiharaauthor=M.+Naritaauthor=T.+Suzukiauthor=A.+Kato&title=Morphine%2C+oxycodone%2C+and+fentanyl+exhibit+different+analgesic+profiles+in+mouse+pain+models&doi=10.1254%2Fjphs.09139fp"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models</span></div><div class="casAuthors">Minami, Kazuhisa; Hasegawa, Minoru; Ito, Hisanori; Nakamura, Atsushi; Tomii, Takako; Matsumoto, Mitsunobu; Orita, Satoshi; Matsushima, Syuichi; Miyoshi, Takako; Masuno, Koichi; Torii, Mikinori; Koike, Katsumi; Shimada, Shinji; Kanemasa, Toshiyuki; Kihara, Tsuyoshi; Narita, Minoru; Suzuki, Tsutomu; Kato, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-72</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">Morphine, oxycodone, and fentanyl are clin. prescribed drugs for the management of severe pain.  We investigated whether these opioids possess different efficacy profiles on several types of pain in mouse pain models.  When the three opioids were tested in the femur bone cancer model, all of them significantly reversed guarding behavior, whereas the effects on limb-use abnormality and allodynia-like behavior differed among the opioids.  Particularly, although oxycodone (5-20 mg/kg) and fentanyl (0.2 mg/kg) significantly reversed limb-use abnormality, not even a high dose of morphine (50 mg/kg) could reverse it.  When the effects of these opioids were examd. in a sciatic nerve ligation (SNL) model of neuropathic pain, oxycodone was the most effective, producing an antinociceptive effect without affecting the withdrawal threshold of sham-treated animals.  When the effects of these opioids were examd. with the tail-flick test using naive animals, oxycodone, morphine, and fentanyl exhibited antinociceptive effects on thermal nociception.  These results show that the three opioids exhibit different efficacy outcomes in multiple pain models and that the efficacy profile of oxycodone does not overlap those of morphine and fentanyl.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXmVdmAiwZZrVg90H21EOLACvtfcHk0ljNWRDzCL6xhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ert7jM&md5=3830bf7a680b3278c1be1e02a1a3c3ff</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1254%2Fjphs.09139FP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.09139FP%26sid%3Dliteratum%253Aachs%26aulast%3DMinami%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DTomii%26aufirst%3DT.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DOrita%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DS.%26aulast%3DMiyoshi%26aufirst%3DT.%26aulast%3DMasuno%26aufirst%3DK.%26aulast%3DTorii%26aufirst%3DM.%26aulast%3DKoike%26aufirst%3DK.%26aulast%3DShimada%26aufirst%3DS.%26aulast%3DKanemasa%26aufirst%3DT.%26aulast%3DKihara%26aufirst%3DT.%26aulast%3DNarita%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DA.%26atitle%3DMorphine%252C%2520oxycodone%252C%2520and%2520fentanyl%2520exhibit%2520different%2520analgesic%2520profiles%2520in%2520mouse%2520pain%2520models%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D111%26spage%3D60%26epage%3D72%26doi%3D10.1254%2Fjphs.09139fp" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moncada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendán, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Pozo, E.</span></span> <span> </span><span class="NLM_article-title">Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/s0014-2999(03)01461-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2FS0014-2999%2803%2901461-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=12650833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitV2nt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2003&pages=53-60&author=A.+Moncadaauthor=C.+M.+Cend%C3%A1nauthor=J.+M.+Baeyensauthor=E.+Del+Pozo&title=Effects+of+serine%2Fthreonine+protein+phosphatase+inhibitors+on+morphine-induced+antinociception+in+the+tail+flick+test+in+mice&doi=10.1016%2Fs0014-2999%2803%2901461-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of serine/threonine protein phosphatase inhibitors on morphine-induced antinociception in the tail flick test in mice</span></div><div class="casAuthors">Moncada, Ana; Cendan, Cruz Miguel; Baeyens, Jose M.; Del Pozo, Esperanza</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">53-60</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the effects of serine/threonine protein phosphatase (PP) inhibitors on morphine-induced antinociception in the tail flick test in mice, and on [3H]naloxone binding to the forebrain crude synaptosome fraction.  Neither okadaic acid nor cantharidin (1-10 000 nM) displaced [3H]naloxone from its specific binding sites, which indicates that they do not interact at the opioid receptor level.  The i.c.v. administration of very low doses of okadaic acid (0.001-1 pg/mouse) and cantharidin (0.001-1 ng/mouse), which inhibit PP2A, produced a dose-dependent antagonism of the antinociception induced by morphine (s.c.).  However, L-nor-okadaone (0.001 pg/mouse-1 ng/mouse, i.c.v.), an analog of okadaic acid lacking activity against protein phosphatases, did not affect the antinociceptive effect of morphine.  On the other hand, high doses of okadaic acid (10 ng/mouse, i.c.v.) and cantharidin (1 μg/mouse, i.c.v.), which also block PP1, and calyculin-A (0.1 fg/mouse-1 ng/mouse, i.c.v.), which inhibits equally both PP1 and PP2A, did not modify the morphine-induced antinociception.  These results suggest that the activation of type 2A serine/threonine protein phosphatases may play a role in the antinociceptive effect of morphine, and that PP1 might counterbalance this activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrynBkEXFNhALVg90H21EOLACvtfcHk0ljNWRDzCL6xhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitV2nt7g%253D&md5=0299389efd988d0d91b20738e314f033</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2901461-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252901461-4%26sid%3Dliteratum%253Aachs%26aulast%3DMoncada%26aufirst%3DA.%26aulast%3DCend%25C3%25A1n%26aufirst%3DC.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%2BM.%26aulast%3DDel%2BPozo%26aufirst%3DE.%26atitle%3DEffects%2520of%2520serine%252Fthreonine%2520protein%2520phosphatase%2520inhibitors%2520on%2520morphine-induced%2520antinociception%2520in%2520the%2520tail%2520flick%2520test%2520in%2520mice%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D465%26spage%3D53%26epage%3D60%26doi%3D10.1016%2Fs0014-2999%2803%2901461-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kliewer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sianati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levitt, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">367</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-08162-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fs41467-018-08162-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30664663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFeks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=367&author=A.+Kliewerauthor=F.+Schmiedelauthor=S.+Sianatiauthor=A.+Baileyauthor=J.+T.+Batemanauthor=E.+S.+Levittauthor=J.+T.+Williamsauthor=M.+J.+Christieauthor=S.+Schulz&title=Phosphorylation-deficient+G-protein-biased+mu-opioid+receptors+improve+analgesia+and+diminish+tolerance+but+worsen+opioid+side+effects&doi=10.1038%2Fs41467-018-08162-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation-deficient G-protein-biased mu-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects</span></div><div class="casAuthors">Kliewer, A.; Schmiedel, F.; Sianati, S.; Bailey, A.; Bateman, J. T.; Levitt, E. S.; Williams, J. T.; Christie, M. J.; Schulz, S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">367</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Opioid analgesics are powerful pain relievers; however, over time, pain control diminishes as analgesic tolerance develops.  The mol. mechanisms initiating tolerance have remained unresolved to date.  We have previously shown that desensitization of the mu-opioid receptor and interaction with beta-arrestins is controlled by carboxyl-terminal phosphorylation.  Here we created knockin mice with a series of serine- and threonine-to-alanine mutations that render the receptor increasingly unable to recruit beta-arrestins.  Desensitization is inhibited in locus coeruleus neurons of mutant mice.  Opioid-induced analgesia is strongly enhanced and analgesic tolerance is greatly diminished.  Surprisingly, respiratory depression, constipation, and opioid withdrawal signs are unchanged or exacerbated, indicating that beta-arrestin recruitment does not contribute to the severity of opioid side effects and, hence, predicting that G-protein-biased mu-agonists are still likely to elicit severe adverse effects.  In conclusion, our findings identify carboxyl-terminal multisite phosphorylation as key step that drives acute mu-opioid receptor desensitization and long-term tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaEj4ARbzSS7Vg90H21EOLACvtfcHk0lieMoFnnkxfHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFeks7k%253D&md5=19fa2354d75d29b28503d21f63754d45</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08162-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08162-1%26sid%3Dliteratum%253Aachs%26aulast%3DKliewer%26aufirst%3DA.%26aulast%3DSchmiedel%26aufirst%3DF.%26aulast%3DSianati%26aufirst%3DS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DBateman%26aufirst%3DJ.%2BT.%26aulast%3DLevitt%26aufirst%3DE.%2BS.%26aulast%3DWilliams%26aufirst%3DJ.%2BT.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DSchulz%26aufirst%3DS.%26atitle%3DPhosphorylation-deficient%2520G-protein-biased%2520mu-opioid%2520receptors%2520improve%2520analgesia%2520and%2520diminish%2520tolerance%2520but%2520worsen%2520opioid%2520side%2520effects%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D367%26doi%3D10.1038%2Fs41467-018-08162-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armenian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vo, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr-Walker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. L.</span></span> <span> </span><span class="NLM_article-title">Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2017.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.neuropharm.2017.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=29042317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslSktbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2018&pages=121-132&author=P.+Armenianauthor=K.+T.+Voauthor=J.+Barr-Walkerauthor=K.+L.+Lynch&title=Fentanyl%2C+fentanyl+analogs+and+novel+synthetic+opioids%3A+A+comprehensive+review&doi=10.1016%2Fj.neuropharm.2017.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review</span></div><div class="casAuthors">Armenian, Patil; Vo, Kathy T.; Barr-Walker, Jill; Lynch, Kara L.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">121-132</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Deaths from opioid use are increasing in the US, with a growing proportion due to synthetic opioids.  Until 2013, sporadic outbreaks of fentanyl and fentanyl analogs contaminating the heroin supply caused some deaths in heroin users.  Since then, fentanyl has caused deaths in every state and fentanyl and its analogs have completely infiltrated the North American heroin supply.  In 2014, the first illicit pills contg. fentanyl, fentanyl analogs, and other novel synthetic opioids such as U-47700 were detected.  These pills, which look like known opioids or benzodiazepines, have introduced synthetic opioids to more unsuspecting customers.  As soon as these drugs are regulated by various countries, new compds. quickly appear on the market, making detection difficult and the no. of cases likely underreported.  Std. targeted anal. techniques such as GC-MS (gas chromatog. mass spectrometry) and LC-MS/MS (liq. chromatog. tandem mass spectrometry) can detect these drugs, but novel compd. identification is aided by nontargeted testing with LC-HRMS (liq. chromatog. high resoln. mass spectrometry).  Fentanyl, fentanyl analogs and other novel synthetic opioids are all full agonists of varying potencies at the μ-opioid receptor, leading to typical clin. effects of miosis and respiratory and central nervous system depression.  Due to their high affinity for μ-opioid receptors, larger doses of naloxone are required to reverse the effects than are commonly used.  Synthetic opioids are an increasingly major public health threat requiring vigilance from multiple fields including law enforcement, government agencies, clin. chemists, pharmacists, and physicians, to name a few, in order to stem its tide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxtCmdklHXLbVg90H21EOLACvtfcHk0lieMoFnnkxfHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslSktbrM&md5=10085cfb511f8fd6316ffba4d39dcdef</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2017.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2017.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DArmenian%26aufirst%3DP.%26aulast%3DVo%26aufirst%3DK.%2BT.%26aulast%3DBarr-Walker%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DK.%2BL.%26atitle%3DFentanyl%252C%2520fentanyl%2520analogs%2520and%2520novel%2520synthetic%2520opioids%253A%2520A%2520comprehensive%2520review%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D134%26spage%3D121%26epage%3D132%26doi%3D10.1016%2Fj.neuropharm.2017.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cherebillo, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elizarov, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polegaev, A. V.</span></span> <span> </span><span class="NLM_article-title">Membrane-introduction mass spectrometry analysis of desflurane, propofol and fentanyl in plasma and cerebrospinal fluid for estimation BBB properties</span>. <i>Exp. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.5607/en.2015.24.3.206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.5607%2Fen.2015.24.3.206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=26412969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A280%3ADC%252BC283msFagsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=206-210&author=V.+Y.+Cherebilloauthor=A.+Y.+Elizarovauthor=A.+V.+Polegaev&title=Membrane-introduction+mass+spectrometry+analysis+of+desflurane%2C+propofol+and+fentanyl+in+plasma+and+cerebrospinal+fluid+for+estimation+BBB+properties&doi=10.5607%2Fen.2015.24.3.206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Membrane-Introduction Mass Spectrometry Analysis of Desflurane, Propofol and Fentanyl in Plasma and Cerebrospinal Fluid for Estimation BBB Properties</span></div><div class="casAuthors">Cherebillo Vyacheslav Yu; Polegaev Andrei V; Elizarov Andrei Yu</div><div class="citationInfo"><span class="NLM_cas:title">Experimental neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">206-10</span>
        ISSN:<span class="NLM_cas:issn">1226-2560</span>.
    </div><div class="casAbstract">A possibility to use the Membrane-Introduction Mass Spectrometry (MIMS) with membrane separator interface has evolved into a powerful method for measurement of anaesthetic agents absolute concentration in blood plasma and cerebrospinal fluid for the study of blood-brain barrier (BBB) properties.  Recent advanced a new membrane material was used for drug concentration measurement in biologic fluids.  A hydrophobic membrane was used in the interface to separate anaesthetic agents from biological fluids: inhalational anaesthetic desflurane,hypnotic propofol, analgesic fentanyl.  The selective detection of volatile anesthetic agents in blood does not require long-term sample processing before injecting the sample into mass-spectrometer interface, in contrast to chromatographic methods.  Mass-spectrometric interface for the measurement of anaesthetic agent concentration in biological fluids (blood plasma and cerebrospinal fluid) is described.  Sampling of biological fluids was performed during balanced inhalational (desflurane, fentanyl) anaesthesia and total intravenous (propofol, fentanyl) anaesthesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSPmBbWtac9RbjnyZkbE8yXfW6udTcc2eYcKdGWBhdhi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283msFagsg%253D%253D&md5=46e9839d6b0284252f013aa1ac4191fd</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.5607%2Fen.2015.24.3.206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5607%252Fen.2015.24.3.206%26sid%3Dliteratum%253Aachs%26aulast%3DCherebillo%26aufirst%3DV.%2BY.%26aulast%3DElizarov%26aufirst%3DA.%2BY.%26aulast%3DPolegaev%26aufirst%3DA.%2BV.%26atitle%3DMembrane-introduction%2520mass%2520spectrometry%2520analysis%2520of%2520desflurane%252C%2520propofol%2520and%2520fentanyl%2520in%2520plasma%2520and%2520cerebrospinal%2520fluid%2520for%2520estimation%2520BBB%2520properties%26jtitle%3DExp.%2520Neurobiol.%26date%3D2015%26volume%3D24%26spage%3D206%26epage%3D210%26doi%3D10.5607%2Fen.2015.24.3.206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fürst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tímar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khrasani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obara, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makuch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przewlocki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przewlocka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidhammer, H.</span></span> <span> </span><span class="NLM_article-title">Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">618</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.075176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1124%2Fjpet.104.075176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=15383636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsVCnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=609-618&author=S.+F%C3%BCrstauthor=P.+Ribaauthor=T.+Friedmannauthor=J.+T%C3%ADmarauthor=M.+Al-Khrasaniauthor=I.+Obaraauthor=W.+Makuchauthor=M.+Speteaauthor=J.+Sch%C3%BCtzauthor=R.+Przewlockiauthor=B.+Przewlockaauthor=H.+Schmidhammer&title=Peripheral+versus+central+antinociceptive+actions+of+6-amino+acid-substituted+derivatives+of+14-O-methyloxymorphone+in+acute+and+inflammatory+pain+in+the+rat&doi=10.1124%2Fjpet.104.075176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat</span></div><div class="casAuthors">Fuerst, Susanna; Riba, Pal; Friedmann, Tamas; Timar, Julia; Al-Khrasani, Mahmoud; Obara, Ilona; Makuch, Wioletta; Spetea, Mariana; Schuetz, Johannes; Przewlocki, Ryszard; Przewlocka, Barbara; Schmidhammer, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-618</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Opioid analgesics with restricted access to the central nervous system represent a new approach to the treatment of severe pain with an improved safety profile.  The objective of this study was to investigate the peripheral and central components of the antinociceptive actions of the 6-amino acid conjugates (glycine, alanine, and phenylalanine) of 14-O-methyloxymorphone.  Their antinociceptive activities were compared with those of the centrally penetrating μ-opioid agonists morphine, fentanyl, and 14-O-methyloxymorphone.  In the tail-flick test in rats, the 6-amino acid conjugates were 45- to 1170-fold more potent than morphine after i.c.v. administration and 19- to 209-fold after s.c. administration.  They showed potencies similar to fentanyl after s.c. administration and were more potent after i.c.v. application.  The time course of action was different between s.c. and i.c.v. administration, with significant long-lasting effects after i.c.v. administration.  Systemic administration of the peripherally selective opioid antagonist naloxone methiodide antagonized the effects after s.c. but not after i.c.v. administration in the tail-flick test.  S.c. 6-amino acid derivs. also elicited antihyperalgesic effects in the formalin test in rats, which were reversed by systemically administered naloxone methiodide.  Although morphine exerts its analgesic effects by central and peripheral mechanisms, the investigated new opioids interact primarily with peripheral opioid receptors after s.c. administration.  The present data indicate that the 6-amino acid conjugates of 14-O-methyloxymorphone have limited access to the central nervous system and can mediate antinociception at peripheral sites.  Also, they might find clin. application when the central actions of opioids are unwanted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPp43K4DtnyLVg90H21EOLACvtfcHk0lg5Y2qyhuT9Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsVCnsbg%253D&md5=28a8bf615e51d49f4746b35e58a956f3</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.075176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.075176%26sid%3Dliteratum%253Aachs%26aulast%3DF%25C3%25BCrst%26aufirst%3DS.%26aulast%3DRiba%26aufirst%3DP.%26aulast%3DFriedmann%26aufirst%3DT.%26aulast%3DT%25C3%25ADmar%26aufirst%3DJ.%26aulast%3DAl-Khrasani%26aufirst%3DM.%26aulast%3DObara%26aufirst%3DI.%26aulast%3DMakuch%26aufirst%3DW.%26aulast%3DSpetea%26aufirst%3DM.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DJ.%26aulast%3DPrzewlocki%26aufirst%3DR.%26aulast%3DPrzewlocka%26aufirst%3DB.%26aulast%3DSchmidhammer%26aufirst%3DH.%26atitle%3DPeripheral%2520versus%2520central%2520antinociceptive%2520actions%2520of%25206-amino%2520acid-substituted%2520derivatives%2520of%252014-O-methyloxymorphone%2520in%2520acute%2520and%2520inflammatory%2520pain%2520in%2520the%2520rat%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D609%26epage%3D618%26doi%3D10.1124%2Fjpet.104.075176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lacko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riba, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giricz, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balogh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiraly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csekő, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosztafi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zadori, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helyes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferdinandy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khrasani, M.</span></span> <span> </span><span class="NLM_article-title">New morphine analogs produce peripheral antinociception within a certain dose range of their systemic administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.233551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1124%2Fjpet.116.233551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27435180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2jt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2016&pages=171-181&author=E.+Lackoauthor=P.+Ribaauthor=Z.+Giriczauthor=A.+Varadiauthor=L.+Cornicauthor=M.+Baloghauthor=K.+Kiralyauthor=K.+Csek%C5%91author=S.+A.+Mousaauthor=S.+Hosztafiauthor=M.+Schaferauthor=Z.+S.+Zadoriauthor=Z.+Helyesauthor=P.+Ferdinandyauthor=S.+Furstauthor=M.+Al-Khrasani&title=New+morphine+analogs+produce+peripheral+antinociception+within+a+certain+dose+range+of+their+systemic+administration&doi=10.1124%2Fjpet.116.233551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">New morphine analogs produce peripheral antinociception within a certain dose range of their systemic administration</span></div><div class="casAuthors">Lacko, Erzsebet; Riba, Pal; Giricz, Zoltan; Varadi, Andras; Cornic, Laura; Balogh, Mihaly; Kiraly, Kornel; Cseko, Kata; Mousa, Shaaban A.; Hosztafi, Sandor; Schafer, Michael; Zadori, Zoltan Sandor; Helyes, Zsuzsanna; Ferdinandy, Peter; Furst, Susanna; Al-Khrasani, Mahmoud</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Growing data support peripheral opioid antinociceptive effects, particularly in inflammatory pain models.  Here, we examd. the antinociceptive effects of s.c. administered, recently synthesized 14-O-methylmorphine-6-O-sulfate (14-OMeM6SU) compared withmorphine-6-O-sulfate (M6SU) in a rat model of inflammatory pain induced by an injection of complete Freund's adjuvant and in a mouse model of visceral pain evoked by acetic acid.  S.c. doses of 14-O-MeM6SU and M6SU up to 126 and 547 nmol/kg, resp., produced significant and s.c. or intraplantar naloxone methiodide (NAL-M)-reversible antinociception in inflamed paws compared with noninflamed paws.  Neither of these doses significantly affected thiobutabarbital-induced sleeping time or rat pulmonary parameters.  However, the antinociceptive effects of higher doses were only partially reversed by NAL-M, indicating contribution of the central nervous system.  In the mouse writhing test, 14-O-MeM6SU was more potent than M6SU after s.c. or intracerebroventricular injections.  Both displayed high s.c./intracerebroventricular ED50 ratios.  The antinociceptive effects of s.c. 14-O-MeM6SU and M6SU up to 136 and 3043 nmol/kg, resp., were fully antagonized by s.c. NAL-M.  In addn., the test compds. inhibited mouse gastrointestinal transit in antinociceptive doses.  Taken together, these findings suggest that systemic administration of the novel compd. 14-O-MeM6SU similar to M6SU in specific dose ranges shows peripheral antinociception in rat and mouse inflammatory pain models without central adverse effects.  These findings apply to male animals and must be confirmed in female animals.  Therefore, titrn. of systemic doses of opioid compds. with limited access to the brain might offer peripheral antinociception of clin. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovZ9vZSEuG87Vg90H21EOLACvtfcHk0lg5Y2qyhuT9Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2jt7fE&md5=280db8d78c6888984aa8195e5d6e1434</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.233551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.233551%26sid%3Dliteratum%253Aachs%26aulast%3DLacko%26aufirst%3DE.%26aulast%3DRiba%26aufirst%3DP.%26aulast%3DGiricz%26aufirst%3DZ.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DCornic%26aufirst%3DL.%26aulast%3DBalogh%26aufirst%3DM.%26aulast%3DKiraly%26aufirst%3DK.%26aulast%3DCsek%25C5%2591%26aufirst%3DK.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26aulast%3DHosztafi%26aufirst%3DS.%26aulast%3DSchafer%26aufirst%3DM.%26aulast%3DZadori%26aufirst%3DZ.%2BS.%26aulast%3DHelyes%26aufirst%3DZ.%26aulast%3DFerdinandy%26aufirst%3DP.%26aulast%3DFurst%26aufirst%3DS.%26aulast%3DAl-Khrasani%26aufirst%3DM.%26atitle%3DNew%2520morphine%2520analogs%2520produce%2520peripheral%2520antinociception%2520within%2520a%2520certain%2520dose%2520range%2520of%2520their%2520systemic%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D359%26spage%3D171%26epage%3D181%26doi%3D10.1124%2Fjpet.116.233551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khalefa, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaqura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khrasani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fürst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span> <span> </span><span class="NLM_article-title">Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids</span>. <i>Eur. J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1002/j.1532-2149.2011.00070.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1002%2Fj.1532-2149.2011.00070.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=22337491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVClurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=690-705&author=B.+I.+Khalefaauthor=M.+Shaquraauthor=M.+Al-Khrasaniauthor=S.+F%C3%BCrstauthor=S.+A.+Mousaauthor=M.+Sch%C3%A4fer&title=Relative+contributions+of+peripheral+versus+supraspinal+or+spinal+opioid+receptors+to+the+antinociception+of+systemic+opioids&doi=10.1002%2Fj.1532-2149.2011.00070.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids</span></div><div class="casAuthors">Khalefa, B. I.; Shaqura, M.; Al-Khrasani, M.; Fuerst, S.; Mousa, S. A.; Schaefer, M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pain (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">690-705</span>CODEN:
                <span class="NLM_cas:coden">EJPAFJ</span>;
        ISSN:<span class="NLM_cas:issn">1090-3801</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The contribution of supraspinal, spinal or peripheral mu-opioid receptors (MORs) to the overall antinociception of systemic centrally penetrating vs. peripherally restricted opioids has not been thoroughly investigated.  Therefore, we examd. paw pressure thresholds in Wistar rats with complete Freund's adjuvant hindpaw inflammation following different doses of intraplantar (i.pl.) as well as i.v. (i.v.) fentanyl (6.25-50 μg/kg), morphine (1-7.5 mg/kg) or loperamide (1-7.5 mg/kg).  Antagonism of the i.v. mu-opioid agonists by intracerebroventricular (i.c.v.), intrathecal (i.t.) or i.pl. naloxone-methiodide (NLXM) revealed the relative contributions of supraspinal, spinal and peripheral MOR to the overall antinociceptive effects.  In parallel, the MOR d. at these three levels of pain transmission was assessed by radioligand binding.  Antinociceptive effects of i.v. fentanyl and morphine, but not of the peripherally restricted loperamide were two- to threefold greater and longer lasting compared with their i.pl. administration.  I.c.v. but not i.pl.  NLXM significantly antagonized fentanyl's and morphine's antinociception by 70-80%, whereas i.t.  NLXM reduced it by 20-30%.  In contrast, antinociception of i.v. loperamide was abolished by i.pl. but not by i.c.v. or i.t.  NLXM. In parallel, a resp. 32- and sixfold higher MOR d. in supraspinal and spinal vs. peripheral sensory neurons was detected.  In conclusion, in comparison with supraspinal and spinal opioid receptors, peripheral opioid receptors do not significantly contribute to the antinociception of systemic fentanyl and morphine during inflammatory pain.  Antinociception of their i.v. administration was superior over both i.v and i.pl. loperamide, acting exclusively via peripheral MOR.  These findings may guide the future development of novel peripherally restricted opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRpcUA5UdgNbVg90H21EOLACvtfcHk0lg5Y2qyhuT9Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVClurw%253D&md5=5db72309db5880bd7322a44a23302ac9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fj.1532-2149.2011.00070.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1532-2149.2011.00070.x%26sid%3Dliteratum%253Aachs%26aulast%3DKhalefa%26aufirst%3DB.%2BI.%26aulast%3DShaqura%26aufirst%3DM.%26aulast%3DAl-Khrasani%26aufirst%3DM.%26aulast%3DF%25C3%25BCrst%26aufirst%3DS.%26aulast%3DMousa%26aufirst%3DS.%2BA.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26atitle%3DRelative%2520contributions%2520of%2520peripheral%2520versus%2520supraspinal%2520or%2520spinal%2520opioid%2520receptors%2520to%2520the%2520antinociception%2520of%2520systemic%2520opioids%26jtitle%3DEur.%2520J.%2520Pain%26date%3D2012%26volume%3D16%26spage%3D690%26epage%3D705%26doi%3D10.1002%2Fj.1532-2149.2011.00070.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonini, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artymyshyn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durkin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boteju, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakhlani, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raddatz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogozalek, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouranova, E. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysse, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetzel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branchek, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowsky, B.</span></span> <span> </span><span class="NLM_article-title">Identification and characterization of two G protein-coupled receptors for neuropeptide FF</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">39324</span>– <span class="NLM_lpage">39331</span>, <span class="refDoi"> DOI: 10.1074/jbc.m004385200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1074%2Fjbc.M004385200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=11024015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD3cXptFSrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=39324-39331&author=J.+A.+Boniniauthor=K.+A.+Jonesauthor=N.+Adhamauthor=C.+Forrayauthor=R.+Artymyshynauthor=M.+M.+Durkinauthor=K.+E.+Smithauthor=J.+A.+Tammauthor=L.+W.+Botejuauthor=P.+P.+Lakhlaniauthor=R.+Raddatzauthor=W.-J.+Yaoauthor=K.+L.+Ogozalekauthor=N.+Boyleauthor=E.+V.+Kouranovaauthor=Y.+Quanauthor=P.+J.+Vaysseauthor=J.+M.+Wetzelauthor=T.+A.+Branchekauthor=C.+Geraldauthor=B.+Borowsky&title=Identification+and+characterization+of+two+G+protein-coupled+receptors+for+neuropeptide+FF&doi=10.1074%2Fjbc.m004385200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and characterization of two G protein-coupled receptors for neuropeptide FF</span></div><div class="casAuthors">Bonini, James A.; Jones, Kenneth A.; Adham, Nika; Forray, Carlos; Artymyshyn, Roman; Durkin, Margaret M.; Smith, Kelli E.; Tamm, Joseph A.; Boteju, Lakmal W.; Lakhlani, Parul P.; Raddatz, Rita; Yao, Wen-Jeng; Ogozalek, Kristine L.; Boyle, Noel; Kouranova, Evguenia V.; Quan, Yong; Vaysse, Pierre J.; Wetzel, John M.; Branchek, Theresa A.; Gerald, Christophe; Borowsky, Beth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">39324-39331</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The central nervous system octapeptide, neuropeptide FF (NPFF),is believed to play a role in pain modulation and opiate tolerance.  Two G protein-coupled receptors, NPFF1 and NPFF2, were isolated from human and rat central nervous system tissues.  NPFF specifically bound to NPFF1 (Kd = 1.13 nM) and NPFF2 (Kd = 0.37 nM), and both receptors were activated by NPFF in a variety of heterologous expression systems.  The localization of mRNA and binding sites of these receptors in the dorsal horn of the spinal cord, the lateral hypothalamus, the spinal trigeminal nuclei, and the thalamic nuclei supports a role for NPFF in pain modulation.  Among the receptors with the highest amino acid sequence homol. to NPFF1 and NPFF2 are members of the orexin, NPY, and cholecystokinin families, which have been implicated in feeding.  These similarities together with the finding that BIBP3226, an anorexigenic Y1 receptor ligand, also binds to NPFF1 suggest a potential role for NPFF1 in feeding.  The identification of NPFF1 and NPFF2 will help delineate their roles in these and other physiol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgOaVTwhLRnbVg90H21EOLACvtfcHk0lhnglzJ4QLZFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXptFSrsLc%253D&md5=1cad618e8e4b53a1be848f2979ec7cc7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M004385200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M004385200%26sid%3Dliteratum%253Aachs%26aulast%3DBonini%26aufirst%3DJ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BA.%26aulast%3DAdham%26aufirst%3DN.%26aulast%3DForray%26aufirst%3DC.%26aulast%3DArtymyshyn%26aufirst%3DR.%26aulast%3DDurkin%26aufirst%3DM.%2BM.%26aulast%3DSmith%26aufirst%3DK.%2BE.%26aulast%3DTamm%26aufirst%3DJ.%2BA.%26aulast%3DBoteju%26aufirst%3DL.%2BW.%26aulast%3DLakhlani%26aufirst%3DP.%2BP.%26aulast%3DRaddatz%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DW.-J.%26aulast%3DOgozalek%26aufirst%3DK.%2BL.%26aulast%3DBoyle%26aufirst%3DN.%26aulast%3DKouranova%26aufirst%3DE.%2BV.%26aulast%3DQuan%26aufirst%3DY.%26aulast%3DVaysse%26aufirst%3DP.%2BJ.%26aulast%3DWetzel%26aufirst%3DJ.%2BM.%26aulast%3DBranchek%26aufirst%3DT.%2BA.%26aulast%3DGerald%26aufirst%3DC.%26aulast%3DBorowsky%26aufirst%3DB.%26atitle%3DIdentification%2520and%2520characterization%2520of%2520two%2520G%2520protein-coupled%2520receptors%2520for%2520neuropeptide%2520FF%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D39324%26epage%3D39331%26doi%3D10.1074%2Fjbc.m004385200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawfik, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sypek, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotoudeh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barres, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span> <span> </span><span class="NLM_article-title">Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1038/nm.4262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fnm.4262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=28092666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=164-173&author=G.+Corderauthor=V.+L.+Tawfikauthor=D.+Wangauthor=E.+I.+Sypekauthor=S.+A.+Lowauthor=J.+R.+Dickinsonauthor=C.+Sotoudehauthor=J.+D.+Clarkauthor=B.+A.+Barresauthor=C.+J.+Bohlenauthor=G.+Scherrer&title=Loss+of+%CE%BC+opioid+receptor+signaling+in+nociceptors%2C+but+not+microglia%2C+abrogates+morphine+tolerance+without+disrupting+analgesia&doi=10.1038%2Fnm.4262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia</span></div><div class="casAuthors">Corder, Gregory; Tawfik, Vivianne L.; Wang, Dong; Sypek, Elizabeth I.; Low, Sarah A.; Dickinson, Jasmine R.; Sotoudeh, Chaudy; Clark, J. David; Barres, Ben A.; Bohlen, Christopher J.; Scherrer, Gregory</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">164-173</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Opioid pain medications have detrimental side effects including analgesic tolerance and opioid-induced hyperalgesia (OIH).  Tolerance and OIH counteract opioid analgesia and drive dose escalation.  The cell types and receptors on which opioids act to initiate these maladaptive processes remain disputed, which has prevented the development of therapies to maximize and sustain opioid analgesic efficacy.  We found that μ opioid receptors (MORs) expressed by primary afferent nociceptors initiate tolerance and OIH development.  RNA sequencing and histol. anal. revealed that MORs are expressed by nociceptors, but not by spinal microglia.  Deletion of MORs specifically in nociceptors eliminated morphine tolerance, OIH and pronociceptive synaptic long-term potentiation without altering antinociception.  Furthermore, we found that co-administration of methylnaltrexone bromide, a peripherally restricted MOR antagonist, was sufficient to abrogate morphine tolerance and OIH without diminishing antinociception in perioperative and chronic pain models.  Collectively, our data support the idea that opioid agonists can be combined with peripheral MOR antagonists to limit analgesic tolerance and OIH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqkX7EcqLR_LVg90H21EOLACvtfcHk0lhnglzJ4QLZFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCls74%253D&md5=d65fbed56aa56dce619b2c6401ddc850</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnm.4262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4262%26sid%3Dliteratum%253Aachs%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DTawfik%26aufirst%3DV.%2BL.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DSypek%26aufirst%3DE.%2BI.%26aulast%3DLow%26aufirst%3DS.%2BA.%26aulast%3DDickinson%26aufirst%3DJ.%2BR.%26aulast%3DSotoudeh%26aufirst%3DC.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DBarres%26aufirst%3DB.%2BA.%26aulast%3DBohlen%26aufirst%3DC.%2BJ.%26aulast%3DScherrer%26aufirst%3DG.%26atitle%3DLoss%2520of%2520%25CE%25BC%2520opioid%2520receptor%2520signaling%2520in%2520nociceptors%252C%2520but%2520not%2520microglia%252C%2520abrogates%2520morphine%2520tolerance%2520without%2520disrupting%2520analgesia%26jtitle%3DNat.%2520Med.%26date%3D2017%26volume%3D23%26spage%3D164%26epage%3D173%26doi%3D10.1038%2Fnm.4262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-H.</span></span> <span> </span><span class="NLM_article-title">Selective blockade of spinal D2DR by levo-corydalmine attenuates morphine tolerance via suppressing PI3K/Akt-MAPK signaling in a MOR-dependent manner</span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1038/s12276-018-0175-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fs12276-018-0175-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30429454" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Snsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=1-12&author=W.-L.+Daiauthor=X.-T.+Liuauthor=Y.-N.+Baoauthor=B.+Yanauthor=N.+Jiangauthor=B.-Y.+Yuauthor=J.-H.+Liu&title=Selective+blockade+of+spinal+D2DR+by+levo-corydalmine+attenuates+morphine+tolerance+via+suppressing+PI3K%2FAkt-MAPK+signaling+in+a+MOR-dependent+manner&doi=10.1038%2Fs12276-018-0175-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of spinal D2DR by levo-corydalmine attenuates morphine tolerance via suppressing PI3K/Akt-MAPK signaling in a MOR-dependent manner</span></div><div class="casAuthors">Dai, Wen-Ling; Liu, Xin-Tong; Bao, Yi-Ni; Yan, Bing; Jiang, Nan; Yu, Bo-Yang; Liu, Ji-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Molecular Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">2092-6413</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Morphine tolerance remains a challenge in the management of chronic pain in the clinic.  As shown in our previous study, the dopamine D2 receptor (D2DR) expressed in spinal cord neurons might be involved in morphine tolerance, but the underlying mechanisms remain to be elucidated.  In the present study, selective spinal D2DR blockade attenuated morphine tolerance in mice by inhibiting phosphatidylinositol 3 kinase (PI3K)/serine-threonine kinase (Akt)-mitogen activated protein kinase (MAPK) signaling in a μ opioid receptor (MOR)-dependent manner.  Levo-corydalmine (l-CDL), which exhibited micromolar affinity for D2DR in D2/CHO-K1 cell lines in this report and effectively alleviated bone cancer pain in our previous study, attenuated morphine tolerance in rats with chronic bone cancer pain at nonanalgesic doses.  Furthermore, the intrathecal administration of l-CDL obviously attenuated morphine tolerance, and the effect was reversed by a D2DR agonist in mice.  Spinal D2DR inhibition and l-CDL also inhibited tolerance induced by the MOR agonist DAMGO.  L-CDLand a D2DR small interfering RNA (siRNA) decreased the increase in levels of phosphorylated Akt and MAPK in the spinal cord; these changes were abolished by a PI3K inhibitor.  In addn., the activated Akt and MAPK proteins in mice exhibiting morphine tolerance were inhibited by a MOR antagonist.  Intrathecal administration of a PI3K inhibitor also attenuated DAMGO-induced tolerance.  Based on these results, l-CDL antagonized spinal D2DR to attenuate morphine tolerance by inhibiting PI3K/Akt-dependent MAPK phosphorylation through MOR.  These findings provide insights into a more versatile treatment for morphine tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7UeLw7xq8MLVg90H21EOLACvtfcHk0lhnglzJ4QLZFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Snsb%252FL&md5=5824ed7d69443034743d2fdcf6e6bd09</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fs12276-018-0175-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs12276-018-0175-1%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DW.-L.%26aulast%3DLiu%26aufirst%3DX.-T.%26aulast%3DBao%26aufirst%3DY.-N.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DB.-Y.%26aulast%3DLiu%26aufirst%3DJ.-H.%26atitle%3DSelective%2520blockade%2520of%2520spinal%2520D2DR%2520by%2520levo-corydalmine%2520attenuates%2520morphine%2520tolerance%2520via%2520suppressing%2520PI3K%252FAkt-MAPK%2520signaling%2520in%2520a%2520MOR-dependent%2520manner%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2018%26volume%3D50%26spage%3D1%26epage%3D12%26doi%3D10.1038%2Fs12276-018-0175-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, R.-x.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-x.</span></span> <span> </span><span class="NLM_article-title">NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.neulet.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19818835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlyltr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2009&pages=95-99&author=R.-x.+Guoauthor=M.+Zhangauthor=W.+Liuauthor=C.-m.+Zhaoauthor=Y.+Cuiauthor=C.-h.+Wangauthor=J.-q.+Fengauthor=P.-x.+Chen&title=NMDA+receptors+are+involved+in+upstream+of+the+spinal+JNK+activation+in+morphine+antinociceptive+tolerance&doi=10.1016%2Fj.neulet.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance</span></div><div class="casAuthors">Guo, Rui-Xian; Zhang, Mei; Liu, Wei; Zhao, Chun-Mei; Cui, Yu; Wang, Chu-Huai; Feng, Jian-Qiang; Chen, Pei-Xi</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-99</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">N-methyl-D-aspartate (NMDA) receptors and c-Jun N-terminal kinase (JNK) have been shown to be involved in morphine antinociceptive tolerance.  However, whether chronic morphine-induced activation of the spinal JNK is NMDA receptor-dependent is unknown.  The present study investigated the link between the spinal NMDA receptor NR2B subunit and the JNK activation during morphine antinociceptive tolerance in rats.  Our results showed that chronic morphine treatment induced upregulation of the NR2B expression and activation of JNK in the spinal cord.  Moreover, the increased NR2B-immunoreactivity (IR) and phosphorylated JNK-IR were obsd. mainly at the superficial dorsal horn laminae of the spinal cord; the spinal p-JNK was mainly expressed in astrocytes and NR2B in neurons.  SP600125, a selective inhibitor of JNK, significantly attenuated morphine tolerance.  MK-801, a noncompetitive NMDA receptor antagonist, not only suppressed morphine antinociceptive tolerance and the increase in NR2B, but also reduced the spinal JNK activation induced by chronic morphine treatment.  These findings demonstrated for the first time that NMDA receptor-dependent activation of the spinal JNK contributes to morphine antinociceptive tolerance and that MK-801 attenuates morphine tolerance partly due to its inhibition on the spinal JNK activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-l5kyzb1qprVg90H21EOLACvtfcHk0lgQWurc4zbcfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlyltr%252FJ&md5=9dbc322620f749f78e098a547051b68e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DR.-x.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DC.-m.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.-h.%26aulast%3DFeng%26aufirst%3DJ.-q.%26aulast%3DChen%26aufirst%3DP.-x.%26atitle%3DNMDA%2520receptors%2520are%2520involved%2520in%2520upstream%2520of%2520the%2520spinal%2520JNK%2520activation%2520in%2520morphine%2520antinociceptive%2520tolerance%26jtitle%3DNeurosci.%2520Lett.%26date%3D2009%26volume%3D467%26spage%3D95%26epage%3D99%26doi%3D10.1016%2Fj.neulet.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Healy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezawada, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coop, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Modeling, and Pharmacological Evaluation of UMB 425, a Mixed μ Agonist/δ Antagonist Opioid Analgesic with Reduced Tolerance Liabilities</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1256</span>– <span class="NLM_lpage">1266</span>, <span class="refDoi"> DOI: 10.1021/cn4000428</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn4000428" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1Sqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=1256-1266&author=J.+R.+Healyauthor=P.+Bezawadaauthor=J.+Shimauthor=J.+W.+Jonesauthor=M.+A.+Kaneauthor=A.+D.+MacKerellauthor=A.+Coopauthor=R.+R.+Matsumoto&title=Synthesis%2C+Modeling%2C+and+Pharmacological+Evaluation+of+UMB+425%2C+a+Mixed+%CE%BC+Agonist%2F%CE%B4+Antagonist+Opioid+Analgesic+with+Reduced+Tolerance+Liabilities&doi=10.1021%2Fcn4000428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Modeling, and Pharmacological Evaluation of UMB 425, a Mixed μ Agonist/δ Antagonist Opioid Analgesic with Reduced Tolerance Liabilities</span></div><div class="casAuthors">Healy, Jason R.; Bezawada, Padmavani; Shim, Jihyun; Jones, Jace W.; Kane, Maureen A.; MacKerell, Alexander D.; Coop, Andrew; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1256-1266</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Opioid narcotics are used for the treatment of moderate-to-severe pain and primarily exert their analgesic effects through μ receptors.  Although traditional μ agonists can cause undesired side effects, including tolerance, addn. of δ antagonists can attenuate said side effects.  Herein, the authors report 4a,9-dihydroxy-7a-(hydroxymethyl)-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one (UMB 425) a 5,14-bridged morphinan-based orvinol precursor synthesized from thebaine.  Although UMB 425 lacks δ-specific motifs, conformationally sampled pharmacophore models for μ and δ receptors predict it to have efficacy similar to morphine at μ receptors and similar to naltrexone at δ receptors, due to the compd. sampling conformations in which the hydroxyl moiety interacts with the receptors similar to orvinols.  As predicted, UMB 425 exhibits a mixed μ agonist/δ antagonist profile as detd. in receptor binding and [35S]GTPγS functional assays in CHO cells.  In vivo studies in mice show that UMB 425 displays potent antinociception in the hot plate and tail-flick assays.  The antinociceptive effects of UMB 425 are blocked by naloxone, but not by the κ-selective antagonist norbinaltorphimine.  During a 6-day tolerance paradigm, UMB 425 maintains significantly greater antinociception compared to morphine.  These studies thus indicate that, even in the absence of δ-specific motifs fused to the C-ring, UMB 425 has mixed μ agonist/δ antagonist properties in vitro that translate to reduced tolerance liabilities in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6OgV4pm0lbVg90H21EOLACvtfcHk0lgQWurc4zbcfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1Sqtbk%253D&md5=6949bbfec033537662cfa64b7d281df5</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fcn4000428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn4000428%26sid%3Dliteratum%253Aachs%26aulast%3DHealy%26aufirst%3DJ.%2BR.%26aulast%3DBezawada%26aufirst%3DP.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%2BW.%26aulast%3DKane%26aufirst%3DM.%2BA.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DCoop%26aufirst%3DA.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSynthesis%252C%2520Modeling%252C%2520and%2520Pharmacological%2520Evaluation%2520of%2520UMB%2520425%252C%2520a%2520Mixed%2520%25CE%25BC%2520Agonist%252F%25CE%25B4%2520Antagonist%2520Opioid%2520Analgesic%2520with%2520Reduced%2520Tolerance%2520Liabilities%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2013%26volume%3D4%26spage%3D1256%26epage%3D1266%26doi%3D10.1021%2Fcn4000428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Moreno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Espinosa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">León-Olea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz, S. L.</span></span> <span> </span><span class="NLM_article-title">Synergistic antinociceptive actions and tolerance development produced by morphine-fentanyl coadministration: Correlation with μ-opioid receptor internalization</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>674</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.10.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ejphar.2011.10.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=22079772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1KisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=674&publication_year=2012&pages=239-247&author=A.+Silva-Morenoauthor=C.+Gonzalez-Espinosaauthor=M.+Le%C3%B3n-Oleaauthor=S.+L.+Cruz&title=Synergistic+antinociceptive+actions+and+tolerance+development+produced+by+morphine-fentanyl+coadministration%3A+Correlation+with+%CE%BC-opioid+receptor+internalization&doi=10.1016%2Fj.ejphar.2011.10.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic antinociceptive actions and tolerance development produced by morphine-fentanyl coadministration: Correlation with μ-opioid receptor internalization</span></div><div class="casAuthors">Silva-Moreno, Arturo; Gonzalez-Espinosa, Claudia; Leon-Olea, Martha; Cruz, Silvia L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">674</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">239-247</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It was described that coadministration of opioids with low doses of other analgesics can reduce adverse effects and increase antinociception, but combinations of 2 μ-opioid receptor agonists were poorly explored.  The objective of this work was 3-fold: (1) to evaluate the antinociceptive combination of i.c.v. morphine and fentanyl at different doses; (2) to compare the antinociception produced by acute or repeated administration of an effective morphine dose (1 μg) alone, or combined with a low fentanyl dose (1 ng); and (3) to correlate these effects with μ-opioid receptor internalization in periaqueductal gray matter and locus coeruleus.  Antinociception was evaluated by the tail-flick test and receptor internalization was analyzed by confocal microscopy in Wistar rats.  Drug interactions were examd. by administering combinations of opioids in 1:3, 1:1, and 3:1 ratios of their resp. ED50 fractions.  For tolerance and internalization studies, animals were i.c.v. injected only once (acute treatment) or twice a day until 5 administrations were completed.  Our results show that morphine and fentanyl have synergistic effects.  The combination of 1 ng fentanyl with 1 μg morphine increases the magnitude and duration of antinociception not only after a single injection, but also after 5 administrations when tolerance develops to morphine alone.  Increased and long-lasting antinociception correlates pos. with increased β-arrestin 2 activity and μ-opioid receptor internalization in periaqueductal gray matter and locus coeruleus.  These results suggest that combined administration of morphine and fentanyl increases long-lasting antinociception and β-arrestin 2 signaling contributes to the combination effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8DcrSowlozrVg90H21EOLACvtfcHk0lgQWurc4zbcfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1KisQ%253D%253D&md5=ba207836ad00734f1b5488b8d26bb0ed</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.10.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.10.034%26sid%3Dliteratum%253Aachs%26aulast%3DSilva-Moreno%26aufirst%3DA.%26aulast%3DGonzalez-Espinosa%26aufirst%3DC.%26aulast%3DLe%25C3%25B3n-Olea%26aufirst%3DM.%26aulast%3DCruz%26aufirst%3DS.%2BL.%26atitle%3DSynergistic%2520antinociceptive%2520actions%2520and%2520tolerance%2520development%2520produced%2520by%2520morphine-fentanyl%2520coadministration%253A%2520Correlation%2520with%2520%25CE%25BC-opioid%2520receptor%2520internalization%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D674%26spage%3D239%26epage%3D247%26doi%3D10.1016%2Fj.ejphar.2011.10.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, F. L.</span></span> <span> </span><span class="NLM_article-title">Characterization of neonatal rat fentanyl tolerance and dependence</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">521</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=9103539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK2sXislWnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1997&pages=514-521&author=S.+R.+Thorntonauthor=F.+L.+Smith&title=Characterization+of+neonatal+rat+fentanyl+tolerance+and+dependence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of neonatal rat fentanyl tolerance and dependence</span></div><div class="casAuthors">Thornton, Suzanne R.; Smith, Forrest L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">514-521</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Fentanyl and morphine are administered to human neonates and infants to provide analgesia and sedation during painful and stressful procedures.  These opioids have often been shown to produce tolerance and dependence during continuous i.v. infusion.  In neonatal animals, morphine produces tolerance and dependence, yet little is known about fentanyl.  This report describes the first model for studying opioid tolerance and dependence in neonatal animals with use of osmotic minipumps.  Postnatal day 6 rat pups were anesthetized and then remained naive or were surgically implanted s.c. with Alzet osmotic minipumps contg. either saline or fentanyl (100 μg/kg/h).  Tolerance and dependence were assessed 72 h after implantation.  The ED50 values for fentanyl antinociception in the tail-flick test were not different between naive and saline pump-implanted animals.  However, the fentanyl pump-implanted animals were tolerant to fentanyl.  The tolerance obsd. was not the result of gender, developmental changes, fentanyl distribution or changes in fentanyl metab.  These results indicate that continuous administration of fentanyl via osmotic minipump can render normal neonatal rats tolerant and phys. dependent on fentanyl in 72 h.  Withdrawal pptd. by naloxone (5 mg/kg s.c.) in the fentanyl pump-implanted animals was characterized by increased spontaneous activity, micturition/defecation, wall climbing, abdominal stretching, tremors, scream on touch and spontaneous vocalization.  This new model may provide a tool for studying the long-term consequences of neonatal opioid exposure in juvenile and adult animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-AJIIX3-8LVg90H21EOLACvtfcHk0lhOjkVRWVdFgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXislWnsr8%253D&md5=4ea61a41bcfd203614766abb22653802</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThornton%26aufirst%3DS.%2BR.%26aulast%3DSmith%26aufirst%3DF.%2BL.%26atitle%3DCharacterization%2520of%2520neonatal%2520rat%2520fentanyl%2520tolerance%2520and%2520dependence%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D281%26spage%3D514%26epage%3D521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitanaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhl, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, M.</span></span> <span> </span><span class="NLM_article-title">Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2018.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.pbb.2018.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=30017858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGlu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2018&pages=9-16&author=N.+Kitanakaauthor=J.+Kitanakaauthor=F.+S.+Hallauthor=T.+Kandoriauthor=A.+Murakamiauthor=K.+Murataniauthor=T.+Nakanoauthor=G.+R.+Uhlauthor=M.+Takemura&title=Tetrabenazine%2C+a+vesicular+monoamine+transporter-2+inhibitor%2C+attenuates+morphine-induced+hyperlocomotion+in+mice+through+alteration+of+dopamine+and+5-hydroxytryptamine+turnover+in+the+cerebral+cortex&doi=10.1016%2Fj.pbb.2018.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex</span></div><div class="casAuthors">Kitanaka, Nobue; Kitanaka, Junichi; Hall, F. Scott; Kandori, Takashi; Murakami, Ayaka; Muratani, Kazuki; Nakano, Tae; Uhl, George R.; Takemura, Motohiko</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-16</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A single administration with morphine (30 mg/kg, i.p.) induced long-lasting hyperlocomotion in male ICR mice.  Pretreatment of mice with a benzoquinolizine deriv. tetrabenazine (TBZ; a reversible vesicular monoamine transporter-2 inhibitor) (1 mg/kg, i.p.) for 30 min significantly attenuated the hyperlocomotion induced by morphine, as compared with vehicle (saline)-pretreated mice.  No significant change in locomotion was obsd. in mice pretreated with TBZ (1 mg/kg) alone.  Mice treated with TBZ (1 mg/kg) showed an increase in immobility time in a tail suspension test, as compared with saline-treated mice.  Pretreatment with TBZ (1 mg/kg) had no effect on morphine (1-30 mg/kg)-induced antinociception.  TBZ at a dose of 1 mg/kg inhibited dopamine turnover (the ratio of 3,4-dihydroxyphenylacetic acid/dopamine) and 5-hydroxytryptamine turnover (the ratio of 5-hydroxyindoleacetic acid/5-hydroxytryptamine) in the cerebral cortex of mice challenged with morphine, as compared with saline-pretreated mice challenged with morphine.  No stereotypic behavior was obsd. in mice treated with morphine (30 mg/kg) in combination with TBZ (1 mg/kg), so the redn. in obsd. locomotion did not result from induction of stereotypical behavior.  Moreover, TBZ (1 and 2 mg/kg) pretreatment had no effect on stereotyped behaviors obsd. in mice challenged with 10 mg/kg methamphetamine.  These data support the potential antagonistic actions of TBZ on some opiate actions, and encourage further exploration of potential effects on morphine reinforcement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrShbDPlcN6dbVg90H21EOLACvtfcHk0lhOjkVRWVdFgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGlu7rN&md5=ffecdee9a12fe72ab2ab5e9a5520328b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2018.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2018.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DKitanaka%26aufirst%3DN.%26aulast%3DKitanaka%26aufirst%3DJ.%26aulast%3DHall%26aufirst%3DF.%2BS.%26aulast%3DKandori%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DA.%26aulast%3DMuratani%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DUhl%26aufirst%3DG.%2BR.%26aulast%3DTakemura%26aufirst%3DM.%26atitle%3DTetrabenazine%252C%2520a%2520vesicular%2520monoamine%2520transporter-2%2520inhibitor%252C%2520attenuates%2520morphine-induced%2520hyperlocomotion%2520in%2520mice%2520through%2520alteration%2520of%2520dopamine%2520and%25205-hydroxytryptamine%2520turnover%2520in%2520the%2520cerebral%2520cortex%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2018%26volume%3D172%26spage%3D9%26epage%3D16%26doi%3D10.1016%2Fj.pbb.2018.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culbertson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanselow, M. S.</span></span> <span> </span><span class="NLM_article-title">Pavlovian conditioning of multiple opioid-like responses in mice</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.drugalcdep.2009.03.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.drugalcdep.2009.03.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19419821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKksLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2009&pages=74-83&author=C.+D.+Bryantauthor=K.+W.+Robertsauthor=C.+S.+Culbertsonauthor=A.+Leauthor=C.+J.+Evansauthor=M.+S.+Fanselow&title=Pavlovian+conditioning+of+multiple+opioid-like+responses+in+mice&doi=10.1016%2Fj.drugalcdep.2009.03.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pavlovian conditioning of multiple opioid-like responses in mice</span></div><div class="casAuthors">Bryant, Camron D.; Roberts, Kristofer W.; Culbertson, Christopher S.; Le, Alan; Evans, Christopher J.; Fanselow, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">74-83</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Conditional responses in rodents such as locomotion have been reported for drugs of abuse and similar to the placebo response in humans, may be assocd. with the expectation of reward.  We examd. several conditional opioid-like responses and the influence of drug expectation on conditioned place preference and concomitant conditional locomotion.  Male C57BL/6J mice were conditioned with the selective mu opioid receptor agonist fentanyl (0.2 mg/kg, i.p.) in a novel context and subsequently given a vehicle injection.  In sep. expts., locomotor activity, Straub tail, hot plate sensitivity, and conditioned place preference (CPP) were measured.  Mice exhibited multiple conditional opioid-like responses including conditional hyperlocomotion, a conditional pattern of opioid-like locomotion, Straub tail, analgesia, and place preference.  Modulating drug expectation via administration of fentanyl to "demonstrator" mice in the home cage did not affect the expression of conditioned place preference or the concomitant locomotor activity in "observer" mice.  In summary, Pavlovian conditioning of an opioid in a novel context induced multiple conditional opioid-like behaviors and provides a model for studying the neurobiol. mechanisms of the placebo response in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSqmCtFwbgdLVg90H21EOLACvtfcHk0lhOjkVRWVdFgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKksLc%253D&md5=b1c4d278907f5ecbc75bb79a98458832</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2009.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2009.03.016%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DC.%2BD.%26aulast%3DRoberts%26aufirst%3DK.%2BW.%26aulast%3DCulbertson%26aufirst%3DC.%2BS.%26aulast%3DLe%26aufirst%3DA.%26aulast%3DEvans%26aufirst%3DC.%2BJ.%26aulast%3DFanselow%26aufirst%3DM.%2BS.%26atitle%3DPavlovian%2520conditioning%2520of%2520multiple%2520opioid-like%2520responses%2520in%2520mice%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2009%26volume%3D103%26spage%3D74%26epage%3D83%26doi%3D10.1016%2Fj.drugalcdep.2009.03.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakubovic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fibiger, H. C.</span></span> <span> </span><span class="NLM_article-title">Fentanyl-induced conditional place preference: lack of associated conditional neurochemical events</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1007/bf02180036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1007%2FBF02180036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=3149777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaL1MXjtlKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1988&pages=534-540&author=J.+M.+Finlayauthor=A.+Jakubovicauthor=A.+G.+Phillipsauthor=H.+C.+Fibiger&title=Fentanyl-induced+conditional+place+preference%3A+lack+of+associated+conditional+neurochemical+events&doi=10.1007%2Fbf02180036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Fentanyl-induced conditional place preference:  lack of associated conditional neurochemical events</span></div><div class="casAuthors">Finlay, J. M.; Jakubovic, A.; Phillips, A. G.; Fibiger, H. C.</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">534-40</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">The unconditional effects of fentanyl (0.04 mg/kg, s.c.) were characterized on neurochem. indexes of dopaminergic activity in rats.  Both acute and repeated fentanyl injections (5 injections administered at 48-h intervals) increased the concns. of the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) within the striatum (STR), nucleus accumbens (NAS), and olfactory tubercle (OT).  Acute injections elicited a greater increase in metabolite concns. in the NAS than in the STR, suggesting that there are regional differences in the sensitivity of dopaminergic neurons to fentanyl.  In expts. 2 and 3, fentanyl (5 injections; 0.04 mg/kg, s.c.) was paired with environmental stimuli using a place-preference conditioning paradigm.  The fentanyl-paired stimuli failed to elicit conditional changes in DOPAC or HVA concns. within the STR, NAS, or OT even though rats exhibited a preference for the drug-paired compartment of the shuttle box.  Thus, the secondary reinforcing effects of stimuli previously paired with fentanyl may not reflect the ability of these stimuli to elicit measurable changes in the activity of mesolimbic or nigrostriatal dopaminergic neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY_nu9bsqZjbVg90H21EOLACvtfcHk0lj4Vw6As453HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXjtlKrtA%253D%253D&md5=37596b0caef77cb1da57e7afc2165b2f</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2FBF02180036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02180036%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DJ.%2BM.%26aulast%3DJakubovic%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DA.%2BG.%26aulast%3DFibiger%26aufirst%3DH.%2BC.%26atitle%3DFentanyl-induced%2520conditional%2520place%2520preference%253A%2520lack%2520of%2520associated%2520conditional%2520neurochemical%2520events%26jtitle%3DPsychopharmacology%26date%3D1988%26volume%3D96%26spage%3D534%26epage%3D540%26doi%3D10.1007%2Fbf02180036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruijnzeel, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajpai, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morey, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M.</span></span> <span> </span><span class="NLM_article-title">Severe deficit in brain reward function associated with fentanyl withdrawal in rats</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2005.07.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.biopsych.2005.07.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=16169528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvVehu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=477-480&author=A.+W.+Bruijnzeelauthor=B.+Lewisauthor=L.+K.+Bajpaiauthor=T.+E.+Moreyauthor=D.+M.+Dennisauthor=M.+Gold&title=Severe+deficit+in+brain+reward+function+associated+with+fentanyl+withdrawal+in+rats&doi=10.1016%2Fj.biopsych.2005.07.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Severe Deficit in Brain Reward Function Associated with Fentanyl Withdrawal in Rats</span></div><div class="casAuthors">Bruijnzeel, Adrie W.; Lewis, Ben; Bajpai, Lakshmi K.; Morey, Timothy E.; Dennis, Donn M.; Gold, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">477-480</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: During the last decade, there has been a strong increase in the use of the mu-opioid receptor agonist fentanyl.  The aim of these studies was to investigate the effects of fentanyl withdrawal on brain reward function and somatic withdrawal signs.  Methods: Fentanyl and saline were chronically administered via minipumps.  An intracranial self-stimulation procedure was used to provide a measure of brain reward function.  Somatic signs were recorded from a checklist of opioid abstinence signs.  Results: The opioid receptor antagonist naloxone induced a dose-dependent elevation in brain reward thresholds and somatic withdrawal signs in fentanyl-treated rats.  Discontinuation of fentanyl administration resulted in a time-dependent elevation of brain reward thresholds and somatic withdrawal signs.  Conclusions: These findings indicate that fentanyl withdrawal is assocd. with affective and somatic withdrawal signs.  The severity of the deficit in brain reward function in this animal model suggests that affective fentanyl withdrawal symptoms may be a strong deterrent to abstinence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN_1ODBEITebVg90H21EOLACvtfcHk0lj4Vw6As453HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvVehu7g%253D&md5=dd93f42ba48b04209cc3a051b681f755</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2005.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2005.07.020%26sid%3Dliteratum%253Aachs%26aulast%3DBruijnzeel%26aufirst%3DA.%2BW.%26aulast%3DLewis%26aufirst%3DB.%26aulast%3DBajpai%26aufirst%3DL.%2BK.%26aulast%3DMorey%26aufirst%3DT.%2BE.%26aulast%3DDennis%26aufirst%3DD.%2BM.%26aulast%3DGold%26aufirst%3DM.%26atitle%3DSevere%2520deficit%2520in%2520brain%2520reward%2520function%2520associated%2520with%2520fentanyl%2520withdrawal%2520in%2520rats%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D477%26epage%3D480%26doi%3D10.1016%2Fj.biopsych.2005.07.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gazal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gellerman, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of novel protected Nα (ω-thioalkyl) amino acid building units and their incorporation in backbone cyclic disulfide and thioetheric bridged peptides</span>. <i>J. Pept. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1034/j.1399-3011.2001.00936.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1034%2Fj.1399-3011.2001.00936.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=12005422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVentrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2001&pages=527-539&author=S.+Gazalauthor=E.+Glukhovauthor=C.+Gilonauthor=G.+Gellerman&title=Synthesis+of+novel+protected+N%CE%B1+%28%CF%89-thioalkyl%29+amino+acid+building+units+and+their+incorporation+in+backbone+cyclic+disulfide+and+thioetheric+bridged+peptides&doi=10.1034%2Fj.1399-3011.2001.00936.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of novel protected Nα(ω-thioalkyl) amino acid building units and their incorporation in backbone cyclic disulfide and thioetheric bridged peptides</span></div><div class="casAuthors">Gazal, S.; Gellerman, G.; Glukhov, E.; Gilon, C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">527-539</span>CODEN:
                <span class="NLM_cas:coden">JPERFA</span>;
        ISSN:<span class="NLM_cas:issn">1397-002X</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">General methods for the prepn. of protected Nα(ω-thioalkyl) amino acids building units for backbone cyclization using reductive alkylation and on-resin prepn. are described.  The synthesis of non-Gly Fmoc-protected S-functionalized N-alkylated amino acids is based on the reaction of readily prepd. protected ω-thio aldehyde with the appropriate amino acid.  Prepn. of Fmoc-protected S-functionalized N-alkylated Gly building units was carried out using two methods: reaction of glyoxylic acid with Acm-thioalkylamine and an on-resin reaction of bromoacetyl resin with Trt-thioalkylamines.  Three model peptides were prepd. using these building units.  The GlyS2 building unit was incorporated into a backbone cyclic analog of somatostatin that contains a disulfide bridge.  Formation of the disulfide bridge was performed by on-resin oxidn. using I2 or TI(CF3COO-)3.  Both methods resulted in the desired product in a high degree of purity in the crude.  The AspS3 building unit was also successfully incorporated into a model peptide.  In addn., the in situ generation of sulfur contg. Gly building units was demonstrated on a Substance P backbone cyclic analog contg. a thioether bridge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8BYlx2DhlZ7Vg90H21EOLACvtfcHk0lj4Vw6As453HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVentrs%253D&md5=deb33953af8d60438a9a14b9e8f47e85</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1034%2Fj.1399-3011.2001.00936.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1034%252Fj.1399-3011.2001.00936.x%26sid%3Dliteratum%253Aachs%26aulast%3DGazal%26aufirst%3DS.%26aulast%3DGlukhov%26aufirst%3DE.%26aulast%3DGilon%26aufirst%3DC.%26aulast%3DGellerman%26aufirst%3DG.%26atitle%3DSynthesis%2520of%2520novel%2520protected%2520N%25CE%25B1%2520%2528%25CF%2589-thioalkyl%2529%2520amino%2520acid%2520building%2520units%2520and%2520their%2520incorporation%2520in%2520backbone%2520cyclic%2520disulfide%2520and%2520thioetheric%2520bridged%2520peptides%26jtitle%3DJ.%2520Pept.%2520Res.%26date%3D2001%26volume%3D58%26spage%3D527%26epage%3D539%26doi%3D10.1034%2Fj.1399-3011.2001.00936.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span> <span> </span><span class="NLM_article-title">The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>476</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2014.08.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2Fj.ijpharm.2014.08.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=25245547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Shsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=476&publication_year=2014&pages=1-8&author=H.+Liuauthor=W.+Zhangauthor=L.+Maauthor=L.+Fanauthor=F.+Gaoauthor=J.+Niauthor=R.+Wang&title=The+improved+blood-brain+barrier+permeability+of+endomorphin-1+using+the+cell-penetrating+peptide+synB3+with+three+different+linkages&doi=10.1016%2Fj.ijpharm.2014.08.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages</span></div><div class="casAuthors">Liu, Hui; Zhang, Wei; Ma, Linnan; Fan, Linlan; Gao, Feiyun; Ni, Jingman; Wang, Rui</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">476</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Endomorphins, although they have high analgesic activity and few undesirable side effects, are not in clin. use because of the blood-brain barrier (BBB).  One promising soln. is to use cell-penetrating peptides (CPPs).  CPPs have the ability to translocate cell membranes and have been successfully applied for delivery of therapeutic mols. across the BBB.  However, little is known about the transport efficiency of different conjugation strategies between cargo and CPPs.  In this study, endomorphin-1 (EM-1) was conjugated with SynB3, an efficient CPP-carrier, via amide, maleimide and disulfide linkages.  The delivery efficiency of three linkers was compared in terms of pharmacodynamics and in vitro metabolic stability.  Near-IR fluorescent and fluorescent microscopy expts. were applied to detect the brain uptake and distribution of CPP delivery qual. and quant.  After the most successful linkage was screened out, the further mechanisms were discussed.  We concluded that compared with the other two linkages, the disulfide bond was the most efficient linkage to deliver EM-1 across the BBB and confirmed that it could be reduced at physiol. conditions in the brain and release its active form.  These findings indicate that for those who need to release a free drug in the brain and maintain activity, a disulfide bond might be the most efficient linkage across the BBB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd-m2iE0KhOLVg90H21EOLACvtfcHk0liiLwKvomkkkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Shsb3F&md5=48e7b5d5fbec399015bc56d0059a6cc0</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2014.08.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2014.08.045%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DR.%26atitle%3DThe%2520improved%2520blood-brain%2520barrier%2520permeability%2520of%2520endomorphin-1%2520using%2520the%2520cell-penetrating%2520peptide%2520synB3%2520with%2520three%2520different%2520linkages%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2014%26volume%3D476%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.ijpharm.2014.08.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egleton, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruscato, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechowski, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruby, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, T. P.</span></span> <span> </span><span class="NLM_article-title">The effect of halogenation on blood-brain barrier permeability of a novel peptide drug</span>. <i>Peptides</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1229</span>– <span class="NLM_lpage">1238</span>, <span class="refDoi"> DOI: 10.1016/s0196-9781(99)00127-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1016%2FS0196-9781%2899%2900127-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10573295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADyaK1MXntVCnsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=1229-1238&author=C.+L.+Gentryauthor=R.+D.+Egletonauthor=T.+Gillespieauthor=T.+J.+Abbruscatoauthor=H.+B.+Bechowskiauthor=V.+J.+Hrubyauthor=T.+P.+Davis&title=The+effect+of+halogenation+on+blood-brain+barrier+permeability+of+a+novel+peptide+drug&doi=10.1016%2Fs0196-9781%2899%2900127-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of halogenation on blood-brain barrier permeability of a novel peptide drug</span></div><div class="casAuthors">Gentry, C. L.; Egleton, R. D.; Gillespie, T.; Abbruscato, T. J.; Bechowski, H. B.; Hruby, V. J.; Davis, T. P.</div><div class="citationInfo"><span class="NLM_cas:title">Peptides (New York)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1229-1238</span>CODEN:
                <span class="NLM_cas:coden">PPTDD5</span>;
        ISSN:<span class="NLM_cas:issn">0196-9781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The utility of a drug depends on its ability to reach appropriate receptors at the target tissue and remain metabolically stable to produce the desired effect.  To improve central nervous system entry of the opioid analgesic [d-Pen2, l-Pen5, Phe6]Enkephalin (DPLEPe-Phe), our research group synthesized analogs that had chloro, brome, fluoro, and iodo halogens on the para positions of the phenylalanine-4 residue.  This study reports on investigation of the effect of halogenation on stability , lipophilicity, an in vitro blood-brain barrier permeability of a novel enkephalin analog DPLPE-Phe.  The stability of each halogenated DPLPE-Phe analog as well as the amidated and nonamidated parent peptide was tested in plasma and brain.  All peptides tested had a half-time disappearance >300 min except for DPLPE-Phe-NH2, which was found to have a half-life of 30 min in plasma.  Octanol/saline distribution studies indicated addn. of halogens to DPLPE-Phe-OH significantly increased lipophilicity except for p-[F-Phe4]DPLPE-Phe-OH.  P-[Cl-Phe4]DPLPE-Phe-OH exhibited the most pronounced increase in lipophilicity.  Para-bromo and para-chloro halogen addns. significantly enhanced in vitro blood-brain barrier permeability, providing evidence for improved delivery to the central nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3ejPXyxyHkrVg90H21EOLACvtfcHk0liiLwKvomkkkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVCnsrg%253D&md5=5c78027002239f8700bb4c52d27ce33c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS0196-9781%2899%2900127-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0196-9781%252899%252900127-8%26sid%3Dliteratum%253Aachs%26aulast%3DGentry%26aufirst%3DC.%2BL.%26aulast%3DEgleton%26aufirst%3DR.%2BD.%26aulast%3DGillespie%26aufirst%3DT.%26aulast%3DAbbruscato%26aufirst%3DT.%2BJ.%26aulast%3DBechowski%26aufirst%3DH.%2BB.%26aulast%3DHruby%26aufirst%3DV.%2BJ.%26aulast%3DDavis%26aufirst%3DT.%2BP.%26atitle%3DThe%2520effect%2520of%2520halogenation%2520on%2520blood-brain%2520barrier%2520permeability%2520of%2520a%2520novel%2520peptide%2520drug%26jtitle%3DPeptides%26date%3D1999%26volume%3D20%26spage%3D1229%26epage%3D1238%26doi%3D10.1016%2Fs0196-9781%2899%2900127-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aryal, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dengler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corder, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguère, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löber, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Duan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherrer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobilka, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of opioid analgesics with reduced side effects</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1038/nature19112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1038%2Fnature19112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=27533032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=185-190&author=A.+Manglikauthor=H.+Linauthor=D.+K.+Aryalauthor=J.+D.+McCorvyauthor=D.+Denglerauthor=G.+Corderauthor=A.+Levitauthor=R.+C.+Klingauthor=V.+Bernatauthor=H.+H%C3%BCbnerauthor=X.-P.+Huangauthor=M.+F.+Sassanoauthor=P.+M.+Gigu%C3%A8reauthor=S.+L%C3%B6berauthor=D.+Da+Duanauthor=G.+Scherrerauthor=B.+K.+Kobilkaauthor=P.+Gmeinerauthor=B.+L.+Rothauthor=B.+K.+Shoichet&title=Structure-based+discovery+of+opioid+analgesics+with+reduced+side+effects&doi=10.1038%2Fnature19112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based discovery of opioid analgesics with reduced side effects</span></div><div class="casAuthors">Manglik, Aashish; Lin, Henry; Aryal, Dipendra K.; McCorvy, John D.; Dengler, Daniela; Corder, Gregory; Levit, Anat; Kling, Ralf C.; Bernat, Viachaslau; Hubner, Harald; Huang, Xi-Ping; Sassano, Maria F.; Giguere, Patrick M.; Lober, Stefan; Da Duan; Scherrer, Gregory; Kobilka, Brian K.; Gmeiner, Peter; Roth, Bryan L.; Shoichet, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">185-190</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Morphine is an alkaloid from the opium poppy used to treat pain.  The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors.  Conversely, G-protein μOR signalling is thought to confer analgesia.  Here we computationally dock over 3 million mols. against the μOR structure and identify new scaffolds unrelated to known opioids.  Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment.  Unlike morphine, PZM21 is more efficacious for the affective component of analgesia vs. the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses.  PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiCff2w3U8iLVg90H21EOLACvtfcHk0liiLwKvomkkkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKmsbvI&md5=b8bb2d8575dadf4a6dc74d94c26d2c1a</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnature19112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19112%26sid%3Dliteratum%253Aachs%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DAryal%26aufirst%3DD.%2BK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DDengler%26aufirst%3DD.%26aulast%3DCorder%26aufirst%3DG.%26aulast%3DLevit%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DBernat%26aufirst%3DV.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DP.%2BM.%26aulast%3DL%25C3%25B6ber%26aufirst%3DS.%26aulast%3DDa%2BDuan%26aufirst%3DD.%26aulast%3DScherrer%26aufirst%3DG.%26aulast%3DKobilka%26aufirst%3DB.%2BK.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26atitle%3DStructure-based%2520discovery%2520of%2520opioid%2520analgesics%2520with%2520reduced%2520side%2520effects%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D185%26epage%3D190%26doi%3D10.1038%2Fnature19112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sirohi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dighe, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madia, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoburn, B. C.</span></span> <span> </span><span class="NLM_article-title">The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.152678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=10.1124%2Fjpet.109.152678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=19435929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFClsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=513-519&author=S.+Sirohiauthor=S.+V.+Digheauthor=P.+A.+Madiaauthor=B.+C.+Yoburn&title=The+relative+potency+of+inverse+opioid+agonists+and+a+neutral+opioid+antagonist+in+precipitated+withdrawal+and+antagonism+of+analgesia+and+toxicity&doi=10.1124%2Fjpet.109.152678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity</span></div><div class="casAuthors">Sirohi, Sunil; Dighe, Shveta V.; Madia, Priyanka A.; Yoburn, Byron C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">513-519</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Opioid antagonists can be classified as inverse agonists and neutral antagonists.  In the opioid-dependent state, neutral antagonists are significantly less potent in pptg. withdrawal than inverse agonists.  Consequently, neutral opioid antagonists may offer advantages over inverse agonists in the management of opioid overdose.  In this study, the relative potency of three opioid antagonists to block opioid analgesia and toxicity and ppt. withdrawal was examd.  First, the potency of two opioid inverse agonists (naltrexone and naloxone) and a neutral antagonist (6β-naltrexol) to antagonize fentanyl-induced analgesia and lethality was detd.  The order of potency to block analgesia was naltrexone > naloxone > 6β-naltrexol (17, 4, 1), which was similar to that to block lethality (13, 2, 1).  Next, the antagonists were compared using withdrawal jumping in fentanyl-dependent mice.  The order of potency to ppt. withdrawal jumping was naltrexone > naloxone >>> 6β-naltrexol (1107, 415, 1).  The relative potencies to ppt. withdrawal for the inverse agonists compared with the neutral antagonist were dramatically different from that for antagonism of analgesia and lethality.  Finally, the effect of 6β-naltrexol pretreatment on naloxone-pptd. jumping was detd. in morphine and fentanyl-dependent mice.  6β-Naltrexol pretreatment decreased naloxone pptd. withdrawal, indicating that 6β-naltrexol is a neutral antagonist.  These data demonstrate that inverse agonists and neutral antagonists have generally comparable potencies to block opioid analgesia and lethality, whereas the neutral opioid antagonist is substantially less potent in pptg. opioid withdrawal.  These results support suggestions that neutral antagonists may have advantages over inverse agonists in the management of opioid overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw-j4cGjagnbVg90H21EOLACvtfcHk0ljo5NojpH3Nng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFClsLc%253D&md5=dcba0f30d77c82cf8a83b83903d37f37</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152678%26sid%3Dliteratum%253Aachs%26aulast%3DSirohi%26aufirst%3DS.%26aulast%3DDighe%26aufirst%3DS.%2BV.%26aulast%3DMadia%26aufirst%3DP.%2BA.%26aulast%3DYoburn%26aufirst%3DB.%2BC.%26atitle%3DThe%2520relative%2520potency%2520of%2520inverse%2520opioid%2520agonists%2520and%2520a%2520neutral%2520opioid%2520antagonist%2520in%2520precipitated%2520withdrawal%2520and%2520antagonism%2520of%2520analgesia%2520and%2520toxicity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26spage%3D513%26epage%3D519%26doi%3D10.1124%2Fjpet.109.152678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maadani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farahanikia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eftekhari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifzadeh, M.</span></span> <span> </span><span class="NLM_article-title">Effect of the methanolic extracts of different parts of Ferula assa-foetida on naloxone-induced withdrawal behavior in morphine-dependent mice</span>. <i>Avicenna J. Phytomed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">426</span>– <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=29062804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVGqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=426-435&author=M.+Khanaviauthor=S.+Maadaniauthor=B.+Farahanikiaauthor=M.+Eftekhariauthor=M.+Sharifzadeh&title=Effect+of+the+methanolic+extracts+of+different+parts+of+Ferula+assa-foetida+on+naloxone-induced+withdrawal+behavior+in+morphine-dependent+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the methanolic extracts of different parts of Ferula assa-foetida on naloxone-induced withdrawal behavior in morphine-dependent mice</span></div><div class="casAuthors">Khanavi, Mahnaz; Maadani, Sajad; Farahanikia, Behnaz; Eftekhari, Mahdieh; Sharifzadeh, Mohammad</div><div class="citationInfo"><span class="NLM_cas:title">Avicenna Journal of Phytomedicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-435</span>CODEN:
                <span class="NLM_cas:coden">AJPVAX</span>;
        ISSN:<span class="NLM_cas:issn">2228-7949</span>.
    
            (<span class="NLM_cas:orgname">Mashhad University of Medical Sciences</span>)
        </div><div class="casAbstract">Objective:Ferula assa-foetida, a native species in Iran, is used for treatment of several diseases particularly for neurol. disorders in Iranian Traditional Medicine.  The aim of this study is to investigate the effect of methanolic roots, fruits, and aerial parts exts. of Ferula assa-foetida on withdrawal syndrome in morphine-dependent mice.  Materials and Methods: Aerial parts, roots, and fruits of the plant were sep. extd. with 80% MeOH.  For induction of dependence, morphine (50, 50 and 75 mg/kg) was injected s.c. three times daily (10 am, 1 pm and 4 pm) for three days and a last dose of morphine (50 mg/kg) was administrated on the fourth day.  Withdrawal syndrome was induced by injection of naloxone (5 mg/kg, i.p.) 2 h after the final dose of morphine.  Different doses of the exts. were administered i.p. 60 min before naloxone injection and withdrawal sign was recorded 2 min after naloxone injection for a period of 60 min.  Results: Pre-treatment of animals with different doses (2.5, 5, 10, 20 mg/kg) of methanolic ext. of the aerial parts of F. assafoetida caused a significant decrease in naloxone-induced behavior.  I.p. administration of different doses (10, 15, 20, 25 mg/kg) of methanolic ext. of the fruit significantly reduced the naloxone-induced withdrawal behavior (p<0.001).  Conclusion: It might be concluded that the exts. of Ferula assa-foetida affect morphine withdrawal syndrome possibly via interference with the neurotransmitters in nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_mKf86XIV6bVg90H21EOLACvtfcHk0ljo5NojpH3Nng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVGqs7g%253D&md5=75f1f3e9ca9b68150f9ec8cb30ffe4f5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKhanavi%26aufirst%3DM.%26aulast%3DMaadani%26aufirst%3DS.%26aulast%3DFarahanikia%26aufirst%3DB.%26aulast%3DEftekhari%26aufirst%3DM.%26aulast%3DSharifzadeh%26aufirst%3DM.%26atitle%3DEffect%2520of%2520the%2520methanolic%2520extracts%2520of%2520different%2520parts%2520of%2520Ferula%2520assa-foetida%2520on%2520naloxone-induced%2520withdrawal%2520behavior%2520in%2520morphine-dependent%2520mice%26jtitle%3DAvicenna%2520J.%2520Phytomed.%26date%3D2017%26volume%3D7%26spage%3D426%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i39"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01367">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_52503"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01367?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01367</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Details of dose- and time-related antinociceptive effects; analgesic mechanism; and antinociceptive tolerance evaluation of analogs after i.c.v. and s.c. injection in the radiant heat tail-flick test (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01367/suppl_file/jm0c01367_si_001.pdf">jm0c01367_si_001.pdf (5.81 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01367&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01367%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01367" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679947126d813cd6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
